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Abstract 
Although the roll-out of effective combination antiretroviral therapy (cART) has brought great 
benefits, concerns remain regarding the development of drug resistance. This thesis uses data 
from the EuroSIDA cohort, the UK Collaborative HIV cohort, the UK HIV Drug Resistance 
Database, the ViroLAB consortium and the EU-Resist collaboration to describe trends in 
resistance testing, prevalence and incidence as well as the impact of drug resistance on CD4 
count declines both in the presence and absence of ART.  
My findings show that the proportion of people tested for resistance following virological 
failure in Europe is low (31.6%) and decreasing. Individuals in Eastern Europe were less likely to 
receive a resistance test (adjusted odds ratio=0.72, 95% confidence interval=0.55-0.94) 
compared with individuals in Southern Europe. However, among those who were tested, the 
proportion with resistance was relatively high (77.9%), indicating a potentially selective 
approach to resistance testing. Among individuals maintained on a failing treatment regimen 
with resistance to at least one drug class, I found that CD4 counts declined less steeply among 
individuals with NRTI resistance, the M184V, D67N or T215Y mutation in the reverse 
transcriptase, or either the V82A or I54V mutation in the protease. In contrast, CD4 counts 
declined faster among individuals with NNRTI resistance and those with the V179D or L74I 
reverse transcriptase mutations. A cluster of mutations, including K103N, was also associated 
with faster CD4 declines. No class of drug resistance or individual mutation had a large impact 
on the rate of CD4 decline before the start of cART.  
These findings have implications for public health policy in Europe aimed at minimizing health 
disparities, and can be used to provide recommendations for the construction of maintenance 
therapies for individuals with no other treatment options. Further research into HIV drug 
resistance is imperative to ensure the continued success of cART.  
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“Did the solution become the problem? I think the answer is no. The problem is the way we 
use the solution." 
 
Paul Farmer from Partners in Health, commenting on drug resistance 
Interviewed for the Academy of Achievement (2009) 
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Chapter 1 . Background 
 
1.1. Introduction and Thesis Objectives 
The face of the global HIV epidemic has changed considerably since the first cases of acquired 
immunodeficiency syndrome (AIDS) were described. Following the development of 
combination antiretroviral therapy (cART), people living with HIV now have a life-expectancy 
similar to that of the general population. It is without doubt that the roll-out of cART has 
brought invaluable benefits, but it has also given rise to a number of new challenges. As people 
develop resistance to drugs in their treatment regimen, they may have to switch to costlier 
second or third line regimens. Transmitted drug resistance (TDR) can limit the effectiveness of 
first-line treatment options, and requires continuous surveillance and monitoring to inform 
drug resistance testing strategies. Despite its importance, many features of HIV drug resistance 
are still not well understood.  
The aims of this PhD thesis were to describe the epidemiology of HIV drug resistance in Europe 
and to estimate the effect of drug resistance on markers of clinical progression. This was done 
through five studies, which form the results chapters of my thesis. Although a large number of 
potential analyses could have been done to address my aims, I chose to conduct analyses that 
addressed relevant outstanding questions in the field of HIV drug resistance and which the 
EuroSIDA cohort study, the primary source of my data, was particularly suited to answer. An 
outline of my thesis structure, together with the rationale and objectives for each analysis is 
provided below.  
Chapter 1: Background 
My first chapter is a comprehensive background chapter covering the epidemiology and 
biology of HIV. It also outlines the basic principles of how drug resistance develops, how it is 
measured and the impact of both acquired and transmitted drug resistance on clinical 
outcomes.  
Chapter 2: Methodology and Data Sources 
The methodology chapter covers the strategy I used to conduct my literature reviews, which I 
conducted for each results chapter to describe the existing research relevant to each specific 
objective. I also describe the data sources and statistical methods used.  
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Chapter 3: Patterns of Resistance Testing and Detected Drug Resistance in Europe 
The aim of this chapter was to describe the prevalence of resistance testing and detected drug 
resistance to the three main drug classes over time in Europe. Data on both the utilisation of 
resistance testing in clinical care and on the prevalence of resistance are of importance in 
order to plan public health activities, and EuroSIDA is an ideal setting to study resistance 
prevalence across Europe due to the standardized nature of the data collection and the 
inclusion of several Eastern European countries in the cohort, which provides data from a 
region that’s typically not well researched.  
Chapter 4: Long-term virological outcomes and resistance patterns among treatment 
experienced HIV patients receiving raltegravir 
Whereas Chapter 3 focuses on resistance to the three major drug classes, the focus of Chapter 
4 was on resistance to a commonly used drug, raltegravir, from a more novel drug class, 
integrase inhibitors. My aim was to describe the long-term risk of virological failure (VF) among 
individuals receiving raltegravir and to describe the prevalence of resistance to integrase 
inhibitors among those who experienced VF to this drug. As genotyping for integrase 
resistance is still not done routinely in clinical care in all EuroSIDA countries, I selected stored 
plasma samples from individuals failing raltegravir and sent them for genotyping using next 
generation sequencing at our collaborating laboratory in Badalona, Spain.  
Chapter 5: The effect of drug resistance mutations on CD4 cell decline in HIV positive 
individuals maintained on a failing treatment regimen 
The aim of Chapter 5 was to describe the effect of acquired drug resistance on CD4 decline 
among HIV infected individuals maintained on a failing regimen. Individuals who have 
exhausted their treatment options, today mainly those receiving care in low income settings, 
are sometimes kept on a failing regimen for extended periods of time. It has been 
hypothesised that preserving certain mutations that have a strong impact on the fitness of HIV 
may lead to clinical benefits for these patients, but this hypothesis has never been tested in a 
large cohort. In order to ensure that I had reasonable power to study the effect of individual 
mutations, I used data from the UK Collaborative HIV Cohort (CHIC) and the UK HIV Drug 
Resistance Database (HDRD) in addition to data from EuroSIDA, making this one of the largest 
analyses attempting to investigate this question to date.  
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Chapter 6: Rate of accumulation of drug resistance mutations during virological failure 
according to the level of viral replication  
One of the primary concerns of keeping individuals on a failing treatment regimen is the risk of 
further accumulation of resistance. In this chapter I estimate the rate of accumulation of drug 
resistance among individuals maintained on a failing treatment regimen, and focus on 
describing how the level of viral replication affects the speed at which resistance develops. The 
relationship between viral exposure levels and resistance accumulation has not yet been well 
characterised, particularly not at low viral loads. EuroSIDA is an ideal cohort to address this 
question due to the relatively large availability of repeat resistance tests, arising primarily from 
retrospective genotyping carried out on stored plasma samples. 
Chapter 7: The effect of primary drug resistance on CD4 cell decline and viral load set point 
in HIV positive individuals before the start of ART 
My final results chapter describes the effect of drug resistance on CD4 count decline before an 
individual starts antiretroviral therapy (ART), as well as its effect on virulence as indicated by 
the viral set point. It has been hypothesised that resistance present before the start of ART 
might affect these factors, and therefore impact the evolution and spread of HIV on a 
population level. Given the potential for TDR to increase as ART is rolled-out more widely in 
low-income settings, an increased understanding of how the epidemic is influenced by drug 
resistance is important. In order to investigate this question, I used data from a large 
collaboration of European HIV clinics which was initiated under the ViroLAB umbrella as well as 
data available in EuroSIDA.  
Chapter 8: Discussion and Concluding Remarks 
Chapter 8 draws together the research findings from each of my results chapters, discusses the 
limitations of this PhD thesis and describes the implications of my findings for clinical care and 
future research.  
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1.2. History of HIV/AIDS 
1.2.1. The beginning of an epidemic 
The first cases of acquired immune-deficiency syndrome (AIDS) were diagnosed in 1981, when 
a cluster of a relatively rare and normally asymptomatic pneumonia, Pneumocystis Carinii 
Pneumonia (PCP), was identified among young gay men in Los Angeles (1). Soon afterwards, 
similar clusters of PCP and a rare infection-related cancer, Kaposis Sarcoma (KS), were 
identified among gay men in New York and San Fransisco (2,3). The cases had an astonishingly 
high mortality rate given the normally asymptomatic nature of the infections in 
immunocompetent individuals (4), and the underlying cause of these rare conditions was later 
found to be a severe immunodeficiency of an unknown cause (4). As the syndrome appeared 
to only affect gay men it was initially referred to in ways linking it to homosexuality, such as 
“gay compromise syndrome” in the medical community (5) and “gay-related 
immunodeficiency syndrome” in the popular press (6,7). Considerable stigma surrounded the 
disease at this time, and gay men were seen as the group exclusively at risk of the disease 
while at the same time posing a risk to the general community (8). However, cases of the 
disease were rapidly identified in both transfusion patients and among heterosexual 
individuals, particularly immigrants from Haiti in the US and people who inject drugs (9–12). In 
1982 the CDC named the syndrome AIDS, defining this as the occurrence of a disease likely to 
be caused by diminished cell-mediated immunity, such as PCP or KS, where no other reason 
for immunodeficiency could be identified (13).  
The epidemiology of AIDS suggested an infectious cause, and in 1983 Luc Montaignier’s team 
at the Pasteur Institute isolated a novel retrovirus from a patient suffering from 
lymphadenopathy, an AIDS-defining illness. Their findings were published in Science, and the 
virus was named LAV, Lymphadenopathy Associated Virus (14). The isolation of this virus 
followed a number of recent scientific advances in retrovirology, including the discovery of 
interleukin II by Robert Gallo’s lab at the National Institute of Health (NIH) , which allowed T-
cells to be grown in-vitro (15). In 1984, Gallo et al published a paper which also described a 
novel retrovirus, HTLV-III, isolated from T-cells of 48 patients with AIDS or at risk of developing 
AIDS (16). Both LAV and HTLV-III were suggested as possible causal agents of AIDS, although it 
quickly transpired that both papers described the same virus (17). This sparked a lengthy 
controversy between the Paris and NIH teams, with allegations of scientific misconduct as it 
transpired that Montagnier had sent his first isolate of LAV to Gallo’s lab before Gallo’s first 
publication. However, Gallo was cleared from all suspicions of misconduct in 1994, and the 
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likely chain of events involves a contamination event at the Pasteur Institute (18). The virus 
was eventually renamed the Human Immunodeficiency Virus (HIV) by the International 
Committee on the Taxonomy of Viruses in 1986 (19), although the conflict between Gallo and 
Montagnier was not fully resolved until an agreement naming both the researchers “co-
discoverers” was jointly endorsed by US president Ronald Reagan and the French Prime 
Minister Jacques Chirac in March 1987 (18,20).  
In 1985 a retrovirus related to but distinct from HIV was isolated from AIDS patients in West 
Africa. This virus was named HIV-2, and the virus isolated from US and European patients 
became known as HIV-1 (21). The discoveries spurred a wave of intense research into the 
molecular biology of HIV, and the first diagnostic test and antiretroviral drugs were licensed in 
1985 and 1987, respectively (22).  
1.2.2. Origin of the HIV virus 
Although AIDS was first recognized in the 1980s, the earliest cases are thought to have 
occurred considerably earlier (23). Medical records indicate that the first case of AIDS, 
retrospectively diagnosed, occurred in 1959 in Leopoldville, now Kinshasa in the Democratic 
Republic of Congo (24). However, modern phylogenetic techniques have estimated that the 
first HIV infection is likely to have occurred even earlier than this, probably in the early 20th 
century (25). Although estimates vary, a recent study has predicted that the first infection with 
the main genetic HIV strain (HIV-1 M) is likely to have occurred in 1921 (95% Confidence 
Interval [CI]=1908-1933) (26).  
HIV-1 was introduced into the human population through zoonosis, cross-species transmission, 
of the Simian Immunodeficiency Virus (SIV), an asymptomatic infection found in non-human 
primates (23). The virus giving rise to HIV-1 has been traced back to SIV strains common in 
chimpanzees (27). HIV-2 is also the result of SIV cross-species transmission, but from sootey 
mangabeys (28). It is currently believed that the zoonosis occurred as a result of the hunting 
and consumption of bush-meat (25). Bush-meat hunting is traditional and a wide-spread 
practice in central and western Africa, as indicated by the fact that the prevalence of SIV 
antibodies in villages where bush meat is hunted has been estimated at 7.8% (29). This makes 
it likely that isolated cases of SIV infection in humans occurred before the early 1900s, and it is 
not known why these isolated viral infections did not turn into epidemics. It is possible that the 
rapidly increasing population density and sudden socio-economic changes occurring as a 
consequence of the colonial expansion provided the conditions required for the infection to 
spread (25,30), but factors such as changes in sexual behaviour, increasing STD prevalence and 
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circumcision practices could also have played a role (31). After entering the human population 
in Africa, the virus spread to a number of different regions in the world while continuously 
genetically diversifying (32). The introduction into the US population occurred via Haiti, 
potentially as a consequence of migration or the sex tourism industry (33). The introduction of 
the virus that gave rise to the majority of HIV circulating in the US today has been traced back 
to a single transmission event, as indicated by the relatively low level of genetic diversity 
present in the US HIV epidemic today (33). This transmission event is likely to have occurred in 
the late 1960s, making it possible that HIV circulated for several years in the general 
population before entering the high-risk gay community, where it could infect enough people 
in a short enough time window to make it noticeable (33,34).  
1.3. Transmission 
HIV can be transmitted sexually, vertically or by contact with infected blood (35). Because of 
this, the main groups at risk of acquiring the infection are individuals engaging in unprotected 
sex, people who inject drugs (PWID) and children born to mothers living with HIV. 
Transmission through blood transfusions is also possible, and haemophiliacs were a key risk 
group in the beginning of the epidemic (36).The sexual transmission risk group is commonly 
separated into heterosexuals and men who have sex with men (MSM) (37). This is partly 
because the prevalence of HIV in the MSM community is higher, which increases the 
probability of becoming infected during unprotected sex (37), and partly due to the fact that 
the risk of HIV transmission is higher during unprotected anal sex, which is more commonly 
practised in the MSM community (38). Despite these risk groups often being treated as 
separate, individuals can share several of the risk factors.  
The infectivity for different routes of transmission and the measures developed to prevent 
new infections are described in more detail below. Infectivity is quantified as the probability of 
becoming infected during one potentially infectious act (39). It should be interpreted as a 
context-dependent measure that is ultimately determined by a combination of host, agent and 
environmental factors (40). Furthermore, although infectivity refers to the transmission 
probability per act of risk behaviour, sexual transmission estimates are sometimes reported 
per partner rather than per act (41).  
1.3.1. Sexual transmission 
The majority of new HIV infections world-wide occur due to sexual transmission (35), and it is 
estimated that around 80% of these infections are the result of sexual transmission among 
people who identify as heterosexual (42,43).  
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1.3.1.1. Vaginal sex 
The risk of acquiring HIV through vaginal sex can differ depending on if transmission occurs 
from male to female or female to male, and estimates are complicated by the fact that anal 
sex is a contributing (often under-reported) risk factor also among heterosexuals (39,41,44). 
Looking explicitly at studies that reported male to female infectivity for vaginal sex, Boily et al 
conducted a systematic review and meta-analysis that reported a pooled infectivity estimate 
of 0.076% per sexual act (41). The overall infectivity estimate for heterosexual sex is somewhat 
higher: 0.18% per act across all study estimates, 0.38% female-to-male and 0.12% male-to-
female (41). This is in agreement with an earlier systematic review by Powers et al, which 
found that the majority of transmission studies conducted in stable, heterosexual relationships 
where the prevalence of concurrent risk factors was rare, estimated transmission probabilities 
of around 1 event per 1000 acts (39). However, both reviews found considerable 
heterogeneity among study estimates, with factors such as study setting, commercial sex work 
and the prevalence of other STI’s being important determinants of the infectivity 
estimates(39,41).  
1.3.1.2. Anal sex 
The risk of HIV acquisition is higher during anal sex than vaginal sex (38). This increased 
transmission probability is thought to be due to the fact that the rectal mucosa is more 
sensitive and easier to damage than the vaginal mucosa, and that it does not have the same 
humoral immune barriers found in vaginal secretions (44). A meta-analysis by Baggaley et al 
estimated that the transmission probability per act of unprotected anal sex is 1.4% (0.2-2.5%) 
(45). Interestingly, this risk was the same among both MSM and heterosexuals. The authors 
further found that the probability of transmission was higher for the receptive partner than 
the insertive partner (45), consistent with findings from a previous study from the US (46).  
1.3.1.3. Oral sex 
The risk of HIV infection during oral sex is harder to study, as oral sex is rarely reported as a 
single exposure with no other concurrent risks (47,48). A systematic review from 2008 found 
that 6 out of 10 identified studies reported a transmission probability of 0% - indicating that 
HIV transmission through oral sex is rare. However, 4 of the studies did report transmission 
events, with transmission probabilities ranging from 1% to 20% depending on the type of oral 
sex and the number of concurrent risk factors. The risk of HIV transmission during oral sex is 
therefore likely to be small, but not zero (47) and increased by factors including the presence 
of ulcers or oral pathogens (48).  
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1.3.1.4. Preventing sexual transmission of HIV 
One of the simplest, most effective ways to prevent the sexual transmission of HIV is by using a 
condom (49). A Cochrane review from 2002 has estimated that consistent condom use can 
result in a reduction in HIV incidence of approximately 80.2% (worst case scenario: 35.4%; best 
case scenario 94.2%) (50), and increasing condom access and promoting condom use has 
become an important aspect of HIV prevention efforts world-wide (49,51). However, factors 
such as inconsistent or incorrect usage can significantly reduce the effectiveness of condoms 
(52), and gender and social inequalities mean that some individuals are not always able to 
negotiate condom use with their sex partners. This is a particular issue for women and 
commercial sex workers (CSW), who may hold very little power over their sex partners (53,54). 
Vaginal microbicides that do not require partner negotiation could prove beneficial to some 
women for this reason, and a recent trial has found that the risk of acquiring HIV could be 
reduced by 39% through usage of a Tenofovir containing gel (55). However, the efficacy of a 
vaginal microbicide depends on its acceptability and uptake, and a another recent trial have 
failed to confirm a protective effect of tenofovir containing gels, possibly due to a lack of 
adherence (56). In addition, a microbicide cannot prevent HIV transmission in instances of rape 
or sexual violence, and it is clear that increasing gender equality and preventing sexual 
violence are crucial policies to pursue alongside strategies aiming to increase 
condom/microbicide use (57).  
 
Other effective ways of preventing sexual HIV transmission include circumcision (58–60) and 
the use of cART (61). cART is an effective preventative tool because transmission is strongly 
dependent on the level of viral replication, which is lowered through cART use (62). The 
landmark HPTN-052 trial of this ‘Treatment as Prevention’ paradigm has found that among 
discordant heterosexual couples, early and successful cART use can lead to a 96% reduction in 
the HIV transmission rate (61). Recently, the results from the PARTNER study has 
demonstrated a similarly strong protective effect of successful cART use among discordant 
homosexual couples; after 2 years of follow-up not a single transmission event has been 
observed (63). Antiretroviral treatment can also prevent HIV transmission when used in a 
prophylactic manner as pre-exposure prophylaxis (PrEP) in some populations (64), and after 
exposure as post-exposure prophylaxis (PEP) if used within 72 hours after exposure (65).  
1.3.2. Vertical transmission 
In 2012, an estimated 260 000 children under 15 became infected with HIV (66). The majority 
of these children have acquired their infection vertically, i.e. while still a foetus or an infant 
30 
 
from their HIV-positive mother. Vertical transmission can occur in utero (intrauterine 
transmission), during delivery and labour (intrapartum transmission) or as a result of 
breastfeeding (postnatal transmission) (67). Breastfeeding considerably increases the risk of 
vertical transmission, and among both breast-feeding and non-breastfeeding populations 
intrapartum transmission is more common than intrauterine transmission (68). The absolute 
risk of a transmission event ranges from 15-40% in the absence of specific interventions (69), 
but this risk is influenced by a range of clinical factors. The most important risk factor for 
vertical transmission is the maternal plasma viral load level (70). Other factors shown to 
influence the risk of transmission include the viral load levels in the genital tract, anaemia, 
prolonged membrane rupture during labour, mode of delivery, breast feeding duration and 
antiretroviral treatment (71).  
1.3.2.1. Preventing vertical transmission of HIV 
Measures that directly address the proximal risk of mother-to-child-transmission (MTCT) 
include HIV testing and counselling at antenatal visits, treatment with ART, safe delivery and 
safe infant feeding (72). It has been known that ART reduces the risk of MTCT since 1994, 
when the PACT-076 trial showed that an intervention of zidovudine monotherapy given to the 
mother during late pregnancy, injected during delivery and given to the infant for 6 weeks 
after birth could reduce the risk of MTCT with two thirds (73). The introduction of this 
intervention led to a quick decline in the number of MTCT events in high income settings, and 
to a lesser extent in low income settings. Simplified ART interventions have been shown to be 
reasonably effective and more practical to roll-out in low income settings (69), but the WHO 
currently recommends that in generalized epidemics all pregnant and breastfeeding women 
with HIV should initiate cART and maintain it as a lifelong treatment. This is known as option 
B+ (72). Although initiating cART is the most effective way to prevent MTCT, formula feeding 
(74) or birth by elective caesarean section could also reduce the transmission risk (69).  
1.3.3. Parenteral transmission 
Parenteral transmission of HIV includes transmission of HIV through contaminated medical 
injections, injecting drug use, accidental needle-stick injuries and blood transfusion. A 
systematic review and meta-analysis from 2006 found extensive heterogeneity among 
infectivity estimates in studies of injecting drug users, with estimates ranging from 0.63%-2.4% 
(75). The risk of acquiring HIV after receiving a contaminated blood transfusion is considerably 
higher, with estimates ranging from 27-100%, and pooling these weighted by study size gives 
an overall infectivity estimate of 80.2% (95%CI=76.7%-83.3%) (75).  
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1.3.3.1. Preventing parenteral transmission of HIV 
As with the other transmission routes, the risk of acquiring HIV parenterally is dependent on a 
range of factors, including viral load and cART. Some measures previously mentioned, 
including PrEP and PEP are also used to minimize the risk of parenteral transmission (76,77). In 
addition, strategies such as offering opioid substitution therapy (OST), clean needle exchanges 
and bleach to disinfect needles with can reduce the risk of acquiring HIV among injecting drug 
users (78). Since it became routine practice to screen blood used for transfusions for HIV, 
transmission events via this route have grown extremely rare in high income settings (79). In 
low income settings the risk of HIV infection through transfusion is higher due to operational 
challenges, including the lack of routine screening of donated blood (80).  
1.4. Current Burden 
1.4.1. The global situation 
Since the start of the epidemic, an estimated 70 million people have been infected with HIV 
and more than 35 million have died as a result of AIDS. In 2012, an estimated 35.3 
(95%CI=32.2-38.8) million individuals were living with HIV world-wide (81).  
Despite the scale of the epidemic, the incidence of HIV has started to fall on a global level. 
Compared to 2001, the number of new HIV infections was 33% lower in 2012, down from 3.4 
(95%CI=3.1-3.7) million to 2.3 (95%CI=1.9-2.7) million (81). This has been accompanied by a 
reduction in the global number of annual AIDS deaths, which declined from a peak of 2.2 
million in 2005 to 1.6 million in 2012. Taken together, this has caused an increase in the 
number of individuals living with HIV despite the concurrent fall in HIV incidence (Figure 1.1) 
(81).  
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Figure 1.1. New HIV infections, AIDS deaths and people living with HIV according to UNAIDS 
(2013) 
 
 
 
 
 
 
 
 
 
Source: (81)  
However, these prevalence and incidence trends vary considerably according to geographical 
region and transmission risk group. Sub-Saharan Africa remains the region most heavily 
affected by the epidemic, accounting for 68% of all people living with HIV in 2011 (Figure 1.2.) 
(82) and 70% of all new HIV infections (81). Heterosexual transmission is the dominant route of 
infection in this region. As a growing number of HIV-positive people in Sub-Saharan Africa are 
gaining access to HIV treatment, condoms and other interventions associated with a reduced 
risk of HIV transmission, HIV incidence has fallen dramatically, with an estimated 34% 
reduction since 2008. Remaining challenges that need to be addressed include a very high rate 
of TB co-infection, a lack of resources and waning political commitment (81).  
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Figure 1.2. Number of people living with HIV, by region 
 
 
 
 
 
 
 
 
Source: (66)  
1.4.2. The European situation 
In Europe1, HIV remains a public health problem despite a comparably low overall population 
prevalence (83). In 2013, the diagnosis rate was estimated at 15.7 per 100 000 in the EU/EEA 
area and Russia, and this has increased over the past decade. However, the burden of HIV is 
not equally distributed across the European region, with 77% of new diagnoses occurring in 
Eastern Europe and Russia (83). It appears that the increase in new HIV diagnoses in Europe is 
mainly driven by a large increase in the absolute number of newly diagnosed individuals in 
Eastern Europe (Figure 1.3). The number of deaths from AIDS in Eastern Europe has also 
increased more than 10-fold during the same period, in contrast to the decline in AIDS deaths 
seen globally (82).  
The HIV epidemic in Eastern Europe is characterised by different key risk groups compared to 
countries in Western Europe (84). The main route of infection in Western and Northern 
European countries remains through MSM, whereas heterosexual transmission and injecting 
drug use are the main routes of infection in Eastern European countries, with just 2% of 
reported cases in Eastern Europe occurring as a result of men having sex with men (83,84). The 
rate of new HIV diagnoses in the region is increasing most rapidly among heterosexuals, 
                                                          
1 Throughout this thesis, “Europe” or “European region” will refer to EU/EEA countries + Switzerland, 
Russia and Belarus, and “WHO European Region” to the WHO European region, which includes an 
additional 11 countries in Central Asia (http://www.who.int/about/regions/euro/en/).  
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whereas there is some indication that diagnoses due to reported injecting drug use is 
decreasing (Figure 1.4), although there is a substantial proportion of missing data on route of 
infection from Eastern Europe (83).  
 
 
 
 
 
 
 
 
Source: (83)  
 
 
 
 
 
 
 
 
Source: (83)  
However, it is important to note that the situation is not homogenous across Eastern Europe, 
and it differs further between Central Eastern and Eastern European countries. Figure 1.5 
shows the rate of new HIV diagnoses over time, plotted by country classified as ‘Eastern 
Europe’ in the WHO European Region (83)  
Figure 1.3. Number of new HIV diagnoses, by geographical area and year of diagnosis 
Figure 1.4. Number of new HIV diagnoses, by transmission mode and year of diagnosis in 
Eastern Europe 
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Source: Plotted from Table 1 in (83)  
Although the rate of new diagnoses is increasing in most countries, there are notable 
exceptions, such as Estonia and Kazakhstan. The estimated rate of new diagnoses also differ 
between countries, with Estonia, Russia and Moldova having notably high rates of new 
diagnoses (83). The increasingly problematic HIV epidemic in many countries in the Eastern 
Europe has its roots in the severe social and economic changes that followed the dissolution of 
the Soviet Union, which resulted in a fragmented healthcare system, economic turmoil and 
rapidly increasing alcohol and drug abuse (85). It is clear that curbing the HIV epidemic in 
Europe will have to include a strong focus on prevention efforts in Eastern European countries, 
including increasing access to harm reduction services (86). In addition, research on clinical 
management and outcomes in the region needs to take into account the increasing 
heterogeneity in both the healthcare need, organisation and delivery that exists within the 
post-soviet states (85,87). 
Figure 1.5. Rates of new HIV diagnoses, by country in Eastern Europe (per 100 000) 
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1.5.Viral Biology  
HIV is a retrovirus, in the family of lentiviruses (88). Retroviruses are unique within the viral 
classification system, as their life cycle involves the production of double-stranded DNA from 
RNA during the process of reverse transcription. This is the opposite of what occurs during 
human DNA replication, where RNA is produced from DNA during transcription (36). In order 
to understand antiretroviral drugs as well as drug resistance, it is important to have a thorough 
understanding of the molecular biology of HIV. This is outlined below.  
1.5.1. Viral structure  
The structure of the HIV virus can be seen in Figure 1.6 below. The genome, consisting of two 
copies of single-stranded RNA, is located within a protein shell called the capsid (89). The HIV 
capsid consists of repeated protein units (p24) arranged as a cone-shaped icosahedron (90,91). 
The capsid serves to protect the genome from the host’s immune system (89).  
Figure 1.6. Structure of the HIV virus 
 
 
 
 
 
 
 
 
 
Source: (92)  
Surrounding the capsid is the envelope, a structure derived from host lipids that provides 
further protection for the genome. The envelope also contains viral glycoproteins, notably 
gp120 and gp41, that form characteristic spikes (36). The two copies of single-stranded RNA 
(Figure 1.7) each contain 3 structural genes (gag, pol and env), 2 regulatory genes (tat and rev) 
and 4 genes coding for accessory proteins (vif, vpr, nef and vpx (HIV-2) or vpu (HIV-1)) (92). 
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Each side of the genome is surrounded by long-terminal repeats (LTR), that contain sequences 
required for the start and stop of transcription (36).  
Figure 1.7. The HIV-1 genome 
 
 
Source: (92) 
The gag gene is translated into structural proteins, env into the surface binding receptors and 
pol contains the information needed to produce the replication enzymes, including reverse 
transcriptase (92). Tat and rev play key roles during HIV replication, with tat stimulating 
transcriptional elongation and rev involved in the transport of mRNA from the nucleus to the 
cytoplasm for transcription. The vif, vpr, vpu/vpx and nef genes code for, amongst other 
things, proteins that increase the infectivity of the virus (36). 
1.5.2. Viral life-cycle 
A diagrammatic representation of the HIV life cycle can be seen in Figure 1.8. Each step is 
described in further detail below.  
 
Figure not available due to copyright restrictions 
38 
 
Figure 1.8. The HIV life cycle 
Source: (92)  
1.5.2.1. Attachment and entry  
HIV enters a host through mucosal surfaces or, in the case of parenteral transmission, by 
injection straight into the blood stream (36). It consequently infects white blood cells of the 
human immune system that express the surface molecule CD4 and a chemokine co-receptor. 
Depending on which surface receptors that are present on the viral surface, the virus infects 
either CXCr4 expressing T-cells (93,94) or CCr5 expressing monocytes/macrophages (95,96). 
The preference of the virus to infect and replicate in a certain type of cell is referred to as 
tropism (36). Viruses binding preferentially to the CXCr4 co-receptor are called X4 tropic, 
whereas viruses binding to CCr5 receptors are called R5 tropic. It is also possible for HIV to 
bind to both CCr5 and CXCr4. These viruses are called X4R5 or dual tropic viruses (97).  
Attachment to the CD4 receptor and appropriate co-receptor triggers a conformational change 
in the virus, which causes the viral envelope to fuse with the cell membrane. This reveals the 
capsid to the intracellular environment, where its structural properties causes it to disintegrate 
in a process called uncoating (98).  
1.5.2.2. Reverse transcription 
After uncoating, the viral RNA is converted to DNA in the cytoplasm by the virally prepackaged 
reverse transcriptase (RT). Each virion contains between 50 and 100 RT enzymes (36). The RT 
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contains two enzymatic sites, an RNA and DNA-dependent DNA polymerase and an RNase H, 
connected by a connection domain (98). The RNA-dependent DNA polymerase reads the 
nucleotide sequence of the RNA genome and uses nucleotide bases present in the host cell to 
create a DNA-RNA hybrid helix. The RNaseH degrades the RNA strand, and the RT completes 
the creation of a double stranded DNA molecule. This is called the proviral DNA. The proviral 
DNA consequently forms a pre-integration complex together with a number of viral and host 
proteins. The preintegration complex crosses into the nucleus through a nuclear pore, where 
the integrase incorporates the proviral DNA into the host genome with the help of host 
enzymes (99). The resulting cell with fully integrated viral DNA is called the provirus (98).  
Transcription of the DNA into mRNA occurs using host RNA dependent RNA polymerases (36). 
During early phases of transcription, short mRNAs encoding regulatory proteins (tat and rev) 
are produced. The late phase of transcription occurs once a sufficient amounts of the 
regulatory protein tat has been produced, and it involves the production of genomic RNA 
copies and longer mRNAs that retain non-coding fragments, or introns (100). These longer 
mRNAs are transported back into the cytoplasm through a rev mediated pathway, and 
translation occurs with the help of host cytosolic polysomes or the rough endoplasmic 
reticulum depending on the gene being translated (101).  
Env is translated into a precursor protein for gp41 and gp120, gp160, and the gag and pol 
genes are translated into a precursor polyprotein for a number of viral enzymes, including the 
RT. Processing of precursor proteins to form the final viral produces is done by the viral 
protease after budding (102).  
1.5.2.3. Assembly, budding and maturation 
After translation, the gag polyprotein directs viral assembly. This requires that proteins and 
pre-cursor proteins all migrate towards the cell surface of the infected cell (102). The genomic 
RNA copies cluster together with pre-cursor proteins and cellular enzymes to form an 
immature core at the cell membrane. At the same time, surface proteins migrate and insert 
into the cell membrane, and capsid proteins assemble around the immature core (92,102). The 
immature viral particles bud from the cell surface, and thereby acquire the host-derived 
envelope. In order for new virus particles to be released effectively, CD4 is downregulated 
from the surface of the infected cell. This downregulation is caused by viral proteins nef, vpu 
and gp160 through a number of different processes (103–106). After successful budding and 
release the viral protease is activated, cleaving the precursor polyproteins to produce the 
integrase, reverse transcriptase and protease (102). This proteolytic cleavage of precursor 
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proteins is referred to as maturation, and viruses that do not undergo maturation remain as 
immature, non-infectious particles (36). 
1.5.2.4. Latency and viral persistence 
Some cells infected by HIV do not go on to produce infectious progeny (92). Instead, HIV 
replication is effectively put on hold while the viral genome remains integrated within the host 
genome. This establishment of post-integration latency allows HIV to persist within a host cell. 
Latent HIV has been observed in resting naïve and memory T-cells, peripheral blood 
monocytes/macrophages, dendritic cells and in some studies also the hematopoietic stem cells 
in the bone marrow. These cells are long-lived, and provide a permanent source for potential 
new HIV viruses (102,107,108). It is not known how HIV establishes latency, but transcriptional 
interference is a necessary step (109). 
In addition to the long half-life of these cells, it has been suggested that HIV can persist within 
a host because of its ability to replicate in tissue compartments such as the central nervous 
system (CNS) or gut-associated lymphoid tissue (GALT) that antiviral drugs penetrate poorly. 
These so called sanctuary sites could also act as an HIV reservoir (110). Latency and low-level 
replication in sanctuary sites makes clearing HIV from an infected host a significant challenge 
(102).  
1.5.3. Genetic variability  
The replication cycle of HIV is both rapid and error prone. Mutations occur at this high rate due 
to the RT lacking proof-reading capacity, meaning that misplaced bases cannot be excised and 
replaced as occurs during human DNA replication (36). As many as 1010 virions are produced 
each day in the absence of treatment, and around 1 incorrectly placed base, or mutation, is 
introduced per genome per replication round (92). Additional genetic variability is introduced 
through recombination between different viruses infecting the same host. The rate of 
recombination is also very high, and with an estimated 3 recombination events occurring per 
genome per replication cycle the recombination rate is actually higher than the mutation rate 
(111).  
On a population level, genetic diversity can also result from the introduction of novel HIV 
strains into human populations. The three main genetic groups of HIV-1, M (most) , O (other) 
and N (new), are all believed to have arisen from independent transmission events (112). 
Within each of these groups there is further genetic diversity. The M genetic group contains 10 
different genetic subtypes, clades, identified by letters A-K. The genetic variation between 
clades ranges from 25-35%, compared to 15-20% within clades (112). Recently, prevalent 
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Figure 1.9. Global distribution of HIV subtypes 
recombinants of different subtypes called circulating recombinant forms (CRF’s) have been 
identified. These arise when an individual infected with more than one subtype consequently 
passes on a recombinant virus (111,112). The distribution of different subtypes across regions 
of the world can be seen in Figure 1.9.  
 
 
 
 
 
 
 
 
 
 
 
 
Source: (113)  
Significant genetic diversity also exist on an intra-host level where so called quasispecies, viral 
populations containing a mix of viral genomes, are often present (36). Mutant viruses present 
at low frequencies, often defined as between 1 and 15% , are often referred to as minority 
variants (114).  
The considerable genetic diversity displayed by HIV has great implications for drug design and 
vaccine development. The majority of drugs are developed for populations infected with 
subtype B, common in Western Europe and North America. In contrast, 50% of all HIV 
infections and 47% of all new infections occur with subtype C (112). Another important 
implication of the genetic variability is the rapid emergence of drug resistance in the presence 
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of sub-optimal drug pressure (111). This will be explored in greater detail in section 1.8 of this 
chapter (page 58).  
1.5.4. The Immune response to HIV infection  
If not treated, HIV infection ultimately leads to the depletion of CD4 expressing cells (36). It is 
believed that CD4 cells are killed through the cytopathic effects of HIV, but apoptosis, impaired 
lymphocyte regeneration and destruction of the infected cells by other branches of the 
immune system may also be implicated (115).  
Despite being the target for HIV infection, the human immune system also displays a range of 
protective responses during the course of infection. Antibodies to HIV generally develop within 
1-3 months following infection, and can mediate the killing of cells infected with HIV through a 
process known as Antibody Dependent Cellular Cytotoxicity (36). Cytotoxic T-cells (CTL’s), 
expressing the surface molecule CD8, can also limit and supress viral replication through direct 
cytotoxic effects and the production of cytokines and chemokines with antiviral effects (116). 
The production of Interferon (IFN)-γ early on during infection restricts HIV replication and 
activates other parts of the immune system, while neutrophils, natural killer cells and γδ T-cells 
all have the ability to kill HIV infected cells through different mechanisms (117). Certain cellular 
restriction factors, notably APOBEC3G, TRIM5a and tetherin, are also effective inhibitors of 
HIV(118–120). During transcription, APOBEC3G can deaminate bases in the negative sense HIV 
DNA genome strand, leading to an accumulation of A->G substitutions so high that it stops the 
genome strand from being transcribed (121). TRIM5-a interferes with the process of 
uncoating, which in turn inhibits reverse transcription (119). Tetherin prevents newly 
synthesized virions being released from the cell by physically linking the cell plasma membrane 
and the virion envelope together (120,121), thus preventing the virion from maturing. A subset 
of individuals also have genetic defences, or genetic resistance to HIV infection. This includes 
individuals homozygous for the delta32- CCr5 deletion, who lack functional CCr5 co-receptors 
and as a result are immune to infection by R5 tropic viruses (122).  
Unfortunately, HIV has evolved ways of evading the immune responses mounted against it, 
and host defences typically fail to control viral replication. As a consequence, the vast majority 
of HIV infections results in a decline in immune function (36). The stages of the infection will 
be outlined in greater detail in section 0 (page 45).  
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1.5.5. Measuring HIV: viral load and CD4 counts  
The amount of HIV circulating in the blood (viral load, VL) as well as the number of CD4 cells 
(CD4 cell count) is used to measure the effectiveness of antiretroviral treatment and the 
progression of HIV infection (36). Both the VL and CD4 count have been proven to be valuable 
prognostic markers (123–130).  
1.5.5.1. HIV viral load (VL) 
The VL is measured by quantifying the number of copies of HIV per millilitre of blood plasma 
(copies/mL). Techniques for measuring VL can be split into technologies that rely on nucleic 
acid testing, such as RT-PCR, and non-nucleic acid based testing (131). RT-PCR involves the 
amplification of a target RNA sequence followed by its quantification (see section 1.8.5.2) (36). 
Non-nucleic acid based technologies quantify correlates of VL rather than measuring nucleic 
acid directly. This can involve measuring RT activity or the level of circulating p24 protein, and 
then correlating this to derive an estimate of the VL level (131). There are also point-of-care 
based tests that can distinguish between VLs above and below different thresholds (132,133) .  
In high income settings, HIV RNA is normally quantified from blood plasma. However, it is also 
possible to use dried blood spots (DBS) to measure the VL (134). This is of particular use in low 
income settings, where clinical sites may need to send specimens to a reference laboratory in 
order to receive VL measurements. HIV RNA can generally be reliably quantified from DBS at 
high VLs, although accuracy is not as good at lower VLs, and can vary according to which 
platform is used (131,135).  
1.5.5.2. CD4 counts  
The CD4 cell count is measured as the number of CD4 cells per mm3 of blood, although it is 
standard practice to also measure the CD4 cell percentage, which is proportion of all 
lymphocytes expressing CD4 (136). Recently, using the CD4/CD8 ratio as a clinical marker has 
also grown more popular, as it may capture signs of immunoactivation and 
immunosenescence in a more comprehensive way compared to the absolute CD4 count 
(137,138).  
Although there are several different methods for measuring CD4 counts available, the gold 
standard is a technique referred to as flow cytometry (139). This involves a focused stream of 
cells being passed through an optic censor, with the degree of light scattering being used to 
estimate the CD4 proportion (140). This can consequently be used to estimate the absolute 
CD4 count using either a haematology analyser (dual platform) or by utilising a pre-determined 
blood volume, sometimes mixed with a known number of fluorescent micro-beads (single 
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platform) (139,140). CD4 counts can also be measured manually, by counting the number of 
cells using a light microscope. However, this technique is very labour-intensive, and 
measurements will be at least partially subjective (140).  
What technology is used will differ according to the resources available. Although the WHO 
recommends a point of care based test, it further states that country-level leadership should 
determine which technology is most appropriate for a given setting (141).  
1.5.5.3. Defining failure and success  
The goal of HIV treatment is to prevent disease and death by ensuring that CD4 counts and 
immune function are preserved. However, as clinical events have grown increasingly rare it is 
common practice to use surrogate laboratory markers to measure the success of HIV 
treatment (142). This has several benefits: the outcome is easy to quantify and may be more 
commonly achieved than a clinical end-point. There are also some drawbacks, as a change in a 
biomarker may not translate into a tangible clinical benefit (143). A meta-analysis evaluating 
the use of VL and CD4 count as surrogate end-points has shown that both have value as 
prognostic markers, but both have also shown discordant effects on clinical outcomes in 
different trials (144). Despite these considerations, achieving an undetectable VL, that is, 
having viral replication supressed to such a low level that no viral RNA can be measured, is 
commonly used as a definition of treatment success in both clinical trials and observational 
studies (142,145). What is considered undetectable will depend on the detection limit of the 
assay used to measure the VL. Many assays now have a detection limit as low as 50 or 20 
copies (cp)/ml, and therefore these cut-offs are often used to define an undetectable viVL 
(146) . A commonly used term to describe a lack of treatment efficacy is virological failure (VF). 
VF has been defined in a plethora of ways across studies, but it is commonly defined as either 
a rebound of the VL to detectable levels following suppression to undetectable levels, or a 
failure to suppress the VL to undetectable levels despite ongoing treatment. The threshold 
with which VF is defined varies according to the assay used.  
Treatment failure can be defined either using virological or immunological measures, but 
virological measures is the recommended approach (72). The WHO defines virological failure 
as a confirmed (two measures within a three month interval, with adherence support between 
measures ) VL of >1000 cp/ml after at least 6 months of using ART (72). In Europe, a lower 
threshold of VL>50 is often used to define virological failure (147).  
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1.5.5.4. Guidelines on monitoring  
Both virological and immunological monitoring is part of standard of care in high income 
settings, although  VL measurements are considered the gold standard for the detection of 
treatment failure (72). In high income settings, both VL and CD4 measurements are taken 
every 3-6 months or more often depending on patient need, although these recommendations 
are primarily based on expert opinions (146).  
For low income settings, the WHO recommends that VL measures are taken 6 months after 
starting ART and then every 12 months. CD4 counts should ideally be done every 6 months 
after the start of treatment. If VL measurements cannot be done, clinical or immunological 
monitoring should be done to detect treatment failure (72). VL monitoring is recommended 
above CD4 or clinical monitoring, as it can aid an earlier detection of treatment failure, thus 
enabling more timely switches to second-line regimens and preventing the accumulation of 
drug resistance (72,148). The ideal frequency of monitoring VL monitoring is not known, and is 
likely to vary between different settings (149). 
1.6. Natural History of HIV infection  
Although the course of the disease has been drastically changed following the discovery and 
introduction of cART, it is still important to understand the process by which HIV can lead to 
disability and eventually death. Due to the lack of an effective treatment in the years following 
the discovery of the HIV virus, the natural history of the disease is relatively well described. 
Without any intervention, the HIV disease process can be broadly split into three stages: the 
primary stage, the asymptomatic stage and the symptomatic stage or AIDS (Figure 1.10) (150). 
Each stage will be described in more detail below, and the impact of treatment will be 
considered in greater detail in section 1.7.8 (page 58).  
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Figure 1.10. The different stages of HIV infection in the absence of treatment 
 
 
 
 
 
 
 
 
Source: Adapted from (150)  
1.6.1. Primary stage 
After HIV enters the body, the virus starts replicating and the VL expands exponentially. At this 
stage there are no antibodies to the virus, but viral antigens such as p24 can be used to 
diagnose the infection (151). The rapid increase in the VL is mirrored by a decline in the CD4 
counts (150,152). After 4-6 weeks antibodies towards the virus start to develop 
(seroconversion) (36), and during this period the individual may experience non-specific 
symptoms similar to those of mononucleosis or influenza, such as a fever, rash, headache, 
muscle aches or nausea (153–155). It has been estimated that between 25-65% of individuals 
experience symptoms of primary infection (152). After the development of antibodies, CD4 
counts recover and the VL stabilises at a level called the viral set-point (152). 
1.6.2. Asymptomatic stage  
The temporary recovery of the CD4 cells marks the beginning of an asymptomatic, chronic 
phase of the disease process that is characterised by stable but high viral turnover (156). It is 
often referred to as a period of ‘clinical latency’, to clarify that the lack of symptomatic disease 
is not indicative of virological latency (156,157). In fact, viral replication is generally high during 
this time, but constrained by the actions of the immune system (116). For a number of reasons 
these immune controls eventually fail, and the early increase in CD4 count is followed by a 
decline (158). CD4 counts have been estimated to decline with 20-78 cells per microliter per 
year, although this is influenced by a range of factors, including the VL burden, age and VL 
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setpoint (150,158–160). Individuals normally remain symptom free as long as CD4 counts are 
above 350 cells per microliter (152). 
1.6.3. Symptomatic stage/AIDS 
After around 10 years, CD4 counts tend to have declined to a level that makes individuals 
susceptible to opportunistic infections (Table 1.1), but the time this takes is variable (150). In 
fact, between 2 and 5% of individuals can maintain CD4 counts within healthy limits for up to 
20-25 years. These individuals are called long-term non-progressors (LTNP) (161). A subset of 
LTNP, so called elite controllers, are in addition able to supress viral replication to levels below 
detection (<50 cp/ml) without treatment (162).  
A diagnosis of AIDS is made based on both laboratory and clinical evidence. Following a 
laboratory confirmed HIV diagnosis, a decline of CD4 counts to less than 200 or the presence 
of one of the opportunistic infections listed in Table 1.1 is commonly used to categorise an 
individual as suffering from AIDS (163). The survival time following an AIDS diagnosis differs 
depending on the presenting condition and has changed considerably over time (164,165). The 
median survival time in the early years of the epidemic (1984-1985) following any AIDS 
diagnosis has been estimated as 11.6 months, varying between 3.3 and 19.1 months 
depending on the opportunistic infection (165). 
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 Source: Adapted from (163) 
1.6.4. Factors determining disease progression  
The rate of disease progression in HIV infection can vary considerably depending on a range of 
genetic, biological, psychosocial and structural factors. The proximal determinant of disease 
progression is the level of viral replication as quantified by the VL. This in turn is influenced by 
viral properties, but also the host immune response (36,166). Individuals infected with HIV-1 
Table 1.1. AIDS defining conditions in laboratory confirmed HIV cases 
Table 1. AIDS defining conditions in laboratory confirmed HIV cases  
Condition Notes 
Bacterial infections, multiple or recurrent Only among children <13 years 
Candidiasis of bronchi, trachea, or lungs  
Candidiasis of esophagus Condition may be diagnosed 
presumptively 
Cervical cancer, invasive Only among adults and adolescents 
aged >13 years 
Coccidioidomycosis, disseminated or extrapulmonary  
Cryptococcosis, extrapulmonary  
Cryptosporidiosis, chronic intestinal  >1 month's duration 
Cytomegalovirus disease (other than liver, spleen, or nodes) Onset at age >1 month 
Cytomegalovirus retinitis (with loss of vision) Condition may be diagnosed 
presumptively 
Encephalopathy attributed to HIV  
Herpes simplex: chronic ulcers) or bronchitis, pneumonitis, or 
esophagitis  
>1 month's duration, onset at age >1 
month 
Histoplasmosis, disseminated or extrapulmonary  
Isosporiasis, chronic intestinal  >1 month's duration 
Kaposi sarcoma Condition may be diagnosed 
presumptively 
Lymphoid interstitial pneumonia or pulmonary lymphoid 
hyperplasia complex 
Only among Children <13 years,  
condition may be diagnosed 
presumptively 
Lymphoma, Burkitt (or equivalent term)  
Lymphoma, immunoblastic (or equivalent term)  
Lymphoma, primary, of brain  
Mycobacterium avium complex or Mycobacterium kansasii, 
disseminated or extrapulmonary 
Condition may be diagnosed 
presumptively, only among adults 
and adolescents aged >13 years 
Mycobacterium tuberculosis of any site, pulmonary, 
disseminated, or extrapulmonary 
 
Condition may be diagnosed 
presumptively 
Mycobacterium, other species or unidentified species, 
disseminated or extrapulmonary 
Condition may be diagnosed 
presumptively 
Pneumocystis jirovecii (previously known as "Pneumocystis 
carinii") pneumonia 
Condition may be diagnosed 
presumptively 
Pneumonia, recurrent Condition may be diagnosed 
presumptively, only among adults 
and adolescents aged >13 years 
Progressive multifocal leukoencephalopathy  
Salmonella septicemia, recurrent  
Toxoplasmosis of brain Onset at age >1 month, condition 
may be diagnosed presumptively 
Wasting syndrome attributed to HIV  
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have a faster disease progression compared to individuals infected with HIV-2 (167). There is 
also some evidence suggesting that the rate of disease progression varies according to viral 
subtype, and individuals infected with a non-A non-B subtype may progress faster to AIDS than 
those infected with subtype A (168,169). Gender (170), older age (171) and ethnicity (172) can 
also affect the rate of disease progression. Since the development of cART, the main 
determinant of disease progression is whether a person is on antiretroviral treatment or not 
(173).  
1.7. Antiviral Drugs  
The first drug against HIV was approved by the U.S Food and Drug Administration (FDA) in 
1987 (174), and since then 27 drugs have been approved by the European Medicines Agency 
(EMA) for the treatment of HIV in Europe, with more currently being developed (174,175). HIV 
drugs are divided into different classes based on what function of the virus they target. The 
three main drug classes are nucleoside reverse transcriptase inhibitors (NRTI) , non-nucleoside 
reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) (36). However, drugs 
targeting the processes of viral attachment, entry, DNA integration, maturation and envelope 
fusion have also been developed (175–179). A comprehensive list of HIV drugs according to 
drug class and date of license can be found in Table 1.2 below. Drugs from different classes 
and even within a specific drug class can have different levels of efficacy and different genetic 
barriers. The genetic barrier refers to the number of mutations HIV needs to develop before 
acquiring resistance to a particular drug (180). Efficacy is often estimated as the proportion of 
people in a clinical trial that achieve an undetectable VL, although a composite end-point such 
as the proportion of people who do not experience VF or switch their treatment can also be 
used (145).  
Current first line HIV therapy consists of a combination of three HIV drugs, referred to as 
combination antiretroviral therapy (cART) or highly active antiretroviral therapy (HAART). 
These combinations consists of two NRTI drugs (referred to as the backbone) and either an 
NNRTI, PI or more recently an Integrase Inhibitor (II) (146,147). All HIV drugs can cause a 
number of side-effects, ranging from mild (such as headache and rash) to severe or even life-
threatening (such as lactic acidosis, kidney failure andincreased suicidality) (181). As side-
effects depend on the mode of action of the drug they tend to be shared across a particular 
drug class, but some individual drugs may have particularly beneficial or risky side-effect 
profiles. The drug classes, together with their mode of action and current use are outlined in 
more detailed below.
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Table 1.2. Drugs licensed for the treatment of HIV infection 
 
Generic Name  Brand Name (Company) Date of License 
(EMA) 
Pivotal Studies  Current Use (EACS guidelines) 
NRTI     
Zidovudine (AZT) Retrovir (ViiV) FDA approval1: 
1987 
(182), (183) Considered in specific circumstances (such as pregnancy 
or TB-coinfection) 
Didanosine (ddI) Videx (Bristol Meyers Squibb) FDA approval1: 
1991 
(184), (185) No longer recommended for use.  
Zalcitabine (ddC) Hivid (Roche) FDA approval1: 
1992 
(186), (187), 
(188) 
No longer recommended for use.  
Stavudine (d4T) Zerit (Bristol Meyers Squibb) 1996 (189) No longer recommended for use.  
Lamivudine (3TC) Epivir (ViiV) 1996 (190), (191) 1st line NRTI backbone (with Abacavir)5 
Abacavir (ABC) Ziagen (ViiV) 1999 (192), (193) 1st line NRTI backbone (with Lamivudine)4 
Tenofovir (TDF) Viread (Gilead) 2002 (194) 1st line NRTI backbone (with Emtricitabine)6 
Emtricitabine (FTC) Emtriva (Gilead) 2003 (195), (196) 1st line NRTI backbone (with Tenofovir) 
NNRTI     
Nevirapine (NVP) Viramune (Boehringer 
Ingelheim Limited) 
1998 (197), (198) 2nd/ 3rd line agent 
Efavirenz (EFV) Sustiva (Bristol Meyers 
Squibb) 
1999 (199) 1st line 3rd agent7  
Etravirine (ETV) Intelence (Janssen-Cilag) 2008 (200), (201) 2nd/ 3rd line agent 
Rilpivirine (RPV) Edurant (Janssen-Cilag) 2011 (202), (203) 1st line 3rd agent8  
Delaviridine   Not approved in 
Europe 
 No longer recommended for use 
PI     
Indinavir (IDV) Crixivan (Merck Sharp & 
Dohme) 
1996 (204), (205) No longer recommended for use 
Ritonavir (RTV) Norvir (AbbVie) 1996 (206) Used with other PI’s as a booster 
Saquinavir (SQV) Invirase (Roche) 1996 (207), (208) Option in certain circumstances, for example 
serodiscordant couples who wish to conceive 
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1.Brought to European market before EMA was founded.  
2.As coformulation with ritonavir. 
3.Only licensed for treatment experienced individuals 
4.Contraindicated if HLA B*5701 positive, should be used with caution if high predicted CV risk 
5.Should not be used if HBsAg positive 
6. Avoid TDF if osteoporosis, renal monitoring required 
7. Not to be given if history of suicide attempts or mental illness, not active against HIV-1 or HIV-1 group O 
8. If VL <100,000 cp/ml and CD4 counts > 200 cells/mm3 
9. Only if CCr5 tropic virus 
 
Source: compiled and adapted from (234), (235), (174),(146) and (147)
Nelfinavir (NFV) Viracept (Roche) 1998 (209) License not renewed for European market  
Amprenavir (AMP) Agenerase (GSK) 2000 (210) License not renewed for European market  
Lopinavir (LPV)2 Kaletra (AbbVie) 2001 (211) 1st line 3rd agent 
Fos(-amprenavir) 
(fAMP) 
Telzir (ViiV) 2004 (212), (213), 
(214) 
2nd/3rd line 3rd agent 
Atazanavir (ATA) Reyataz (BMS) 2004 (215), (216), 
(217) 
1st line 3rd agent 
Tipranavir (TPV) Aptivus (Boehringer Ingelheim 
Limited) 
2005 (218), (219) 2nd/3rd line 3rd agent 
Darunavir (DRV)  Prezista (Janssen-Cilag) 2007 (220), (221), 
(222), (223) 
1st line 3rd agent 
Entry/Fusion 
Inhibitors 
    
T-20/Enfuvirtide 
(T20) 
Fuzeon (Roche) 2003 (224), (225), 
(178) 
2nd/3rd line 3rd agent 
Maraviroc (MVC)3 Celsentri (ViiV)  2007 (226), (227) 2nd/3rd line 3rd agent9 
Integrase inhibitors     
Raltegravir (RGV) Isentress (Merck Sharpe and 
Dohme Limited) 
2007 (228), (229), 
(177) 
1st line 3rd agent 
Elvitegravir (EGV) Vitekta (Gilead) 2013 (230) 1st line 3rd agent 
Dolutegravir (DGV) Tivicay (ViiV) 2014 (231), (232), 
(233) 
1st line 3rd agent 
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1.7.1. NRTI 
NRTIs are structural analogues of the cellular nucleosides/nucleotides used by the HIV RT to 
construct viral DNA (236). There are currently (2012) 8 licensed NRTIs, all with a similar 
mechanism of action (237). After absorption, the drug is phosphorylated by cellular kinases in 
order to convert it into its active form. The resulting substrate is consequently incorporated 
into the growing DNA chain by the HIV RT, where it terminates chain elongation and thus 
inhibits viral replication due to the lack of an hydroxyl group required for further bases to be 
attached (237,238). Zidovudine, or AZT, was the first compound to be licensed for the 
treatment of HIV infection following trials showing that it could reduce short-term mortality 
among individuals with AIDS (182). Despite this initial success, zidovudine is rarely used today 
because of its side-effects (146,183) , although it may occasionally be prescribed for individual 
patients with reduced number of drug options or pregnant women (147). Several alternative 
NRTIs were developed shortly after zidovudine, but many are no longer recommended for use 
because of their associated toxicities (146). Current recommendations in high income settings 
list tenofovir and emtricitabine as the most suitable NRTI backbone in first line HIV treatment, 
with abacavir and lamivudine as alternatives (72,146,147).  
Many of the side-effects of NRTIs have been linked to mitochondrial dysfunction induced by 
the drugs. Such side effects include potentially fatal liver damage, myopathy, cardiotoxicity 
and peripheral neuropathy and lipodystrophy; a syndrome of localised fat redistribution where 
wasting occurs on the face, legs, arms and buttocks and fat accumulation occurs around the 
abdomen, breasts and neck (147,239,240). Evidence from the Data Collection on Adverse 
Events of Anti-HIV Drugs (D:A:D) collaboration has suggested that abacavir is associated with 
an increased risk of myocardial infarction (MI) (241), and tenofovir has been associated with 
an increased risk of both acute and chronic nephrotoxicity (242). A systematic review of 
prospective studies has confirmed the association between tenofovir and kidney dysfunction, 
although the magnitude of the effect when pooled across studies is modest from a clinical 
perspective, and may not warrant changes in first line therapy in settings where kidney 
monitoring is feasible (243). The association between abacavir and MI has not been 
reproduced in a large FDA meta-analysis of clinical trials (244).  
1.7.2. NNRTI 
NNRTIs are group of diverse molecules that induce and bind to a hydrophobic pocket near the 
active site in the RT (237,245). Binding of the NNRTI induces a conformational change in the RT 
active site, which disrupts its normal function and inhibits viral replication (236). The first 
compounds discovered that could inhibit the RT in this way were discovered through two 
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separate processes: as a result of chance (HEPT derivatives, (246)) and following a large 
programme of rational drug screening (TIBO derivatives, (247)). This allowed for the rational 
design and discovery of several other compounds that shared a similar mode of action. 
However, despite over 50 molecules discovered that can be classed as NNRTIs (248), only four 
(efavirenz, etravirine, rilpivirine and nevirapine) have made it to the European market 
(234,237,249). All of these are effective only against HIV-1, as HIV-2 has structural differences 
that renders it intrinsically resistant to NNRTIs (250). 
The current WHO guidelines recommend that efavirenz is used as the third agent in first line 
HIV therapy (72), even though concerns are starting to be raised regarding the potential harm 
of CNS side-effects that have been linked to the drug (251). Next-generation NNRTIs, such as 
rilpivirine, have a slightly better side-effect profile and a higher genetic barrier against 
resistance (252), but also slightly more complex dietary requirements (146). All NNRTIs can 
cause a number of non-specific side-effects, the most common one being a fairly mild and self-
limiting rash (253).  
1.7.3. PI 
PIs differ from NRTI and NNRTIs in that their main target is the viral protease rather than the 
RT (237).They were discovered through rational drug design in 1990, and there are currently 
10 different licensed PIs (indinavir, ritonavir, nelpinavir, fos-amprenavir, atazanavir, tripanavir, 
lopinavir, saquinavir, lopinavir, darunavir) (234,254). PIs contain a motif that mimics the 
proteolytic area of the viral protein that the protease is normally required to cleave. However, 
as the drug itself cannot be cleaved it instead binds to and inhibits the protease, thereby 
preventing newly produced virus from maturing (236,255). Recently, it has been suggested 
that in addition to preventing maturation, PIs also affect viral entry, reverse transcription and 
post-transcription events, although the mechanisms behind these activities are not yet fully 
elucidated (256). The first licensed PI inhibitor, indinavir, was brought to market in 1996, and it 
was quickly followed by the development of ritonavir (234). Both these drugs are no longer 
used in clinical practice because of limited potency as well as toxicity issues, however, ritonavir 
instead used at low doses to boost the bioavailability of co-administered PIs (257,258), as it is a 
potent inhibitor of the cP450 metabolic pathway (259). Current guidelines recommend that a 
PI is used as a third agent in the case of VF, although depending on patient and clinician 
preference it could also be used as part of first line therapy (146).  
Mild side-effects are common among patients receiving PIs and include non-specific symptoms 
such as nausea and diarrhoea (234). More severe side-effects include hyperglycaemia and 
54 
 
lipodystrophy, which has been reported as more common for PIs compared to NRTIs (240). 
Recently developed drugs, such as Darunavir, have been associated with less severe side 
effects (260).  
1.7.4. Entry inhibitors/CCr5 antagonists 
Two currently approved drugs, enfuvirtide and maraviroc, interfere with the ability of HIV to 
enter into new cells (237). Enfuvirtide is a peptide that prevents the fusion of the viral and cell 
membrane by interacting with a domain in the gp41 protein (261). Maraviroc is a small 
molecule that binds to the CCr5 co-receptor, thereby preventing its interactions with the viral 
gp120 protein (96). Because it binds to the CCr5 co-receptor, maraviroc is only effective in 
individuals with an R5 tropic virus (176).  
Enfuvirtide is not commonly used, as its chemical structure means it is not orally bioavailable. 
Instead, it needs to administered through subcutaneous injection twice a day (236). The need 
for an injection is associated with side-effects, including localised injection-site reactions (262). 
Although enfuvirtide can still be an option for patients with few remaining drug options, its 
side effects, low efficacy and low genetic barrier limits its clinical usefulness (262,263).  
1.7.5. Integrase inhibitors 
The final class of drugs currently licensed for the treatment of HIV infection are integrase 
strand transfer inhibitors (INSTIs), or integrase inhibitors (II), which target the viral integrase 
(236). Their mode of action involves inhibiting the process of strand transfer, through which 
viral DNA becomes attached to cellular DNA (264). There are currently three licensed II’s that 
all seem to be well-tolerated and potent: raltegravir, elvitegravir and dolutegravir (236). 
Current guidelines recommend integrase inhibitors as one possible option as a third agent for 
starting antiretroviral therapy, and dolutegravir in particular has been shown to be effective 
when used as salvage therapy, even among patients who previously failed raltegravir 
(146,265).  
The side effect profile of INSTIs are favourable, likely due at least in part to the lack of a cellular 
equivalent of the integrase (266). However, they can still cause nausea, headache and 
diarrhoea. The use of dolutegravir has additionally been associated with sleep disturbances 
(266).  
1.7.6. Novel drug developments  
New treatments for HIV are continuously being developed. Recently, the results from a phase 
IIb trial of a new attachment inhibitor, BMS-663068 or fostemavir, were published (179). 
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Fostemavir interferes with the ability of HIV-1 gp120 to bind to the CD4 receptor, and it has 
been shown to have comparable efficacy to boosted atazanavir with a similar side effect 
profile (179). The drug has recently entered into phase III trials in treatment experienced 
individuals (267). A number of maturation inhibitors that target the gag polyprotein, thereby 
preventing the cleavage event that is necessary for the production of mature virions, have 
recently been developed (268). BMS-955176 showed similar efficacy to boosted atazanavir, 
and is currently undergoing phase 2b dose-finding studies (269). Although monoclonal 
antibodies were found to be ineffective for the treatment of HIV in early clinical trials, 
antibodies produced using more modern single-cell based cloning methods appear to have 
good potential for supressing viral replication in animal models as well as in humans (270). The 
3BNC117 antibody is currently being evaluated for safety and antiretroviral activity in Phase I 
clinical trials (271).  
Developments of drugs in the existing drug classes are also occurring. Doravirine, a next 
generation NNRTI, has a different resistance profile compared to older NNRTIs, and has 
recently completed phase IIb studies with promising results (272). New formulations of older 
drugs are also being brought to the market. A long-acting formulation of rilpivirine that can be 
given by monthly injections rather than orally, of particular use for patients with adherence 
problems, has recently been developed (273). In order to address concerns over kidney 
toxicity, a new formulation of tenofovir as tenofovir alafenamide, TAF, has recently been 
licensed. TAF has been shown to be non-inferior in virological efficacy compare to tenofovir 
(274), but has a better safety profile for renal and bone health (275). There are also on-going 
investigations looking at optimal dosing strategies for already approved drugs. The ENCORE 
study compared 400 mg efavirenz to the standard 600 mg dose, and found that the reduced 
dose was non-inferior to the 600 mg dose, but with a better side effect profile (276).  
There has also been a recent focus on developing treatment strategies and drugs that could 
potentially cure HIV. One such group of treatments are the histone deacetylase (HDAC) 
inhibitors (277). HDAC inhibitors operate by preventing the de-acetylation of histones 
associated with viral DNA. This can cause latent HIV to reactivate (278). Combined with 
effective cART, the aim of HDAC containing therapy is to eradicate the viral reservoirs through 
a ‘shock and kill’ strategy (279). Although in-vitro studies of this approach have been 
promising, the effectiveness of HDACs in the clinic is still uncertain (280) .  
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1.7.7. Treatment strategies 
In the early 90s HIV treatment consisted of only one drug (monotherapy) due to the limited 
number of drugs available. However, it was quickly realised that patients receiving zidovudine 
alone would develop resistance to the drug (281). A formal evaluation of dual-therapy for HIV 
infection occurred in 1995 in the ACTG 175 study (282). In this trial, comparing zidovudine 
alone, zidovudine + didanosine, zidovudine + zalcitabine and didanosine alone, Hammer et al 
found that dual therapy was more effective than zidovudine alone and equally effective as 
didanosine alone among patients with no previous ART exposure (282). This was confirmed a 
year later in the DELTA trial (283). However, despite the important effects these medications 
had on short-term outcomes or surrogate markers, it quickly transpired that dual therapy was 
not effective in patients with advanced HIV disease (284), patients who had received prior 
zidovudine monotherapy (285) or for the prevention of long-term mortality (286). The 
development of the first PIs opened up the for combination therapy based on two different 
classes of drugs, and the evaluation of triple therapy for treating HIV followed shortly after this 
in 1996 (207). In a trial published in the New England Journal of Medicine, Collier et al 
compared a combination regimen of saquinavir, zidovudine and zalcitabine to dual regimens of 
zidovudine and either saquinavir and zalcitabine for patients who had previously received 
zidovudine for at least 4 months. The triple-combination arm was more effective in reducing 
viral replication and increasing CD4 counts than were either of the dual therapy arms (207). 
This was later confirmed for ART-experienced individuals in the MRK 035 study (287) and for 
treatment-naïve individuals in the INCAS study (198). Regimens consisting of four different 
drugs have also been compared to triple-therapies in large trials, but not found to be superior 
to triple therapy (288), although a recent small proof-of-concept study found that initial 
therapy with four drugs may be slightly more beneficial for individuals with a baseline VL 
>100,000 cp/ml (289).  
The large number of drugs licensed to treat HIV has raised questions about which combination 
of drugs is the most effective, and a plethora of trials attempting to answer this question have 
been undertaken (290). Potential first line treatment combinations according to different 
guidelines can be seen in Table 1.3 (291). There are a number of recent studies that have 
compared the efficacy of different first line combinations. The ACTG 5257 study found that a 
regimen of two NRTIs + raltegravir was superior to a regimen of two NRTIs and a boosted PI 
(292). The SINGLE study found that abacavir/lamivudine + dolutegravir was superior to a 
tenofovir/emtricitabine/efavirenz regimen (293), and the FLAMINGO trial found that a 
combination of 2 NRTI + dolutegravir outperformed a two NRTI + boosted PI regimen (294). 
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The current treatment recommendations are based on a combination of the efficacy of the 
regimen, cost and availability (72,146), and the ideal regimen is likely to also differ according to 
patient preference (295).  
Treatment guidelines are continuously evolving, and recent studies have cast some doubt on 
whether triple combination therapy is still necessary now that more potent drugs have been 
developed. The GARDEL trial evaluated dual therapy of a boosted protease inhibitor (lopinavir) 
and one NRTI versus standard cART of lopinavir and two NRTIs. At 48 weeks, patients on dual 
therapy did not have significantly worse outcomes than patients on triple therapy (296). These 
findings have been confirmed for lopinavir in the OLE trial (297) and for atazanavir in the SALT 
trial (298). Monotherapy with protease inhibitors has been shown to be non-inferior for HIV 
maintenance therapy (299), and is likely to be more cost-effective than triple therapy, even if it 
were to lead to a higher rate of virological failure (300). Preliminary studies have also reported 
surprisingly good outcomes for patients on dolutegravir monotherapy (301) or dual therapy of 
dolutegravir and lamivudine (302).  
Table 1.3. Recommended first line cART regimen according to different guidelines 
 NRTI NNRTI PI II 
US DHHS 2015 (303) TDF/FTC 
ABC/3TC 
-- DRV/r DTG, EVG, RAL 
IAS-USA 2014 (304) TDF/FTC 
ABC/3TC 
EFV/RPV ATV/r 
DRV/r 
DTG, EVG, RAL 
EACS 2014 (147) TDF/FTC 
ABC/3TC 
EFV/RPV ATV/r 
DRV/r 
DTG, EVG, RAL 
WHO 2014 (72) TDF+3TC or FTC EFV - - 
BHIVA 2015 (146) TDF/FTC 
 
RPV ATV/r 
DRV/r 
EVG 
RAL 
Source: Adapted from (291) 
Traditionally, when to start ART has been determined by CD4 counts. The first HIV treatment 
guidelines, presented at the International AIDS Society (IAS) conference in Vancouver 1996, 
stated that individuals with a CD4 count below 200, or who presented with a CD4 count 
between 200-500 and with symptoms of AIDS should initiate zidovudine monotherapy; all 
other individuals were recommended no therapy (305). This has evolved considerably. In 2015, 
results from the START trial were published, which showed that starting treatment 
immediately irrespective of CD4 count, rather than waiting until it decreased to below 350, as 
per guidelines at the time, was associated with a lower risk of clinical events (306). This was 
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also confirmed in the TEMPRANO study of early antiretroviral therapy and isoniazid 
preventative therapy in Cote d’Ivore (307). Most guidelines, including the WHO, have now 
been updated and recommends that individuals diagnosed with HIV should start treatment 
immediately (72,146,147).  
1.7.8. HIV in the post-cART era 
With effective treatment, HIV positive individuals in high income settings now have a life-
expectancy that is approaching that of the general population (308,309). However, even 
though effective cART has transformed the way that HIV is managed, the infection and its 
treatment can still cause a number of unwanted complications, including an increase in the co-
morbidities associated with ageing (310). Studies suggest that HIV infected individuals are at 
an increased risk of non-AIDS related events, including heart disease, liver dysfunction, kidney 
disease, osteoporosis, neurocognitive impairment and non-AIDS related cancers compared to 
the general population: a risk only partly explained by the presence of traditional behavioural 
risk factors in some studies (311). This has given rise to a hypothesis of accelerated 
immunsenescence. Immunosenescence is the process by which the immune system declines in 
function as a result of natural ageing (310). In HIV, the presence of chronic low-level 
inflammation and immune activation may cause this process to accelerate (312). Current 
research is generally supportive of this hypothesis, and biomarkers indicative of inflammation 
has been linked to an increased risk of cardiovascular disease (313), cancer (314) and 
neurocognitive impairment (315). However, some studies show contrasting results. A Danish 
cohort found that the excess risk of morbidity and mortality seen in HIV positive individuals 
were mainly due to risk factors that we present before the start of cART, and that survival in 
patients on cART without the presence of traditional risk factors was almost identical to that in 
the general population (316). In addition, there is no trial showing a clear benefit of reducing 
the excess inflammation caused by HIV (317). As the HIV positive population continues to age, 
the interest in the areas of chronic immune activation, inflammation and co-morbidities in the 
management of HIV is likely to continue to grow (318).  
1.8. Drug Resistance  
1.8.1. Principles of resistance  
Despite the success of combination therapy in prolonging the survival of HIV-infected 
individuals, resistance to one or more of the drugs in a regimen can develop (36,319). Drug 
resistance is defined as changes to a microorganism that cause a reduction in drug 
susceptibility (320). For HIV, this is primarily caused through mutations in the viral genome 
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that emerge as a consequence of the very high replication rate of the reverse transcriptase, its 
poor proof-reading capacity and the high rate of genetic recombination (described in detail in 
section 1.5.3, page 40). Due to natural selection (321), resistant viruses will be selected for 
survival in the presence of selective drug pressure over strains that do not carry resistance 
mutations. The resistant strains will eventually expand to dominate the existing viral 
population (36,322). An illustration of this process can be seen in Figure 1.11.  
Figure 1.11. Selection of drug resistance 
 
 
 
 
 
 
 
When resistance develops during treatment as a consequence of selective drug pressure, it is 
referred to as secondary or acquired resistance. This is in contrast to primary or transmitted 
resistance, which is present before the start of antiretroviral treatment. Escape mutations 
refer to mutations in the HIV genome that allow the virus to evade the response of the host’s 
immune system (323). Such mutations often can develop before the start of treatment and 
include mutations that change the HIV epitope; the pattern of surface antigens that make the 
virus recognisable to host’s immune system (323).  
Most mutations that confer resistance are caused by single base (nucleotide) substitutions, but 
duplications and insertions can also lead to resistance (322). As there are many combinations of 
nucleotides that can code for the same amino-acid, a given base change does not necessarily 
change the amino-acid. For example, the amino acid arginine (Arg, A) is encoded through both 
the codon “AGU” and “AGC”. A change in the 3rd position of such a triplet from ‘U’ to ‘C’ would 
not result in a change in the amino-acids. Such nucleotide changes are referred to as silent 
mutations. 
60 
 
In HIV drug resistance, all mutations are described according to the same standardised system, 
which involves numbering the amino-acid residues in the different HIV genes. The residue 
number will be preceded by a letter indicating the wild-type (WT)sequence amino-acid, and 
followed by a letter indicating the amino-acid identified in the sequence under study (Figure 
1.12). If the amino acid in the studied sequence is different from that in a reference sequence, 
a mutation is considered to be present. It is common practice to use the sequence of a subtype 
B laboratory strain (HXB2 or NL43) or a subtype B consensus sequence summarising the most 
common amino-acid residues at different positions as the reference strain, as there is no clearly 
defined HIV WT sequence due to the high genetic variability of the virus (324).  
Figure 1.12. Illustration of genotypic data for HIV 
 
 
 
In the absence of selective pressure, viral strains carrying resistance mutations often disappear 
from the majority circulating virus. This occurs at different speeds depending on a range of 
factors, including the fitness cost of particular mutations (325,326) and the number of back-
mutations required for resistance to reverse (327). Nonetheless, strains carrying particular 
resistance mutations can persist as archived genomes in latently infected cells, and can rapidly 
emerge once a drug regimen is re-initiated (328). 
1.8.1. Viral fitness and replicative capacity  
The amount of time it takes for resistance to develop and be selected for will depend both on 
the prevalence of a mutation, the amount of drugs present, and the selective advantage 
conferred by the mutation (322). Selective advantage is defined as the traits of an organism 
that allows it to stay alive and reproduce to a greater extent than other organisms in a given 
environment (321). This is a concept closely linked to the fitness of the virus, which refers to 
the ability of a virus to replicate and spread in a given environment. When a mutation appears, 
this is often associated with a reduction in the fitness. Some mutations, called compensatory 
mutations, can however enhance viral survival by restoring viral fitness while not influencing 
the susceptibility to a particular drug (329). Viral fitness is often approximated by measuring 
the viral replicative capacity (RC) (330). The RC refers to the average number of cells that are 
infected by one typical virus-infected cell. In practice, this is measured through comparing how 
well a particular viral isolate replicates in comparison to a WT reference strain. A variety of 
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assays that quantify viral replication in different ways can be used for this purpose, such as 
specific infectivity assays, single-cycle replication capacity assays, parallel culture assays and 
competitive growth virus co-culture (331). The RC is reported as a proportion or a percentage, 
and it’s calculated using the level of replication of the reference strain as the denominator 
(332). This makes the RC of the reference strain equal to 1 (or 100%). Values for the RC less 
than 1 (or 100%) imply impaired RC and fitness of the mutant strain (332). The theoretical 
definition of RC implicitly includes the effect of the human immune system on the viral 
replication rates. However, in-vitro assays cannot take this restrictive effect of the immune 
system into account, and estimates of RC from assays should be interpreted with this in mind 
(330). Fitness can also be characterised using what is called a fitness landscape, which 
describes the fitness of the virus as a mathematical function of its amino acid sequence (Figure 
1.13) (333). The benefit of using a fitness landscape to quantify the impact of mutations on a 
genome is that it explicitly takes interactions between mutations into account. Interactions 
between mutations, where the presence of one mutation either enhances or supresses the 
effect of another mutation, are called epistatic interactions.  
Figure 1.13. Illustration of fitness landscape 
 
 
 
 
 
 
 
Source: (333) 
1.8.2. Mechanisms of drug resistance 
Resistance emerges in different ways depending on the drugs taken. The main mechanisms 
that can lead to resistance to each of the main drug classes are outlined briefly below. 
 
 
 
Figure not available due to copyright restrictions 
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1.8.2.1. NRTIs 
Resistance to NRTIs mainly develop by two different mechanisms. Firstly, the appearance of 
certain mutations can allow the RT to discriminate between NRTIs and the cellular nucleotides 
used to construct DNA, thereby avoiding the incorporation of the drug into the growing DNA 
strand (319). Mutations that cause resistance in this way include M184V/I, K65R, 70E/G, L74V, 
Y115F and the relatively rare Q151M complex (319,334,335). In many populations the most 
common of these mutations are M184V/I, which alone is enough to confer high-level 
resistance to lamivudine and emtricitabine (335,336)).  
Secondly, the NRTI can be removed from the DNA chain through ATP (adenosine 
triphosphate)-mediated phosphorolysis after incorporation. The thymidine analogue 
resistance mutations (TAMs) confers resistance through this mechanism (334,337). They are 
referred to as TAMs as they are primarily selected for by zidovudine and stavudine, which are 
both structural analogues of the cellular nucleotide thymidine (337). The TAMs tend to 
develop according to two characteristic patterns: TAM 1 (41L, 210W, 215Y) and TAM 2 (67N, 
70R and 219E/Q) (338,339). There is also evidence that mutations can arise as a result of 
APOBEC3G/F induced diversification (section 1.5.4, page 42). The inhibition of APOBEC3G/F 
activity by the viral protein vif is in some cases only partial, which can lead to levels of genetic 
diversity that are not lethal (340). Such diversity can actually result in the development of 
mutations that confer drug resistance, including resistance to lamivudine (341).  
1.8.2.2. NNRTI 
Resistance to NNRTIs develops relatively easily, and most of the mutations to these drugs 
affect the binding of the NNRTI to its target hydrophobic pocket in the RT (319). This can 
involve mutations causing either alterations to the size of the binding pocket or physical 
changes to the structure of the binding pocket that prevent drug access (334). A single 
mutation can be enough to confer resistance to several of NNRTIs (342). The L1001 mutation 
confers resistance to efavirenz, rilpivirine and nevirapine and the K103N mutation is commonly 
found among individuals failing efavirenz (50% of patients) and nevirapine (30% of patients) 
(343). Newer generation NNRTIs such as etravirine and rilpivirine have a higher genetic barrier 
than the older drugs, although resistance to these drugs can still develop. Mutations E138K 
and M184I have been associated with high-level resistance to both etravirine and rilpivirine 
(344).  
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1.8.2.3. PI 
Development of resistance to PIs is complex, and for ritonavir boosted PIs it requires the 
development of at least two mutations (one or more major and one or more compensatory) in 
the protease gene (319). It can also involve mutations in the gag polyprotein (345). Major 
mutations in the protease gene affect the binding of the protease to its polyprotein target 
(335). Compensatory PI mutations are often referred to as minor PI mutations, and are very 
common (346). They can improve viral fitness, but in the absence of major PI resistance 
mutations they have little effect on treatment outcomes (346). Compensatory mutations 
include mutations in the cleavage site of the gag polyprotein, which increases the ability of the 
protease to bind to this substrate, leading to more efficient production of viral progeny (345).  
Boosted PIs have a higher genetic barrier than NRTIs and NNRTIs, at least partly due to the fact 
that the development of resistance requires more than a single mutation to arise. This has led 
to the suggestion that VF on PIs primarily occurs in people who do not adhere to their 
treatment, rather than as a result of drug resistance (319). However, it could also be that the 
mutations associated with protease resistance have not yet been fully characterised or that 
resistance occurs in other regions of the HIV genome than the protease. Recently, mutations in 
the env gene that encodes the HIV envelope have been reported to be associated with 
resistance to PIs (256), but how common these mutations are found among patients failing PIs 
remain to be elucidated (347).  
1.8.2.4. Entry inhibitors 
Resistance to maraviroc, a CCr5 receptor antagonist, can occur through a shift in co-receptor 
usage by the virus or through changes in the viral envelope that allows for binding to the CCr5 
receptor despite the presence of the inhibitor (348,349). Changes in co-receptor usage mainly 
occurs if there is a mix of R5 and X4 tropic viruses present at the start of therapy (319), and 
existing data indicate that the changes in the viral envelope is a more common cause of 
maraviroc resistance (348). Resistance to the fusion inhibitor enfuviritide can develop through 
mutations in a domain of 10 amino acids (36-45) in the gp41 gene (335,349).  
1.8.2.5. Integrase inhibitors 
First generation integrase inhibitors raltegravir and elvitegravir have a relatively low genetic 
barrier compared to protease inhibitors, and a single point mutation (such as T66K, E92Q, 
G188R, F121T or N155H/S/T) can confer resistance to either of these drugs (342). However, 
the exact mechanisms by which resistance arises are still unclear (350). It has been suggested 
that mutations that have been associated with resistance affect the flexibility of the integrase 
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(350), and an increased rate of drug dissociation could also be implicated (351). Dolutegravir 
has a higher genetic barrier to resistance, and it has been shown to be effective at suppressing 
VL levels even among patients who have previously failed raltegravir (265). Although rare, 
resistance to dolutegravir has been observed among patients pre-exposed to integrase 
inhibitors (352), but not among patients starting the drug from naïve (353).  
1.8.3. Acquired drug resistance 
The prevalence of acquired resistance after VF varies, and estimates range from 76%-90% 
among viraemic individuals tested for resistance (354). Individuals more likely to acquire 
resistance include those who receive suboptimal regimens (180) and those who are poorly 
adherent (355). The prevalence and risk factors for acquired resistance will be investigated and 
discussed in more detail chapter 3.  
1.8.3.1. Clinical implications of acquired resistance 
The presence of drug resistance limits the number of available treatment options (356,357), 
and individuals with drug resistant viruses are typically forced to rely on either complex multi-
drug regimens, older more toxic treatments or newer, more expensive drugs in order to 
supress viral replication (180). Some individuals can develop extensive drug resistance to all 
three major drug classes (triple-class resistance; TCR) (358). Although TCR is rare nowadays, 
estimated at 3% of all treatment experienced patients, it is complex to the compose a regimen 
that fully controls viral replication for these cases (358,359). A further negative consequence is 
the potential for individuals who have acquired drug resistance to transmit viruses with 
mutations causing resistance, which in turn can compromise the use of standard first-line 
regimens (360). 
The effect of acquired drug resistance on markers of clinical progression in the presence of 
continued treatment remains partially undocumented, and depends both on the extent and 
type of resistance present. Some studies have shown that individuals with acquired drug 
resistance can preserve CD4 counts despite VF in the presence of continued treatment 
(357,361,362). Furthermore, a study by Sigaloff et al has indicated that individuals failing first 
line therapy with drug resistance are not more likely to experience consequent VF, even if the 
second-line regimen is predicted to have reduced effectiveness (363). It is possible that some 
drugs are still able to exert residual activity despite the presence of resistance (332), and the 
fitness cost of certain mutations could also limit the effect they have on clinical progression 
(364). However, several large cohorts have shown that the emergence of drug resistance 
during therapy is associated with increased mortality and morbidity (365,366), particularly 
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among individuals with triple-class resistance (367–369). The effect of acquired drug resistance 
on immunological prognostic markers will be investigated and further described in chapter 6.  
1.8.4. Transmitted drug resistance (TDR) 
Transmitted drug resistance is present in about 10% of new infections in Europe, and the 
proportion of new infections with TDR in Europe is stable (370) and possibly decreasing in the 
some countries (such as the UK) (371). Risk factors for being infected with a resistant viral 
strain include Caucasian race and potentially viral subtype, although this is likely to be at least 
in part explained by the higher availability of cART in certain geographical areas (372).  
1.8.4.1. Clinical implications of TDR 
TDR has been shown to increase the risk of VF unless genotypic testing is conducted to 
construct a fully suppressive regimen (373,374). The presence of TDR has also been shown to 
increase the rate of CD4 decline before the start of treatment in the first year of following 
infection (375), and is predicted to have a significant effect on mortality outcomes on a 
population level (376). The effect of TDR on clinical progression before the start of treatment 
will be investigated and described in chapter 7.  
As mentioned in section 1.8.1, viruses with resistant mutations tend to be less fit than drug-
susceptible viruses, and therefore transmission of resistance occurs less often than what 
would be expected given the potential pool of transmitters (377). The lower fitness of drug 
resistant variants also means that viruses carrying resistance mutations may gradually be 
outcompeted by non-resistant variants in the absence of treatment (360), although some 
studies have indicated that TDR mutants can persist for longer than previously thought despite 
the lack of drug pressure (378). This is believed to occur when the infection is established by a 
relatively homogenous population of resistant viruses, which may require multiple reversions 
in order for a drug-susceptible variant to arise (378) or because of the decreased fitness of 
different mutants (379,380). Irrespective of the persistence of TDR in the majority circulating 
virus, resistant variants may still remain archived within a host due to the establishment of 
latency, and the composition of the initial regimen for a patient with TDR should take this into 
account (360,381,382).  
1.8.5. Testing for drug resistance  
In order to guide the choice of antiretroviral drugs, resistance testing can be performed. This 
can be done in two different ways; as genotypic resistance testing or phenotypic resistance 
testing (319). Genotypic resistance testing involves determining the order of the nucleotides, 
sequencing, in the genome of the virus, whereas phenotypic testing involves measuring how 
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quickly the growth of a viral strain can be inhibited by different drug concentrations (383). 
These techniques will be outlined in more detail below.  
1.8.5.1. Phenotypic resistance testing 
Phenotypic resistance testing involves growing a recombinant viral strain in cell culture in the 
presence of different dilutions of the drug of interest (319). This allows the degree of viral 
replication to be measured and plotted for each drug concentration. The resulting sigmoid 
dose response curve can be used to find the concentration of drug that inhibits 50% of viral 
replication. This value is called the inhibitory coefficient (IC) 50, although the IC90, the 
concentration at which 90% of drug replication is inhibited is sometimes also reported (319). In 
order to ease the interpretation of these results, they are often reported as “fold-resistance”, 
in which the degree of viral inhibition is calculated by comparing the IC50 of the resistant virus 
with the IC50 from a wild-type or consensus virus (354). 
 
 
 
 
 
 
 
 
 
Source: (384)  
The main benefit of phenotypic testing is that complex resistance patterns can be interpreted 
relatively easily, as the cumulative effect of all mutations are reported. On the other hand the 
procedure is slower and more expensive compared to genotypic resistance testing (385). There 
are currently two main phenotypic resistance assays, Antivirogram (Virco) and PhenoSense 
(ViroLogic) (386), although neither is commonly used as part of current clinical care in Europe.  
Figure 1.14. Result of phenotypic resistance test (IC50) 
 
 
 
 
Figure not available due to copyright restrictions 
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1.8.5.2. Genotypic resistance testing  
Genotyping resistance testing involves sequencing specific genes or gene regions, normally the 
protease and RT (383). All sequencing methods require a certain amount of DNA in order to 
work effectively, and the HIV genome is therefore converted to DNA and amplified before it is 
sequenced (387). Amplification commonly occurs through polymerase chain reaction (PCR). 
Briefly, amplification occurs by placing the DNA sample together with key enzymes and buffers 
in a thermal cycler. Samples are then heated, which causes the DNA to denature, or separate. 
The temperature is then lowered slightly, which triggers the amplification of a target section of 
each DNA strand. This process is then repeated a large (>20) number of times. Once a 
sufficient number of copies of the target sections of the genome have been generated, 
sequencing can take place (387). Classic Sanger sequencing using the dideoxy chain-
termination method follows a principle similar to PCR, but instead of adding substrates (dNTP) 
to the samples that allow copies to be made, a mixture of cellular dNTPs and ddNTP, which 
terminates chain elongation due to the lack of an 3’ OH group, are added (388). This means 
that the polymerization process generates a number of partial copies of the original strand, all 
of a different length. These are consequently separated through gel-electrophoresis, and 
fluorescent labels are used to identify the terminating ddNTP in each position. Specialised 
software can consequently translate this into a DNA sequence that represents the average 
sequence present in the sample of the PCR products (387). The two main Sanger sequencing 
platforms in use are the Trugene HIV-1 assay (Visible Genetics Inc.) and the Viroseq assay 
(Abbott Laboratories) (383). These normally require that the VL in the original plasma sample 
contain at least 1000 copies of the virus per ml for optimal performance, although sequencing 
at VLs between 500-1000 can also be achieved (383). Ultrasensitive sequencing using different 
protocols can enable genotyping at VLs even lower than this (389). 
Recently, so called next-generation sequencing (NGS) technologies have been developed. 
Although the term covers a wide variety of technologies using different protocols, all of them 
parallelise the sequencing process, which means that many different DNA strands can be 
processed simultaneously (390). The end-result gives you a read-out of each sequence present 
in the sample, rather than an average as in Sanger sequencing (391), as is illustrated in Figure 
1.15 below. This means that the data generated can be used to study minority variants that 
could not be described using Sanger methods, and is the reason why it is sometimes referred 
to as ‘ultra-deep’ sequencing. Ultra-wide sequencing refers to the sequencing of the entire 
length of the viral genome (392). NGS is still come at a relatively high cost, and the large 
amount of data generated also make data analysis time-consuming, and requires 
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bioinformatics expertise (390). This currently limits the use of NGS technologies in clinical 
practice. There are also mutation-specific assays that only assess the presence of a given 
mutation in a specific position (392). These could be of particular use in low income settings 
(393).  
Irrespective of the method, the final result of a genotypic resistance test is a description of the 
RNA sequence or sequences, which is compared to a reference HIV strain to generate a list of 
mutations (324). Mutations considered indicative of drug resistance will generally have been 
identified through in vitro passage experiments, susceptibility testing of laboratory or clinical 
isolates, sequencing of individuals who are failing a particular drug and/or studies of the 
association between baseline genotype and consequent virological response (335). 
 
 
 
 
 
 
 
 
 
Source: (392)  
A mutation list can be interpreted in different way using different interpretative tools:  
1) Lists of mutations that are considered associated with each drug, such as the IAS-US list 
(338) 
2) Expert based genotypic interpretation systems that assign a “score”, often referred to 
as a genotypic sensitivity score (GSS), to each drug depending on which mutations are 
present and the degree of resistance they are considered to confer. These systems include 
the ANRS score system, the Stanford Resistance database, HIV-GRADE and the 
AntiRetroScan system (342,394–396).  
Figure 1.15. Output from different types of sequencing 
 
 
 
 
Figure not available due to copyright restrictions 
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3) Web-based bio-informatics tools that can predict treatment response based on a 
number of factors, including resistance. These include EU-Resist and RDI HIV-TrePS 
(397,398).  
Comparisons of the different interpretation systems have found reasonable agreement 
between them (399,400), and all predict virological outcomes (401). A final way of interpreting 
genotypic data is to relate it to phenotypic susceptibility, for example using the Geno2Pheno 
or Virtual Phenotype platform (402). There are also tools that use results from both genotypic 
and phenotypic tests to generate an interpretation (e.g. Phenosense GT) (403).  
1.8.5.3. Guidelines for resistance testing 
Resistance testing is recommended in high income settings by all major guidelines both before 
the start of therapy, ideally as soon after infection as possible, and upon treatment failure 
(146,147). At present, most guidelines recommend genotypic over phenotypic testing at least 
for initial resistance testing, as it tends to be quicker, cheaper and can detect resistance that is 
still evolving (319). Several randomized controlled trials have shown a benefit from genotypic 
resistance testing to guide therapy switches after VF, but trials evaluating phenotypic 
resistance testing have failed to show a benefit as compared to either no resistance testing or 
genotypic testing alone (Table 1.4). Nonetheless, phenotypic resistance testing may still have 
some value for patients who have experienced multiple failures and therefore may have 
complex resistance patterns (354,383).  
When interpreting the evidence underlying these policy recommendations, it is important to 
take into account that the majority of these trials were done at a time when a higher 
proportion of patients had been exposed to mono or dual therapy before starting their first 
cART regimen and at a time when future drug options were limited (404). The changing clinical 
context of HIV care is likely to influence the utility of resistance testing (385), and a 2004 
review of trials of resistance testing has found that the overall clinical benefit from resistance 
testing may be relatively small (404). Clinicians are likely to take into account factors such as 
the patients adherence, technological availability, cost and the number of available treatment 
options in addition to the advice provided by guidelines when deciding whether or not to do a 
resistance test (385), and the utility of the test will depend both on previous drug history of 
the patient and the number of available treatment options. The use of resistance testing in 
clinical practice will be investigated and described in chapter 3.  
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Table 1.4. Clinical trials evaluating the utility of resistance testing following virological failure 
Table X.  Trial (Reference) Year  Comparison  N Population Result  
Viradapt (405) 1999 Genotype v Standard of Care (SOC) 65 v 43 Patients in whom therapy was not 
successful (a VL of >10,000 after at least 6 
months’ treatment with a protease 
inhibitor) 
Genotypic resistance testing 
resulted in a significantly better 
virological response at 6 months 
GART (406) 2000 Genotype + Expert Advice (EA) v SOC 78 v 75 Patients with a threefold or greater rise in 
plasma HIV-RNA on at least 16 weeks of 
combination therapy  
Genotypic resistance testing gave 
a better virological response over 
12 weeks.  
ARGENTA (407) 2002 Genotype v SOC  85 v 89 At least 2 month of HAART and a VL of 
greater than 2000 cp/ml on two 
consecutive determinations or less than 1 
log reduction of RNA more than 2 months 
after the start of the last regimen  
Genotypic resistance testing led to 
a better virological response at 3 
months but not at 6 months 
compared to SOC.  
Havana1 (408) 2002 Genotype v SOC 
EA v SOC 
207 v 119 
164 v 162 
Patients on stable cART who presented 
with VF (HIV RNA>1000 cp/ml) after being 
on a particular regimen for more than 6 
months  
Genotypic resistance testing 
showed benefit at 12 weeks 
compared to SOC in the main ITT 
analyses; EA showed benefit in a 
sub-group analysis or in per-
protocol analyses only.  
VIRA3001 (409) 2002 Phenotype v SOC 142 v 130 Patients who failed to achieve or maintain 
virological suppression (HIV-1 RNA plasma 
level >2000 cp/ml) after taking triple 
therapy for at least 1 month.  
No evidence that phenotypic 
resistance testing provided 
virological benefit at 16 weeks; 
some evidence of benefit in 
secondary analyses.  
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CCTG 575 (410) 2001 Phenotype v SOC Total 2562 Patients with 6 months of previous ART, 
exposure to no more than two prior PI’s 
and failure of the current regimen (HIV 
RNA?400 cp/ml) and a stable regimen (no 
change at least 4 weeks prior to screening)  
Virological response was not 
different at 6 months or 12 
months.  
Narval (411) 2003 Genotype or phenotype v SOC 183 v 183 
v 152 
HIV plasma RNA >1000 cp/ml, previous 
exposure to at least one PI for 3 months, 
unchanged antiretroviral regimen for the 2 
preceding months.  
Genotypic resistance testing was 
associated with improved 
virological response at 12 weeks 
compared to SOC in multivariate 
analyses, but not phenotypic 
resistance testing.  
CERT (412) 2004 Access to genotype v Access to 
phenotype v SOC 
151 v 152 
v 146 
Patients who received stable ART 
containing at least 2 drugs for 8 weeks 
before randomization 
No benefit of either genotypic or 
phenotypic resistance testing on 
long-term outcomes over SOC.  
RealVirFen (413) 2003 Phenotype v Virtual Phenotype 139 v 137 HIV infected adults failing their current ART 
(RNA >1000 cp/ml) 
No difference between phenotype 
and virtual phenotype. 
ERA (414) 2005 Genotype v Phenotype and Genotype 152 v 159 Patients who had swapped ART, with a 
most recent RNA measurement above 2000 
cp/ml and the clinician could not select a 
potent regimen of 3 or more drugs without 
access to a resistance test  
No added benefit of phenotypic 
resistance testing in terms of 
virological response at 12 months.  
CREST (415) 2006 Genotype v Genotype + Virtual 
Phenotype 
170 v 168 Patients with an RNA >2000 who wanted to 
change therapy  
No added benefit of virtual 
phenotype in terms of virological 
response at 48 weeks.  
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1.8.6. Preventing drug resistance  
The development of drug resistance can be prevented in several different ways. As mentioned 
previously, the benefit of using cART is the rapid suppression of viral replication to such low 
levels that development of resistance is prevented. This means that in the context of cART, 
acquired resistance is often the consequence and not the cause of VF (322). Adherence is a key 
factor that affects the likelihood of a person experiencing VF, and is also strongly linked to the 
development of drug resistance (416). The relationship between adherence and resistance 
development is not straight-forward, and it likely differs depending on the drug class (Figure 
1.16). Single PI resistance is most likely to develop at moderate to high levels of adherence, 
resistance to ritonavir boosted PIs at moderate levels of adherence and NNRTI resistance at 
low to moderate levels of adherence (417). Very low adherence is likely to lead to a removal of 
selective drug pressure, which would prevent the development of resistance. 
Figure 1.16. Resistance development as a consequence of adherence 
 
 
 
 
 
 
 
 
 
Source: (417)  
There are several ways adherence can be improved. For example, it has been shown that 
individuals who have a greater understanding of the disease process and resistance 
development are more likely to show good adherence (418). Counselling and patient support 
programs could also improve adherence and thereby prevent resistance development (419). 
The use of regimens with a higher genetic barrier, such as boosted PI based cART or 
dolutegravir based cART, could prevent the development of resistance compared to use of 
NNRTI cART which has a low genetic barrier compared to these options. Regimens which 
encourage good adherence, such as those with a relatively low pill burden and no complex 
dosing requirements may also prevent the development of resistance (420). Finally, addressing 
structural factors, including stigma, could improve individuals adherence to ART (421). There 
are also programmatic actions that can be taken to prevent the development of drug 
 
 
 
Figure not available due to copyright restrictions 
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resistance. This includes ensuring frequent VL monitoring, improving the supply of drugs to 
prevent stock outs and the removal of barriers for accessing continued treatment, such as 
financial or travel-related barriers (422,423). Continuous surveillance of both acquired and 
transmitted drug resistance is also important in order to inform policy that can ensure that 
levels of drug resistance do not compromise the response to the HIV epidemic.  
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Chapter 2 . Methodology and Data Sources 
 
2.1. Literature Reviews 
Literature reviews were conducted through PubMed for each chapter (424) . The questions 
and search terms used to identify relevant articles are shown below in Table 2.1. Each search 
was built up using medical subject headings (MeSH) terms. For topics where MeSH headings 
were not available, I used the PubMed option “all fields” to search for that term. For each 
search, the same search strategy was applied (Figure 2.1).  
Figure 2.1. Search strategy 
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Table 2.1. Literature review questions and search terms utilised, per chapter 
Chapter Aim  Search Question Search Terms  Exclusion Criteria  
Chapter 3 1 What is the utilisation of HIV resistance 
testing after virological failure (VF) in 
European or high income settings and 
what factors are associated with having a 
resistance test performed?  
 
("hiv infections"[MeSH Terms] OR "anti-hiv agents"[MeSH 
Terms] OR "hiv-1"[MeSH Terms]) AND ("drug resistance, 
multiple, viral"[MeSH Terms] OR "drug resistance, 
viral/genetics"[Mesh Terms] OR "mutation"[MeSH Terms] 
OR "genotype"[MeSH Terms] OR "drug resistance, 
viral"[Mesh Terms]) AND ("prevalence"[MeSH Terms] OR 
"epidemiology"[MeSH Terms] OR "prospective 
studies"[MeSH Terms]) NOT (transmitted[All Fields] OR 
transmission[All Fields]) 
 
Papers reporting on resistance testing 
from Asia, Sub-Saharan Africa or South 
America 
Case Reports  
Studies that focus on a single drug or a 
single mutation  
  2 What is the probability of detecting drug 
resistance when performing a resistance 
test after VF and what are the risk factors 
for having drug resistance, given that a test 
was conducted? 
Chapter 4 1 What is the probability of VF among 
people receiving RAL from ART 
experienced?  
 
("hiv infections"[MeSH Terms] OR "anti-hiv agents"[MeSH 
Terms] OR "hiv-1"[MeSH Terms]) AND "hiv integrase 
inhibitors"[MeSH Terms] OR ("raltegravir 
potassium"[MeSH Terms] OR ("raltegravir"[All Fields] AND 
"potassium"[All Fields]) OR "raltegravir potassium"[All 
Fields] OR "raltegravir"[All Fields]) AND (Viral Failure[All 
Fields] OR Virological Failure[All Fields] OR ("treatment 
failure"[MeSH Terms] OR ("treatment"[All Fields] AND 
"failure"[All Fields]) OR "treatment failure"[All Fields]) OR 
"Viral Rebound"[All Fields] OR "outcome"[All Fields] OR 
"outcomes"[All Fields]) 
Papers reporting on resistance testing 
from Asia, Sub-Saharan Africa or South 
America 
Case Reports  
Randomized controlled trials 
 2 What is the prevalence of integrase 
resistance among people failing an INSTI? 
Chapter 6 1 How does resistance development depend 
on the level of viral replication? 
("hiv infections"[MeSH Terms] OR "anti-hiv agents"[MeSH 
Terms] OR "hiv-1"[MeSH Terms]) AND ("drug resistance, 
multiple, viral"[MeSH Terms] OR "drug resistance, 
viral/genetics"[Mesh Terms] OR "mutation"[MeSH Terms] 
OR "genotype"[MeSH Terms] OR "drug resistance, 
Paediatric studies 
Studies in specific sub populations (eg 
only women or TB co-infected patients) 
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viral"[Mesh Terms]) AND ("prevalence"[MeSH Terms] OR 
"epidemiology"[MeSH Terms] OR "prospective 
studies"[MeSH Terms] OR “Rate” [All Fields] OR 
“Accumulation” [All Fields]) NOT (transmitted[All Fields] 
OR transmission[All Fields]) 
Studies that focus on a single drug or a 
single mutation  
Case Reports  
 
Chapter 5 1 What is the effect of drug resistance on 
CD4 count changes among individuals 
maintained on a failing regimen after the 
start of ART?  
 
• ("hiv infections"[MeSH Terms] OR "anti-hiv agents"[MeSH 
Terms] OR "hiv-1"[MeSH Terms]) AND ("drug resistance, 
multiple, viral"[MeSH Terms] OR "drug resistance, 
viral/genetics"[Mesh Terms] OR "mutation"[MeSH Terms] 
OR "genotype"[MeSH Terms] OR "drug resistance, 
viral"[Mesh Terms]) AND (CD4 Lymphocyte Count OR 
• CD4-Positive T-Lymphocytes/drug effects OR 
CD4-Positive T-Lymphocytes/immunology AND 
(“transmitted” [All Fields] OR “naïve” [All Fields] OR 
“primary” [All Fields]) 
Paediatric studies 
Case Reports  
 
   
Chapter 7 1 What is the effect of TDRM on CD4 count 
changes before the start of ART?  
 
• ("hiv infections"[MeSH Terms] OR "anti-hiv agents"[MeSH 
Terms] OR "hiv-1"[MeSH Terms]) AND ("drug resistance, 
multiple, viral"[MeSH Terms] OR "drug resistance, 
viral/genetics"[Mesh Terms] OR "mutation"[MeSH Terms] 
OR "genotype"[MeSH Terms] OR "drug resistance, 
viral"[Mesh Terms]) AND (CD4 Lymphocyte Count OR 
• CD4-Positive T-Lymphocytes/drug effects OR 
• CD4-Positive T-Lymphocytes/immunology) 
AND (transmitted [All Fields] OR Naive [All Fields] OR 
Primary [All Fields]) 
Paediatric studies 
Case Reports  
•  
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 2  What is the effect of TDRM on viral load 
changes, including viral load set point, 
before the start of ART? 
• ("hiv infections"[MeSH Terms] OR "anti-hiv agents"[MeSH 
Terms] OR "hiv-1"[MeSH Terms]) AND ("drug resistance, 
multiple, viral"[MeSH Terms] OR "drug resistance, 
viral/genetics"[Mesh Terms] OR "mutation"[MeSH Terms] 
OR "genotype"[MeSH Terms] OR "drug resistance, 
viral"[Mesh Terms]) AND (“Viral Load” [MeSH Terms] OR 
“Viral Replication” [All Fields] OR “RNA, Viral” [MeSH 
Terms]) AND (transmitted[All Fields] OR Naive[All Fields] 
OR Primary[All Fields]) 
Paediatric studies 
Case Reports  
•  
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Conference abstracts were included provided that enough information to determine eligibility 
was available in the abstract. As the literature reviews were not the primary objective of this 
thesis, formal review protocols were not published, secondary reviewers were not used to 
screen the papers and meta-analyses were not conducted. Flow diagrams of studies screened, 
assessed for eligibility and included in the reviews are included in each chapter. The results are 
presented in a narrative format in order to provide a summary of the existing state of 
knowledge at the time the work was undertaken. 
2.2. Data Sources 
The data used in this thesis comes primarily from the EuroSIDA cohort, a large, prospective 
cohort study of HIV-infected individuals in Europe, Israel and Argentina. However, data from 
other HIV cohorts and clinics have also been used. In chapter 6, the UK Collaborative HIV 
cohort (UK CHIC) Study and the UK HIV Drug Resistance Database (UK HDRD) contributed data. 
Data from the ViroLAB collaboration, EU-Resist collaboration, London St Mary’s and Royal Free 
Hospitals, and the University of Bari were used for chapter 7. These contributing clinics are 
referred to as the “EU-TDR” collaboration throughout the thesis. For each collaborative 
analysis, data was merged with the EuroSIDA study. More detailed descriptions of the design 
of the different studies can be found below. As the EuroSIDA cohort contributed the majority 
of the data to this thesis, the focus of this chapter is on the methodology and design of 
EuroSIDA.  
Table 2.2. Chapters and data sources in this thesis 
Chapter Data Source Data included until Considered for Inclusion  Included  
Chapter 3 EuroSIDA  <03/2013 18,473 8,469 
Chapter 4 EuroSIDA  <02/2016 21,879 2,447 
Chapter 5 EuroSIDA  <03/2015 18,914  
5,357  UK CHIC/UK 
HDRD  
<2014 47,201 
Chapter 5 EuroSIDA  <02/2016 21,879 464 
Chapter 7 EU TDR 
Collaboration 
<2006 5,203  
6,180 
 EuroSIDA  <03/2015 18,914 
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2.2.1. EuroSIDA: Study overview and coordination  
EuroSIDA is a prospective observational cohort study that has been collecting data since May 
1994 (425). To date, 21,880 patients from 108 centres in 35 European countries (Austria, 
Belarus, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, The Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, 
Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom), Israel and Argentina have 
been enrolled (Figure 2.2). These countries are commonly grouped into different geographical 
regions, as can be seen in Table 2.3 below.  
Figure 2.2. Countries and regions in EuroSIDA 
 
 
 
 
 
 
 
 
 
 
The EuroSIDA study developed out of the AIDS in Europe retrospective cohort study initiated 
by Professor Jens Lundgren (University of Copenhagen) (426). The initial focus of the EuroSIDA 
Table 2.3. Countries included in each geographical region of Europe and Argentina 
Southern  Central Western  Northern  Central Eastern  Eastern  Argentina 
Spain France United Kingdom Poland Estonia Argentina 
Portugal Belgium Ireland Czech Republic Latvia  
Italy Luxembourg the Netherlands Slovakia Lithuania  
Greece Switzerland Denmark Hungary Belarus  
Israel Austria Sweden Romania Ukraine  
 Germany Norway Serbia Russia  
  Finland Bulgaria   
   Croatia   
 
 
 
 
Figure not available due to copyright restrictions 
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study was to report on prognostic factors and regional differences in HIV-related mortality and 
morbidity (427). Following the improvements in HIV treatment that dramatically prolonged 
survival for people living with HIV (PLWH), the focus of the EuroSIDA cohort has expanded. 
Although the study still aims to report on long term clinical, virological and immunological 
outcomes; analyses of clinically important co-morbidities, including Hepatitis B and C co-
infection, renal function and cardiovascular disease have taken on greater importance (428). 
The latest round of data collection will exclusively enrol patients co-infected with Hepatitis C in 
order to provide data on the uptake and consequence of the roll-out of direct acting antivirals 
(DAA) for the treatment of Hepatitis C.  
The study organisation is outlined in Figure 2.3. The management and coordination of 
EuroSIDA is done by the coordinating centre at the Centre for Infectious Disease Research 
(CHIP, Previously Copenhagen HIV Programme) at Rigshospitalet, University of Copenhagen. 
The coordinating team is responsible for questionnaire design, data collection, data entry and 
quality assurance. The EuroSIDA coordinating centre works in close collaboration with the 
statistical centre based in the Department of Infection and Population Health at UCL. The 
statistical centre provides statistical and analytical support to the study, but also leads a 
number of analyses and projects utilising data from the study with support from clinicians in 
the coordinating centre. Virological work, including genotyping for HIV and HCV, was done in 
London at the International Clinical Virology Centre until 2004. Since then this work has been 
undertaken at the collaborating laboratory at the IrsiCaixa Foundation in Badalona, Spain 
under the leadership of Dr Roger Paredes.  
Figure 2.3. Organisation of the EuroSIDA study 
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The study is controlled by a steering committee consisting of 15 investigators as well as 
representatives from the coordinating centre, statistical centre and the collaborating 
laboratory. The steering committee is responsible for securing study funding and for approving 
research proposals and output from the study. Members of the steering committee are 
elected for a 5-year period. In turn these members elect a committee chair and a vice-chair 
from amongst themselves. The group communicates via phone conferences every two months 
and annually at one of the HIV scientific conferences. The EuroSIDA study group meets 
annually at an investigator face-to-face meeting, and a full list of the group can be found in 
Appendix I.  
All research proposals submitted to EuroSIDA, including those from researchers outside the 
immediate study group, undergo a rigorous review process (429). All proposals must be 
submitted according to a standardised format. These are then sent for review by two 
independent members of the steering committee. Their responses are discussed at the 
subsequent EuroSIDA steering committee teleconference (TC), and any requested changes or 
additions to the proposals must be addressed before it is granted approval to proceed. The 
steering committee also review conference abstracts, presentations and journal articles before 
these are submitted for publication.  
2.2.1.1. Inclusion criteria and recruitment 
Individuals recruited into EuroSIDA are required to be HIV-positive, aged above 16, and are 
recruited in rounds (referred to as cohorts). Since 1994, there have been 9 cohorts, recruiting 
an average of around 2000 individuals each (Table 2.4). Initially, patients were enrolled only 
when their CD4 counts were below 500 (425), but this requirement was lifted in 1999. The 
inclusion criteria for cohort X have changed to reflect the evolving aims of EuroSIDA, and 
individuals are now required to be Hepatitis C antibody positive, as well as HIV positive, in 
order to be enrolled.  
Table 2.4. Number of patients recruited per cohort in EuroSIDA 
Cohort  Year N 
Cohort I Spring 1994 3115 
Cohort II Winter 1995 1364 
Cohort III Spring 1997 2837 
Cohort IV Spring 1999 1225 
Cohort V Winter 2001 1223 
Cohort VI Winter 2003 2118 
Cohort VII Winter 2005 2458 
Cohort VIII Summer 2008 2254 
Cohort IX Spring 2012 2500 
Cohort X  Status as of May 2016 3878 (80% of target recruitment) 
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After a centre agrees to participate in the EuroSIDA study, individuals are recruited 
consecutively until a pre-specified cap, set by the coordinating centre in collaboration with the 
participating clinic, is reached. Patients provide informed consent in accordance with local 
clinical guidelines; signed consent forms are held by the coordinating centre in Copenhagen. 
Clinicians are offered reimbursement for recruiting a patient, for each consequently submitted 
FU form and for submitting data relating to particular areas of interest. The reimbursement 
levels that were in place during the time-frame of this PhD thesis can be seen in Table 2.5.  
1. Causes of Death form 
 
2.2.1.2. Data items, collection and quality assurance 
A number of clinical and demographic variables are collected for all EuroSIDA participants on a 
standardised Case Report Form (CRF) every 6 months. An overview of the items collected can 
be seen in Table 2.6 on page 83. It includes information on gender, age, ethnicity, mode of HIV 
transmission, CD4 and RNA data, stop and start dates for ART as well as data on AIDS defining 
illnesses (according to the 1993 CDC definition) and non-AIDS events. The EuroSIDA network of 
clinics has also been used to administer one-off surveys on the clinical management of HIV 
patients in Europe. Examples of such surveys include the Atripla Survey (430), which collected 
data on the use of Atripla® (efavirenz/emtricitabine/tenofovir) at different clinics in Europe, 
and the EuroSIDA clinic survey (431), which collected additional information on the clinical 
management of HIV-positive patients. Data collection is now done through an online system 
called RED-CAP (432), but initially physical copies of the forms were submitted to the 
coordinating centre where the data was entered into the EuroSIDA database manually.  
A number of measures are taken by the coordinating centre to ensure that the quality of the 
data collected is of a high standard (428,433). This is done partly through annual monitoring of 
a number of sites in order to ensure accurate enrolment and data collection. Case notes are 
checked against the existing information submitted to the study for all clinical events and for a 
Table 2.5. EuroSIDA reimbursement levels  
Form/module Current reimbursement (2015) Future reimbursement (2017) 
Follow-up form 13.60 € 20 € 
HCV treatment form 50.00 € 30 € 
HCV follow-up form NEW 10 €  
HCV adverse event form 50.00 € 50 € 
HSR/liver toxicity form  161.64 $ 50 € 
HSR/liver toxicity form - - 
CoDe1 161.64 $ 20 € 
Enrolment form 18.14 € 18.68 € 
Plasma samples 5.67 € 5.84 € 
Resistance data 5.67 € N/A 
D:A:D event form 161.64 $ N/A 
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random sample of 10% of patients. When a site is found to have incorrectly recorded data, 
feedback is provided to the centre and more frequent monitoring occurs to ensure that 
accuracy improves. There are also a number of data quality checks done by the data 
management team at the coordinating centre; these are outlined in detail in the quality 
assurance document published on the CHIP webpage (429) . Recently, the monitoring has been 
shifted from site monitoring to central monitoring at the coordinating centre. 
Loss to follow-up (LTFU) is an important source of potential bias in many observational studies 
for two main reasons. Firstly, as patients with more chaotic lifestyles are more likely to be 
LTFU this has the potential to introduce systematic differences in the amount of FU time and 
information provided by individuals from different risk groups and demographics. Secondly, if 
many patients are LTFU it reduces the power of the study. Defining LTFU is challenging, 
especially for long-term conditions such as HIV, where patients may not be seen in clinic that 
often. A one-year gap in clinical data does not necessarily indicate that a patient is LTFU. A 
discussion around the challenges in defining LTFU and estimates of LTFU in EuroSIDA has been 
previously published (433). Measures are taken to help sites minimize the number of patients 
that are LTFU (433). Firstly, investigators are educated on the importance of continued follow-
up and reporting. If a patient is LTFU, sites are contacted in order to see if more information 
can be obtained. And finally, sites with a high proportion of patients LTFU are approached to 
see if the underlying reasons for the high LTFU can be elucidated. These sites also receive extra 
support and training that can help reduce LTFU (433).  
Table 2.6. Summary of data collected for the EuroSIDA study  
Demographics Gender Comments 
 Date of Birth  
 Mode of Infection  
 Country of Origin  
 Race  
 Weight  
 Height  
HIV: Laboratory Measures RNA  
 CD4  
HIV: Virology Date of resistance test  
 Result from resistance test  
HIV: Treatment ART start and stop dates  
 Reasons for discontinuation  
 Adherence rating as reported by the treating 
physician 
Not validated 
HIV: AIDS  Date and type of opportunistic infections  
 Treatment against opportunistic infections  
 Date and Diagnosis of AIDS defining 
malignancies 
 
Death Death date  
 Autopsy  
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 CoDE case report  
Laboratory values Serum total cholesterol  
 Serum HDL cholesterol  
 Serum triglycerides  
 S-creatinine  
 Haemoglobin  
 Platelet count  
 ALT  
 AST  
 INR  
 Bilirubin  
 S-lactate  
 S-amylase  
 Toxoplasmosis antibody  
 CMV antibody  
 Proteinuria  
Hepatitis Hepatitis B antigen Since 1997 
 Hepatitis B antibody  
 HBV-DNA  
 Hepatitis C antibody  
 HCV-RNA  
 HCV-genotype  
 Copies of liver biopsy results Since 2010 
Clinical (non-AIDS) Cardiovascular disease  
 Metabolic events  
 Other organ events  
 Treatment for clinical/non-AIDS conditions  
 Date and diagnosis of non-AIDS malignancies  
Other data Blood Pressure  
 Smoking status  
 Family history of MI  
 Alcohol abuse (past or current) Not validated 
 Pregnancy outcome (if pregnant)  
 
2.2.1.3. The sample repository 
Since 1997, EuroSIDA has been collecting plasma samples for a plasma repository held at the 
coordinating centre in Copenhagen. Plasma samples of one ml are requested for all 
participants every six months, and these are shipped to the coordinating centre where they 
are frozen and stored in the plasma repository. The samples have been used for a variety of 
different projects relating to antiretroviral resistance, hepatitis, pharmacokinetics and 
biomarkers.  
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2.2.1.4. EuroSIDA resistance data 
Data on drug resistance and resistance testing has been collected since 1997 in three different 
ways. Firstly, there is a question in RED-CAP where the clinician can indicate whether or not a 
person has been genotyped since their last clinic visit (Figure 2.4) 
 
Figure 2.4. Screen shot of resistance collection for EuroSIDA (RED-CAP) 
 
 
 
 
 
Secondly, a clinician can submit a report of genotypic data which is consequently added to a 
resistance database. The form of this report varies: occasionally a list of mutations is attached 
as part of a virological report, and in other instances FASTA files with sequences are attached 
electronically. The data is formatted by the virology team in Badalona and kept in a centralised 
database. For the most recent analyses included in this thesis, data on 5,196 resistance tests 
from 3,191 individuals submitted as paper forms were available. As the genotyping of these 
samples is done locally, the method used for genotyping and interpretation varies depending 
on the clinical standards and available technologies in each centre. Finally, genotypic data has 
also been added to the resistance database as a result of retrospective genotyping of plasma 
samples from the plasma repository. This genotyping is done by the collaborating laboratory 
for specific projects. In D40, data on 5,966 centrally performed resistance tests from 3,060 
patients were available. Since many rounds of retrospective genotyping have been done over 
time, several different methods for genotyping have been used. The method used for 
genotyping also varies according to the project aim. In recent years there has been a shift 
towards using next generation sequencing methods for projects. This is the approach that was 
taken in Chapter 4, where the Illumina MiSeq platform was used to genotype people who were 
failing on an integrase inhibitor containing regimen. In total, D40 held genotypic data on 
11,162 resistance tests from 5,265 patients.  
EuroSIDA also collects a measure of adherence which is of considerable relevance to analyses 
of resistance data. However, this adherence measure is provided by the treating physician and 
is likely to at least partly be influenced by the results from VL tests. It has not been validated, 
has a high proportion of missing data and it is not clear to what extent this measure accurately 
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reflects patient adherence. Following the recommendation of the study PIs and SC, the 
adherence data has therefore not been used in this thesis.  
2.2.1.5. Funding and ethics 
At the time of writing (October 2015), primary funding for EuroSIDA was provided by the 
European Union’s Seventh Framework Programme for research; technological development 
and demonstration under EuroCOORD grant agreement n˚ 260694. Support also included 
unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc. and 
GlaxoSmithKline LLC. The participation of centres from Switzerland was supported by the Swiss 
National Science Foundation (Grant 108787). The study is also supported by a grant [grant 
number DNRF126] from the Danish National Research Foundation. 
Each centre that contributes data to the EuroSIDA study has sought and been granted ethics 
approval from the relevant local and national authorities. A copy of each approval form is held 
at the coordinating centre in Copenhagen, and these are available per request from 
eurosida.rigshospitalet@regionh.dk. Where the local and/or national ethics committees 
require individual patient consent, this is taken before individuals can be enrolled in the study.  
2.2.1.6. Summary of the EuroSIDA study to date  
By February 2016, EuroSIDA had recruited 21,880 patients; a brief description of the 
characteristics of these patients at enrolment can be seen in Table 2.7. In the analyses done 
for this thesis, different inclusion criteria were applied and the numbers and characteristics of 
the study population may therefore vary from chapter to chapter. However, the overall 
baseline characteristics are presented here to give an indication of the study characteristics. 
Additional information on baseline characteristics is also presented per chapter.
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Table 2.7. Characteristics of individuals in each study at enrolment1  
  EuroSIDA (D42, 2016) UK CHIC (2014) EU-TDR (2010) 
  N % N % N % 
Total  21,880 100 47,201 100 5,203 100 
Gender Male 15,931 72.8 34,202 72.4 3,721 71.5 
 Female  5,573 25.5 12,995 27.5 1,179 22.7 
 Missing 376 1.7 4 0.01 303 5.8 
Enrolment Age Median [IQR], Years 37.5 31.3-45.6 37.7 32.1-41.7 35.7 29.5-42.5 
 Missing Age 402  1.8 4 0.01 60  1.1 
Ethnicity  White 18,959  86.7 24,612 52.1 Not available - 
 Non-white 2,397 11.0 19,690 41.7 - - 
 Missing 524 2.4 2,899 6.1 - - 
Risk Group  MSM 7928 36.2 23,341 49.5 2,099 40.3 
 IDU 6073 27.8 1,694 3.6 462 8.9 
 Heterosexual 6020 27.5 17,191 36.4 1,663 32.0 
 Other 1356 6.2 1,862 3.9 654 12.6 
 Missing 503 2.3 3,113 6.60 325 6.3 
Region Southern 5,657  25.9 0 0 Not available - 
 Central Western 4,886 22.3 0 0 - - 
 Northern 4,964 22.7 47,201 100 - - 
 Central Eastern 2,532 11.6 0 0 - - 
 Eastern 3,199 14.6 0 0 - - 
 Argentina 642 2.9 0 0 - - 
Enrolment CD4 count  Median [IQR], Cells/mm3 340  180-520 315  150-496 434 (298-599)  
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1. Approximated by the first available CD4 count for the EU-TDR clinic data, as a first visit date was not available.  
 
 Missing enrolment CD4 534 2.4 26,910 57.0 0 0 
Enrolment Viral Load Median [IQR], copies/ml 200  39-9,505 16,188.5 553-99,900 29,500 8,243-103,140 
 Missing enrolment VL 6,092 27.8 31,511 66.8 606  11.6 
Hepatitis C  Yes 6,511  42.0 748  1.2 Not available - 
 No 9,003 58.03 8955 19.0 - - 
 Missing 6,366 29.1 37,498 79.4 - - 
Hepatitis B  Yes 1,018 6.7 655 1.4 Not available - 
 No 14,182 93.3 10,870 23.0 - - 
 Missing 6,680 30.5 35,676 75.6 - - 
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2.2.2. UK CHIC: study overview and coordination  
The UK CHIC study collates routinely collected data from a number of HIV and Sexual Health 
clinics from across the UK. It was set up in 2001 by Professor Caroline Sabin (UCL), and includes 
all data on patients seen at participating centres since January 1996 (434). The overall aim of 
the study is to create a nationally representative database of individuals who receive care for 
HIV in the UK, in order to describe long-term outcomes of cART and factors associated with 
virological and immunological responses to cART. Currently, 21 centres contribute data to the 
study (Appendix II). The study complements the existing UK HIV surveillance data by collecting 
more detailed information than it is possible to do using current routine surveillance 
structures.  
UK CHIC is coordinated by a team of epidemiologists and statisticians from the Department of 
Infection and Population Health, UCL. The steering committee has 31 members, and consists of 
representatives from the centres that contribute data, the Medical Research Council Clinical 
Trials Unit (MRC-CTU), Public Health England (PHE) and community organisations (HIV i-Base). 
The steering committee meets every 3-6 months, and is responsible for approving research 
proposals and outputs from the study. Members of the steering committee are also 
encouraged to submit their own research proposals. There are also a number of research sub-
groups that study areas of specific interest. These include renal disease, viral hepatitis, 
pregnancy and ageing (434).  
2.2.2.1. Inclusion criteria and recruitment 
Individuals included in the UK CHIC study are HIV-positive individuals aged 16 and above who 
have attended one of the collaborating centres for care at any time since 1/1/1996. Healthcare 
centres do not actively recruit patients, but instead submit copies of the data they already 
collect on all patients seen for care who meet the inclusion criteria.  
2.2.2.2. Data collection and quality assurance 
Data for UK CHIC is submitted to a database held at the MRC CTU electronically, and include 
demographics, laboratory measures including CD4 counts and viral load measures, data on ART 
history and AIDS diagnoses (435). The data is held in a secure, integrated, relational database, 
and entries are pseudo-anonymised. Updates of the dataset are provided by participating 
centres on an annual basis.  
A number of procedures to ensure high accuracy and completeness of the data submitted are 
in place (Figure 2.5) (434). This involves a comparison of the data held in clinic databases with 
the clinical case notes for a random selection of 1% of patients’ records at each centre. 
Patients who attend more than one clinic have their records linked on the bases of their 
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soundex code, date of birth and other clinical information. Details on the matching algorithm 
have been previously published (435).  
Figure 2.5. Data collection procedure in UK CHIC 
 
 
 
 
 
 
 
 
2.2.2.3. The UK HIV Drug Resistance Database (UK HDRD) 
The UK HDRD is a repository for all the resistance tests performed as part of routine care since 
2001 in the UK (436). By the end of 2013, the database held over 114,000 test results, 
primarily viral gene sequences. The database has a steering committee that meets regularly 
Appendix III), and is coordinated by the MRC CTU (Medical Research Council – Clinical Trials 
Unit) at UCL. Data is submitted to the HDRD on annual basis and imported into a central SQL 
database (Figure 2.6). The submitted nucleotide sequences are consequently processed 
through the Stanford University Genotyping Resistance Interpretation Algorithm (394). This 
produces data on amino acid mutations and drug susceptibility. The resistance database is 
annually linked with existing clinical cohorts, including UK CHIC, in order to provide data on 
resistance patterns for epidemiological analyses. As the HDRD collects data on all resistance 
tests done as part of clinical care, the UK is one of few European countries that can provide 
nationally representative data on HIV drug resistance without conducting prevalence surveys.  
 
 
 
 
 
 
 
 
 
Figure not available due to copyright restrictions 
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Figure 2.6. Organisation of the UK HIV Drug Resistance Database 
 
 
 
 
 
 
 
 
 
 
2.2.2.4. Funding and ethics 
The UK CHIC study and UK HDRD are been funded by the MRC, UK. In August 2014, the UK 
CHIC Study and the UK HIV Drug Resistance Database (UK HDRD) were jointly awarded a 
further 5 years of support from the MRC, enabling the projects to continue until August 2019 
(grant code M004236). 
UK CHIC has been approved by a multi-centre research ethics committee as well as by local 
ethics committees. As the data is pseudonomised, individual patient consent is not necessary 
for the study. 
2.2.2.5. Summary of the UK CHIC/UK HDRD 
The characteristics of the patients enrolled in UK CHIC (linked with the UK HDRD) at their first 
visit date can be seen in Table 2.7 (page 87). 
 
 
 
 
Figure not available due to copyright restrictions 
92 
 
2.2.3. European Transmitted Drug Resistance (EU TDR) Collaboration: study 
overview and coordination  
Part of the data used in chapter 7 comes from a collaboration, which for simplicity, is 
referred to as the European Transmitted Drug Resistance collaboration (EU-TDR). This 
database was obtained by merging the databases of two European collaborative 
consortiums on antiretroviral drug resistance (the Virolab Consortium and the EuResist 
Consortium) with data from three additional UK centres and one Italian centre caring for 
HIV-positive patients (St. Mary's Hospital, Imperial College London; Royal Free Hospital and 
"Policlinico" hospital, University of Bari). The database created as part of the ViroLab project 
(http://www.virolab.org/about-virolab.html) contained resistance information as well as 
clinical and demographic data of patients who had a HIV genotypic resistance test as part of 
clinical practice in seven different European clinics (Tropical and Infectious Diseases clinic, 
University of Brescia (Italy); Catholic University of the Sacred Heart in Rome (Italy); Hospital 
Germans Trias i Pujol, Foundation IrsiCaixa of Barcelona (Spain); Rega Institute for Medical 
Research, Catholic University of Leuven (Belgium)). The EuResist integrated database 
(http://engine.euresist.org/database/) included clinical, demographic and sequence data 
collected in Italy (ARCA database), Germany (AREVIR database), Sweden (Karolinska 
Infectious Diseases and Clinical Virology Department), Luxembourg (Retrovirology 
Laboratory, CRP-Santé), Portugal (Instituto de Higiene e Medicina Tropical) and Russia 
(Ivanovsky Institute of Virology). In order to avoid duplicates, patients from Catholic 
University of the Sacred Hearth included in the ARCA database were excluded from the 
merge. 
2.2.3.1. Data collection and inclusion criteria 
Participating clinics were requested to send specific data items on patients meeting the 
inclusion criteria for the aims of the collaboration, which related to the study of transmitted 
drug resistance in relation to the viral load, CD4 counts and viral fitness estimates. The 
inclusion criteria for data submission were the existence of a resistance test performed 
between 1996-2009 while the patient was naïve to ART, being above the age of 16 and HIV-
positive. The data items requested were gender, age, mode of infection, country of origin, CD4 
and VL measurements taken before the start of ART, as well as the date and result of the 
resistance test and subtype identification if done. All data were sent to the University of 
Brescia, where an integrated database of the patient data was created. Primary data collection 
occurred once in 2007, followed by an update and expansion of the database to include the 
non-ViroLAB laboratories in 2009. This expanded database was used for the analysis in Chapter 
7.  
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As the dataset is a collaboration, the data quality checks in place differ depending on the clinic. 
No centralised queries or data quality checks are in place, and the accuracy of the existing 
dataset reflects accuracy of the data submitted to the study.  
2.2.3.2.Funding and ethics 
The data collected for the EU-TDR collaboration was supported by the European Commission 
(FP6 Virolab Project Grant IST-027446; FP6 EuResist Project Grant IST-027173) and in part by a 
grant from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO G.0692.14N).). 
Ethics was granted by national and local committees to each of the collaborating clinics.  
2.2.3.3. Summary of the EU-TDR dataset 
A summary of the characteristics of the participants in the EU-TDR cohort at their first 
available date can be seen in Table 2.7 (page 87). 
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2.3. Statistical Methods  
Several different statistical methods have been used throughout this thesis, and a summary of 
which methods were used for each chapter can be found in Table 2.8. For each chapter, 
descriptive statistics and basic univariable tests were used in addition to regression models. All 
methods, together with the steps taken before analysis, are described in general terms below 
and in more detail in each particular chapter.  
 Table 2.8. Key outcomes and statistical methods, per chapter  
Chapter End-point(s) Main Statistical Methods 
Chapter 3 (1) Proportion with a resistance test after 
VF  
(2) Proportion with detected drug 
resistance after a resistance test 
Logistic Regression with 
generalised estimating 
equations (GEE) 
Chapter 5 (1) Time to VF after receiving Raltegravir Kaplan-Meier, Cox Regression 
Chapter 6 (1) Change in CD4 count Principal Component Analysis, 
Linear mixed models 
Chapter 4 (1) Rate of resistance development Poisson regression with GEE 
 
Chapter 7 (1) Change in CD4 count 
(2) VL set-point  
Principal Component Analysis, 
Linear mixed models 
 
2.3.1. Data cleaning and management 
In addition to the quality assurance undertaken at the coordinating centre, a certain amount of 
data management and cleaning is undertaken by the statistical centre depending on the 
requirements of each analysis. Such data management can include the selection of an 
appropriate study population according to pre-specified inclusion criteria and the preparation 
of time-updated variables. As EuroSIDA collects data from routine clinic appointments, data is 
not collected at specific dates or at a specific point beyond baseline. This means that 
measurements for an individual are not always taken at the same time-points. When doing 
analyses involving time-updated data, it is therefore often necessary to approximate the value 
of a particular variable on a particular date. Throughout this thesis, this has mostly been done 
by carrying forward the last recorded value until a new value occurred, regardless of the lag-
time. Other strategies for dealing with missing data are discussed in Section 2.3.5.4. It is also 
common that the data is reformatted from wide (one row per individual) to long (multiple 
rows per individual) to suit the requirements of different analyses.  
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The data cleaning procedures undertaken vary according to the requirements of each analysis, 
but it commonly involves finding and cleaning out duplicate values, removing implausible 
dates or implausible amino-acid substitutions in the resistance data.  
2.3.2. Descriptive statistics  
Descriptions of categorical data were done using proportions, and for continuous variables the 
mean (normally distributed data) or median (skewed data). For continuous variables, the 
spread was quantified using the standard deviation (normally distributed data) or the 
interquartile range (skewed data). Where relevant, graphical representations of the data (such 
as histograms and scatterplots) were used to assess the spread and distribution of the data, as 
well as to identify potential outliers.  
2.3.3. Significance tests 
Following a descriptive investigation, simple statistical tests are often used to compare 
baseline characteristics and to explore the research question. Statistical tests generate a p-
value; the probability of obtaining results at least as extreme as those observed if the null 
hypothesis (H0) is true (437). The smaller the p-value is, the greater the evidence against the 
H0, the hypothesis of a null/no effect/difference. By convention, a p-value less than 0.05 is 
often used as indicating whether or not a result is ‘statistically significant’, that is, small 
enough to provide reasonable evidence against the null hypothesis. Despite the fact that 
denoting results as significant or not based on this cut-off is very common, it has been widely 
criticised as it encourages a focus on an arbitrary cut-off point and discourages reporting of the 
actual p-value obtained (438–442). Throughout this thesis, results are interpreted using p-
values in conjunction with effect sizes and confidence intervals, as well as the likely clinical 
importance and plausibility of the findings (439,443). Multiple testing can impact the 
probability of finding a low p–value, and the implications of this are discussed below in section 
2.3.3.1.  
The choice of statistical test depends on the type of data. In order to test for differences in a 
binary outcome between two or more levels of a categorical variable, Pearson’s chi-squared 
test was used. For small sample sizes where the expected cell counts are estimated to be less 
than 5, the chi-squared test is not reliable and I instead used Fisher’s exact test (437). For 
binary exposures, the t-test was used to test for differences between means for normally 
distributed continuous data and the Wilcoxon rank-sum test comparing medians for skewed 
data. For categorical exposures with more than two categories, ANOVA was used to test for 
differences in normally distributed continuous data and the Kruskal-Wallis test for skewed data 
(437).  
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2.3.3.1. Multiple testing 
As previously mentioned the probability of finding a low p-value increases with the number of 
tests conducted (441). There are methods to correct for multiple testing, and these are 
appropriate in certain instances, notably where a very large number of tests are done in the 
absence of a-priori hypotheses regarding the expected associations. For most research 
questions however, methods that control for multiple testing can be overly conservative and it 
is instead recommended to base the interpretation of the results on confidence intervals and 
effect sizes in addition to the p-value, rather than correcting for multiple testing (444). In this 
thesis I corrected for multiple testing when I tested large (>30) numbers of exposures selected 
on the basis of arbitrary rules or data-driven approaches, such as expert lists of mutations and 
prevalence thresholds (chapter 5 and 7). In these instances I corrected p-values using the false 
discovery rate (FDR) as described by Benjamini and Hochberg (445). This involves sorting the p-
values in ascending order and adjusting each p-value using their percentile rank (446). The 
resulting adjusted p-value is referred to as a q-value, and it represents the probability that a 
particular finding is a false positive. I used the SAS procedure PROC multtest to automatically 
calculate q-values.  
2.3.4. Regression models 
In epidemiology, regression models are commonly used to estimate the effect of one or more 
exposures (independent variables) on an outcome (dependent variable). In univariable models, 
the effect of one exposure variable on the outcome is estimated. Multivariable models, which 
contain more than one exposure variable, estimate the effect of an exposure on the outcome 
conditional on all the other variables in the model. The main benefit of using regression 
models over the statistical tests introduced in section 2.3.3 is that they can take the effect of 
more than one exposure into account, that is, control for the potentially confounding effect of 
one or more exposure variables on the association of interest (437). Confounding is introduced 
separately in section 2.3.5.1, and a brief introduction to the regression models used in this 
thesis is provided below.  
2.3.4.1. Linear regression 
Linear regression models are used to estimate the effect of one or more predictors (x1, x2, …,xn) 
on a continuous outcome (y). Linear regression models take the form described in Equation 2.1 
below.  
 Equation 2.1. Linear regression 
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The β values represent the regression coefficients, or parameters, associated with the 
exposure variables. The estimated value for a given β represents the impact on y of a one-unit 
increase in x when all other variables are held constant. The β0, or intercept, represents the 
value of y when all other explanatory variables are zero (437). Although linear regression was 
not applied directly in this thesis, I utilised linear mixed models in chapter 5 and 7. These 
models are extensions of the linear regression equation that can deal with repeated measures, 
and they are discussed in more detail in section 2.3.5.3  
2.3.4.2. Logistic regression 
When outcome variables are binary (for example, a yes or no outcome) rather than 
continuous, logistic regression models are used. Logistic regression models follow a similar 
form to linear regression, although the outcome variable is transformed using a link function, 
in this case the logit function (447). The resulting model describes the linear relationship 
between the logit(p) and one or more exposures as can be seen in  Equation 2.2, where p is 
the probability of the outcome event occurring and logit(p) is the natural logarithm of the odds 
of the outcome.  
 Equation 2.2. Logistic regression 
 
 
Given that 1 represents an event occurring, the parameter estimates β will give the log odds of 
y=1 given a one unit increase in x when all other values are held constant. By taking the 
exponential of the β terms an odds ratio can be derived (447).  
2.3.4.3. Survival analysis 
Data where subjects are followed over periods of time until a pre-specified event occurs are 
called survival data (437). A key feature of survival data is that observations can be censored; 
which means that even if an individual does not experience the event of interest during their 
follow-up time, their follow-up time can be stopped (‘censored’) at a pre-specified time. Data 
can be either right-censored, meaning that the survival time ends at the last know visit, or left-
censored, which means that follow-up available before a defined baseline is not taken into 
account (437). Analysis of survival data, called survival analysis, involves statistical methods 
that allow us to take into account the varying length of follow-up produced by the censoring of 
data. 
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Biomedical measures such as viral load values can also be censored, as the tools used to 
measure such variables often cannot quantify exact values below a certain limit of detection 
(LOD). This also results in censored data, as although the exact value of the variable is 
unknown, it is known that the measured quantity was below the LOD. In this context, the data 
is referred to as truncated. In this thesis a simple approach of replacing the value <LOD with 
LOD was taken.  
2.3.4.4. Kaplan-Meier  
The distribution of survival times can be described by a mathematical function called the 
survival, or survivor function (Equation 2.3).  
Equation 2.3. Survival function 
 
Here F(t) gives the probability that the event has occurred by duration t, and S(t) therefore the 
probability of the event not having occurred by duration t. It is often of interest to estimate 
what S(t), or the probability of survival to at least time t, is. We can do this using a method 
known as Kaplan Meier. The Kaplan Meier estimator calculates the probability of survival in 
given time-intervals within the whole period of follow-up, with subjects censored before the 
specific time-point excluded from the denominator. The cumulative probability of survival 
from baseline until time t is then calculated by multiplying the probability of survival at each 
time interval. This is shown in Equation 2.4, where ni is the number of individuals still at risk at 
the beginning of time interval ti, and di the number of events during time ti.  
Equation 2.4. Kaplan Meier estimator 
 
 
The resulting estimates can be plotted as a Kaplan Meier, or survival, curve. These graphs are 
characterised by a series of horizontal steps and ‘drops’ which represent the occurrence of an 
event. The difference between two survival curves is most commonly tested using the log-rank 
test (437).  
2.3.4.5. Cox proportional hazards regression  
In order to estimate the effect that a number of exposures have on survival, Cox Proportional 
Hazards Regression can be used. This allows the natural logarithm of the hazard to be 
modelled as a linear function of a number of exposure variables (Equation 2.5).  
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Equation 2.5. Cox regression 
 
 
The hazard is defined as the instantaneous probability of having an event at time t, conditional 
on the event not having occurred by that time, and it is mathematically related to the survival 
function. Cox regression assumes that the relative hazards do not change over time 
(“proportional hazards”). Whether this assumption holds can be investigated in many different 
ways. In this thesis the proportional hazard assumption was assessed by testing for an 
interaction between given exposures and time (437). Using Cox regression allowed me to 
derive hazard ratios and 95% CI.  
2.3.4.6. Poisson regression  
Another model that can be used to analyse data with varying follow-up time is Poisson 
regression. Poisson takes a form similar to linear regression, although the outcome in this case 
is a count variable. Poisson regression uses a link function to transform the mean response Y to 
the natural logarithm of Y (Equation 2.6) (447).  
Equation 2.6. Poisson regression 
 
In order to use Poisson regression to model a rate rather than counts, we need to use the 
number of events per exposure time (Y/exposure time, i.e. the rate) as the outcome rather 
than just the count (Y). By multiplying both sides of the regression equation with the exposure 
time (t), the exposure time variable can be moved to the right-hand side of the equation. As 
both sides of the equations are log-link transformed, the final regression equation will have 
the natural logarithm of the exposure time added to the regression coefficients (Equation 2.7).  
Equation 2.7. Poisson regression with an offset 
 
The natural logarithm of the exposure time in the above equation is called an offset variable, 
and its regression coefficient is constrained to be 1. After including the offset, the 
exponentiated outcome variable represents the incidence rate (448). Poisson regression can 
therefore be used to derive incidence rate ratios, together with 95% CI and p-values. In a 
model with only the intercept β0, this term will equal the incidence rate in the population. Cox 
and Poisson regression can both be used for time to event data, although there are some key 
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differences between these two modelling approaches. In Poisson regression, the baseline rate 
is modelled directly and assumed to be constant over time within strata of the included 
exposures (437). In contrast, the baseline hazard is not directly modelled in Cox regression, 
and therefore no assumptions regarding its shape have to be made. This makes Cox regression 
a semi-parametric model. The hazard can also vary over time without breaking any model 
assumptions, presuming that the ratio of the hazards remains constant. This means that for 
data where the rate of the outcome is expected to change quickly, Cox regression may be 
more appropriate than Poisson regression. However, in most instances changing rates can be 
taken into account by including time-updated covariates in a Poisson model, and both types of 
models tend to give similar answers (437).  
2.3.5. Principal Component Analysis 
Principal component analysis (PCA) is a variable reduction technique that takes a number of 
correlated variables and transforms them into a smaller set of variables that are no longer 
linearly correlated (449). These new variables are referred to as principal components. 
Although a detailed explanation of the mathematics underlying PCA is outside the scope of this 
thesis, it can be understood graphically as a procedure which rotates values in a dataset into a 
set of new positions (450). These positions are chosen so that the axes of the new dataset lie in 
the direction of the greatest variability (Figure 2.7). The new axes are the principal 
components, and the transformed data values represent values on a given principal 
component. It is common to choose new axes, or components, that lie perpendicular to each 
other, as this ensures that the components are linearly unrelated. This type of rotation is called 
an orthogonal rotation, and a commonly used orthogonal rotation is the Varimax rotation 
(451).  
Figure 2.7. A basic illustration of the PCA principle 
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The number of principal components extracted from a PCA is always the same as the number 
of variables entered into it, but the amount of the total variance that is explained by each 
component differs. What proportion of the variance that is explained by a given component is 
given by its eigenvalue (450). As the aim of PCA is to reduce the number of variables in a 
dataset, a decision has to be made as to how many components should be retained. A 
common strategy is to retain all components with an eigenvalue greater than one, which 
indicates that a component explains more of the total variance than a single variable (451). 
Another way is to utilise a scree plot. A scree plot is a plot of the components against their 
eigenvalues. The number of components to retain is indicated by a breakpoint (Figure 2.8), and 
it is common practice to retain all components above a certain breakpoint (451). In this thesis 
the latter strategy has been chosen, as retaining all components with eigenvalues larger than 
one can result in a very large number of components if the dataset is large and the variables 
entered into the PCA only weakly correlated.  
Figure 2.8. Example of a scree plot 
 
 
 
 
 
 
 
 
As described above, each variable entered into the PCA will have a certain value on each 
extracted component. If a variable has a high value on an extracted component this indicates 
that it contributes strongly to that component, and it is said to “load” onto that component. A 
cut-off of 0.4 is commonly used to identify significant loadings (451). By looking at which 
variables load onto a component, it is possible to construct interpretations of what pattern a 
given component is describing. I used PCA as a tool to study patterns of mutations. Mutations 
were entered as binary variables into the PCA, and clusters of mutations were identified by 
studying which mutations loaded significantly onto each component.  
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It is possible to use the loadings of variables to construct component based scores for each 
individual in the dataset. These scores indicate how closely an individual’s data pattern aligns 
with that described by the extracted components. I used component based scores to study the 
impact of clusters of mutations on pre-specified outcomes (see Chapter 5 and 7). For 
simplicity, a binary cut-off point using the 75th percentile was used to categorise an individual’s 
mutational pattern as either “mostly conforming” or “not conforming” to a mutational 
pattern.  
2.3.6. Issues in statistical modelling 
 
2.3.6.1. Confounding and effect modification 
A confounding factor (CF) has classically been defined as a variable that is associated with the 
exposure (E), is an independent risk factor of the outcome (O) and not on the causal pathway 
between the exposure and outcome (Figure 2.9).  
Figure 2.9. Classical illustration of confounding 
 
 
 
Source: (452) 
In this representation, the confounding factor can be seen as a common cause of both the 
outcome and the exposure. The presence of confounding can both decrease and amplify the 
observed effect of an exposure on an outcome, and in some instances even reverse the 
observed association. A typical confounder in HIV research and indeed most epidemiological 
studies is age. For example, when studying the effect of a given treatment on mortality, age 
can act as a confounder as it determines the probability of death and it is conceivable that the 
probability of receiving a particular treatment will vary with age. In this hypothetical example 
age is a common cause of both receiving the treatment and death, and it is not on the causal 
pathway.  
It is important to account for confounding, either through study design or analysis. Accounting 
for confounding through study design can be achieved through randomization (if the study size 
is sufficiently large), through restricting entrance into the study to individuals who fall into a 
specific category of the confounder or through matching, where subjects are selected so that 
levels of the confounder are distributed equally in all study groups (447). Confounding can also 
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be adjusted for in multivariable models. By including a suspected confounder as a covariate in 
a regression model, inferences for the exposure of interest are done conditional on the 
confounding variables. The benefit of controlling for confounding in statistical models is that 
many confounders can be taken into account simultaneously (453).  
A concept similar to but distinct from confounding is that of effect modification. Effect 
modification refers to the process by which an exposure has a different effect on the outcome 
in different strata of an effect modifier. Effect modification is sometimes called interaction. 
Interactions can be quantitative (same direction of effect, different magnitude) or qualitative 
(opposite direction of the effect). The first is sometimes called synergy, the latter antagonism. 
For a hypothetical example of effect modification, consider the effect of a drug on the risk of 
death. If a particular drug decreases the risk of death among men whereas it increases the risk 
of death among women, this would be an example of qualitative effect modification by 
gender.  
Interactions may be of clinical or policy-related interest, and the aim should be to describe 
rather than to adjust for them. It is not routine to test for all possible interactions, as statistical 
significance is dependent on the sample size (452) and the likelihood of finding a false positive 
increases with the number of tests done (see Section 2.3.6.5). Instead, possible interactions 
that are deemed to be of clinical interest (and therefore, which should be investigated) are 
decided upon a-priori. 
2.3.6.2. Directed acyclic graphs and model selection  
In this thesis, I used the findings from my literature reviews and discussions with clinical and 
statistical experts to identify potential confounders or relevant risk factors. I also used Directed 
Acyclic Graphs (DAG) as a visual aid to support the selection of variables for inclusion in the 
multivariable models where the aim was to identify the casual effect of a single exposure on an 
outcome (454–457). DAGs are graphical representations of assumed relationships between the 
exposure of interest, covariates and the outcome. DAGs aim to identify a set of minimally 
sufficient confounders that need to be adjusted for in order to estimate a causal effect, by 
taking into account the potential for biases that can be induced through adjustment (458–
461). A key to the symbols commonly used in a DAG (as drawn by the program DAGitty) can be 
found in Figure 2.10. below, and an example DAG shown in Figure 2.11.  
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Figure 2.10. Key to symbols used in DAGs 
 
 
 
 
 
 
 
 
Figure 2.11. A simple example DAG 
 
 
 
 
 
In the DAG above, the exposure (E) is associated with an outcome (D). In this example, there is 
one confounder Z, which is a common cause of both E and D. This is the classical definition of 
confounding. A is a cause of the exposure, but as it is not a cause of the outcome, it is not a 
confounder. B is associated with the outcome, but as it’s not a cause of the exposure, it is not a 
confounder. This DAG implies that only adjustment for Z is necessary to estimate the direct 
total effect of E on D, and that additional adjustment for A or B would be unnecessary.  
DAGs have been used in epidemiology to illustrate the types of biases that can be introduced 
through adjustment from confounders (458,461–463). One such potential bias is called 
collider-stratification bias (458,459). Briefly, a collider is any variable that is the descendant (or 
effect) of any two variables. An illustration of a collider (Z) is provided in Figure 2.12 below.  
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Figure 2.12. Illustration of a collider 
 
 
 
 
 
 
 
In Figure 2.12, Z is a collider as it is a descendant of two different variables: A and B. Bias arises 
when such a collider variable is adjusted for, as associations among the causes of a collider 
change upon adjustment for it. Using the illustration provided in Figure 2.12: if Z is adjusted 
for, this will induce an association between A and B that was not previously there, which can 
introduce bias if the aim is to accurately describe the association between E and D. An applied 
example of collider-stratification bias is a classical epidemiological bias, Berkson’s bias 
(464,465). Berkson’s bias can occur when both cases and controls in a case-control study are 
sampled from a hospital. If the aim is to describe an association between two diseases, 
sampling participants from a hospital could make it appear as if two diseases are associated 
even though they are not, because people with two diseases are more likely to be hospitalised 
than people with one disease. In other words, selecting people conditional on their 
hospitalisation (H), will introduce a spurious association between disease one (D1) and disease 
two (D2). This is illustrated using a DAG in Figure 2.13.  
Figure 2.13. Berkson’s bias, illustrated using DAG’s (adapted from Snoep et al (464))  
 
 
 
 
Graph theory generalises an intuitive situation such as Berkson’s bias, and predicts that bias 
can be introduced following stratification on any collider in given scenarios (458). This 
illustrates why, when the aim is to estimate a causal effect of one exposure on one outcome, 
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DAGs can offer some advantages compared to traditional epidemiological methods, such as 
forward/backward selection or change-in-estimate approaches in terms of guiding the model 
building. However, DAGs rely on a set of assumptions. The key assumption is that the DAG 
accurately reflects the true causal relations between the variables, that no variable that causes 
any pair of variables is missing and that variables are measured without error. Although these 
are strong assumptions, all model building strategies imply a particular causal structure (466). 
A benefit of DAGs is that they make the assumptions regarding the causal relationships 
transparent, which allows it to be critically assessed and improved (457).  
I used the free open source software DAGitty (467) to construct DAGs for the main models in 
Chapters 5, 6 and 7, where the aims were to estimate causal effects. For these chapters, DAGs 
were used after potential confounders had been identified through literature reviews and 
discussions with experts in the field. Their function was as a visual aid, representing the 
thought process behind covariate adjustment, and as a check to ensure that bias, such as 
collider-stratification bias, was not introduced through over-adjustments.  
 
2.3.6.3. Dealing with repeated measures  
Including repeated measures taken over time on the same individual introduces correlation 
into a dataset. This is because measures taken from the same individual are likely to be more 
similar than measures taken from different individuals. This can overinflate the power of an 
analysis unless it is taken into account. To deal with repeated measures (Chapter 3, 5, 6 and 7) 
I used different techniques. In Chapter 3 and 6, generalised estimating equations (GEE) which 
account for the correlation through the specification of a ‘working’ correlation matrix were 
used (468). These allowed me to estimate population-averaged odds or rate ratios for the 
association between the risk factors and the outcomes. For Chapter 5 and 7 I used mixed 
models, which include random as well as fixed effects (469). Specifying a variable as a random 
effect allows predicted values for that variable to vary across individuals. Fixed effects on the 
other hand are constrained to have the same predicted coefficients across subjects. Mixed 
models combine subject-specific estimates from random effects to derive an overall regression 
parameter that is corrected for the correlation in the data. The key difference between GEE 
and mixed methods approaches is that the parameter estimates derived from mixed models 
are subject-specific, while those estimated in GEE are population-averaged. Although these 
differences are rather minor, it does influence the interpretation of the effect estimates. 
However, for the linear mixed model applied in this thesis, the parameter estimates are equal 
to the population-averaged estimates (470). The other main difference between GEE and 
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mixed models lie in that mixed models estimate and model the variance and covariance 
explicitly, whereas the covariance is treated as a nuisance parameter in GEE.  
2.3.6.4. Dealing with missing data 
Missing data is a common problem in analyses of cohort studies. In this thesis I used two 
different approaches in situations where the value of a covariate was missing for some of the 
participants. For variables where the amount of missing data was low and therefore did not 
drastically reduce the analysis population, I used a complete-case strategy whereby data lines 
with missing data was excluded from the model. This method can produce unbiased estimates 
when the data is missing completely at random, although this is rarely the case (447). 
However, when the number of individuals with missing data was large, an indicator variable 
for the missing category was included in the analyses. This increases statistical power and 
reduces the risk of selection bias, but may also introduce bias (447). Although advanced 
methods to account for missing data, including multiple imputation, may be preferable to the 
complete-case or missing-indicator method, they can also lead to bias (471), and it is 
important that all strategies for dealing with missing data are clearly specified and that the 
limitations of the chosen approach are made clear (472).  
2.3.7. Analytical software  
The analyses for this PhD thesis were carried out using SAS software, version 9.3 and 9.4 of the 
SAS System for Windows (SAS Institute Inc., Cary, NC, USA). Figures were created using 
Microsoft Office (Excel and PowerPoint) unless otherwise specified.  
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Chapter 3 . Patterns of Resistance Testing and 
Detected Drug Resistance in Europe 
 
3.1. Introduction and Objectives  
Due to the potential for drug resistance to limit the efficacy of specific ART drugs both on an 
individual and on a population level, it is important to monitor and study trends in the 
prevalence of drug resistance. The key issue when using routine data from clinical cohorts to 
estimate the prevalence of resistance is that not everyone who fails therapy with drug 
resistance will have a genotypic resistance test (GRT) result available (473). Genotypic 
resistance testing is recommended for all individuals in high income settings before the start of 
cART as well as after treatment failure (146,147). These recommendations are built on 
evidence from a number of clinical trials conducted primarily in the period 1999-2004 (Table 
1.4, page 70). Since this time a number of new drugs and drug classes to use following 
virological failure (VF) have become available and patient populations have changed, both of 
which could limit the generalisability of these early trial findings. The evidence supporting the 
use of drug resistance testing as part of routine clinical care was questioned by Dunn et al. as 
early as 2004 (404), and it is likely that guidelines recommending universal resistance testing 
are not always followed in clinical practice. Although doubts surrounding the evidence 
supporting the use of routine GRT may be one of the reasons that clinical practice diverges 
from guidelines, a range of other factors are also likely to affect whether a GRT is done for a 
particular patient. These include the changing clinical context, a growing motivation to only 
use cost-effective or cost-saving interventions and limited availability of equipment and 
technical competency in low income settings.  
Taken together, these factors have led to a changing and selected proportion of individuals 
being tested for drug resistance over time, which in turn complicates the choice of 
denominator for resistance prevalence analyses. A number of different approaches have been 
taken, which have resulted in different denominators being used in different studies. The 
possible denominators that could be used to estimate the prevalence of resistance in a 
population are:  
i) the total number of genotypic tests (474,475) 
ii) the total number of individuals with virological failure (VF) (476,477), 
iii) the total number of individuals treated (478,479)  
109 
 
iv) the total population available irrespective of treatment history (480) 
There have also been some attempts to estimate the resistance prevalence among those with 
no test result available, using multiple imputation (MI) (473) and data completion algorithms 
(481). All of the above approaches have advantages and limitations, and can be used to answer 
different questions (479). Using the whole treated population as the denominator gives an 
indication of the population burden of resistance, which is useful for public health planning 
(479). However, this requires comprehensive coverage of genotypic data, as it presumes that 
all those without a resistance test did not have resistance (473). Using the total number of 
individuals with VF as the denominator requires making a similar assumption: that all those 
who experience VF fail due to resistance, and not due to other factors such as poor adherence. 
Using the total number of GRTs as the denominator avoids making such assumptions at the 
cost of limited generalisability. Prevalence estimates using this denominator instead describe 
the clinical experience; that is, the probability of detecting resistance given that a test is done. 
Although the use of multiple imputation avoids making the strong assumptions outlined for 
the first two denominators to a certain extent, the accuracy of these estimates is still 
dependent on a number of assumptions, and the final estimates describe the burden of 
resistance in the population rather than the situation in clinics.  
In this chapter I take approach (i), and use the total number of GRTs as the denominator in 
order to estimate the probability of detecting drug resistance over time in clinics. In order to 
provide a context for these estimates, I also describe trends in the probability of receiving a 
resistance test after VF, as well as predictors for receiving a resistance test.  
The specific objectives of my analysis are:  
1)  
a. To estimate the proportion of individuals who received a resistance test after VF 
per calendar year of follow-up (FU) 
b. To identify predictors of receiving a resistance test among those who experience 
VF 
 
2)   
a. To estimate the proportion of individuals in EuroSIDA who have detected 
resistance per calendar year of FU.  
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b. To identify predictors of having detected resistance among those who 
experienced VF and had a resistance test result available 
 
3.2. Literature Review  
A review of the literature relating to these aims was conducted according to the principles and 
pre-defined search strategies outlined in Chapter 2. The selection of papers can be seen in 
Figure 3.1, the studies are described briefly in Table 3.1 and Table 3.2, and the findings 
summarised below.  
3.2.1. Aim 1: Utilisation of resistance testing  
In this literature review, eight papers reporting on the use of resistance testing were identified 
(Figure 3.1). Overall, these studies suggested a marked variation in the utilisation of resistance 
testing according to the setting and time-period studied. However, all studies found that the 
rate of resistance testing following VF is lower than the level which is recommended in current 
guidelines, which advises universal testing (Table 3.1). Pillay et al., in 2005, studied resistance 
prevalence in the UK in the period of 1999-2002. They found that around 30% of treatment 
switches were guided by a resistance test done within the 6 months preceding a switch (479). 
This is a relatively similar result to an analysis of data from the US HIV Outpatient Study (HOPS) 
cohort 1999-2005. Of 2,699 individuals who experienced virological failure in their analysis, 
only 915 (34%) had a GRT (482). A previous EuroSIDA analysis studying resistance testing up 
until 2008 also found relatively low overall rates of resistance testing (36.2%) (483). However, 
other cohort studies from the US (481,484) and Canada (475,485) have found higher rates of 
resistance testing following failure, with estimates ranging from 45%-82%.  
In terms of time-trends, two studies identified for this literature review reported a decrease in 
the probability of receiving a resistance test after 2004 (483,485), three studies reported a 
stable proportion receiving a GRT over time in the time-periods 1999-2002 (479), 1999-2006 
(484) and 1997-2011 (478). Two studies reported an increase in the proportion of individuals 
who received a resistance test over time, one in the US (481) 2000-2005 and one in Canada 
(1997-2010) (475). 
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Figure 3.1. Identification of articles for the literature review studying the use of resistance testing (Aim 1) and the prevalence of resistance (Aim 2) 
 
 
 
 
 
 
 
 
 
1) 2) 
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1. REF=reference. 
Table 3.1. Papers reporting on the use and predictors of receiving a GRT following VF (Aim 1) 
Author Year Design and Setting Study Size Main Results  REF 
Cescon et al. 2014 Cohort study in Canada, 1997-
2010 
Not reported  The proportion of those with VF with a resistance test increased from 41% in 1997 to 
82% in 2010.  
(475) 
Bontell et al. 2013 Prospective analyses of all 
patients receiving care in 
Sweden, 1997-2011 
6,537 Found a relatively stable % received a GRT over time.  (478) 
Eyawo et al. 2011 Cohort study in Canada (LISA), 
2000 onwards 
651 Of individuals eligible for resistance testing due to VF, a majority received a GRT. 
37.6% did not receive a GRT. The odds of receiving a GRT were lower among 
individuals starting HAART in 2004 or later. The only other predictor of receiving a 
GRT was younger age.  
(485) 
Fox et al. 2011 Cohort study across Europe 
(EuroSIDA), 2002 onwards.  
1,090 Overall, 36.2% of VFs were followed by a resistance test. This proportion decreased 
in more recent calendar years. Predictors of having a resistance test included 
geographical region, having had a previous resistance test and calendar year.  
(483) 
Abraham et al. 2011 Cohort Study in the US (NA-
ACCORD), 2000-2005 
9,289 The proportion of those with VF with a resistance test increased from 55% in 2000 to 
62% in 2005.  
(481) 
Buchacz et al. 2010 Cohort Study in the US (HOPS), 
1999-2006 
3,995 Among patients with VF, 45% received a GRT at any point. This increased until 2003 
and stabilised at around 30% per year of those eligible for a test afterwards. 
Predictors of having a resistance test included older age, female gender, lower CD4 
count, higher VL and previous failure to at least two drug classes.  
(484) 
Palella et al. 2009 Cohort Study in the US (HOPS), 
1999-2005 
2,699 Of patients with VF, 915 (34%) had a GRT. Predictors of having a GRT were white 
race, MSM, having health insurance, a history of AIDS, low nadir CD4 and previous 
experience of mono/dual therapy.  
(482) 
Pillay et al. 2005 Cohort study in the UK, 1999-
2002 
4,218 with 
resistance: 
Denominator 
not reported 
Up until 2002, only about 30% of treatment switches in the cohort were preceded by 
a resistance test within 6 months; although this proportion remained reasonably 
stable between 1999-2002 
(479) 
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Table 3.2. Papers reporting the prevalence and predictors of detected drug resistance following a successful GRT (Aim 2) 
Author Year Design and Setting Study Size  Denominato
r 
Main Findings Summarised REF 
Franzetti et al. 2014 Cohort study in Italy (ARCA 
cohort), 2003-2012 
5,246  GRT Described resistance prevalence over time and found a marked decrease 
over calendar time for all classes (NRTI: 79-40%; NNRTI:78-54%; PI-60-
19%). Predictors of detecting resistance were: Gender, viral load (VL) at 
Failure, Previous VF and time.  
 (486) 
Paquet et al. 2014 Prospective analysis of the 
commercial database from 
Monogram Biosciences in San 
Francisco, 2003-2012 
62,397$ GRT Described resistance prevalence in sequences submitted to the laboratory. 
Found a marked decrease in PI and NRTI resistance (PI: 44-21%; NRTI:79-
57%), but an increase in NNRTI resistance (68-75%) 
 (480) 
Cescon et al. 2014 Cohort study from BC, Canada, 
1997-2010 
Not 
reported 
GRT Studying resistance prevalence among patients tested with an 
unsuppressed viral load; prevalence decreased from 52%-18%.  
 (475) 
Menezes et al. 2013 Cross-sectional study of 
prisoners in North Carolina, 
2006-2010 
367 ART Representative surveillance study reporting an overall population 
prevalence of 28% resistance among inmates.  
 (487) 
Bontell et al. 2013 Prospective analyses of all 
patients receiving care in 
Sweden, 1997-2011 
6,537 ALL Among all those treated for HIV, resistance to all drug three drug classes 
decreased over time. NRTI resistance decreased linearly, but resistance to 
NNRTI peaked in 2003-2004, decreased until 2007-2009 and increased in 
more recent calendar years. PI resistance peaked in 2001 and then 
decreased.  
 (478) 
De Luca et al. 2013 Cohort collaboration in 
Western Europe (SEHERE 
database), 1997-2008 
20,323 GRT Reported an overall resistance prevalence of 80% among individuals 
tested for resistance, and a significant decrease over time for all classes 
(overall: 81%-71%).  
 (488) 
Assoumou et 
al. 
2012 Cross-sectional analysis of the 
ANRS cohort in France in 2009 
506 GRT Resistance found in 59% of genotyped patients. Compared to a previous 
analysis from 2004, this was significantly lower.  
 (489) 
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Miller et al. 2012 Repeated cross-sectional 
analysis of the commercial 
database from Monogram 
Biosciences in San Francisco, 
2003 and 2010 
107,231 $ GRT Studied prevalence of individual NRTI mutations in sequences submitted 
to a laboratory. Found a decreased prevalence of several major NRTI 
resistance mutations in 2010 compared to 2004.  
(481) 
Abraham et al. 2011 Cohort study in the US (NA-
ACCORD), 200-2005 
9,289 ALL Found a decreasing trends in those with any cumulative resistance when 
only using the existing data among those tested, however when imputing 
data for all those failing therapy they found a stable or possibly increasing 
trend. Also found that the prevalence of resistance in the entire cohort 
was much lower than in those with testing.  
 (474) 
Bannister et al. 2011 Cross-sectional analysis using 
multiple imputation from the 
EuroSIDA cohort in 2008 
6,498 ART Estimated that the prevalence of drug resistance among 6498 patients 
receiving ART was 43% NRTI, 15% NNRTI and 25% PI resistance.  
 (473) 
Gill et al. 2010 Cohort study from BC, Canada, 
1997-2008 
5,422 ART Studied incidence rather than prevalence; found decreasing incidence of 
drug resistance among everyone receiving ART over time; from 1.73 cases 
with resistance per 100 PYFU to 0.13 cases per 100 PYFU.  
 (490) 
Buchacz et al. 2009 Cohort study in the US (HIV 
Outpatient Study), 1999-2008 
906 GRT Some evidence of a decrease in resistance among those tested; from 88% 
in 1999 to 79% in 2008, although this was not significant in regression 
models (p=0.054).  
 (491) 
Von Wyl et al. 2009 Cohort study in Switzerland 
(Swiss HIV Cohort Study), 1999-
2007 
8,064 ALL The overall prevalence of resistance among ART experienced patients 
decreased form 57% in 1999 to 45% in 2007. The overall prevalence using 
those experiencing VF or exposed to mono/dual therapy as the 
denominator was 77%.  
 (492) 
Audelin et al. 2009 Nationwide population based 
cohort in Denmark, 1998-2005 
1,829 ART Estimated incidence of resistance using all personyears of FU treated with 
HAART as the denominator. Found a decrease over time in the incidence 
of resistance to all 3 major drug classes.  
 (493) 
Rumyantseva 
et al. 
2009 Phylogenetic analysis from 
Russia 
47 VF Among individuals experiencing VF on HAART, only 45% had detected 
resistance.  
 (494) 
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Santoro et al. 2008 Cross-sectional analyses from a 
clinic in Bulgaria, 2002-2006  
58 GRT Among patients with ARV experience and a plasma sample that could be 
genotyped, 70.1% were found to have any drug resistance. 
 (495) 
Vercauteren et 
al. 
2008 Cohort study of a Portuguese 
resistance database, 2001-2006 
3,394 $ GRT In a total of 3394 sequences and using the total number of tests available 
as the denominator, the authors found a decrease in the prevalence of 
multi-class resistance; from 5.7 in 2001 to 2.7% in 2006 (however, as 
resistance was not carried forward in a cumulative manner this is referred 
to as incidence by the authors). Time on therapy was a significant 
predictor of multi class resistance.  
 (496) 
McColll et al. 2008 Prospective analysis of the 
commercial database from 
Monogram Biosciences in San 
Francisco, 2003-2006 
60,487 $ GRT Studied trends in NRTI resistance among clinical isolates. Found down-
ward time-trends in individual NRTI mutations.  
 (497) 
Costagliola et 
al. 
2007 Cross-sectional analysis of ANRS 
cohort data from France, 2004 
488 VF Of 488 patients with VF, 88% (ANRS) or 83% (Stanford) had detected 
resistance 
 (477) 
Napravnik et 
al. 
2007 Cross-sectional analysis of US 
cohort 
1,724 ART Of patients receiving some form of ART, 8% had resistance to all 3 drug 
classes. Predictors of TCR included nadir CD4, peak RNA, a previous AIDS 
defining condition, earlier calendar year of ART initiation, a history of non-
HAART initial therapy and receiving a greater number of antiretroviral 
drugs.  
 (498) 
Garcia-
Guerrero et al. 
2006 Cross-sectional analysis of 
prisoners in Spain 
90 ART 38.6% of all treatment experienced prisoners were estimated to harbour 
resistance to any drug.  
 (499) 
Tozzi et al. 2006 Cohort study at a hospital in 
Rome, Italy 
602 VF 28.5% had class-wide NRTI resistance, 57.7% had class wide NNRTI 
resistance and 19.9% had PI class wide resistance. Time on treatment and 
a history of more previous regimens increased the odds of having class-
wide resistance. AIDS was associated with an increased risk of class-wide 
resistance. Female gender and younger age decreased the odds of PI class 
wide resistance. Lower viral load was not associated with class-wide 
resistance to NNRTI or NRTI, but marginally associated with a lower risk of 
class-wide PI resistance.  
(500) 
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Pillay et al. 2005 Cohort study in the UK (UK CHIC 
and HIV DRB), 1998-2002 
4,218 GRT Among patients tested for resistance, resistance prevalence remained 
fairly constant between 75% and 82%. Using all patients receiving 
treatment as the denominator, the prevalence of resistance to any drugs 
increased until 2000 and then stabilised at around 17%.  
 (479) 
Phillips et al. 2005 Cohort study in the UK (UK CHIC 
and UK HIVDRB), 1998-2005 
4,306 ART The long-term probability of developing resistance among patients who 
started ART with 3 or more drugs was estimated at 26% by 6 years. There 
was no evidence that the probability of detecting resistance at 2 years 
after the start of ART had decreased during the study period. Predictors of 
resistance included younger age, starting ART with a high VL, having an 
unknown sexual risk group, having low CD4 count, previous AIDS and type 
of ART.  
 (501) 
Richman et al. 2004 Cross-sectional analysis of 
cohort study in the US (HCSUS 
study), 1998 
1,797 VF Cross-sectional estimate of resistance prevalence in 1998 was 76.3% 
among those experiencing VF and 48% among all of those treated. 
Predictors of resistance were advanced HIV disease, Current Viral Load, 
CD4 nadir, Sexual Risk Group, Insurance Coverage and Education Level. In 
multivariable analyses only current viral load and CD4 nadir was 
associated with higher odds of detecting resistance.  
 (476) 
Holodniy et al. 2004 Cross-sectional study in San 
Francisco, 2004 
168 ART Estimated that the prevalence of resistance among 168 treatment 
experienced patients was 36%. Predictors of resistance included race, 
health, insurance and ARV history.  
 (502) 
Scott et al. 2004 Surveillance estimates from the 
UK, 1998-2000 
300 ART Estimated that the prevalence of any resistance among those treated for 
HIV in the UK was 27% in 1998, 41% in 1999 and 27% in 2000.  
 (503) 
Tamalet et al. 2003 Prospective study of a hospital 
database in France, 1999-2002 
7,799 GRT Among genotyped patients, the overall prevalence of resistance was 78% 
NRTI, 39% NNRTI and 47% PI. NRTI trends were stable throughout the 
study period, whereas NNRTI and PI prevalence increased dramatically in 
the early 90s.  
 (504) 
Gallego et al. 2002 Cross-sectional study in Spain, 
2002 
540 VF Among patients who experienced failure, 79% had drug resistance; 77% 
NRTI, 53% PI and 42% PI.  
 (505) 
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Plettenberg et 
al. 
2001 Cross-sectional analysis from a 
hospital in Hamburg, 2001 
52 VF Found a resistance prevalence of 80% among heavily pre-treated patients 
experiencing VF.  
 (506) 
1. REF=reference.  
$ Where possible, the number of individuals who contributed data was reported. When only the number of sequences was reported in the paper, this number is given an instead, highlighted with 
the symbol. 
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3.2.2. Predictors of receiving a resistance test 
Predictors of receiving a resistance test varied across study settings, and included 
demographics such as age (484,485), gender (491) , and risk group (482), as well as clinical 
variables such as low current CD4 count, low CD4 nadir, and having a higher current VL 
(482,491). A history of mono/dual therapy or a previous resistance test was also reported to 
increase the probability of receiving resistance test in several studies (482,483,491).  
3.2.3. Aim 2: prevalence of HIV drug resistance in high income settings  
32 articles describing the prevalence of drug resistance in a variety of setting over different 
time-periods were identified (Figure 3.1). Of these, 13 used the proportion with a resistance 
test, 10 used the population of all treated individuals as the denominator and six used the 
proportion treated and experiencing failure, and. Finally, three reported comparative 
estimates using several different denominators (Table 3.2). Among the studies reporting it, the 
prevalence of resistance to any drug class varied from 59%-88% when using those tested for 
resistance as the denominator, 28-48% when using the population of treated individuals as the 
denominator and 45%-80% when using the population of treated individuals experiencing 
virological failure as the denominator. All studies that reported class-wide resistance found 
that NRTI resistance was more commonly detected than both NNRTI and PI resistance (Table 
3.2).  
Several studies reported on time-trends in resistance prevalence, with results differing 
somewhat depending on time-period, region of study and the denominator used. A recent 
study by Franzetti et al. analysing time-trends between 2003 and 2012 among individuals 
experiencing VF who were tested for resistance in Italy reported a marked decrease in the 
prevalence of resistance for both NRTI, NNRTI and PI resistance (486). This echoes the results 
of a 2013 study by De Luca et al., which studied trends in resistance prevalence among over 
20,000 individuals with a genotype from the SEHERE collaboration in Western Europe. They 
reported a decrease over time for the prevalence of any resistance, as well as class-specific 
resistance and triple-class resistance (474). A decrease in resistance prevalence among those 
with a GRT has also been reported in Canada (475), France (488) and, looking at triple-class 
resistance specifically, in Portugal (496). Studies using the population of all treated individuals 
as the denominator have also reported a decrease in resistance prevalence over time in 
Canada (490), Denmark (493), Sweden (478), and Switzerland (492).  
Some of these studies have reported a more marked resistance decrease after 2004 for NNRTI 
resistance, and a somewhat earlier peak for PI and NRTI resistance; with the highest 
prevalence estimates for these drug classes found around 2001 (478,507) . This is in 
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agreement with a number of studies conducted before 2002 that reported increasing or stable 
resistance prevalence for all drug classes before this time (479,503,504). 
Data from the USA are more ambiguous. A recent study of resistance prevalence using 
sequences in the Monogram Biosciences commercial database in San Francisco found evidence 
of a decrease in NRTI and PI resistance, but an increase in NNRTI resistance (480). A study from 
the HIV outpatient study (HOPS) reported on an overall decrease in the prevalence of 
resistance, from 88% of those with a GRT in 1999 to 79% in 2008; however the statistical 
evidence supporting this decrease was of borderline statistical significance (p=0.054) (491). A 
study of resistance data in the US NA-ACCORD collaboration found a decreasing trend in 
resistance prevalence when using the individuals with a resistance test as the denominator, 
but when imputing data for all those with a missing GRT and using the number of people 
failing therapy as the denominator they found stable resistance trends (481).  
3.2.4. Predictors of detecting drug resistance  
Those studies that reported on predictors of drug resistance have found that gender (486), 
sexual risk group (474,501), VL at failure (476,486) or at the start of therapy (501), a previous 
VF (486), history of AIDS (476,501), low CD4 counts (476,501), type of ART (474,501) and 
subtype (474) were associated with the risk of detection of any resistance. Time spent on 
therapy (496,498,500), nadir CD4, peak VL, a history of AIDS and exposure to a greater number 
of antiretroviral drugs (498) have been associated with the detection of triple class resistance. 
3.2.5. What the current analysis adds 
As shown in this literature review, previous analyses of resistance testing have only reported 
on time-trends up until 2008, and there is a lack of data on how clinicians use resistance 
testing in more recent calendar years. Although there is a lot of published data on time-trends 
in resistance, most of the reported data is either country-specific or, where data is reported on 
a European level, restricted to countries in Western Europe with data from other European 
regions more scarce. Comparative estimates of the risk of detecting resistance in geographical 
regions of Europe have also not been reported. EuroSIDA is the ideal setting for this type of 
analysis as people from different regions of Europe are enrolled following standardised 
inclusion criteria and monitoring procedures.  
3.3. Methods  
3.3.1. Inclusion Criteria 
This analysis used the D36 update of the EuroSIDA database, which includes 18,473 individuals. 
The selection process for inclusion in the analysis can be seen in Figure 3.2.  
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Figure 3.2. Selection of individuals for inclusion in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my first aim, looking at the utilisation of and predictors of resistance testing, I included 
individuals who had evidence of VF after the 1st of January 1997. I defined VF as having a single 
viral load (VL) measurement >500 copies/mL while on ART after at least 6 months of ART 
exposure. This is in line with the EACS recommendations at the time the analysis was conducted 
(2013) (147). Although this is the main definition, a large number of alternative definitions of VF 
were considered (described in detail in section 3.3.4, page 122). I consciously used a broad 
definition of VF for my primary analysis in order to maximise the number of individuals that we 
could include. I only considered VFs occurring after 1997, as this was when resistance data was 
first collected in EuroSIDA. For any given calendar year, a person was included in the 
denominator if they experienced VF in that year, and considered as having a resistance test 
associated with the VF (numerator) in that year if they had a resistance test no more than one 
month before or 12 months after the date of VF. If the same resistance test could be linked to 
more than one VF date in different calendar years, it was attributed to the VF date occurring 
closest to the test.  
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For the second aim of studying the prevalence and predictors of detected drug resistance, I 
included individuals who had a resistance test as well as genotypic results from this test. 
Individuals could contribute data for more than one calendar year if they had GRT and GRT 
results corresponding to multiple VF episodes, and were not excluded after they had their first 
VF or resistance test. The characteristics of the study population at the time of their first included 
VF were summarised using standard summary statistics and tests (section 2.3.2, page 95).  
3.3.2. Resistance data 
The structure of the EuroSIDA resistance data is described in detail in Chapter 2, Section 2.2.14. 
For all analyses, retrospective resistance tests - where the resistance results had been obtained 
from retrospectively testing samples stored in the EuroSIDA repository - were excluded. The 
rationale for excluding these tests was that it is difficult to establish whether these GRTs would 
also have been prescribed as part of routine practice. For the first aim, I therefore considered 
the date of all prospective resistance tests available in the EuroSIDA resistance database. I also 
considered a variable entered separately by the clinician on the case report form (CRF) which 
indicated the date of the latest resistance test. Where this did not overlap with the data in the 
EuroSIDA resistance database, I used this as an indicator that a separate resistance test had been 
performed. This latter variable did not have genotypic data associated with it, and these tests 
were therefore not counted for my second aim.  
Resistance mutations were defined using the IAS-USA (2013) guidelines (335). Throughout the 
chapter, ‘any resistance mutation’ will refer to >1 detected IAS-USA resistance mutation to NRTI, 
NNRTI or PI drug classes, excluding minor PI mutations. Resistance to other drug classes, such 
as fusion or integrase inhibitors, is not routinely collected and was therefore not considered for 
this analysis. Integrase resistance is discussed in more detail in Chapter 4. As the aim of the 
analysis was not to estimate the current level of resistance likely to present in participants’ body 
at the time of current GRT, but simply the probability to detect resistance at the specific point 
in time when the person was tested, resistance mutations detected in previous GRTs were not 
carried forward in a cumulative manner. 
3.3.3. Statistical methods 
The proportion of individuals with a resistance test following virological failure, and detected 
resistance after having a test, was plotted against calendar year with 95% confidence intervals 
(CI). Logistic regression models with generalised estimating equations (GEE) (508,509) were 
used to identify predictors and to test for changes in the prevalence of resistance testing and 
detected resistance. The GEE allowed me to account for non- independence of the statistical 
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units (people contributing to more than one year) in the model. The covariates and their 
categorisation is listed in Table 3.3.  
Table 3.3 Categorisation of variables of interest  
Variable Categories Time-updated 
Gender Female; Male No 
Ethnicity White, Non-white No 
Age Continuous (per 10 years) No 
Mode of Transmission MSM; PWID; Heterosexual; Other No 
Geographical Region Southern, Central West, 
Northern, Central East, Eastern 
No 
Type of ARV used at VF PI (boosted), PI (unboosted), 
NNRTI, PI and NNRTI, Neither PI 
or NNRTI  
No 
History of mono-dual 
therapy 
Yes, No No 
VL at VF <1000, 1000-10000, 10000-
50000, >50000 
No 
CD4 at VF  Continuous, per 100 cells/mm3 
higher 
No 
Number of previous 
resistance tests  
None, 1, 2-4 ,>4 No 
HIV Subtype1 B, Non-B, Unknown No 
Mono or dual therapy 
before cART 
Yes, No No 
Calendar Year of VF  97-98, 99-00, 01-02, 03-04, 05-06 
07-08, 09-10, 11-12 
No 
1. Only in the model of resistance prevalence 
3.3.4. Sensitivity, sub group and exploratory analyses 
Several sensitivity analyses were performed using a number of definitions of virological failure, 
as well as number of sub-group and exploratory analyses. The main analysis was considered 
definition A.  
Sensitivity analyses:  
Definition B: Defining VF as at least two consecutive measures >500 instead of a single 
value, after at least 6 months on ART.  
Definition C: Defining VF as a single value above the detection limit of the test used 
after at least 6 months on ART (cut-offs ranging from 20 copies/mL to 1000 
copies/mL).  
Definition D: Defining VF as a single VL >1000 (instead of >500) after at least 6 months 
on ART. 
 
The rationale for these analyses was to test how much the results may vary depending on the 
type of viral load assay used as well as the exact definition of VF.  
123 
 
 
Sub-group and exploratory analyses:  
Definition E: Primary VF definition (A), but also requiring an individual to have supressed 
VL to <500 before a subsequent failure could be included in the analysis.  
Definition F: Primary VF definition (A), but also requiring that a VF was followed by a 
switch to a drug belonging to a class that was not included in the regimen started >6 
months earlier. 
The rationale for these analyses was to disentangle the effect that poor adherence, which may 
discourage a clinician to switch an individual’s medication, may have on my results. 
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3.4. Results  
3.4.1.Resistance testing 
3.4.1.1. Trends in resistance testing 
Of the 8,469 individuals experiencing virological failure, 2,676 (31.6%) were tested for 
resistance in at least one of the years in which they had evidence of VF. Among those who had 
a test, the median time between the date of VF and a resistance test was 0.7 months (IQR: 0-4 
months; range: -1–12 months). Of those with at least one resistance test, 60.7% had one test, 
23.5% had two tests, 8.5% had three tests and 7.3% had four or more resistance tests 
performed over the calendar years in which they contributed data. The proportion of 
individuals with a resistance test around the time of VF increased from just 2% in 1997 to 29% 
in 2004 and then declined back to 7.7% in 2012; Figure 3.3) 
3.4.1.2. Factors associated with the probability of having a resistance test  
The association between calendar year of VF and the probability of having a resistance test 
was confirmed in multivariable analysis (global p<.001, Table 3.4). Other predictors of having a 
resistance test around the date of VF included region: compared to Southern Europe, 
individuals were more likely to be tested for resistance in Northern Europe (aOR=2.15, 
95%CI=1.96-2.36, p<.001) and Central Western Europe (aOR=1.66, 95%CI=1.51-1.82, p<.001). 
In contrast, individuals in Eastern Europe were less likely to be tested for resistance (aOR=0.72, 
95%CI=0.55-0.94, p=0.02) compared to individuals in Southern Europe. Due to a small number 
of individuals being tested for resistance per region and per calendar year, I could not perform 
a formal interaction test as mathematical execution of the test was prevented by a lack of 
data. However, plotting the time-trends by region (Figure 3.3) showed that both the rise and 
decline in resistance testing following VF was somewhat more marked in Northern, Central 
Western, and Southern Europe when compared to Central Eastern and Eastern Europe. It is 
important to note that these trends are hard to interpret due to the small sample size within 
the subgroups. As expected, individuals with VL-levels of 1,000-10,000 copies/mL at VF were 
more likely to have a resistance test compared to individuals with lower viral loads (aOR=2.10, 
95%CI=1.86-2.37, p<.001 compared to 500-999 copies/mL, Table 3.4).  
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Figure 3.3. Proportion of individuals with a resistance test following VF overall (a) and by 
region (b) 
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Table 3.4. Factors associated with having a resistance test after VF 
Table X.  
    Unadjusted Adjusted1,2  
  OR (95% CI) p-value OR (95% CI) p-value Global p-value 
Age, per 10 year increase   1.26 (1.22 - 1.31) <.001 1.03 (0.99 - 1.08) 0.10 0.12 
 
CD4 at failure, per 100 increase2   0.99 (0.97 - 1.00) 0.09 1.01 (1.00 - 1.03) 0.07 0.08 
Gender Male  1.00    1.00   0.75 
  Female 0.86 (0.79 - 0.95) 0.002 0.98 (0.89 - 1.08) 0.75  
Ethnic Group White  1.00    1.00    
  Non-white 1.16 (1.04 - 1.30) 0.01 0.83 (0.75 - 0.92) <.001 <.001 
Risk Group MSM  1.00    1.00    
  PWID 0.68 (0.61 - 0.75) <.001 0.91 (0.82 - 1.00) 0.05 0.03 
  Heterosexual 0.88 (0.80 - 0.97) 0.01 1.03 (0.93 - 1.14) 0.54  
  Other 1.03 (0.89 - 1.20) 0.68 1.10 (0.96 - 1.26) 0.19  
Region South  1.00    1.00   <.001 
  Central West 1.56 (1.40 - 1.72) <.001 1.66 (1.51 - 1.82) <.001  
  North 2.03 (1.84 - 2.24) <.001 2.15 (1.96 - 2.36) <.001  
  Central East 0.98 (0.84 - 1.15) 0.82 0.94 (0.81 - 1.09) 0.41  
  East 0.55 (0.42 - 0.71) <.001 0.72 (0.55 - 0.94) 0.02  
ARVs used at failure PI (boosted)  1.00    1.00   0.01 
  PI (unboosted) 0.67 (0.58 - 0.76) <.001 0.92 (0.80 - 1.05) 0.202  
  NNRTI 1.08 (0.91 - 1.29) 0.36 1.11 (0.93 - 1.33) 0.24  
  PI and NNRTI 1.76 (1.58 - 1.96) <.001 0.96 (0.86 - 1.07) 0.49  
  Neither PI or NNRTI 0.50 (0.60 - 0.42) <.001 0.77 (0.65 - 0.91) 0.003  
History of mono/dual therapy No  1.00    1.00   0.48 
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1. The multivariable model is adjusted for all the variables listed in the table.  
2. 26 individuals were excluded from the model with CD4 count as a covariate as well as the multivariable model due to missing CD4 counts.  
  Yes 1.27 (1.15 - 1.40) <.001 0.96 (0.86 - 1.07) 0.47  
RNA at failure <1000  1.00    1.00   <.001 
  1000-10000 1.91 (1.71 - 2.14) <.001 2.10 (1.86 - 2.37) <.001  
  10000-50000 2.38 (2.12 - 2.67) <.001 2.74 (2.43 - 3.10) <.001  
  >50000 2.48 (2.18 - 2.82) <.001 2.68 (2.34 - 3.07) <.001  
Previous Resistance Test None  1.00    1.00   <.001 
  1 10.32 (9.26 - 11.51) <.001 6.26 (5.51 - 7.12) <.001  
  2-4 11.19 (9.72 - 12.89) <.001 6.76 (5.75 - 7.93) <.001  
  >4 14.85 (9.59 - 22.99) <.001 11.23 (7.04 - 17.92) <.001  
Previous Virological failure No  1.00    1.00   0.002 
  Yes 3.16 (2.88 - 3.46) <.001 1.19 (1.06 - 1.33) 0.003  
Calendar Year 97-98 0.08 (0.07 - 0.10) <.001 0.11 (0.09 - 0.14) <.001 <.001 
  99-00 0.39 (0.36 - 0.44) <.001 0.49 (0.43 - 0.55) <.001  
  01-02 0.75 (0.68 - 0.82) <.001 0.85 (0.76 - 0.95) 0.003  
  03-04  1.00    1.00    
  05-06 0.84 (0.75 - 0.94) 0.002 0.77 (0.68 - 0.89) <.001  
  07-08 0.52 (0.45 - 0.60) <.001 0.46 (0.39 - 0.54) <.001  
  09-10 0.32 (0.26 - 0.39) <.001 0.33 (0.27 - 0.41) <.001  
  11-12 0.22 (0.17 - 0.28) <.001 0.25 (0.19 - 0.32) <.001  
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Other factors associated with the probability of having a resistance test included ethnicity, 
with individuals of non-white ethnicity being less likely to receive a resistance test (aOR=0.83, 
95%CI=0.75-0.92, p<0.001) compared to individuals of white ethnicity. There was also some 
evidence that people who inject drugs (PWID) were less likely to receive a resistance test 
compared to men who have sex with men (MSM; aOR=0.91, 95%CI=0.82-1.00, p=0.05). 
Individuals with a history of mono or dual therapy before starting cART were more likely to 
receive a resistance test in univariable analyses compared to those who those who had no 
history of mono or dual therapy (unadjusted odds ratio [uOR]=1.27, 95%CI=1.15-1.40, 
p<0.001), but not after adjustment for previous VFs (aOR=0.96, 95%CI=0.86-1.07, p=0.47) 
which appeared to be the main confounder for this association. It is possible that there is some 
overlap between what these variables are trying to capture (exposure to previously 
inadequate treatment), and a phi correlation test showed a significant but moderate 
correlation between the two variables (phi=0.22, p<0.0001). However, collinearity did not 
appear to be a problem for the overall model (all variance inflation factors [VIF] < 1.5). 
Individuals who had previously experienced a VF were more likely to have a resistance test 
(p=0.003) as were individuals with a large number of prior resistance tests (p<0.001). The type 
of ARV therapy used at failure was also associated with the odds of receiving a resistance test, 
with individuals currently receiving aPI or an NNRTI sparing cART regimens being less likely to 
receive a resistance test (aOR=0.77, 95%CI=0.65-0.91 compared to people using boosted PI 
cART). I did not find any strong evidence supporting an association between gender or age and 
receiving a resistance test (p=0.12 and 0=0.88 respectively, Table 3.4).  
3.4.2. Detected drug resistance  
3.4.2.1.Trends in detected drug resistance 
In total, drug resistance was detected in 2,431 (77.9%) of the 3119 resistance test results 
included. The prevalence of mutations with a prevalence of >10% is shown in Figure 3.5. 
Overall, NRTI resistance was most commonly detected (in 70.3% of tests), followed by NNRTI 
(51.6%) and PI (46.1%) resistance. The most commonly detected individual mutations were 
M184V (46.3%, associated with NRTI resistance), K103NS (23.4%, associated with NNRTI 
resistance) and L90M (26.8%, associated with PI resistance).  
Changes in the proportion of individuals with detected drug resistance by calendar year can be 
seen in Figure 3.4, both overall and after stratification by drug class. Univariable models 
indicated that calendar year was associated with the risk of detection of drug resistance 
(global p <.001). This trend was not linear, and the prevalence appeared to increase until 2003-
2004, followed by a tendency towards a decrease. In 1997, just less than two thirds of the 
population had detected resistance, and this was somewhat higher (84%) by 2003. In 2012, an 
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estimated 79% of individuals had detected drug resistance. Comparing specific time periods in 
univariable models, I found strong evidence (all p<.01) that the odds of detecting resistance 
were lower in the years of 97-98, 99-00 and 09-10 compared to 03-04 (Table 3.5).  
Figure 3.4. Prevalence of detected drug resistance among individuals with GRT following VF, 
by drug class 
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Figure 3.5. Prevalence of detected drug resistance mutations (with a prevalence of >10%)1 
 
1. Absolute numbers in each category are shown on top of the bars.  
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3.4.2.2. Factors associated with the risk of detecting drug resistance 
The odds of detecting drug resistance varied by calendar time also in multivariable models 
(global p<.001), with the odds of detecting any resistance, again, being lower before and after 
2003-2004 (Table 3.5). Individuals were less likely to have resistance detected in Northern 
(aOR=0.29, 95%CI=0.21-0.39, p<.001) and Central Eastern Europe (aOR=0.47, 95%CI=0.29-0.76, 
p=0.002) compared to Southern Europe.  
A number of other factors were independently associated with the risk of resistance detection. 
Individuals with a history of mono/dual therapy before starting cART were more likely to have 
detected drug resistance (aOR=1.54 vs. those who started cART from ART-naive, 95%CI=1.14-
2.08, p=.007), as were individuals who had previously experienced virological failure (aOR=1.85 
vs. those who experienced VF for the first time, 95%CI=1.40-2.45 p<.001). Individuals with RNA 
levels between 1,000 and 10,000 copies/mL were more likely to have detected resistance 
(aOR=1.63, compared to individuals with RNA levels less than 1,000 95%CI=1.19-2.23, 
p=0.002). Interestingly, individuals with very high RNA levels (>50,000 copies/mL) were not 
significantly more likely to have detected resistance (aOR=1.20, 95%CI=0.84-1.72) compared to 
individuals with RNA levels less than 1,000. There was some weak evidence that women and 
people who inject drugs were less likely to have detected drug resistance given that a test was 
done compared to men and men who have sex with men respectively (aOR=0.74, 95%CI=0.55-
0.98, p=0.04 and aOR=0.69, 95%CI=0.51-0.95, p=0.02, respectively).  
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Table 3.5. Factors associated with having detected resistance (any class) 
 
    Unadjusted Adjusted1,2  
  OR (95% CI) p-value OR (95% CI) p-value  Global p-value 
Age <35  1.00    1.00    
  35-40 1.35 (1.01 - 1.80) 0.04 1.13 (0.82 - 1.55) 0.45 0.95 
  45-50 1.47 (1.09 - 1.99) 0.01 1.06 (0.75 - 1.50) 0.73  
  50-55 1.41 (1.05 - 1.90) 0.02 1.11 (0.78 - 1.57) 0.57  
  >55 1.43 (0.99 - 2.07) 0.05 1.13 (0.75 - 1.72) 0.55  
Gender Male  1.00   1.00    
  Female 0.75 (0.60 - 0.94) 0.01 0.74 (0.55 - 0.98) 0.04 0.04 
Ethnic Group White  1.00    1.00    
  Non-white 0.87 (0.67 - 1.12) 0.28 0.94 (0.70 - 1.26) 0.66 0.67 
Risk Group MSM  1.00    1.00    
  IDU 0.90 (0.69 - 1.17) 0.43 0.69 (0.51 - 0.95) 0.02 0.04 
  Heterosexual 1.04 (0.82 - 1.32) 0.75 1.12 (0.82 - 1.53) 0.48  
  Other 1.05 (0.71 - 1.56) 0.79 0.93 (0.60 - 1.44) 0.76  
Region South  1.00        
  Central West 0.74 (0.55 - 1.00) 0.05 0.81 (0.58 - 1.13) 0.22 <.0001 
  North 0.28 (0.21 - 0.37) <.001 0.29 (0.21 - 0.39) <.001  
  Central East 0.43 (0.27 - 0.69) <.001 0.47 (0.29 - 0.76) 0.002  
  East 0.63 (0.31 - 1.29) 0.21 1.03 (0.46 - 2.32) 0.94  
History of mono/dual therapy No  1.00        
  Yes 1.63 (1.31 - 2.01) <.001 1.54 (1.14 - 2.08) 0.004 0.007 
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1. The multivariable model is adjusted for all the variables listed in the table.  
2. 3 individuals were excluded from the model with CD4 count as a covariate as well as the multivariable model due to missing CD4 counts.  
  
 
Subtype B  1.00        
  Non-B 0.78 (0.59 - 1.04) 0.09 0.80 (0.57 - 1.10) 0.17 0.23 
  Unknown 1.07 (0.84 - 1.36) 0.60 0.83 (0.63 - 1.09) 0.18  
RNA at failure <1000  1.00        
  1000-10000 1.67 (1.25 - 2.24) <.001 1.63 (1.19 - 2.23) 0.002 0.002 
  10000-50000 1.86 (1.39 - 2.51) <.001 1.68 (1.22 - 2.31) 0.002  
  >50000 1.35 (0.98 - 1.85) 0.06 1.20 (0.84 - 1.72) 0.32  
CD4 at failure, per 100 increase2   0.98 (0.95 - 1.02) 0.39 0.95 (0.91 - 0.99) 0.01 0.02 
Previous Resistance Test No  1.00        
  Yes 1.07 (0.89 - 1.28) 0.46 0.88 (0.71 - 1.09) 0.23 0.23 
Previous Virological failure No  1.00        
  Yes 2.53 (2.02 - 3.15) <.001 1.85 (1.40 - 2.45) <.001 <.0001 
Calendar Year 97-98 0.24 (0.16 - 0.36) <.001 0.31 (0.19 - 0.49) <.001 <.0001 
  99-00 0.52 (0.39 - 0.69) <.001 0.47 (0.34 - 0.65) <.001  
  01-02 0.77 (0.60 - 1.00) 0.05 0.75 (0.57 - 0.99) 0.04  
  03-04  1.00        
  05-06 0.82 (0.62 - 1.08) 0.15 0.73 (0.55 - 0.98) 0.03  
  07-08 0.85 (0.59 - 1.23) 0.39 0.90 (0.60 - 1.35) 0.61  
  09-10 0.47 (0.30 - 0.72) <.001 0.49 (0.30 - 0.79) 0.003  
  11-12 0.56 (0.31 - 0.99) 0.05 0.68 (0.36 - 1.27) 0.23  
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3.4.3. Sensitivity, sub-group and exploratory analyses  
The estimates of the prevalence of resistance tests following VF and resistance from the 
sensitivity, subgroup and exploratory analyses are shown in Table 3.6. Briefly, the proportion 
of individuals with a resistance test was higher when using stricter criteria to define virological 
failure, but remained below 50%. This included insisting on a confirmatory value >500 copies 
(37%) and when defining VF as only episodes followed by a switch in regimen (47%). The 
proportion of resistance tests with detected drug resistance remained reasonably stable 
regardless of the definitions of virological failure used. 
Multivariable results from these analyses are shown for two variables of interest: region and 
calendar year, in Table 3.7-Table 3.10 below. These results from the sensitivity analyses 
(Definitions B-D) were consistent with the primary analysis for both the model of resistance 
testing and the model of resistance prevalence. Although some findings did not reach 
statistical significance as the sample size decreased, the odds ratios remained reasonably 
stable, confirming the geographical and time-trends reported for both resistance testing and 
the prevalence of detected resistance. This was also the case for the subgroup and exploratory 
analyses. 
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1. Primary definitions.  
2. Defining VF as at least 2 consecutive measures >500 instead of a single value, after at least 6 months on ART.  
3. Defining VF as a single value above the detection limit of the test used after at least 6 months on ART.  
4. Defining VF as a single VL >1000 (instead of >500) after at least 6 months on ART. 
5. Defining failure as a single viral load >500, requiring an individual to supress to <500 before a subsequent failure was included in the analysis.  
6. Defining VF as a single viral load >500 followed by a switch to a drug belonging to a class that was not included in the regimen started >6 months earlier. 
 
 
Table 3.6. Prevalence of testing and resistance in sensitivity, sub-group and exploratory analyses  
 Definition A1 Definition B2 Definition C3 Definition D4  Definition E5 Definition 
F6  N (%) N (%) N (%) N (%)  N (%) N (%) 
Failing 8468 6017 9661 7828  5748 3776 
Resistance test/individual 2676 (31.6) 2204 (36.6) 2210 (22.9) 2547 (32.5)  1863 (32.4) 1767 (46.8) 
Detected resistance/test 2431 (77.9) 2085 (81.4) 1899 (76.8) 2309 (78.8)  1788 (76.5) 737 (83.6) 
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1. Adjusted for age, gender, ethnicity, mode of HIV transmission, previous history of mono/dual therapy use, number of available previous resistance tests, CD4 count at failure, VL at failure and 
previous history of VF. 
2. Primary definition. 
3. Defining VF as at least 2 consecutive measures >500 instead of a single value, after at least 6 months on ART.  
4. Defining VF as a single value above the detection limit of the test used after at least 6 months on ART.  
5. Defining VF as a single VL >1000 (instead of >500) after at least 6 months on ART. 
Table 3.7. Region and calendar year associations with having a resistance test in sensitivity analyses (Definition B-D)1 
  Definition A2  Definition B3  Definition C4  Definition D5  
  aOR (95% CI) Global P aOR (95% CI) Global P aOR (95% CI) Global P aOR (95% CI) Global P 
Region South  1.00   1.00  1.00  1.00  
  Central West 1.66 (1.51 - 1.82) <.0001 1.58 (1.42 - 1.76) <.0001 1.55 (1.38 - 1.73) <.001 1.61 (1.46 - 1.77) <.001 
  North 2.15 (1.96 - 2.36)  2.18 (1.96 - 2.43)  2.16 (1.94 - 2.41)  2.09 (1.90 - 2.31)  
  Central East 0.94 (0.81 - 1.09)  0.96 (0.82 - 1.14)  0.73 (0.62 - 0.87)  0.98 (0.85 - 1.13)  
  East 0.72 (0.55 - 0.94)  0.63 (0.46 - 0.86)  0.67 (0.50 - 0.89)  0.72 (0.55 - 0.95)  
Calendar Year 97-98 0.11 (0.09 - 0.14) <.0001 0.10 (0.08 - 0.12) <.0001 0.09 (0.06 - 0.14) <.001 0.11 (0.09-0.14) <.001 
  99-00 0.49 (0.43 - 0.55)  0.48 (0.42 - 0.55)  0.43 (0.37 - 0.50)  0.50 (0.44-0.57)  
  01-02 0.85 (0.76 - 0.95)  0.84 (0.74 - 0.95)  0.83 (0.74 - 0.93)  0.86 (0.77-0.97)  
  03-04  1.00   1.00   1.00  1.00  
  05-06 0.77 (0.68 - 0.89)  0.74 (0.63 - 0.86)  0.79 (0.69 - 0.89)  0.79 (0.69-0.91)  
  07-08 0.46 (0.39 - 0.54)  0.48 (0.39 - 0.58)  0.43 (0.37 - 0.50)  0.45 (0.38-0.53)  
  09-10 0.33 (0.27 - 0.41)  0.34 (0.26 - 0.45)  0.32 (0.26 - 0.39)  0.31 (0.25-0.39)  
  11-12 0.25 (0.19 - 0.32)  0.33 (0.21 - 0.49)  0.21 (0.17 - 0.27)  0.26 (0.19-0.34)  
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1. Adjusted for age, gender, ethnicity, mode of HIV transmission, previous history of mono/dual therapy use, number of available previous resistance tests, CD4 count at 
failure, VL at failure and history of previous VF 
2. Primary definition. 
3. Defining failure as a single viral load >500, requiring an individual to supress to <500 before a subsequent failure was included in the analysis.  
4. Defining VF as a single viral load >500 followed by a switch to a drug belonging to a class that was not included in the regimen started >6 months earlier 
 
 
Table 3.8. Region and calendar year associations with having a resistance test in sensitivity analyses (Definition E-F)1 
  Definition A2   Definition E3  Definition F4  
  aOR (95% CI) Global P  aOR (95% CI) Global P aOR (95% CI) Global P 
Region South  1.00 <.0001  1.00 <.0001 1.00 <.0001 
  Central West 1.66 (1.51 - 1.82)   1.62 (1.45 - 1.81)  1.40 (1.17 - 1.66)  
  North 2.15 (1.96 - 2.36)   2.12 (1.91 - 2.36)  1.78 (1.48 - 2.12)  
  Central East 0.94 (0.81 - 1.09)   0.91 (0.76 - 1.09)  0.73 (0.55 - 0.96)  
  East 0.72 (0.55 - 0.94)   0.59 (0.42 - 0.84)  0.74 (0.47 - 1.18)  
Calendar Year 97-98 0.11 (0.09 - 0.14) <.0001  0.09 (0.08 - 0.12) <.0001 0.07 (0.05 - 0.10) <.0001 
  99-00 0.49 (0.43 - 0.55)   0.50 (0.44 - 0.58)  0.40 (0.33 - 0.49)  
  01-02 0.85 (0.76 - 0.95)   0.86 (0.76 - 0.97)  0.75 (0.62 - 0.92)  
  03-04  1.00    1.00   1.00  
  05-06 0.77 (0.68 - 0.89)   0.77 (0.67 - 0.88)  0.73 (0.57 - 0.94)  
  07-08 0.46 (0.39 - 0.54)   0.48 (0.40 - 0.57)  0.42 (0.30 - 0.57)  
  09-10 0.33 (0.27 - 0.41)   0.35 (0.28 - 0.44)  0.31 (0.21 - 0.45)  
  11-12 0.25 (0.19 - 0.32)   0.29 (0.21 - 0.41)  0.42 0.25 - 0.71)  
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1. Adjusted for age, gender, ethnicity, mode of HIV transmission, previous use of mono/dual therapy, number of available previous resistance tests, viral subtype, CD4 count, VL at failure and 
previous history of VF. 
2. Primary definition. 
3. Defining VF as at least 2 consecutive measures >500 instead of a single value, after at least 6 months on ART.  
4. Defining VF as a single value above the detection limit of the test used after at least 6 months on ART. 
5. Defining VF as a single VL >1000 (instead of >500) after at least 6 months on ART. 
 
Table 3.9. Region and calendar year associations with the risk of detecting resistance according to sensitivity analyses (Definition B-D)1 
  Definition A2  Definition B3  Definition C4  Definition D5  
  aOR (95% CI) Global P aOR (95% CI) Global P aOR (95% CI) Global P aOR (95% CI) Global P 
Region South  1.00  1.00  1.00  1.00  
  Central West 0.81 (0.58 - 1.13) <.0001 0.92 (0.62 - 1.37) <.0001 0.57 (0.40 - 0.81) <0.001 0.87 (0.62-1.22) <0.001 
  North 0.29 (0.21 - 0.39)  0.27 (0.19 - 0.39)  0.27 (0.19 - 0.38)  0.29 (0.21-0.40)  
  Central East 0.47 (0.29 - 0.76)  0.52 (0.29 - 0.94)  0.44 (0.26 - 0.74)  0.51 (0.31-0.85)  
  East 1.03 (0.46 - 2.32)  1.09 (0.38 - 3.14)  1.33 (0.58 - 3.07)  1.01 (0.46-2.3)  
Calendar Year 97-98 0.31 (0.19 - 0.49) <.0001 0.31 (0.18 - 0.54) <.0001 0.45 (0.18 - 1.13) 0.13 0.28 (0.17-0.46) <0.001 
  99-00 0.47 (0.34 - 0.65)  0.46 (0.31 - 0.67)  0.64 (0.42 - 0.95)  0.47 (0.33-0.66)  
  01-02 0.75 (0.57 - 0.99)  0.77 (0.56 - 1.07)  0.85 (0.63 - 1.15)  0.76 (0.56-1.01)  
  03-04  1.00   1.00   1.00  1.00  
  05-06 0.73 (0.55 - 0.98)  0.86 (0.59 - 1.25)  0.77 (0.58 - 1.02)  0.70 (0.50-0.93)  
  07-08 0.90 (0.60 - 1.35)  1.25 (0.71 - 2.20)  0.82 (0.55 - 1.22)  0.85 (0.55-1.31)  
  09-10 0.49 (0.30 - 0.79)  0.36 (0.20 - 0.63)  0.59 (0.38 - 0.92)  0.34 (0.22-0.61)  
  11-12 0.68 (0.36 - 1.27)  1.25 (0.47 - 3.37)  0.66 (0.38 - 1.14)  0.59 (0.31-1.13)  
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1. Adjusted for age, gender, ethnicity, mode of HIV transmission, previous use of mono/dual therapy, number of available previous resistance tests, viral subtype, CD4 
count, VL at failure and previous history of VF. 
2. Primary definition. 
3. Defining failure as a single viral load >500, requiring an individual to supress to <500 before a subsequent failure was included in the analysis.  
4. Defining VF as a single viral load >500 followed by a switch to a drug belonging to a class that was not included in the regimen started >6 months earlier 
Table 3.10. Region and Calendar Year associations with the risk of detecting resistance in subgroup and exploratory analyses 
(Definition E-F)1 
  Definition A2  Definition E3  Definition F4  
  aOR (95% CI) Global P aOR (95% CI) Global P aOR (95% CI) Global P 
Region South  1.00 <.0001 1.00 <0.0001 1.00 <0.0001 
  Central West 0.81 (0.58 - 1.13)  0.99 (0.69-1.43)  0.95 (0.53 - 1.73)  
  North 0.29 (0.21 - 0.39)  0.33 (0.23-0.48)  0.28 (0.16 - 0.48)  
  Central East 0.47 (0.29 - 0.76)  0.50 (0.30-0.87)  1.06 (0.34 - 3.27)  
  East 1.03 (0.46 - 2.32)  1.96 (0.75-5.11)  0.68 (0.14 - 3.29)  
Calendar Year 97-98 0.31 (0.19 - 0.49) <.0001 0.38 (0.22-0.66) 0.0002 0.24 (0.10 - 0.59) 
0.31 (0.17 - 0.54)    
0.70 (0.40 - 1.21)  
 
0.0045 
  99-00 0.47 (0.34 - 0.65)  0.43 (0.29-0.63)  0.31 (0.17 - 0.54)  
  01-02 0.75 (0.57 - 0.99)  0.64 (0.47-0.88)  .70 ( .40 - 1.21)  
 
 
  03-04  1.00  1.00  1.00  
  05-06 0.73 (0.55 - 0.98)  0.67 (0.49-0.92)  0.54 (0.30 - 1.00)  
  07-08 0.90 (0.60 - 1.35)  0.77 (0.50-1.19)  0.81 (0.32 - 2.08)  
  09-10 0.49 (0.30 - 0.79)  0.43 (0.26-0.71)  0.86 (0.26 - 2.85)  
  11-12 0.68 (0.36 - 1.27)  0.47 (0.23-0.98)  0.79 0.27 - 2.32)  
140 
 
3.5. Discussion  
3.5.1. Resistance testing 
The analyses in this chapter describes the changing utilisation of resistance testing in Europe, as 
well as the prevalence of drug resistance over time among those who had a resistance test 
following virological failure. The first main finding is that among all individuals experiencing VF, 
only around 1/3 of individuals received a resistance test within 12 months of experiencing VF, 
and this proportion decreased after 2004. The relatively low proportion of individuals receiving 
a resistance test around the date of VF extend previous EuroSIDA findings (483) to more recent 
calendar years. Presuming that EuroSIDA accurately captures resistance data, this indicates that 
there is a possible discrepancy between clinical practice and current guidelines which 
recommend always testing for resistance after virological failure.  
 Clinical decisions are complicated by numerous factors and it is not uncommon that guidelines 
are not followed exactly in real life. My findings are in agreement with those of Pillay et al. in 
the UK, who found that around 1/3 of treatment switches were guided by a resistance test. 
However, their analysis was carried out in a much earlier time-period (1999-2002) (479). In 
addition, an analysis from the US by Palella et al. from the HOPS cohort also found that around 
1/3 of patients had a resistance test following VF over the study period 1999-2005 (482). In 
contrast, the proportion of individuals receiving a resistance test is higher in other analyses of 
US data (484) as well as in analyses of Canadian (481,485) and Swedish (478) data. An analysis 
of data from the UK CHIC cohort has shown that 46% of individuals had a resistance test after 
viral rebound prior to a change in therapy, similar to the estimate of 47% I found when 
defining failure as a high VL which was followed by a switch in the regimen (510). The higher 
frequency found in this subgroup suggests that one of the reasons that clinicians do not 
prescribe a resistance test is perceived non-adherence, which reduces the utility of resistance 
testing. It could be that when seen in a clinical setting, the reason for the VF may be put down 
to poor adherence, a chaotic lifestyle, or personal issues rather than drug resistance. This is in 
agreement with the higher proportion of presumed adherent individuals having a resistance 
test observed in the sensitivity analyses, as well as the fact that individuals of a non-white 
ethnicity and those who inject drugs - both groups with known adherence issues and issues 
regarding access to treatment (511,512) - were less likely to receive a resistance test. 
However, it should be noted that the validated adherence data that is not available in 
EuroSIDA. 
In terms of time-trends, Eyawo et al., in a 2011 study of resistance testing in a Canadian cohort 
study, found that individuals initiating HAART after 2004 were less likely to receive a resistance 
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test (485); whereas Buchacz et al. found that the probability of receiving a resistance test in the 
US was reasonably stable over time in the period 1999-2006 (484). One North American (481) 
and one Canadian (475) study reported an increase in the proportion of individuals receiving a 
resistance test following VF over time. There are a number of additional possible reasons for 
these discrepancies, including differing definitions of virological failure used in the various 
analyses, differences in access to GRT technology in different geographical regions as well as 
differences in clinical practice. It is possible that a greater availability of different drug classes, 
as well as a changing composition of the cohort (e.g., individuals with complex treatment 
histories are seen more rarely in recent calendar years (492)) make clinicians less likely to test 
for resistance following VF. In addition, the marked reduction in the proportion of individuals 
experiencing VF documented here confirms previous observations that VF is growing very rare 
(513).  
I found marked regional differences in the utilisation of resistance testing. Clinicians from 
Central Western and Northern Europe were more likely to offer a resistance test compared to 
clinicians in Southern Europe, whereas clinicians in Eastern Europe were less likely to test for 
resistance compared to Southern Europe. This could reflect geographical differences in 
healthcare expenditure as well as access to resistance testing technologies and the ability to 
provide this data to EuroSIDA. Individuals with a history of mono and dual therapy before 
starting cART were more likely to receive a resistance test in univariable analyses, but not after 
adjustment for previous virological failure. Although these two factors were correlated, it could 
suggest that the overall extent of treatment exposure due to viral failure was the factor that 
influenced the decision of whether to order a GRT or not, regardless of whether the person had 
specifically been exposed to mono or dual therapy before cART. Similarly, having a previous 
resistance test was also associated with an increased probability of another resistance test, as 
has been previously reported (483). I also found that individuals who had a low RNA at failure 
(<1000 copies/mL) were less likely to receive a resistance test. As mentioned previously, one of 
the possible explanations for this finding is technical and related to the difficulty in genotyping 
at low viral loads.  
3.5.2. Resistance prevalence 
Despite the observed declining trend in resistance testing, drug resistance was detected in a 
relatively high proportion, almost 80%, of tests included in this analysis. This is broadly 
comparable to what has been found in other studies using the same denominator to study 
resistance testing, where estimates ranged from 59-88% depending on the study (Table 3.2). 
The fact that drug resistance was detected so frequently may indicate that clinicians may be 
taking a selective approach to resistance testing, where those individuals judged as most likely 
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to have resistance are also the ones who are offered a test. In other words, where clinicians 
suspect poor adherence they may not order resistance tests, as performing a GRT on an 
individual who is not taking cART will not yield any results.  
The proportion of tests detecting any resistance peaked in 2003-2004, and there was some 
evidence to suggest that this proportion had declined in more recent calendar years. A decline 
in the prevalence of resistance in recent years among individuals experiencing VF has been 
found in a number of other studies in high income settings (336,478,486,488–491,514), as 
outlined in the literature review (Table 3.2). Such a decrease could possibly be explained by 
improvements in the potency of drugs used, minimized side effects and an increase in 
therapeutic options that have all lowered the risk of developing drug resistance (336,514). This 
could have led, in turn, to lower levels of transmitted resistance and consequently even fewer 
people failing because of resistance when starting these potent new cART regimens from an 
ART-naïve status. Simplified drug regimens that are easier to take, combined with efforts to 
educate HIV positive people, and the development and use of drugs with a high genetic barrier 
may also play an important role. Taken together with the reduced proportion of individuals 
experiencing VF in more recent calendar years, the current analysis documents a marked 
reduction in the number of individuals experiencing VF with drug resistance, echoing findings 
from other European cohorts (515).  
An other predictor of detecting resistance was geographical region. Conditional on having a GRT 
done, the probability of detecting resistance when doing a test was lower in Northern and 
Central Eastern Europe compared to Southern Europe. I also found that individuals who had a 
history of mono or dual therapy were more likely to have detected resistance, as were 
individuals who had experienced previous virological failure, in agreement with a previous 
analysis of US data by Napravnik et al (498). We found some evidence that people who inject 
drugs were less likely to have detected resistance compared to MSM, as mentioned previously 
this could be explained by the fact that PWID are typically less adherent to treatment than MSM.  
Overall, these results indicate that clinical attitudes to resistance testing may differ according to 
geographical region. Clinicians in Northern Europe were the most likely to prescribe a resistance 
test following VF, but also least likely to see drug resistance in the virology report once the test 
was performed. In contrast, clinicians in Eastern Europe were comparatively less likely to test 
for resistance following VF compared to Central Western and Northern Europe, but also more 
likely to observe resistance when a test was done compared to Central Eastern and Northern 
Europe. As it is unlikely that the biological risk of developing drug resistance in a situation of VF 
varies by region of Europe, it is possible that the lower testing rates in Eastern Europe are causing 
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individuals to be maintained on failing therapies for longer, thus leading to the development of 
resistance. Clinicians in Eastern Europe may also be even more selective about who they test for 
resistance, targeting those who they are certain have failed due to resistance. This has also been 
indicated in a recent survey of the EuroSIDA clinics (431).  
By using the proportion with a GRT in the denominator in this analysis, I have been able to 
describe the likelihood of observing resistance when ordering a test from a clinical point of view. 
Although this helps us understand the situation and potential clinical strategies chosen by 
clinicians in different regions of Europe, or in different calendar years, it is important to note 
that the prevalence estimates here do not represent population-level prevalence estimates of 
the burden of resistance. Such an estimate would require either assuming that all individuals 
without a GRT did not harbour resistance, or using some form of multiple imputation. This latter 
approach has already been taken in a previous EuroSIDA publication by Bannister et al. (473).  
3.5.3. Limitations and strengths 
The analyses presented here are subject to several limitations. First of all, my chosen definition 
of VF may not capture all VFs, particularly as the definition for this has changed over time. I 
chose the definition used by the European AIDS Clinical Society treatment guidelines at the 
time of conducting this analysis, as this is likely to be broadly representative for clinics across 
Europe. It was also a relatively non-strict definition of VF, which allowed me to maximise the 
sample size. However, it is likely that what a clinician considers to be VF has varied over time 
and is different across different geographical regions. I attempted to address this possible bias 
in sensitivity analyses, and although the proportion receiving a test was higher using more 
stringent definitions of VF, it still remained relatively low and decreased over time. However, I 
cannot exclude that some instances of VF have been misclassified. If the definition I used for 
VF is too relaxed, this means that I have classified individuals as experiencing VF even though 
they’re not, which could lead to an underestimate of the proportion tested. However, if the 
definition used for VF is too stringent, for example in the most recent calendar years, this 
could lead to an overestimate of individuals who are tested. The way this bias operates is likely 
to vary over time, making it complex to predict what the effects on my results are.  
Another potential limitation is that the number of resistance tests in the EuroSIDA database 
may not accurately reflect all the tests that are done as part of routine clinical care. Although 
rigorous efforts are made to minimise such under-reporting by quality control visits as outlined 
in Chapter 2, Section 2.2.1.2, the financial incentive for clinicians to return complete resistance 
forms as compared to other aspects of the EuroSIDA CRF is relatively low. It is possible that the 
lower rate of resistance testing found in Eastern Europe simply reflects the fact that less data is 
144 
 
reported from these clinics. However, my results are in agreement with an additional survey of 
self-reported clinical HIV management conducted in EuroSIDA centres, which should be less 
affected by a lack of financial incentives (431). The number of tests done in recent calendar 
years may also have been underestimated due to reporting delay.  
As with all observational studies, I cannot rule out the possibility that there are unmeasured 
confounding variables affecting some of the associations reported here. Although I was able to 
evaluate a large number of clinically relevant predictors of receiving a resistance test and 
detecting predicted resistance, there may be other factors, such as the availability of different 
drugs, that I was not able to assess in multivariable models that may explain some of the 
observed associations. Finally, EuroSIDA clinics may not be representative of all HIV clinics or 
the entire population of HIV infected individuals in Europe, as some countries are represented 
by relatively few centres of excellence. Therefore, the results may not be generalizable to the 
HIV-infected population in Europe as a whole.  
Despite these limitations, the analysis does have a number of strengths. EuroSIDA is one of few 
studies that collect data from centres across the European region, including from countries in 
Eastern Europe. Although the estimates from the Central Eastern and Eastern European region 
presented here may suffer somewhat from limited generalisability, there is scarce data on 
resistance testing and prevalence from the region as a whole. As the EuroSIDA cohort has been 
running since 1994, I was able to assess time-trends for a considerable time-period. The 
breadth of variables collected also allowed me to evaluate a reasonably large number of 
potential risk factors, which most surveillance databases cannot do.  
3.5.4. Conclusions  
To conclude, my findings indicate that the clinical approach to resistance testing may diverge 
from that laid out in guidelines, and I observed calendar year and regional differences both in 
resistance testing and the probability of detecting resistance. Public health policy aiming at 
minimizing the emergence of drug resistance might benefit from targeting specific regions of 
Europe, and efforts to minimize inter-regional differences in the availability and utilisation of 
resistance testing in the European Union may be warranted. The implications of these findings 
for further research and policy will be discussed further discussed in Chapter 8 of this thesis.  
3.5.5. Dissemination of results 
Preliminary results from this chapter were presented as an oral presentation at the 2013 
European AIDS conference and were published in AIDS in 2015 (Appendix VI).  
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Chapter 4 . Long-term virological outcomes and 
resistance patterns among treatment experienced 
HIV patients receiving raltegravir 
 
4.1.Introduction and Objectives  
Traditionally, HIV has been treated with a combination of drugs from three main drug classes: 
nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase 
inhibitors (NNRTI) and protease inhibitors (PI). However, as outlined in Chapter 1, drugs 
targeting other stages of the viral life cycle have also been developed. The recently licensed 
integrase strand transfer inhibitors (INSTI) prevents the HIV genome from replicating by 
inhibiting the process of viral integration (516). Viral integration consists of two main steps: 3’ 
processing and strand transfer. 3’ processing involves the removal of a dinucleotide from the 
end of the viral DNA. This cleaved DNA product is consequently covalently linked to the host 
genome through a process called strand transfer (517). INSTIs attach to the integrase by 
binding to metal cations (Mg2+ or Mn2+) present in the active site. This prevents the integrase 
from binding to the viral DNA, and thus inhibits the strand transfer step of integration (518). 
The first developed INSTI, raltegravir (RAL; Isentress® Merck & Co), has been licensed for use in 
Europe since 2007, its structural analogue elvitegravir (ELV) was licensed in 2013 and the 
second generation INSTI dolutegravir (DTG) was approved in 2014. These drugs have grown 
more popular over time due to their high virological efficacy and favourable side-effect 
profiles, and INSTIs are now recommended as an alternative option for use as part of first line 
therapy in many high income settings (146,147).  
RAL is the most well-studied among the INSTIs, and has been shown to have high virological 
efficacy among both treatment naïve (519–521) and experienced (522–524) patients. 
Compared to other first-line third agent options, such as the NNRTI efavirenz (EFV), RAL 
appears to be associated with fewer central nervous system (CNS) related side-effects (525). 
Interestingly, data from the STARTMRK trial has suggested that patients receiving RAL may 
experience a faster VL decrease compared to patients receiving EFV (519). However, RAL also 
has a low genetic barrier to resistance, and a single mutation is sufficient to confer high level 
resistance to RAL (526–528).  
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Individuals who fail RAL have been found to develop resistance according to 3 main pathways 
involving positions Y143, N155 or Q148 (527), usually in combination with characteristic 
secondary mutations (Table 4.1) (528).  
Table 4.1 Primary resistance pathways for RAL  
Resistance Pathways RAL fold resistance, relative to wild-type (WT) 
Y143 pathway  
Y143C <10 
Y143R <50 
Y143C/T97A >100 
Y143R/T97A >100 
Y143G/T97A/L74M <50 
Y143G/T97A/L74M/E138A <20 
N155 pathway  
N155H <50 
N155H/E92Q <100 
N155H/L74M <50 
Q148 pathway   
Q148H <20 
Q148K <100 
Q148R <50 
Q148H/E138K <10 
Q148K/E138K >100 
Q148R/E138K >100 
Q148H/G140S >100 
Q148K/ G140S <10 
Q148R/ G140S >100 
Q148H/E138A/G140S/Y143H >100 
Adapted from Quashie et al, ref: (529) 
Both the Q148 and Y143 mutations adversely affects the function of the integrase, but this is 
compensated for by the emergence of the G140S and T97A mutations (530). Although the 
emergence of substitutions in position N155 also has negative effects on viral fitness, the E92Q 
mutation that characteristically follows N155H does not compensate this loss to the same 
extent as G140S or T97A. This means that N155H pathways tend to be replaced over time in 
the presence of selective drug pressure (528,529).  
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Mutations in position N155 and Q148 confer resistance to ELV in addition to RAL, which means 
that RAL and ELV cannot be used sequentially (528). However, DTG has a higher barrier to 
resistance and there is less cross-resistance between RAL/ELV and DTG. The VIKING-III trial 
showed that patients who have previously failed RAL can re-supress on DTG (531). However, it 
was found that they are less likely to do so if they carry the Q148 resistance mutation (527), 
particularly if this is present in combination with mutations at position 138, 140, 92 and 97 
(528).  
Data from clinical trials indicate that rates of virological failure with resistance are likely to be 
low for RAL, although they do vary according to treatment history. Estimates range from 0-3% 
among patients starting RAL from naïve, 2-7% among those starting RAL from treatment 
experienced and up to 20% amongst individuals starting RAL following triple class failure (TCF) 
(Table 4.2). However, clinical trials often have very strict inclusion criteria coupled with careful 
and regular monitoring of patients, conditions which may not be replicated in routine care. 
Adherence to medication may also be higher in clinical trials than in clinical practice (532). As 
RAL requires twice-daily dosing and high adherence to prevent resistance from emerging 
(533,534), studying its long-term efficacy and risk of resistance development in routine 
practice is of informative, and can complement the existing information from trials.  
The objectives of this chapter were therefore to:  
1) Describe time to failure and risk factors for failing RAL  
2) Describe resistance patterns among those failing RAL with available resistance test 
results 
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Table 4.2. Phase III trials evaluating RAL efficacy or non-inferiority, virological outcomes and INSTI resistance prevalence 
Trial Year Comparison Population1 Virological Outcome INSTI Resistance (%) 2 Reference 
NEAT 001/ANRS 143 (96 
weeks) 
2016 DRV/r+RAL OR TDF/FTC TN 19% Treatment Failure  14 (5/36 )  
 
(535) 
ACTG 5257 (96 weeks) 2014 FTC/TDC + ATV OR RAL OR DRV TN 94% VL<50  17 (11/65 ) (292) 
SPRING-2 (96 weeks) 2014 OBT + RAL OR DTG TN 76% VL<50  5 (1/20 ) (232) 
SPRING-2 (48 weeks) 2013 OBT + RAL OR DTG TN 85% VL<50  5 (1/19 ) (536) 
STARTMRK (240 weeks) 2013 FTC/TFD + RAL OR EFV TN 71% VL<50 17 (4/23 ) (519) 
PROGRESS (96 weeks) 2013 LPV/r + RAL or TDF/FTC TN 66.3% VL<40 37.5% (3/8) (537) 
SPARTAN (24 weeks) 2012 ATV + RAL OR TDF/FTC TN 74.6% VL<50 66 (4/6) (538) 
PROGRESS (48 weeks) 2-11 LPV/r + RAL or TDF/FTC TN 83.2% V<40 25 (1/4) (539) 
STARTMRK (156 weeks) 2011 FTC/TFD + RAL OR EFV TN 75.4% VL<50 44 (4/19 ) (520) 
STARTMRK (96 weeks) 2010 FTC/TFD + RAL OR EFV TN 81% VL<50 33 (4/12 ) (521) 
STARTMRK (48 weeks) 2009 FTC/TFD + RAL OR EFV TN 86.1% VL<50 44 (4/9 ) (228) 
SECOND-LINE (96 weeks) 2015 LOP/r+2 /3NRTI OR RAL TE 80% VL<200 Not reported (540) 
SAILING (48 weeks) 2013 OBT + RAL OR DTG TE 64% VL<50 42 (16/38 ) (233) 
Study 145 (96 weeks) 2013 
PI/r+1 additional drug + RAL OR 
EVG 
TE 45% VL<50 28 (26/93 ) (541) 
SECOND-LINE (48 weeks) 2013 LOP/r+2 /3NRTI OR RAL TE 83% VL<200 14 (7/49 ) (542) 
Study 145 (48 weeks) 2012 
PI/r+1 additional drug + RAL OR 
EVG 
TE 58% VL<50 22 (15/72 ) (230) 
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SWITCHMRK (24 weeks) 2010 OBT + LOP/r or RAL TE 84% VL<50 57 (8/14 ) (229) 
BENCHMRK (240 weeks) 2013 
OBT + RAL OR Placebo (RAL 
offered after week 156) 
TCF 51% VL<50  64 (95/148 ) (524) 
BENCHMRK (96 weeks) 2010 OBT + RAL OR Placebo TCF 57% VL <50 Not reported (523) 
BENCHMRK (48 weeks) 2008 OBT + RAL OR Placebo TCF 62.1% VL<50 Not reported (522) 
1. TN=Treatment Naïve; TE=Treatment Experienced; TCF=Triple Class Failure, OBT=Optimized Background Therapy  
2. Prevalence of INSTI resistance reported as a % of those successfully genotyped, raw numbers given within brackets (numerator/denominator). 
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4.1.1.Trends in virological failure and baseline characteristics 
8,469 individuals out of 18,473 in D36 (46%) experienced VF (as defined by a VL > 500 
copies/mL) at least once and were included in the analysis for Aim 1 (Figure 3.2). The 
probability of experiencing VF declined over time: compared to 74.2% (95%CI=72.9-75.4) of 
individuals with at least one VL measurement in 1997, only 5.1% (95%CI=3.2-8.0) showed 
evidence of VF in 2012 (Figure 4.2). As can be seen in Figure 4.1, the decline appeared to be 
nearly linear, and it was therefore decided to model calendar year as a linear variable when 
identifying risk factors for VF. This decline in the probability of VF was consequently confirmed 
in multivariable models (Adjusted Odds Ratio [aOR]=0.79 per more recent calendar year, 95% 
Confidence Interval [95%CI]= 0.78-0.79, p<.001). Including an interaction term in the model 
showed that there was evidence that this decline differed according to geographical region 
(interaction p-value<0.001), with the odds of experiencing VF declining most steeply in Central 
Eastern Europe (aOR=0.90, 95%CI=0.87-0.93, p<0.001 and less markedly in Eastern Europe 
(aOR=0.95, 95%CI=0.91-0.99, p=0.01). In the most recent calendar year for which we had data 
(2012) the lowest absolute levels of virological failure were seen in Northern Europe (3.0%) 
and the highest levels in Eastern Europe (15.1%; Figure 4.2).  
Figure 4.1. Proportion of individual on ART each year who experienced VF with a VL>500 
copies/mL 
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Figure 4.2. Proportion of individuals on ART each year who experienced VF with a VL>500 
copies/mL, by region 
 
 
 
 
 
 
 
 
 
 
The characteristics of the individuals showing evidence of VF at date of the first VF are shown in 
Table 4.3. The majority of individuals included were male (75%) and white (86%), and 40% had 
acquired their HIV infection through sex with another man. There was reasonable 
representation from all geographical regions, with the largest number of participants coming 
from Southern Europe (2639, 31%), followed by Central (2175, 26%) and Northern (2090, 25%) 
Europe. 743 participants came from Central Eastern Europe (9%) and 607 (7%) from Eastern 
Europe. In terms of treatment history, the majority of the individuals had been exposed to 
mono/dual therapy (68%), although fewer had met our pre-specified definition of virological 
failure before their baseline date (21%) and very few had received a resistance test (4%). In 
terms of current ART regimens, the majority of the participants received cART - defined as 
receiving at least 3 drugs - at baseline (85%). The most common regimen among these included 
unboosted PI’s (35.2%), followed by boosted PIs (18.4%). This possibly reflects the relatively 
early calendar year most participants were included, with a median baseline date of October 
1997 (IQR=March 1997-September 2000). Laboratory markers indicated that individuals were 
doing relatively poorly, with a median CD4 count of 289 (167-446) and a median viral load of 
4233 (1200-24,000).  
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The median VL at the first failure varied with calendar year, and decreased somewhat from 5831 
(1500-30000) copies/mL in 1997/1998 to 4378 (1230-21902) copies/mL in 2011/2012 (p<0.001). 
Conversely, the number of VL measurements per patient per year decreased over time, from a 
median of 4 (3-6)/year in 1997/1998 to 3 (2-4)/year in 2011/2012 (p<0.001). 
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 Table 4.3. Baseline Characteristics of the Study Population 
  
  
 
    Total experiencing VF Did not have resistance test Had resistance test1  
    N (%)  N (%) N (%) P-value2 
Demographics  8469 (100) 5793 (100) 2676 (100) 0.006 
Gender Male 6344 (74.9) 4288 (74.0) 2056 (76.8) 0.03 
  Female 2125 (25.1) 1505 (26.0) 620 (23.2)  
Ethnicity White 7305 (86.3) 5030 (86.8) 2275 (85.0)  
  Non-white 1164 (13.7) 763 (13.2) 401 (15.0)  
Risk Group MSM 3401 (40.2) 2212 (38.2) 1189 (44.4) <.001 
  IDU 2068 (24.4) 1530 (26.4) 538 (20.1)  
  Heterosexual 2381 (28.1) 1640 (28.3) 741 (27.7)  
  Other 619 (7.3) 411 (7.1) 208 (7.8)  
Region Southern 2639 (31.2) 1856 (32.0) 783 (29.3) <.001 
  Central 2175 (25.7) 1382 (23.9) 793 (29.6)  
  Northern 2090 (24.7) 1296 (22.4) 794 (29.7)  
  Central East 743 (8.8) 560 (9.7) 183 (6.8)  
  East 607 (7.2) 541 (9.3) 66 (2.5)  
 Treatment History      
 Type of ART used at failure PI (boosted) 1560 (18.4) 979 (16.9) 581 (21.7) <0.001 
 PI (unboosted) 2981 (35.2) 2030 (35.0) 951 (35.5)  
 NNRTI 812 (9.6) 635 (11.0) 177 (6.6)  
 PI and NNRTI 1431 (16.9) 965 (16.7) 466 (17.4)  
 Neither PI or NNRTI 1685 (19.9) 1184 (20.4) 501 (18.7)  
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1. Defined as in section 3.3.1; requiring either the presence of resistance results in the EuroSIDA database or an indication by the clinician that a test was done.  
2. P-values compare those with and without a resistance test, and are calculated using a chi-squared test (categorical variables) and Kruskal-Wallis (continuous variables).  
 History of mono/dual therapy No 2688 (31.7) 2080 (35.9) 608 (22.7) <0.001 
 Yes 5781 (68.3) 3713 (64.1) 2068 (77.3)  
On CART No 1284 (15.2) 889 (15.3) 395 (14.76) 0.49 
  Yes 7185 (84.8) 4904 (84.7) 2281 (85.2)  
 Previous VF No 6666 (78.7) 4721 (81.5) 1945 (72.7) <0.001 
 Yes 1803 (21.3) 1072 (18.5) 731 (27.3)  
 Previous resistance test No 8121 (95.9) 5560 (96.0) 2561 (95.7) 0.55 
 Yes 348 (4.1) 233 (4.0) 115 (4.3)  
Continuous variables   Median (IQR) Median (IQR) Median (IQR)  
Age  Year 38 (33.0 - 44.7) 38 (33.0 - 44.9) 38 (33.0 - 44.3) 0.44 
CD4  Cells/mm3 289 (167.0 - 446.0) 299 (171.0 - 459.0) 271 (157.0 - 420.0) <.001 
RNA  Copies/mL 4233 (1200 - 24000) 3599 (1080 - 21200) 6072 (1600 - 29000) <.001 
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4.2. Literature Review  
I searched the literature for observational studies reporting virological outcomes and/or 
integrase resistance prevalence among individuals receiving RAL in routine clinical care. The 
search terms are specified in Chapter 2. The original search returned 474 articles, of which 63 
were deemed potentially relevant. Following abstract screening, 24 records were deemed 
relevant. Two of these did not have full-text versions available, and the abstract lacked key 
information. Therefore, 22 articles were accessed and assessed for inclusion in the review. In 
total, 21 articles were included, and the review process is outlined in Figure 4.3.  
Figure 4.3. Selection process for the literature review 
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The results from the literature review are presented in Table 4.4. A large number of different 
definitions were used to define virological outcomes. The majority of the studies, 17/21, used 
an estimate of virological suppression (VS) as the endpoint whereas 4 studied virological 
failure (VF). There was also large variation in the cut-off points, with 40, 50 and 200 copies/ml 
all used to indicate VS/VF. For studies where more than one cut-off point was used, I chose to 
summarise the results using only the highest VL cut-off. Where the probability of VS/VF was 
assessed using Kaplan Meier methods and reported at a certain time-point, this time-point is 
specified in the table. Estimates were commonly reported separately according to whether 
patients started RAL with a supressed viral load (SVL) versus a raised viral load (RVL). Different 
methods were also used to analyse time to event data, with both Intention to Treat (ITT) and 
Per Protocol (PP) approaches reported. Finally, different methods for dealing with missing data 
were reported. Although none of the studies used multiple imputation, there were some 
differences in estimates according to whether individuals with missing viral loads were classed 
as failures (“m=f”) or whether missing data was reduced using a more liberal last-observation-
carried forward (LOCF) approach. 
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Table 4.4. Observational studies reporting virological efficacy data for RAL and/or INSTI resistance prevalence 
Author Year Population1  N (FU time) 2 Virological Outcome3 Risk Factors for outcome4 INSTI Resistance (%) 5 Ref6 
Santos  2015 TE/TN 2,782 (NR) 4.4% VL>200 Higher VL and low adherence.  79 (26/33) (543) 
Jaeckle  2015 TE/TN 295 (24/48 weeks) 
71% VL<200, 24 weeks 
69% VL<200, 48 weeks 
NR 52 (12/23) (544) 
Van Halsema 2015 TE/TN 215 (NR) 4.70%. NR NR 50 (2/4) (545) 
Squires 2013 TE/TN 206 (48 weeks) 
64% VL<50, RVL 
76% VL<50, SVL 
NR 29 (11/38) (546) 
Gras 2012 TE/TN 81 (6 months) 15% VL>40  
Adherence and duration of 
treatment interruption but not 
raltegravir plasma levels or prior 
duration of viral suppression 
20 (2/10) (534) 
Buchacz 2015 TE 472 (1 year) 68% VL<50 NR NR (547) 
Fourati 2014 TE 502 (NR) NR NR 39 (194/5027) (548) 
Capetti 2014 TE 333 (4 years) 
73% VL<50, ITT 
93.4% VL<50, PP 
Risk of VF higher with higher 
baseline VL and having a complex 
treatment history.  
58 (15/26) (549) 
Marcelin 2013 TE 468 (6 months) 71%% VL<50  
Lower baseline VL, higher baseline 
CD4 count, use of two or more new 
drugs among DRV/ETR/MVC or ENF  
78 (49/63) (550) 
Capetti 2012 TE 320 (96 weeks) 
8.4% VL>50, ITT 
NR, PP 
Lower CD4 counts, Advanced AIDS 
(ITT) 
None (PP)  
79 (11/14) (551) 
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Armenia 2012 TE 23 (24 weeks) 39% VL<50 None 57 (8/11) (552) 
Da Silva 2010 TE 51 (6 months) 78% VL<50 NR 81 (9/11) (553) 
Engsig 2010 TE 32 (72 weeks) 100% VL<51 N/A N/A (554) 
Towner 2009 TE 52 (24 weeks) 94.20% VL<50 NR NR (555) 
Wittkop 2009 TE 51 (24 weeks) 78% VL<1.7 log10 copies  Baseline VL and nadir CD4  81 (9/11) (556) 
Grant 2009 TE 14 (24 weeks) 86% VL<50 NR NR (557) 
Rusconi 2013 TCF 105 (24 weeks) 74.3% VL<50  
Older age, higher GSS and time in 
cohort  
50 (12/24) (558) 
Bucciardini 2012 TCF 101 (48 weeks) 25.7% VL>50 None identified NR (559) 
Scherrer 2010 TCF 243 (24 weeks) 
69.2% VL<50, m=f, RVL 
80.9% VL<50, m=f, SVL 
76.1% VL<50, LOCF, RVL 
95.8% VL<50, LOCF, SVL 
None  NR (560) 
Teague 2010 TCF 57 (48 weeks) 
84% VL<50, RVL 
92% VL<50, SVL 
NR NR (561) 
Harris 2008 TCF 
35 (7 months, 
median) 
97% VL<50 NR NR (562) 
1. N=Treatment Naïve; TE=Treatment Experienced; TCF=Triple Class Failure.  
2. NR=Not Reported 
3. ITT=Intention to Treat; PP=Per Protocol; m=f = missing equals failure; LOCF= Last observation carried forward 
4. Can be either risk factors for VF or factors associated with suppression; the outcome is specified in the “Virological Outcome” column.  
5. Prevalence of INSTI resistance reported as a % of those successfully genotyped, raw numbers given within brackets (numerator/denominator). 
6. Ref=Reference 
7. The proportion with VF; the proportion genotyped not reported  
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4.2.1.Virological outcomes  
Although a reasonably large number of observational studies were identified, none of them 
assessed virological outcomes among treatment naïve patients alone, and the majority of the 
studies only included treatment-experienced patients. Five studies studied efficacy exclusively 
among patients who had experienced TCF. Although it is hard to compare results across 
studies given the large number of different definitions used for VS/VF, the variable duration of 
follow-up time and the different study populations, the vast majority of studies appeared to 
find favourable outcomes of RAL and drew positive conclusions regarding the efficacy of RAL. 
Among studies including both treatment experienced and treatment naïve individuals, 
estimates of virological efficacy ranged from 64-76% VS and 4-15% VF (Table 4.4). 
Unsurprisingly, these proportions varied according to the time-point studied. Jaeckle et al 
analysed data from a clinical database in Germany, and described estimates of constant VS 
which decreased somewhat with increasing FU-time: from 71% at 24 weeks to 69% at 48 
weeks (544). Such a decline was also observed in clinical trials (522–524).  
Squires et al described results from the industry-sponsored REALMRK cohort of patients in 
clinical centres in the US, Brazil, South Africa and Jamaica (546). The aim of the REALMRK study 
was to describe the efficacy of RAL in a more diverse setting than that studied in clinical trials. 
The study recruited a higher proportion of women and individuals of non-white ethnicities 
compared to the BENCHMRK studies, and followed individuals for 48 weeks. REALMRK 
reported good efficacy of RAL, with 76% of patients who switched to RAL or started the drug 
from ART- naïve reaching virological suppression by 48 weeks. Rates were lower when RAL was 
used as salvage therapy: 54% (546).  
Results were more diverse in the studies included in the review conducted on treatment 
experienced patients, where estimates of virological suppression ranged over 39-100% 
according to the time frame used and the study population included (552,554). The particularly 
low efficacy estimate of 39% by 24 weeks comes from an analysis by Armenia et al of 
treatment experienced patients starting RAL at 4 clinical centres in Italy. However, only 23 
patients were included in this analysis, all were heavily treatment experienced with a high viral 
load at baseline and a low baseline GSS. In addition, the aim of this analysis was to assess the 
effect of baseline polymorphisms to RAL on virological response rather than to study 
virological efficacy (552). In contrast, the estimate of 100% efficacy by 72 weeks comes from 
the Danish population based cohort – and again, reflects a very small (N=32) population (554). 
Smaller studies are more likely to report more extreme results than larger studies as a result of 
a number of biases, including publication bias (563). The studies including more than 100 
individuals all reported virological efficacy around 70% in ITT analyses irrespective of the time-
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frame applied (547,549,550). Per-protocol analyses did, as expected, generate a higher 
probability of virological suppression: 93.4% (549). Only one study estimated the risk of VF 
specifically. In the Italian SALIR-E cohort, 8.4% of patients experienced VF by 96 weeks in ITT 
analysis. Per protocol estimates of the risk of VF were not reported (551).  
Estimates of virological suppression among patients with TCF also varied, and ranged from 70-
97%. The largest of these studies was an analysis by Scherrer et al from the Swiss Cohort Study 
(560). They included patients who experienced TCF and studied virological response to RAL-
based regimens at 24 weeks. The first key conclusion from their analysis is the fact that the 
probability of virological suppression varied depending on whether patients started RAL as 
salvage treatment or as a switch for safety reasons. At 24 weeks, 76.1% of salvage patients 
reached VS as compared to 95.8% of switch patients (560). Sherrer et al also report the impact 
of using different methods for handling missing data, and show that using an approach such as 
LOCF lead to considerably more favourable outcomes compared to using a missing=failure 
approach, which most trials adopt. However, due to the large proportion of missing data 
present in the Swiss cohort study, and indeed in many studies, the authors argue that the LOCF 
results are the most informative for this context (560). The difference in outcomes between 
salvage and switch patients was also found in an analysis by Teague et al, which described 
outcomes for TCF patients receiving care at the Chelsea and Westminster hospital in London. 
They found that 84% of salvage patients compared to 93% of switch patients achieved a 
supressed viral load by 48 weeks (561). Again, only one study estimated the risk of VF directly. 
Bucciardini et al analysed the probability of VF by 48 weeks in the Italian ISS-NIA cohort of 
individuals experiencing TCF who started INSTIs, and found a cumulative probability of VF at 
26% (559).  
In terms of predictors of virological outcomes, these were only reported in 9/21 studies. A 
higher baseline viral load was consistently associated with the risk of failure to achieve VS 
(543,550,551,556). Baseline (550,551) and nadir (556) CD4 count was also associated with 
virological outcomes, as was a complex previous treatment history (551,558). Marcelin et al, in 
a 2013 analysis of the French ANRS cohort, also found that the use of two or more new drugs 
among DRV/ETR/MVC or ENF together with RAL was predictive of virological success (550). 
Adherence was associated with worse virological outcomes in two studies (534,543). One of 
these, the RALTECAPS study by Gras et al, utilised a validated measure of adherence (the 
MEMS caps system). They found that although RAL plasma levels were not predictive of VF, 
adherence patterns, in particular the duration of the treatment interruption, was a strong 
predictor of VF (534). No demographic determinants of virological outcomes were reported, 
apart from older age reported as being predictive of achieving VS in one study (558).  
161 
 
4.2.2. Integrase resistance prevalence following RAL VF 
Although the majority of the studies in the review reported on integrase resistance patterns 
following VF, the analyses generally involved a very small number of individuals due to the 
relative rarity of experiencing VF. As a proportion of those genotyped, the prevalence of 
integrase resistance ranged from 20% (534) to 81% (553,556). Clinical trials also report very 
varied prevalence of integrase resistance (Table 4.2), with estimates ranging from 5-66%. The 
largest observational study of integrase resistance prevalence identified for this review was 
undertaken by Fourati et al in the French ANRS cohort. They found a prevalence of integrase 
resistance of 39% among individuals experiencing VF on RAL, although the proportion of 
successfully genotyped samples was not reported (548). The N155 and Q148 resistance 
pathways predominated, followed by Y143. Although no patient was found to harbour the 
R263K Dolutegravir resistance mutation, 13.9% of all patients failing were still predicted to be 
resistant to Dolutegravir, primarily as a consequence of the Q148 mutation in combination 
with the G140 substitution (548). Only one study reported specifically using next generation 
sequencing (NGS) techniques to study minority variants (552). Armenia et al used the Ultra-
Deep-454 pyrosequencing platform to study the impact of low-frequency baseline 
polymoprhisms on response to RAL containing regimens, and also performed ultra-deep 
sequencing (UDS) of 11 individuals who failed RAL. Their analysis also found 3 main resistance 
pathways involving either Y143, Q148 or N155 (552). 
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4.2.3. What this analysis adds 
Virological outcomes following the initiation of RAL-based regimens have been assessed in a 
relatively large number of observational studies in resource-rich settings, but the majority of 
these have been small, restricted to a single country and only reported on shorter-term 
outcomes. The number of studies reporting on risk factors for RAL failure or on integrase 
resistance patterns is also relatively small. Only one study reported using NGS to study the 
minority integrase resistance mutations, which could influence the response to consequent 
therapy. EuroSIDA is one of few large HIV cohorts that collect data from across Europe in a 
standardized manner with long-term follow-up, meaning that this analysis contributes 
important data on RAL virological outcomes and resistance patterns in different European 
regions. In addition, the availability of stored samples within EuroSIDA provides an opportunity 
to study integrase resistance patterns despite the fact that genotyping of the integrase gene is 
still not commonly done in routine practice in all European countries through genotyping of 
samples from the plasma repository. Centrally genotyping individuals who fail RAL also allows 
us to apply NGS technology, which has the potential to generate important information on 
minority variants that would not have been possible to study using routinely collected data 
which is done using Sanger sequencing.  
 
163 
 
4.3. Methods  
4.3.1. Inclusion criteria and study population  
I used the D42 (February 2016) version of the EuroSIDA database for this analysis, which held 
data on 21,879 individuals. Due to the timing of the analyses, I was restricted to use resistance 
test results from earlier dataset rounds (June 2013). The samples selected for retrospective 
genotyping were selected from the March 2015 update of the repository database. The 
inclusion process is outlined below in Figure 4.4. Briefly; I included ART-experienced individuals 
who started RAL for the first time after 1/1/2006 with no prior exposure to INSTIs. The 
1/1/2006 was chosen as a cut-off date as it is approximately two years prior to EMA approval 
of RAL, which allows for the inclusion of individuals who may have accessed RAL through 
compassionate early-access programs. As very few individuals (N=193, 7%) started RAL from 
ART-naïve it was not possible to conduct a separate analysis of this patient group, and to ease 
the interpretations of my findings these individuals were excluded. I further required 
individuals to have a baseline VL measurement and at least 1 day of follow-up with RAL 
exposure in order to be included. Baseline was defined as the first date of starting the RAL-
based regimen. Patients were separated into two different groups:  
• RAL start with a raised VL (RVL group): Started RAL with a baseline viral load (bVL) 
>200 copies/mL  
• RAL start with a suppressed VL (SVL group): Started RAL from a bVL<200 copies/mL  
All analyses were conducted separately in these two groups, as clinical experience and the 
previous literature (Table 4.4) indicated that it was likely that the reason for starting RAL and 
consequent virological outcomes would differ in these two groups. Baseline VL was 
approximated using any VL measurement taken before baseline, with no time restrictions. 
However, this was evaluated in a sensitivity analysis. Individuals with a VL recorded as below 
the detection limit of a VL higher than 200 (eg, 499 for 500) were classed as starting RAL with a 
raised VL, although different cut-offs were also evaluated in sensitivity analyses. 
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Figure 4.4. Selection of participants in EuroSIDA 
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The virological outcome I chose to study was VF, and I describe both time to and risk factors 
for VF. VF was defined differently according to VL at the time of RAL start, and was defined 
using both VL values and considering the discontinuation of drugs as indicative of VF.  
• RAL start with a raised VL (RVL group): Confirmed VL>200 after at least 6 months of 
receiving RAL (“failure to supress”)  
• RAL start with a suppressed VL (SVL group): Confirmed VL>200 (“viral rebound”)  
• For both groups: Discontinuation of RAL or a drug used with RAL with the main reason 
for stopping given by the treating physician as VF 
If an individual met more than one VF definition, the earliest date for VF was used. For the 
purposes of sample selection (Section 4.3.2 below) VF was considered to be on-going until RAL 
was stopped or VL declined to below 200 copies/ml, whichever occurred first. I chose to use a 
200 copies/ml cut-off for the main analyses as EuroSIDA collects data from some countries that 
are relatively resource poor, and may still be using genotyping technology with this higher cut-
off point, particularly at early follow-up times included in this analysis. The date of failure was 
put to the first of the two consecutive VL measures.  
4.3.2. Resistance data and sample selection 
I calculated a baseline GSS for the drugs received at the time of staring RAL using the ANRS 
(2015) interpretation rules. As the inclusion criteria guaranteed that individuals did not have 
any prior INSTI exposure, the GSS was calculated only for the rest of the regimen, defined as all 
drugs excluding RAL (564). Existing data on integrase resistance is limited in the EuroSIDA 
database, and I therefore selected a number of stored plasma samples to be retrospectively 
genotyped at the EuroSIDA central laboratory in Badalona, Spain. The samples were selected 
according to the following rules:  
1. The date of the sample occurred between the first date of RAL failure and the last 
date of RAL failure  
 
or 
 
2. The date of the sample occurred up to 3 months before the first date of RAL failure 
given that VL>50 copies/ml  
 
or 
 
3. The date of the sample occurred up to 3 months after the last date of RAL failure 
given that VL>50 copies/ml 
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When more than one sample could be identified for a patient, I chose to include the earliest 
possible sample given that the viral load at the time of the sample was >50 copies per mL. Fifty 
copies/ml was considered the lowest VL it was considered feasible to genotype from (565–
567). The principles were laid out in collaboration with virological experts and approved by the 
EuroSIDA steering committee.  
4.3.2.1. Sequencing 
Identified samples were sent to Badalona from the EuroSIDA plasma repository at the 
University of Copenhagen by the EuroSIDA coordinating centre staff in June 2015. They were 
sequenced using the Illumina Miseq platform, which is an NGS technology. The principles of 
NGS are described in more detail in Chapter 1. The reads generated by sequencing were 
aligned to the HIV-1HXB2 clonal sequence (GenBank ID: K03455|HIVHXB2CG). The Illumina 
platform uses paired-end sequencing, which involves both forward and reverse reads starting 
from the 3’ and 5’ end of the RNA strands respectively. To ensure that mutants were well 
balanced, the ratio of the forward and reverse reads should be close to 1. The minimum 
number of reads (“coverage”) required to call a base using Illumina was estimated at 500 
(R.Paredes, personal communication). Median (IQR) ratios of forward/reverse reads and total 
coverage is reported as an indication of the quality of the genotyping.  
The main benefit of using an NGS platform is the ability to study minority variants, commonly 
defined as viral strains present at frequencies that are not detectable by Sanger sequencing. 
For the purposes of this analysis, this was defined as a frequency between 1-25% (568). 1% is 
chosen as the lower cut-off to remove variants detected a very low level and likely to be false 
positive detections.  
4.3.3. Statistical methods 
Patients’ characteristics at baseline were compared between the raised viral load (RVL) and 
suppressed viral load (SVL) groups using the basic statistical inference techniques outlined in 
Chapter 2. The proportion of individuals receiving RAL was described per year and 
geographical region, using all individuals in EuroSIDA on ART with at least one RNA 
measurement in a given year as the denominator. The cumulative risk of experiencing VF to 
RAL was described using Kaplan Meier plots, and risk factors for failing RAL identified using Cox 
Proportional Hazards models.  
In accordance with prior research (549), two different analyses were conducted, an intention to 
treat (ITT) analysis and one per protocol (PP) analysis. In the ITT analysis, individuals were 
censored at their last available clinic visit date and any drug switches were ignored. In the PP 
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analysis, individuals were censored at their last available clinic visit date or when RAL was 
stopped, whichever came first. These analyses answer different questions, both of which were 
considered to be of clinical importance. The ITT analysis presents estimates of the risk of VF after 
an individual has been prescribed RAL, whereas the PP analysis estimates the risk of VF while an 
individual is receiving RAL. For both the ITT and PP analysis, the last visit date was defined as the 
maximum visit date, date of RNA or CD4 measurement or ART start/stop date. Kaplan Meier 
plots were only drawn until less than 30 individuals remained in the risk set, which occurred 
after year 7. No events occurred in this period for either analysis group. Factors associated with 
successful genotyping were identified using the chi-squared test/kruskal wallis and logistic 
regression as appropriate. Only a descriptive analysis of the results from the genotyping is 
presented due to low sample size of patients with resistance tests. 
4.3.3.1.Variable categorisation and missing data 
The risk factors for VF evaluated in this analysis were identified based on the results from the 
literature review and the opinions of clinical experts. The selected variables, together with 
their final categorisations, can be seen in Table 4.5.  
Table 4.5 Categorisation of potential risk factors for VF  
Variable Categories Time-updated 
Gender Female; Male No 
Ethnicity White, Non-white No 
Age Continuous (per 10 years) No 
Risk Group MSM; PWID; Heterosexual; Other No 
Geographical Region1  Southern, Central West, 
Northern, Central East, Eastern 
No 
Co-infection with Hepatitis 
B (Ever positive for surface 
antigen (HBVGS)) 
Yes, No, Missing No 
Co-infection with Hepatitis 
C (Ever antibody positive) 
Yes, No, Missing No 
Baseline VL2,3 Continuous, log10 scale higher No 
Baseline CD43  Continuous, per 100 cells/mm3 
higher 
No 
Baseline triple class  
resistance (resistance to 
NRTI, NNRTI and PI 
drugclasses) 
Yes, No No 
HIV Subtype B, Non-B, Unknown No 
Mono or dual therapy 
before cART 
Yes, No No 
Calendar Year of RAL start  Continuous, per more recent year No 
1. For the analysis of risk factors among individuals starting RAL with a suppressed VL, limited numbers meant that 
East and Central East had to be considered together. Argentina was considered together with Southern Europe as 
per EuroSIDA standard practice, as there were not enough individuals in each group to fit the model with separate 
categories.  
2. Not considered for the analysis of risk factors among individuals starting RAL with a suppressed VL.  
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3. Any measurement prior to baseline was used to estimate these values. In sensitivity analyses, a shorter time-
window (12 months) for defining baseline VL was used.  
Missing data for the main outcome measurement, VL, was handled using a last observation 
carried forward (LOCF) approach, although this was evaluated in sensitivity analyses. 
4.3.4. Sensitivity analyses 
I conducted the following sensitivity analysis to assess the impact of some of the assumptions:  
1) Censoring individuals FU-time 6 months after a VL measurement until a new VL 
measurement was taken. Individuals re-entered the analysis when a new VL 
measurement was taken 
 
2) Defining VF as a confirmed VL>50 (for the SVL group), a confirmed VL>50 after at 
least 6 months of RAL (for the RVL group) or a physician indicated stop of RAL due 
to VF (regardless of group) 
 
3) Same as (2) but using the threshold of 500 copies/mL for VF 
 
 
4) Individuals with a baseline VL taken more than 12 months before baseline were 
excluded from the analysis 
 
5) Individuals with less than 2 VL measurements available after their baseline VL 
measurement were excluded from the analysis 
 
When the definitions of outcomes 2) and 3) were adopted, the cut off for the baseline value of 
VL used to define the SVL and RVL groups was changed accordingly. I was not able to use the 
limit of detection to do a sensitivity analysis as in Chapter 3, as this data was unfortunately not 
available in later versions of the EuroSIDA database due to changes to the data collection 
forms. For simplicity, only the results from the ITT analysis are shown for the sensitivity 
analyses. 
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4.4. Results  
4.4.1. Use of raltegravir and baseline characteristics  
In total, 2,447 individuals were included in the analyses. Those who started RAL but who were 
nonetheless excluded due to missing baseline VL or FU data were more likely to have Hepatitis 
C (p<0.001), have unknown Hepatitis B status (p<0.001), be injecting drug users (p<0.001) and 
they were also slightly more likely to originate from Southern, Central Eastern or Eastern 
Europe (p=0.006). They were also likely to be younger, have lower baseline CD4 counts and 
higher baseline VL values compared to those who were included (all p<0.0001).  
Of those 2,447 included, the majority (1,642, 67%) started RAL with a suppressed VL (SVL 
group). Although EuroSIDA does not collect reasons for starting drugs, overall, 1584 (64.7%) of 
individuals had a reason for stopping a previous drug given in the month before starting RAL. A 
breakdown of these reasons is displayed according to the stratification groups in Table 4.6.  
Table 4.6. Reasons for discontinuation a drug before starting RAL 
 Reason Suppressed bVL (SVL) Raised bVL (RVL) 
 N (%) N (%) 
Treatment Failure 80 (7.1) 264 (57.5) 
Abnormal Fat Redistribution 63 (5.6) 6 (1.3) 
Concern of cardiovascular disease 28 (2.5) 4 (0.9) 
Dyslipidaemia 74 (6.6) 4 (0.9) 
Cardiovascular disease 22 (2.0) 1 (0.2) 
Hypersensitivity Reaction 3 (0.3) 6 (1.3) 
Toxicity, predominantly abdomen/GI tract 35 (3.1) 6 (1.3) 
Toxicity - GI tract 46 (4.1) 9 (2.0) 
Toxicity – Liver 31 (2.8) 9 (2.0) 
Toxicity – Pancreas 3 (0.3) 2 (0.4) 
Toxicity, predominantly CNS 28 (3.4) 5 (1.1) 
Toxicity, predominantly kidneys 85 (7.6) 2 (0.4) 
Toxicity, predominantly endocrine 4 (0.4)  
Diabetes 4 (0.4) 1 (0.2) 
Haematological toxicity 5 (0.4) 2 (0.4) 
Hyperlactataemia/lactic acidosis 2 (0.2)  
Toxicity, any other 69 (6.1) 16 (3.5) 
Patient’s choice 59 (5.2) 8 (1.7) 
Physician’s choice 302 (26.8) 70 (15.3) 
Structured Treatment interruption 4 (0.4) 1 (0.2) 
Other, not specified 149 (13.2) 42 (9.2) 
 
Among those in the SVL group, the most common reason for stopping a drug close to the date 
of RAL start was ‘physician’s choice’ (26.8%), although when considering all toxicities together, 
48% were indicated to have stopped because of toxicity. It is conceivable that most of those 
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reporting ‘physicians’ choice’ were switches for simplification in people with suppressed VL. As 
expected, treatment failure was the most common reason for stopping a drug among those 
starting RAL in the RVL group (57.5%).  
The use of RAL increased significantly over time in all geographical regions (chi-squared test for 
trend p<0.0001, all regions), although the increase was more marked in Southern, Central 
Western and Northern Europe. RAL use showed an increase over time in Central Eastern and 
Eastern Europe, but the absolute number of individuals on cART receiving RAL in these regions 
was low, particularly in Eastern Europe (Figure 4.5). For completeness, the frequency of use of 
other drugs in the INSTI class is also shown in Figure 4.3. The use of ELV and DTG remained low 
across the study period, although DTG use increased significantly between 2014 and 2015 in 
Southern, Central Western and Northern Europe.  
Baseline characteristics of the included participants according to bVL group can be seen in 
Table 4.7. Individuals in the RVL group were more likely to be female (p=0.003), originate from 
Central East or Eastern Europe (p<0.001) and to have acquired HIV through injecting drug use 
or heterosexual sex (p=0.003). They were also likely to be younger (p<0.001) and have started 
RAL in an earlier calendar year (p<0.001) than those in the SVL group. By definition, individuals 
in the RVL group higher bVL values (p<0.001), lower baseline CD4 counts (p<0.001) and lower 
CD4 count nadir (p=0.003) compared to those in the SVL group.  
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Figure 4.5 Use of integrase inhibitors over time in EuroSIDA, by geographical region1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. The proportion of individuals on each INSTI shown as a proportion of individuals under FU on ART in a given year, defined as having an RNA measurement taken in that particular year and being on at least 1 drug 
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Table 4.7. Baseline characteristics of included patients  
    All RVL SVL P 
    N (%)  N (%) N (%)   
Total   2,377 (100) 805 (32.9) 1642 (67.1)   
Gender Male 1,809 (76.1) 571 (72.4) 1238 (78.0) 0.003 
  Female 568 (23.9) 218 (27.6) 350 (22.0)   
Ethnicity White 2,017 (85.6) 656 (83.7) 1361 (86.5) 0.064 
  Not White 340 (14.4) 128 (16.3) 212 (13.5)   
Region South 794 (32.4) 273 (33.9) 520 (31.7) <.001 
  Central West 944 (38.6) 260 (32.3) 684 (41.7)   
  Northern 427 (17.5) 144 (17.9) 283 (17.2)   
  Central East 240 (9.8) 105 (13.0) 135 (8.2)   
  East 43 (1.7) 23 (2.9) 20 (1.2)   
Risk Group MSM 983 (41.7) 289 (36.8) 694 (44.1) 0.003 
  PWID 554 (23.5) 204 (26.0) 350 (22.2)   
  Heterosexual 645 (27.3) 237 (30.2) 408 (25.9)   
  Other 178 (7.5) 55 (7.0) 123 (7.8)   
Baseline GSS >3 968 (39.6) 362 (45.0) 592 (36.1) <.001 
  <3 112 (4.6) 61 (7.6) 65 (4.0)   
  Unknown 1,367 (55.9) 382 (47.5) 985 (60.0)   
Subtype B 831 (34.0) 303 (37.6) 528 (32.2) <.001 
  Not B 154 (6.3) 66 (8.2) 88 (5.4)   
  Unknown 1,462 (59.8) 436 (54.2) 1026 (62.5)   
Hepatitis C No 1,254 (51.3) 401 (49.8) 853 (51.9) <.001 
  Yes 1,072 (43.8) 344 (42.7) 728 (44.3)   
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  Unknown 121 (4.9) 60 (7.5) 61 (3.7)   
Hepatitis B No 1,966 (80.3) 616 (76.5) 1350 (82.2) 0.003 
  Yes 122 (5.0) 44 (5.5) 78 (4.8)   
  Unknown 359 (14.7) 145 (18.0) 214 (13.0)   
History of mono/dual therapy No 1,560 (63.8) 530 (65.8) 1034 (63.0) 0.165 
  Yes 887 (36.3) 275 (34.2) 608 (37.0)   
  Median (IQR) Median (IQR) Median (IQR)  
Age Years 49 (44-55) 47 (41 - 53) 50 (45 - 56) <.001 
Baseline VL log10 cp/ml 49 (36-1,400) 10,528 (1,500 – 75,000) 39 (19 - 49) <.001 
Baseline CD4 cells/mm3 441 (260-659) 277 (159 - 449) 525 (352 - 735) <.001 
Nadir CD4 cells/mm3 113 (38-205) 100 (31 - 193) 120 (42 - 210) 0.003 
Month/Year of RAL start Year 10/10 (01/09-11/12)  11/09 (06/08-(11/11)  04/11 (06/09-03/13)  <.001 
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4.4.2. Baseline treatment and resistance patterns.  
A large number of different treatment combinations were used: 778 different combinations in 
total. The most common treatment regimen was RAL + Tenofovir (TDF) and Emtricitabine (FTC) 
among both patient groups (6.4 and 8.6% in the RVL and SVL groups respectively (Table 4.8).  
Table 4.8. Most common treatment combinations used with RAL 
Regimen N % 
Among patients with a raised baseline VL 
Tenofovir/Emtricitabine 105 6.39 
Tenofovir/Emtricitabine/Darunavir(r) 72 4.38 
Lamivudine/Abacavir 68 4.14 
Among individuals with a supressed baseline VL 
Tenofovir/Emtricitabine 69 8.57 
Darunavir (r)/ Etravirine 27 3.35 
Darunavir (r) 26 3.23 
 
Drugs used before and after RAL can be seen in Table 4.9 below.  
 
 
 
 
 
 
 
 
 
 
1. Before baseline describes drugs given the day before RAL was started 
 
The majority of individuals in both patient groups were on PI-containing cART both before and 
after initiation of RAL. The median number of drugs used increased from 3 (3-3) in both groups 
to 4 (3-5) and 4 (3-6) in the RVL and SVL groups respectively at baseline. RAL was commonly 
paired with Darunavir (DRV), particularly among individuals in the SVL group (45.5%).  
 
Table 4.9. Drugs given before and with RAL at baseline 
 RVL SVL 
Before baseline N (%) N (%) 
NRTI 1374 (83.7) 590 (73.3) 
NNRTI 480 (29.2) 143 (17.8) 
PI (any) 1146 (69.8) 472 (58.6) 
LPV/r 355 (21.6) 148 (18.4) 
DRV/r 282 (17.2) 90 (11.2) 
T20 91 (5.5) 34 (4.2) 
Number of drugs (Median, IQR) 3 (3-3) 3 (3-3) 
At baseline  N (%) N (%) 
NRTI 1429 (87.0) 680 (84.5) 
NNRTI 536 (32.6) 283 (35.2) 
PI (any) 1105 (67.3) 595 (73.9) 
Lopinavir (r) 313 (19.1) 142 (17.6) 
Darunavir (r) 445 (27.1) 366 (45.5) 
T20 75 (5.6) 67 (8.3) 
Number of drugs (Median, IQR) 4 (3-6) 4 (3-5) 
175 
 
1080 (44%) of individuals had a resistance test result at baseline; 423 (53%) in the RVL and 530 
(32%) in the SVL group. The resistance test was done a median of 5.3 years (IQR=2.1-8.9) 
before the start of RAL (7.1 (4.2-10.2) and 2.3 (0.3-5.9) among the SVL and RVL groups 
respectively). Out of those tested for resistance, the vast majority had any detected resistance 
in both groups (Figure 4.6). However, most were also treated with regimens that had at least 
two active drugs (90.1 and 85.6 in the SVL and RVL groups respectively).  
 
Figure 4.6. Resistance patterns at baseline according to RVL/SVL RAL use 
 
 
 
 
 
 
 
 
 
 
 
 
A total of 401 (16.4%) of patients had resistance to all 3 major drug classes, 203 (25.2%) of RVL 
patients and 198 (12.1%) of SVL patients. 
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4.4.3. Time to and risk factors for virological failure  
In total, 262 individuals experienced VF in the ITT analyses and 192 individuals in PP analyses. The 
majority of VF’s occurred in the RVL group (58% in ITT and 61% in PP analyses). People in the RVL 
group were also followed-up for longer: a median of 3.9 (1.7-5.8, ITT) and 2.8 (0.8-5.2, PP) years and 
those in the SVL group for 3.1 (1.5-5.0, ITT) and 2.4 (1.0-4.5, PP) years respectively. KM estimates 
with 95% CI of time to VF according to bVL group can be seen in Figure 4.7 below. The cumulative 
probability of experiencing VF by 7 years was estimated at 12.0% (95%CI=8.4-16.8) (ITT) and 8.7% 
(95%CI=5.6-12.6) (PP) for individuals in the SVL group. These estimates were two-fold higher for 
those in the RVL group: 24.8% (19-32) (ITT) and 22.2% (16.3-29.9) (PP) respectively. As expected, 
estimates from the ITT analyses were higher than those form the PP analyses. Of those who did fail, 
the median VL at failure was relatively low: 2,119 (406-24,5999 copies/ml in the RVL group and 361 
(39-8,260) copies/ml in the SVL group.  
Risk factors associated with failing RAL can be seen in Table 4.10 (SVL group) and Table 4.11 (RVL 
group). Among those in the SVL group, a low number of events made it challenging to identify any 
risk factors for VF. However, there was some evidence that individuals with higher baseline CD4 
counts were less likely to experience VF (aHR=0.92, 95%CI=0.85-0.99), although the evidence 
supporting this finding was weak (p=0.04). There was also an indication that the probability of RAL 
failure decreased with calendar time of starting RAL (aHR=0.89, 95%CI=0.79-1.01, p=0.077). 
Although the HR’s were similar in both ITT and PP analyses, the weak evidence associated with both 
of these findings was even more attenuated in the PP analyses (p=0.17 and p=0.2 respectively), 
possibly as a result of the lower number of events included in the PP analysis.  
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Figure 4.7. Time to VF following RAL start in ITT (a) and PP (b) analyses 
 
 
 
 
 
b) a) 
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Table 4.10. Factors associated with failing RAL among patients in the SVL group 
 
   ITT  PP  
    aHR (95% CI) P aHR (95% CI) P 
Gender Male       
  Female 1.06 (0.61 - 1.85) 0.835 0.83 (0.42 - 1.65) 0.600 
Age Per 10 years older 0.85 (0.69 - 1.05) 0.139 0.86 (0.67 - 1.12) 0.265 
Ethnicity White         
  Not White 0.66 (0.34 - 1.28) 0.217 0.57 (0.25 - 1.28) 0.173 
Region South   0.895   0.719 
  Central West 1.11 (0.67 - 1.84)   1.29 (0.70 - 2.38)   
  Northern 0.94 (0.51 - 1.74)   1.02 (0.47 - 2.19)   
  Central East and East 0.86 (0.35 - 2.10)   0.78 (0.26 - 2.33)   
Risk Group MSM   0.215   0.335 
  PWID 1.21 (0.65 - 2.26)   1.49 (0.69 - 3.22)   
  Heterosexual 0.87 (0.47 - 1.60)   1.27 (0.63 - 2.57)   
  Other 1.78 (0.93 - 3.41)   2.03 (0.93 - 4.44)   
Baseline CD4 Per 100 cells/mm3 higher 0.92 (0.85 - 0.99) 0.037 0.94 (0.85 - 1.03) 0.171 
CD4 nadir Per 100 cells/mm3 higher 1.15 (0.96 - 1.38) 0.122 1.10 (0.88 - 1.38) 0.414 
Subtype B   0.278   0.532 
  Not B 1.07 (0.47 - 2.47)   1.22 (0.45 - 3.32)   
  Unknown 0.71 (0.45 - 1.12)   0.78 (0.44 - 1.36)   
Triple Class Resistance No   0.432   0.229 
  Yes 1.23 (0.73 - 2.06)   1.46 (0.79 - 2.69)   
History of mono or dual therapy No   0.980   0.215 
  Yes 1.00 (0.67 - 1.47)   0.73 (0.45 - 1.20)   
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Hepatitis B No   0.502   0.919 
  Yes 0.74 (0.34 - 1.62)   1.15 (0.35 - 3.71)   
  Unknown 0.53 (0.18 - 1.54)   0.96 (0.23 - 4.09)   
Hepatitis C No   0.893   0.885 
  Yes 0.93 (0.59 - 1.47)   1.04 (0.59 - 1.84)   
  Unknown 0.77 (0.22 - 2.69)   0.71 (0.15 - 3.31)   
Calendar Year of RAL start Per more recent year 0.89 (0.79 - 1.01) 0.071 0.91 (0.79 - 1.05) 0.200 
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Risk factors for VF were different among those in the RVL group. Among this group, individuals were 
more likely to experience VF if they were of a non-white ethnicity (aHR=1.92 comparing non-white 
vs. white, 95%CI=1.18 - 3.10, p=0.008), receiving care in central eastern or eastern Europe (aHR=2.29 
compared to Southern Europe, 95%CI=1.34-3.90 and aHR=3.22, 95%CI=1.39-7.46 respectively, 
p<0.001). There were also differences according to baseline VL and CD4 levels: individuals with 
higher baseline VL levels were more likely to experience VF (aHR=1.22 per log10 higher, 95%CI=1.01-
1.46, p=0.04), whereas individuals with higher nadir CD4 counts were less likely to experience VF 
(aHR=0.82 per 100 cells higher, 95%CI=0.66-1.01), although the evidence supporting the latter was 
weak (p=0.07). The results also suggested that individuals with diagnosed Hepatitis C were less likely 
to experience VF on RAL compared to those with no Hepatitis C (aHR=0.57, 95%CI=0.36-0.90, 
p=0.03). The adjusted hazard ratio for calendar year indicated that the risk of VF had decreased with 
later years of RAL start in a similar manner to that seen among individuals who started RAL with a 
suppressed bVL (aHR=0.90, 95%CI=0.80-1.01), although this difference could be due to chance 
(p=0.07). 
Some of the results of the PP analysis were different from those found in the ITT analysis. 
Geographical region, CD4 nadir and hepatitis C remained associated with VF, and the association 
between the risk of VF and calendar time grew slightly stronger (aHR=0.88, 0.78-1.00, p=0.04). 
However, there was no evidence to support an association with ethnicity and baseline VL. 
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Table 4.11. Factors associated with failing RAL among patients in the RVL group 
 
Multivariable  ITT  PP  
    aHR (95% CI) P aHR (95% CI) P 
Gender Male   0.383   0.295 
  Female 0.82 (0.53 - 1.28)   0.76 (0.46 - 1.27)   
Age Per 10 years older 0.83 (0.67 - 1.02) 0.076 0.82 (0.65 - 1.03) 0.093 
Ethnicity White   0.008   0.336 
  Not White 1.92 (1.18 - 3.10)   1.33 (0.74 - 2.38)   
Region South   <.001   0.002 
  Central West 0.81 (0.50 - 1.31)   0.81 (0.47 - 1.40)   
  Northern 0.72 (0.42 - 1.24)   0.84 (0.46 - 1.54)   
  Central East 2.29 (1.34 - 3.90)   2.53 (1.39 - 4.60)   
  East 3.22 (1.39 - 7.46)   3.05 (1.22 - 7.63)   
Risk Group MSM   0.048   0.047 
  PWID 2.11 (1.22 - 3.64)   2.28 (1.22 - 4.23)   
  Heterosexual 1.39 (0.85 - 2.27)   1.55 (0.88 - 2.73)   
  Other 1.85 (0.94 - 3.64)   2.13 (1.03 - 4.43)   
Baseline VL Per log10 cp/ml higher 1.22 (1.01 - 1.46) 0.035 1.10 (0.89 - 1.36) 0.381 
Baseline CD4 Per 100 cells/mm3 higher 0.92 (0.84 - 1.02) 0.125 0.94 (0.84 - 1.05) 0.243 
CD4 nadir Per 100 cells/mm3 higher 0.82 (0.66 - 1.01) 0.065 0.79 (0.62 - 1.01) 0.059 
Subtype B   0.124   0.626 
  Not B 0.76 (0.41 - 1.41)   0.70 (0.33 - 1.48)   
  Unknown 0.65 (0.42 - 0.99) 0.689 0.89 (0.55 - 1.43) 0.796 
Triple Class Resistance No TCR         
  TCR 0.92 (0.59 - 1.41) 0.532 0.94 (0.57 - 1.53) 0.198 
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History of mono or dual therapy No         
  Yes 1.12 (0.78 - 1.61)   1.31 (0.87 - 1.97)   
Hepatitis B No   0.007   0.026 
  Yes 2.35 (1.28 - 4.32)   1.90 (0.92 - 3.91)   
  Unknown 0.61 (0.30 - 1.23)   0.44 (0.19 - 1.01)   
Hepatitis C No   0.035   0.030 
  Yes 0.57 (0.36 - 0.90)   0.55 (0.33 - 0.93)   
  Unknown 1.09 (0.46 - 2.60)   1.42 (0.54 - 3.76)   
Calendar Year of RAL start Per more recent year 0.90 (0.81 - 1.01) 0.064 0.88 (0.77 - 1.00) 0.043 
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4.4.4.Sensitivity analyses 
A number of sensitivity analyses were performed by varying the inclusion criteria and the definition 
of VF as described in the methods. The number of failure events and FU time included as a result of 
changing these definitions in the various can be seen in Table 4.12Table 4.16. As expected, more 
failure events were detected when using the lower VL cut-off of 50 copies/mL compared to the 200 
copies/mL threshold used in the main analysis. The results of the sensitivity analyses were very similar 
to those found in the main analysis. For those with a suppressed bVL (Table 4.13), the findings 
indicated borderline associations with baseline CD4 and calendar year in all these alternative analyses. 
For individuals starting RAL with a raised bVL (Table 4.15), there were some differences in terms of 
statistical significance across sensitivity analyses for ethnicity, baseline VL, CD4 nadir and calendar 
year, although the aHR were all similar. The most consistent finding across all analyses was a higher 
risk of VF in central eastern and eastern Europe as compared to southern Europe.  
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Table 4.12. Number of patients, FU time and VFs with a raised and supressed viral load under different assumptions 
  Main analysis Sensitivity 1 Sensitivity 2 Sensitivity 3 Sensitivity 4 Sensitivity 5 
  Cut-off: 200 Cut-off: 50 Cut-off: 500 Censor: 6m Baseline VL taken 
<12 m of baseline  
At least 2 VL 
measures after 
baseline 
   N (%) N (%) N (%) N (%) N (%) 
Total  2,447 2,447 2,447 2,447 2,213 2,214 
N (sup.) N (%)1 1,642 (67.1) 1,453 (59.4) 1,741 (71.2) 1,642 (67.1) 1,557 (70.4) 1,495 (67.5) 
N (not sup.) N (%)1 805 (32.9) 994 (40.6) 706 (28.9) 805 (32.9) 656 (29.6) 719 (32.5) 
ITT        
FU (sup.) Median (IQR) 3.1 (1.5-5.0) 2.9 (1.3-4.8) 3.2 (1.5-5.1) 2.8 (1.4-4.5) 3.1 (1.5-5.1) 3.4 (1.9-5.2) 
FU (not sup.) Median (IQR) 3.9 (1.7-5.8) 2.8 (1.0-5.2) 4.0 (1.7-5.9) 3.0 (1.3-5.0) 3.8 (1.5-5.8) 4.1 (1.9-6.0) 
Failures (sup.) N (%)2 110 (12.0) 173 (28.3) 100 (10.6) 110 (12.4) 106 (12.0) 110 (11.9) 
Failures (not sup.) N (%)2 152 (24.8) 307 (41.2) 118 (22.4) 152 (26.4) 139 (27.1) 150 (27.1) 
PP        
FU (sup.) Median (IQR) 2.4 (1.0-4.5) 2.3 (0.9-4.3) 2.5 (1.0-4.5) 2.2 (1.0-3.9) 2.4 (1.0-4.5) 2.7 (1.3-4.7) 
FU (not sup.) Median (IQR) 2.8 (0.8-5.2) 2.2 (0.6-4.6) 3.1 (0.9-5.4) 2.2 (0.8-4.3) 2.7 (0.8-5.3) 3.2 (1.0-5.4) 
Failures (sup.) N (%)2 74 (8.7) 142 (30.1) 64 (7.4) 74 (8.8) 72 (8.9) 74 (8.8) 
Failures (not sup.) N (%)2 118 (22.3) 251 (38.6) 87 (19.0) 118 (24.3) 110 (25.1) 118 (23.3) 
1. As a proportion of the total  
2. KM proportion at end of FU 
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Table 4.13. Factors associated with failing RAL among patients with a suppressed baseline VL, sensitivity analyses (ITT) 
  Sensitivity 1 
Cut-off: 50 
Sensitivity 2 
Cut-off: 500 
Sensitivity 3 
Censor: 6m 
    aHR (95% CI) P aHR (95% CI) P aHR (95% CI) P 
Gender Male         
  Female 0.70 (0.44 - 1.12) 0.139 0.92 (0.51 - 1.64) 0.769 1.07 (0.61 - 1.87) 0.822 
Age Per 10 years 0.94 (0.79 - 1.13) 0.514 0.92 (0.74 - 1.16) 0.485 0.85 (0.69 - 1.05) 0.142 
Ethnicity White             
  Not White 0.88 (0.53 - 1.48) 0.637 1.03 (0.57 - 1.87) 0.926 0.66 (0.34 - 1.28) 0.221 
Region South   0.244   0.660   0.903 
  Central West 0.73 (0.49 - 1.07)   1.26 (0.75 - 2.14)   1.10 (0.67 - 1.82)   
  Northern 0.64 (0.39 - 1.05)   1.03 (0.55 - 1.95)   0.92 (0.50 - 1.70)   
  Central East and East 0.70 (0.33 - 1.48)   0.73 (0.25 - 2.15)   0.88 (0.36 - 2.15)   
Risk Group MSM   0.343   0.142   0.241 
  PWID 1.41 (0.87 - 2.28)   1.31 (0.67 - 2.53)   1.22 (0.65 - 2.27)   
  Heterosexual 1.05 (0.65 - 1.70)   0.89 (0.47 - 1.69)   0.87 (0.47 - 1.60)   
  Other 1.53 (0.85 - 2.73)   1.95 (1.00 - 3.77)   1.74 (0.90 - 3.33)   
Baseline CD4 Per 100 cells/mm3 higher 0.95 (0.89 - 1.01) 0.085 0.91 (0.83 - 0.99) 0.025 0.92 (0.84 - 1.00) 0.038 
CD4 nadir Per 100 cells/mm3 higher 1.04 (0.90 - 1.20) 0.574 1.19 (0.98 - 1.44) 0.073 1.15 (0.96 - 1.38) 0.124 
Subtype B   0.357   0.213   0.297 
  Not B 0.82 (0.40 - 1.71)   1.13 (0.51 - 2.52)   1.07 (0.46 - 2.46)   
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  Unknown 0.76 (0.53 - 1.11)   0.68 (0.42 - 1.10)   0.72 (0.46 - 1.13)   
Triple Class  
Resistance 
No   0.677   0.541   0.411 
  Yes 1.10 (0.71 - 1.70)   0.84 (0.48 - 1.48)   1.24 (0.74 - 2.08)   
History of mono or  
dual therapy 
No   0.891   0.727   0.963 
  Yes 1.02 (0.74 - 1.41)   0.93 (0.61 - 1.40)   0.99 (0.67 - 1.47)   
Hepatitis B No   0.480   0.443   0.512 
  Yes 0.68 (0.36 - 1.28)   0.62 (0.29 - 1.30)   0.73 (0.33 - 1.59)   
  Unknown 0.75 (0.34 - 1.64)   0.62 (0.22 - 1.72)   0.53 (0.18 - 1.55)   
Hepatitis C No   0.362   0.862   0.904 
  Yes 0.87 (0.59 - 1.28)   1.03 (0.64 - 1.68)   0.92 (0.58 - 1.47)   
  Unknown 1.48 (0.68 - 3.20)   0.73 (0.21 - 2.58)   0.79 (0.23 - 2.78)   
Calendar Year of RAL 
start 
Per Year 0.86 (0.78 - 0.94) 0.002 0.83 (0.73 - 0.95) 0.008 0.89 (0.79 - 1.00) 0.057 
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Table 4.14. Factors associated with failing RAL among patients with a suppressed baseline VL, sensitivity analyses (ITT) 
  Sensitivity 4 
Baseline VL taken <12 m of baseline 
Sensitivity 5 
At least two VL after baseline 
     aHR (95% CI) P aHR (95% CI) P 
Gender Male      
  Female  1.05 (0.60 - 1.86) 0.859 1.06 (0.61 - 1.86) 0.826 
Age Per 10 years  0.87 (0.70 - 1.08) 0.195 0.85 (0.69 - 1.06) 0.145 
Ethnicity White          
  Not White  0.68 (0.35 - 1.33) 0.259 0.66 (0.34 - 1.29) 0.223 
Region South    0.966   0.917 
  Central West  1.06 (0.63 - 1.76)   1.10 (0.66 - 1.81)   
  Northern  0.97 (0.53 - 1.80)   0.94 (0.51 - 1.74)   
  Central East and East  0.85 (0.35 - 2.08)   0.86 (0.35 - 2.09)   
Risk Group MSM    0.346   0.227 
  PWID  1.20 (0.63 - 2.26)   1.22 (0.66 - 2.28)   
  Heterosexual  0.89 (0.48 - 1.64)   0.87 (0.47 - 1.61)   
  Other  1.67 (0.85 - 3.28)   1.76 (0.92 - 3.38)   
Baseline CD4 Per 100 cells/mm3 higher  0.92 (0.85 - 1.00) 0.055 0.92 (0.85 - 0.99) 0.037 
CD4 nadir Per 100 cells/mm3 higher  1.12 (0.94 - 1.35) 0.211 1.15 (0.96 - 1.38) 0.129 
Subtype B    0.226   0.279 
  Not B  1.03 (0.45 - 2.39)   1.07 (0.46 - 2.46)   
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  Unknown  0.68 (0.43 - 1.08)   0.71 (0.45 - 1.12)   
Triple Class  
Resistance 
No    0.491   0.424 
  Yes  1.20 (0.71 - 2.03)   1.23 (0.74 - 2.06)   
History of mono or  
dual therapy 
No    0.815   0.969 
  Yes  0.95 (0.64 - 1.43)   0.99 (0.67 - 1.47)   
Hepatitis B No    0.724   0.513 
  Yes   0.83 (0.36 - 1.92)   0.75 (0.34 - 1.63)   
  Unknown   0.64 (0.21 - 1.95)   0.53 (0.18 - 1.55)   
Hepatitis C No    0.894   0.904 
  Yes  0.92 (0.57 - 1.48)   0.93 (0.59 - 1.48)   
  Unknown  0.78 (0.22 - 2.74)   0.78 (0.22– 2.73)   
Calendar Year of RAL 
start 
Per Year  0.91 (0.80 - 1.03) 0.141 0.90 (0.80 - 1.02) 0.112 
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Table 4.15. Factors associated with failing RAL among patients with a raised baseline VL, sensitivity analyses (ITT) 
  Sensitivity 1 
Cut-off: 50 
Sensitivity 2 
Cut-off: 500 
Sensitivity 3 
Censor: 6m 
  
aHR (95% CI) P aHR (95% CI) P aHR (95% CI) P 
Gender Male 
 
0.232  0.274  0.487  
Female 0.83 (0.60 - 1.13) 
 
0.76 (0.46 - 1.25)  0.85 (0.55 - 1.33)  
Age Per 10 years older 0.90 (0.78 - 1.03) 0.127 0.73 (0.58 - 0.94) 0.013 0.83 (0.67 - 1.02) 0.083 
Ethnicity White 
 
0.088  0.349  0.013  
Not White 1.34 (0.96 - 1.88) 
 
1.31 (0.75 - 2.29)  1.85 (1.14 - 2.99)  
Region South 
 
<.001  0.003  <.001  
Central West 0.87 (0.63 - 1.20) 
 
0.82 (0.48 - 1.40)  0.85 (0.52 - 1.37)   
Northern 0.78 (0.54 - 1.13) 
 
0.60 (0.32 - 1.12)  0.74 (0.43 - 1.28)   
Central East 1.32 (0.88 - 1.96) 
 
1.87 (1.03 - 3.37)  2.38 (1.40 - 4.06)   
East 2.86 (1.60 - 5.09) 
 
3.46 (1.39 - 8.64)  3.13 (1.35 - 7.24)  
Risk Group MSM 
 
0.203  0.090  0.036  
PWID 1.43 (0.97 - 2.10) 
 
2.10 (1.14 - 3.89)  2.16 (1.25 - 3.72)   
Heterosexual 1.36 (0.97 - 1.90) 
 
1.59 (0.92 - 2.73)  1.36 (0.83 - 2.23)   
Other 1.31 (0.80 - 2.15) 
 
1.18 (0.50 - 2.78)  1.92 (0.98 - 3.78)  
Baseline VL log10 cp/ml higher 1.14 (1.02 - 1.28) 0.024 1.16 (0.93 - 1.45) 0.192 1.22 (1.02 - 1.46) 0.033 
Baseline CD4 100 cells/mm3 higher 0.99 (0.93 - 1.05) 0.778 0.93 (0.83 - 1.05) 0.234 0.92 (0.83 - 1.02) 0.108 
CD4 nadir 100 cells/mm3 higher 0.89 (0.78 - 1.02) 0.085 0.80 (0.63 - 1.02) 0.073 0.81 (0.65 - 1.00) 0.052 
Subtype B 
 
0.030  0.264  0.196  
Not B 0.72 (0.46 - 1.15) 
 
1.04 (0.53 - 2.05)  0.79 (0.43 - 1.46)   
Unknown 0.68 (0.51 - 0.92) 
 
0.69 (0.43 - 1.11)  0.68 (0.44 - 1.04)  
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Triple Class 
Resistance 
No TCR 
 
0.505  0.569  0.663 
 
TCR 0.90 (0.67 - 1.22)  0.87 (0.53 - 1.41)  0.91 (0.59 - 1.40)  
History of mono 
or dual therapy 
No 
 
0.526  0.395  0.491 
 
Yes 1.08 (0.85 - 1.39) 
 
1.19 (0.80 - 1.79)  1.13 (0.79 - 1.62)  
Hepatitis B No 
 
0.290  0.054  0.010  
Yes 1.37 (0.85 - 2.19) 
 
2.00 (1.00 - 4.02)  2.33 (1.27 - 4.28)  
 Unknown 0.83 (0.53 - 1.30)  0.60 (0.27 - 1.30)  0.66 (0.32 - 1.36)  
Hepatitis C No  0.144  0.107  0.044 
 Yes 0.78 (0.57 - 1.06)  0.60 (0.36 - 1.01)  0.58 (0.37 - 0.91)  
 Unknown 1.21 (0.68 - 2.14)  1.18 (0.46 - 3.04)  1.09 (0.45 - 2.64)  
Calendar Year of RAL start Per more recent year 0.93 (0.86 - 1.00) 0.064 0.87 (0.77 - 0.99) 0.038 0.90 (0.81 - 1.01) 0.070 
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Table 4.16. Factors associated with failing RAL among patients with a raised baseline VL, sensitivity analyses (ITT) 
  Sensitivity 4 
Baseline VL taken <12 m of 
baseline 
Sensitivity 5 
At least two VL after baseline 
     aHR (95% CI) P aHR (95% CI) P 
Gender Male    0.861   0.509 
  Female  0.96 (0.61 - 1.52)  0.86 (0.55 - 1.35)   
Age Per 10 years older  0.79 (0.63 - 0.99) 0.039 0.81 (0.66 - 1.01) 0.058 
Ethnicity White   0.024  0.016 
  Not White  1.80 (1.08 - 3.01)  1.82 (1.12 - 2.96)   
Region South   <.001  <.001 
  Central West  0.84 (0.51 - 1.40)  0.79 (0.49 - 1.29)   
  Northern  0.92 (0.53 - 1.63)  0.72 (0.42 - 1.25)   
  Central East  2.72 (1.55 - 4.76)  2.23 (1.30 - 3.82)   
  East  3.33 (1.42 - 7.81)  3.12 (1.35 - 7.24)   
Risk Group MSM   0.020  0.067 
  PWID  2.10 (1.20 - 3.70)  2.05 (1.19 - 3.56)   
  Heterosexual  1.08 (0.64 - 1.82)  1.32 (0.80 - 2.16)   
  Other  2.09 (1.05 - 4.15)  1.76 (0.89 - 3.47)   
Baseline VL log10 cp/ml higher  1.26 (1.04 - 1.53) 0.018 1.21 (1.00 - 1.45) 0.045 
Baseline CD4 100 cells/mm3 higher  0.91 (0.82 - 1.01) 0.074 0.92 (0.83 - 1.02) 0.108 
CD4 nadir 100 cells/mm3 higher  0.79 (0.63 - 0.99) 0.044 0.82 (0.66 - 1.02) 0.079 
Subtype B   0.389  0.138 
  Not B  0.85 (0.45 - 1.63)  0.77 (0.42 - 1.43)   
  Unknown  0.73 (0.47 - 1.14)  0.65 (0.42 - 1.00)  
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Triple Class  
Resistance 
No TCR   0.341   0.730 
  TCR  0.81 (0.52 - 1.26)  0.93 (0.60 - 1.43)  
History of mono  
or dual therapy 
No   0.391   0.477 
  Yes  1.18 (0.81 - 1.72)  1.14 (0.79 - 1.64)   
Hepatitis B No   0.021  0.007 
  Yes  2.32 (1.25 - 4.28)  2.42 (1.31 - 4.46)   
  Unknown  0.82 (0.35 - 1.92)  0.62 (0.29 - 1.30)   
Hepatitis C No   0.075  0.040 
  Yes  0.60 (0.37 - 0.95)  0.58 (0.37 - 0.91)   
  Unknown  1.10 (0.41 - 2.94)  1.14 (0.46 - 2.80)   
Calendar Year of 
RAL start 
Per more recent year  0.91 (0.81 - 1.02) 0.108 0.92 (0.82 - 1.03) 0.139 
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4.4.5.Resistance profiles at failure  
No individual who experienced VF in this study had data on integrase resistance submitted to 
the EuroSIDA study. Thirty-three samples stored in the plasma repository were identified and 
sent for NGS genotyping. Individuals with stored plasma samples were more likely to originate 
from central eastern Europe (p<0.0001) and had lower baseline CD4 counts (p<0.001) 
compared to those experiencing failure without a stored sample. The characteristics of these 
samples can be seen in Table 4.17. Most samples selected were taken during RAL failure, 
although three samples occurred before the defined first date of failure and five samples after 
the first defined date of failure.  
The overall genotyping success rate was low (11/33, 34%). Factors associated with successful 
genotyping can be seen in Table 4.18. The only factors associated with genotyping success was 
the VL at the time of sample (uOR=3.7, 95%CI=1.4-10.0 per log10 higher increase, p=0.009) and, 
marginally, VL at the time of VF (uOR=2.2, 95%CI=0.99-4.9 per log10 higher increase, p=0.05). 
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Table 4.17. Characteristics of samples and genotyping success  
Patient  Sample Date RNA  
Sample 
taken before 
(B), After (A) 
or During (D) 
failure 
episode 
Time 
between 
the date of 
first failure 
and 
sample 
date 
(months) 
Time between 
RNA 
measurement 
date and sample 
date (days) 
Success 
1 03-Feb-09 4120 D 2.9 0 No 
2 17-May-11 23000 D 0 0 Yes 
3 30-May-11 351 D 0 0 No 
4 06-Jan-11 287000 D 0 0 No 
5 02-Dec-10 209000 B -2.1 -23 Yes 
6 04-Nov-13 382 D 0  0 No 
7 12-Dec-11 262 D 14 -68 No 
8 16-Jul-10 847 D 0 -27 No 
9 27-Aug-13 397 D 31 0 No 
10 03-Nov-09 21200 D 0 0 No 
11 02-Jun-11 9360 D 5.5 0 Yes 
12 16-Jun-10 1380 D 3.0 0 No 
13 16-Jun-10 59100 D 0 0 Yes 
14 09-Nov-10 690 D 3.2 0 No 
15 10-Nov-09 29700 D 0 0 Yes 
16 13-Jan-11 267 D 0 0 No 
17 27-Aug-12 8260 D 2.8 -84 Yes 
18 02-Dec-08 1790 D 1.4 0 No 
19 02-Mar-11 73000 D 4.6 0 Yes 
20 30-Jun-09 14774 D 3.0 -1 No 
21 24-May-10 2517 D 0 0 Yes 
22 20-May-11 270 A 1.7 -22 No 
23 20-Dec-10 5400 A 4.5 0 No 
24 22-Sep-10 17198 D 9.7 -35 Yes 
26 31-May-12 498 D 2.8 -84 Yes 
27 21-Apr-08 127 B -1 -105 No 
28 28-Feb-13 101 B -2 0 No 
29 29-Sep-09 552 A 1.9 -1 Yes 
30 11-Feb-10 867 D 1.5 0 No 
31 23-Jan-12 71 A 32.4 -7 No 
32 21-Oct-08 284 A 2.1 -8 No 
33 29-Feb-12 1680 D 0 0 No 
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Table 4.18. Factors associated with successful genotyping  
  Total (N=32) Successful (N=11) Not Successful (N=21)  uOR (95% CI)  P 
 N (%)       
Treatment category Salvage 21 (66) 6 (29) 15 (71) 1.00  0.34 
 Switch 11 (34) 5 (45) 6 (55) 2.1 (0.5-9.5)   
Geographical Region Southern 4 (13) 2 (50) 2 (50) 1.00  0.97 
 Central Western 7 (22) 2 (29) 5 (71) 0.4 (0.-3-5.2)   
 Northern 4 (13) 1 (25) 3 (75) 0.33 (0.02-6.66)   
 Central Eastern 16 (50) 6 (38) 10 (63) 0.60 (0.06-5.45)   
 Eastern 1 (3) 0 1 (100) Not estimable    
Time in relation to failure Before 3 (9) 1 (9) 2 (10) 1.00  1.00 
 During 23 (72) 8 (73) 15 (71) 0.94 (0.1-6.3)   
 After 6 (19) 2 (18) 4 (19) 0.94 (0.07-12.0)   
 Median (IQR)       
RNA at failure Copies/ml 1,436 (467-23,250) 23,000 (1,330-33,993) 773 (382-4960) 2.2 (0.99-4.9)  0.05 
RNA at sample Copies/ml 1,530 (367-15,986) 17,198 (2,517-59,100) 690 (270-1,790) 3.7 (1.4-10.0)  0.009 
Time between failure and 
sample 
Months 1.6 (0-3.1) 1.5 (0-3.0) 1.9 (0-4.6) 0.95 (0.84-1.08)  0.44 
Time between RNA and 
sample 
Days 0 (-13-0) 0 (-7-0) 0 (-35-0) 0.99 (0.96-1.01)  0.37 
Date of sample  Year  2010 (2009-2011) 2010 (2010-2011) 2010 (2009-2011) 1.01 (0.60-1.71)  0.96 
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The total coverage and ratio of forward and reverse reads can be seen in Table 4.19 below, 
and showed good coverage and balance for those samples with successful genotyping. 
1. Not applicable as only one read direction was reported. 
Resistance patterns at failure and baseline for all individuals who were successfully genotyped 
are shown in Table 4.20. Overall, 8/11 (73%) of individuals had any detected resistance upon 
VF and 4/11 (36%) had any detected integrase resistance. INSTI resistance patterns consistent 
with the N155H and Q148H pathway were detected, although the Y143H mutation was not 
detected. One individual (labelled as #13) developed a major accessory INSTI mutation, T97A, 
which can confer resistance to ELV. Individual #15 developed the mutations Q148H and G140S, 
which confer resistance to both RAL and ELV and at least partial resistance to DTG when 
administered using twice-daily dosing. Either of the mutations in isolation would confer 
resistance to DTG if administered using once-daily dosing. Individual #17 developed the N155H 
mutation which confers resistance to RAL, ELV and which could, depending on the dosing, 
confer resistance to DTG. A minority variant, E92Q was also detected in this individual, and 
when present in combination these two mutations confer resistance to DTG when 
administered using twice-daily dosingThe final individual with INSTI resistance, #29, had only 
the N155H mutation detected in the integrase gene. The N155H does confer resistance to DTG 
when this drug is administered once-daily. Although numbers were too limited to draw wider 
conclusions, this means that DTG susceptibility was likely to be compromised in at least 2 of 4 
individuals experiencing RAL failure with detected INSTI resistance
 
Table 4.19. Coverage and coverage ratios for successfully genotyped samples.  
Patient  Genotyping quality 
 Total Coverage 
Median (IQR) 
Ratio FW/RV coverage 
Median (IQR) 
2 2,877 (N/A1) 1.00 (N/A1) 
5 8,092 (7,215-9,160) 1.00 (1.00-1.00) 
11 10,500 (8,207-10,584) 1.01 (1.01-1.60) 
13 1,370 (1,206.-2,491) 1.00 (0.98-1.28) 
15 5,884 (4,201-6,900) 1.39 (1.0-1.62) 
17 3,174 (2,560-3,918) 1.00 (1.00-1.00) 
19 7,565 (7,532-8,322) 0.99 (0.65-1.00) 
21 4,599 (3,755-5,552) 1.00 (0.80-1.00) 
24 1,640 (1,527-1,825) 1.00 (1.00-1.01) 
26 10,980 (10,647-11,405) 1.00 (0.88-1.00) 
29 6,324 (5,222-11,837) 1.00 (0.99-1.00) 
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Table 4.20 Resistance patterns among successfully genotyped patients 
Patient  Baseline Resistance Resistance at failure Predicted 
INSTI GSS 
 NRTI NNRTI PI NRTI NNRTI PI INSTI New mutations  
2 UN2 UN UN   I62V 
 
 N/A RAL=1 
EVG=1 
DTG=1 
5 M184V     L89M, I62V 
V77I, M36I 
 4 RAL=1 
EVG=1 
DTG=1 
11 K219E, M184V 
K70R 
 L90M, A71T   M36I*, I93L 
L90M*,I62V 
L63P 
 4 RAL=1 
EVG=1 
DTG=1 
13 UN UN UN M184V P225H, K103N 
 
I93L*,M36I 
H69K,L89M 
T97A 
 
N/A RAL=1 
EVG=0 
DTG=1 
15 T215Y, L210W 
M184V, L74V, 
D67N, M41L 
K103N, K101P L90M, V82F 
G73S, A71V 
I62V, I54V 
M46I, K20R 
L10I 
K70E,T215Y 
D67N,M184V* 
L210W, M41L  
K103N 
 
L33F,I54V 
V77I,I62V 
A71V,V32I  
L63P,K20R 
M46I, M36I 
K43T,L90M 
I93L, V82L 
I84V 
Q148H, 
G140S 
 
3 RAL=0 
EVG=0 
DTG=0.5 
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17 UN UN UN F116Y,F77L 
A62V,M184V 
Q151M 
 
 M36I,I64V N155H,E92Q* 
 
N/A RAL=0 
EVG=0 
DTG=0 
19 M184V   L74V*  L90M, L63P 
A71V*, I93L 
 5 RAL=1 
EVG=1 
DTG=1 
21 UN UN UN   I62V, L90M 
L63P, A71T 
I93L* 
 N/A RAL=1 
EVG=1 
DTG=1 
24 UN UN UN   I93L, M36I 
L63P,H69K 
 N/A RAL=1 
EVG=1 
DTG=1 
26 M184V Y181C, V106A, 
V106I 
L90M, L89V 
I84V, V82T 
A71T, I62V 
I54V, M36I 
K20M, V11I 
L10I 
 
 K103N*, 
V90I* 
I62V,F53L 
L90M,K20M 
M36I*,V82A 
L63P,A71V 
  RAL=1 
EVG=1 
DTG=1 
            29 T215Y, L210W 
M184V, Q151M,  
F77L, V75I 
L74V, A62V, M41L 
H221Y, G190A 
Y181C, K103N, 
A98G 
L90M, L89V 
I84V, V82T,  
A71V, I62V,  
I54V, M36I 
K20M 
M41L, T215Y, 
H221Y, L210W 
V90I, K103N, 
Y181C, 
V82A,L24I 
I64V,I54V 
L63P 
N155H RAL=0 
EVG=0 
DTG=12 
*describes minority variant, present in less than 25% of the circulating virus 
1. Excludes minor PI mutations; 2. UN=undetectable 
2. Assumes twice-daily dosing of DTG; 0 if once-daily dosing. 
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4.5.Discussion  
4.5.1. Time to and risk factors for RAL VF 
In this analysis I found a probability of RAL failure of up to 12% by 7 years for individuals 
starting RAL with a suppressed bVL and 25% for those starting RAL with a raised bVL. Results 
from both ITT and PP analyses were very similar, although as expected rates were slightly 
lower in the PP analyses. Although direct comparisons between different studies should be 
done with caution, these findings are in line with those from both clinical trials (522–524,569) 
and observational studies (547,550,551,553,556) which have shown RAL to have durable 
virological efficacy among treatment experienced patients. However, the long-term estimates 
of risk of VF found here are lower than those reported in the BENCHMRK trial, where the 240 
week KM estimate of time to virological suppression was 51% (524). This could reflect the fact 
that BENCHMRK required individuals to have experienced triple class failure in order for them 
to be enrolled. In the current study population the baseline GSS was relatively high and only 
16.4% of individuals with available resistance data were found to have resistance to all three 
major drug classes.  
The risk of VF differed according to baseline VL, and in agreement with findings from other 
authors was found to be considerably higher among patients starting RAL with a raised bVL 
(546,559–561). I chose to describe the results and risk factors separately according to the bVL, 
hypothesising that this would serve as a proxy for reason of RAL start. The reasons and risk 
factors for VF are likely to differ among people who switch to RAL for toxicity reasons and 
those who switch to suppress VL (559,560). However, as EuroSIDA does not collect the reason 
for starting a particular drug, I was not able to directly separate out these two groups and was 
forced to use bVL as a proxy for reason of starting RAL. To give an indication of how well 
splitting the study population according to bVL reflected the reason for starting RAL I looked at 
the reasons for stopping a drug in the month before RAL was started. Physician reported 
treatment failure was the most common reason for stopping a drug prior to starting RAL in the 
group with raised bVL, whereas toxicity (any kind) was the most common reason for stopping a 
drug prior to starting RAL in the group with suppressed VL, indicating that use of bVL was a 
reasonable proxy for reason of starting RAL. 
I could not find any strong associations between the potential risk factors investigated here and 
the risk of experiencing VF among those starting RAL with a suppressed bVL. There were weak 
associations suggesting that the risk of VF decreased with higher baseline CD4 counts and more 
recent calendar year of RAL initiation (p=0.04 and 0.08 respectively). The fact that rates of 
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virological failure are lower in recent years have been consistently shown in cohort studies of 
people receiving cART with or without RAL (570,571). The associations with risk of failure was 
attenuated in the PP analysis as compared to the ITT analysis. Although PP analyses are often 
performed to evaluate the virological potency of a drug after removing the confounding effect 
of stopping due to toxicity, reduced statistical power is the most likely explanation of this finding.  
In contrast, a number of factors were associated with the risk of experiencing VF among 
individuals starting RAL with a raised bVL. In terms of demographic predictors, individuals of a 
non-white ethnicity were at a higher risk of experiencing VF in multivariable ITT analyses. 
Individuals of a non-white ethnicity have been reported as having a higher risk of experiencing 
VF in a number of studies (572–574), and my findings are in agreement with this. However, the 
increased risk of VF was not as marked in PP analyses. Again, this could be due reduced 
statistical power or to the fact that genuinely the virological potency of RAL is the same 
regardless of ethnicity and the difference in the ITT analysis is due the difference in rate of 
failure in those who stopped RAL because of toxicity (excluded in the PP analysis). There is 
evidence that adherence patterns to ART differ by ethnicity (574) so it is conceivable that the 
Caucasian population was generally more adherent both to the RAL-based and subsequent 
regimens used and consequently at lower risk of VF. 
The risk of VF was also significantly higher among individuals receiving care in Central East and 
Eastern Europe compared to Southern Europe. This is consistent with the results from previous 
EuroSIDA analyses (575–579), and there are a number of possible reasons that could explain 
these findings. RAL was used relatively rarely in Central Eastern and Eastern Europe compared 
to other European regions. This likely reflects the high cost of the drug (580), and could 
indicate that RAL is being prioritised for those individuals most in need or issues with the 
supply chain of RAL in these countries. This would mean that individuals in Central Eastern and 
Eastern Europe who receive RAL may be at a more advanced disease stage than those who 
receive it in other areas of Europe. Although my analysis took into account a number of factors 
associated with disease severity, including baseline CD4 count, CD4 nadir and treatment 
history, it is possible that differences in disease severity at time of starting RAL in East and 
West Europe are not fully captured by these measured indicators. However, it is also possible 
that the increased risk of VF in East and Central Eastern Europe reflect differences in the health 
care policy, as post-Soviet states have struggled to modernize an underfinanced and neglected 
healthcare system (581).  
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I identified a number of other risk factors for VF on RAL among those starting it with a raised 
bVL. There was weak evidence that individuals with higher baseline VL levels and lower nadir 
CD4 were more likely to experience RAL failure, in agreement with a study by Wittkop et al of 
the French ANRS cohort (556). Baseline VL was the factor most commonly identified as 
associated with an increased risk of VF in other analyses (543,550,551,556). The evidence 
supporting a difference according to levels of bVL among those starting RAL with a raised bVL 
was relatively weak in this analysis, something which could be explained by the fact that the 
the relatively small range of VL levels among those with a VL>200 copies/mL. It is possible that 
a pooled analysis, considering risk factors for those starting RAL with a raised and suppressed 
bVL together, would have shown that bVL was a stronger risk factor. However, the 
interpretation of such an analysis would be less clear-cut given the combination of two study 
populations for which the indication for starting RAL was different.  
The raised risk of VF among individuals starting RAL with a raised bVL, as well as the weak 
linear association with bVL and the risk of VF identified here indicates that individuals with 
very high VL values who switch treatment in order to suppress VL are at a particularly high risk 
of experiencing VF. It is possible that a very high VL indicates a problem with adherence, which 
has previously been shown to be a key determinant of the success of RAL treatment (534). 
Although the role of adherence could not be evaluated specifically in this study due to a lack of 
availability of data, the results supports the recommendation that individuals with high bVL 
should be particularly targeted for adherence interventions. I did not find any differences in 
the risk of VF among individuals starting RAL with a raised bVL according to an individuals’ 
exposure to mono or dual therapy before the use of cART or GSS of the RAL regimen, in 
contrast to Capetti et al who found that individuals with a more complex treatment history 
were more likely to experience VF (549). It could be that exposure to mono or dual therapy 
before starting cART is not an adequate measure of treatment history, and that the relatively 
high GSS of the regimens used in this study masked any negative effect.  
Changing the viral load cut-off point, censoring individuals during times of infrequent VL 
measurements or using a more specific measure to define the bVL did not impact any of these 
conclusions markedly, suggesting that my findings were robust to the changes in the 
definitions used. 
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4.5.2. Resistance profiles following VF  
The VL at failure among both patient groups was relatively low, and the availability of 
genotypic data limited. No individuals had reported data on integrase resistance testing done 
in clinics, and only 33 samples could be identified that met the criteria for genotyping. Of these 
33 samples, 11 (34%) were successfully amplified and genotyped. Two factors acted as a strong 
determinant of genotyping success: VL at the time of failure and VL at the time of the sample. 
This indicates that the cut-off limits used to send samples for genotyping was too low in this 
study. The rationale for using such a low VL was based both on previous reports of successful 
genotyping at low VLs (566), and to ensure that the highest possible number of test results was 
available for analysis even if this meant a potentially large number of unsuccessfully genotyped 
samples. 
Despite the limited data availability, the results from the genotyping showed some interesting 
results. Firstly, major RAL mutations were detected in 4/11 (36%) patients that were 
genotyped. The N155H mutation, which can compromise the response to DTG depending on 
the dosage and whether or not it is present with other mutations, such as Q148R or E92Q, was 
observed in 2/4 patients with INSTI resistance. The other resistance patterns observed were 
the Q148H/G140S pathway and a single instance of the accessory T97A, which primarily 
compromises the efficacy of ELV. Although minority variants were commonly detected in the 
RT and PR gene, only one minority variant in the integrase gene was detected: E92Q. This 
mutation occurred in combination with N155H, and when these two mutations are present in 
combination they confer resistance to DTG, also when it is administered twice daily (394). The 
pathways described here confirm findings from other analyses of INSTI resistance patterns 
(550,556).  
4.5.3. Strengths and limitations  
This analysis has a number of significant limitations. The first main limitation is the limited 
sample size. Although EuroSIDA is a large cohort with a reasonable number of individuals 
receiving RAL, the availability of resistance data and stored plasma samples was limited. I used 
a reasonably broad cut-off for identifying stored plasma samples of +/- 3 months if a sample 
during RAL failure was not available. This allowed me to capture samples that may give 
information on RAL resistance despite the potential for small inaccuracies in the dates 
collected. Resistance patterns on RAL can evolve rapidly, and following cessation of RAL 
resistance mutations can disappear as fast as 4 weeks after RAL withdrawal (582), indicating 
that a longer time-window would have risked sending samples for genotyping which would 
have inaccurately shown an absence of INSTI resistance. A second limitation is the relatively 
low success rate of the genotyping (36%). This seemed to primarily be explained by the 
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relatively low VL levels at the time of the sample. Although other studies have demonstrated 
that genotyping can be done at low VL levels (389,566), technology, operating protocols and 
conditions differ across different laboratories. In order to ensure efficient use of EuroSIDA 
funding, future studies utilising the EuroSIDA plasma bank to genotype individuals should 
consider prioritising samples taken during periods of higher viral replication. Nonetheless, the 
number of individuals genotyped for resistance (N=11) is still as high or higher than a number 
of previous studies (534,545,551,553,556,566) and the amount of information provided by the 
NGS platform is very valuable and not available in many other settings. A further limitation is 
the restriction of this chapter to only studying RAL use, and not EVG and DTG. This was mainly 
due to the low number of people with exposure to these drugs in EuroSIDA at the time of this 
analysis. 
In terms of the analysis of virological efficacy, a limitation is the lack of a control group to put 
the failure rates into context. This was a conscious decision, which was taken given the 
difficulties in identifying a reasonable comparison group using routinely collected 
observational data. Another limitation of using observational data is the potential variation in 
and infrequency of VL measurements, although the sensitivity analysis where individuals were 
censored 6 months after each measurement led to consistent results. The final limitation is the 
potential lack of generalizability. The individuals with data available for inclusion in this 
analysis differed from those that could not be included, and the conclusions are not likely to be 
generalizable to all individuals living with HIV in Europe. These limitations are characteristic of 
most observational studies, and have to be balanced with the benefit of analysing data from 
routine clinical care, such as generalisability that is likely greater than that in clinical trials 
which employ much stricter inclusion criteria. 
204 
 
4.5.4. Conclusion  
This analysis adds to a growing body of evidence showing that RAL has durable virological 
efficacy over long periods of FU, in this case, of up to 7 years with a maximum of 25% 
experiencing virological failure by this time on the drug if started with a VL >200 copies/mL. 
The risk of VF was higher among individuals who started RAL with a higher baseline viral load, 
and particular attention should be given to these patients in order to ensure that they 
promptly achieve viral suppression. Other risk factors for VF on RAL among individuals starting 
the drug with a raised bVL include a low CD4 nadir, geographical region and possibly non-white 
ethnicity. Very few individuals had data available on INSTI resistance, even after central 
genotyping of samples. Nonetheless, I identified a number of mutations following RAL failure 
that can compromise the efficacy to DTG. Although DTG has shown reasonable efficacy among 
RAL experienced patients in clinical trials, these findings suggest that sequential use of RAL and 
DTG should be accompanied by resistance testing. The role of minority INSTI mutations on 
consequent treatment responses to DTG requires further research, and existing cohort studies 
should prioritise the collection of high-quality information on integrase resistance in order to 
provide data on the evolution of INSTI mutations in routine clinical practice. More detailed 
suggestions for future research are provided in Chapter 8.  
 
4.6. Dissemination of results  
An early version of these results was presented at the 2015 Antiviral Therapy Meeting in 
London and the 2015 European AIDS conference (Appendix VII). A manuscript is in 
preparation. 
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Chapter 5 . The effect of drug resistance mutations 
on CD4 cell decline in HIV positive individuals 
maintained on a failing treatment regimen 
 
 
5.1. Introduction and Objectives  
In Chapter 3 and 4 I showed how virological failure with resistance is becoming increasingly 
rare, particularly in high income settings such as Western Europe. However, this situation is 
not homogenous across geographical regions. As many as 17% of individuals starting first line 
regimens in South Africa may experience virological failure (VF) within 5 years of starting 
treatment (583), and a recent systematic review also suggests that individuals in low income 
settings may be more likely to have resistance once they are diagnosed with VF compared to 
individuals in high income settings (584). This is likely due to how people are monitored,how 
quickly treatment is modified as well as the number of available treatment options in low 
income settings as compared to high income settings. Although an effective second or third 
line regimen of antiretrovirals not previously used, including those from new drug classes, can 
often be prescribed for individuals who experience VF (585), constructing a suppressive 
regimen can still be challenging for people whose viruses have complex resistance patterns or 
because of limited drug availability. This is particularly the case in low income settings, where 
access to 3rd or higher line regimens is generally limited (586). This could affect a potentially 
large number of people. In a 2010 multicohort analysis, Pujades-Rodriguez and colleagues 
estimated that 19% of individuals receiving second line therapy in a variety of low income 
settings met WHO failure criteria after a median of 11.9 months following the start of second 
line therapy, meaning they would need access to third line regimens (587). In situations such 
as these, people living with HIV may be forced to take a non-suppressive regimen for extended 
periods of time (72,588).  
It has been known for over a decade that individuals who receive a non-suppressive ART 
regimen can still derive a clinical benefit from the treatment and may experience stable or 
increasing CD4 counts despite ongoing viral replication (332,364). In a small 2001 trial of 23 
men, Deeks et al found that people who were maintained on an ART regimen despite having a 
detectable viral load had higher CD4 counts and lower viral load levels over time compared to 
those who interrupted treatment (332). This was proposed to be due to a combination of 
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residual antiretroviral activity and the preservation of a virus population with low replicative 
capacity (RC). In 2004, the large PLATO collaboration reported that among individuals 
experiencing triple-class failure, CD4 counts increased as long as viral load levels were below 
10,000 copies/ml, and that those receiving more drugs experienced more favourable CD4 
count changes despite ongoing VF (364). The authors suggested that this latter result could be 
due to more drugs leading to more resistance mutations and thus a lower RC. Several 
additional studies have also shown stable or increasing CD4 counts despite the presence of 
ongoing viral replication (589–591), and a low RC has been directly linked with beneficial CD4 
count changes (592–594).  
Although there is agreement that the composition of a regimen that fully supresses viral 
replication should be the aim of cART (507), this is not always possible. It has been suggested 
that the preservation of certain resistance mutations that are known to reduce RC may 
clinically benefit individuals for whom a fully suppressive regimen cannot be constructed. 
Specifically, maintaining patients on lamivudine (3TC) in order to preserve the M184V 
mutation that has been repeatedly associated with lower fitness levels (595,596) has been 
proposed as a potential treatment strategy (597). However, the evidence available in support 
of this strategy is far from strong. A small proof-of-concept study by Castagna et al evaluated 
this hypothesis, and they found that patients remaining on 3TC monotherapy experienced 
improved immunological and clinical outcomes compared to patients who interrupted all 
treatment (598). However, the COLATE randomized controlled trial found no added 
immunological or virological benefit of maintaining patients on Lamivudine in the context of 
cART after patients had experienced VF (599). The COLATE investigators suggested that any 
effects of a M184V preserving strategy may have been masked by the effect of potent cART, as 
most individuals in the trial switched to a new regimen with a high genotypic sensitivity score 
(GSS). It is possible that any benefits of an M184V preservation strategy may only be seen for 
patients with few or no remaining treatment options. Despite this limited evidence in support 
of a fitness targeting treatment strategy, 2016 updates of HIV treatment guidelines still 
mention M184V preservation strategies as a potential treatment approach for special cases 
where treatment options are severely limited (600,601). The role of other mutations on CD4 
count trends in the context of VF also remains largely unknown, and whether the effect of a 
reduced RC on the CD4 count occurs via viral load replication (e.g. HIV-RNA levels) or through 
other mechanisms has also never been convincingly determined.  
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Given this lack of evidence, I used data from the EuroSIDA cohort, the UK CHIC cohort and the 
UK HIV Drug Resistance Database (RDB) to evaluate the effect of drug resistance mutations 
(DRM) on CD4 count changes among patients who are maintained on a failing treatment 
regimen. The specific objectives for the analyses were as follows:  
 
1) Estimate differences in CD4 decline among individuals with and without drug 
resistance who remain on a failing treatment regimen.  
 
2) Evaluate the effect of detected resistance to either of three major drug classes (NRTI, 
NNRTI and PI) and individual DRM on CD4 decline among individuals with at least one 
DRM detected.  
 
3) Identify clusters of DRM using principal component analysis (PCA) and investigate the 
effect of these clusters on CD4 decline.  
 
5.2. Literature Review  
I conducted a literature review with the aim of investigating what was known about the effect 
of DRM on CD4 count changes. The initial search strategy (Chapter 2, page 74) returned 1,565 
articles, of which 38 were deemed potentially relevant based on their title. This was reduced 
to 22 articles after abstract-scanning, and these 22 papers were assessed for inclusion in the 
review. The majority of these were excluded as they used direct laboratory measures of the 
replicative capacity as either the exposure or outcome rather than DRM and CD4 counts 
specifically (N=10). As their findings are nonetheless relevant to the topic, these are 
summarised where relevant in the discussion. In total, nine articles addressed the specific 
question of the effect of resistance on CD4 counts and were therefore included in the review 
(Figure 5.1).  
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Figure 5.1. Identification of articles for inclusion in the literature review 
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A summary of the articles that formed part of the review can be found in Table 5.1. Briefly, the 
majority of the studies (5/9) were small, with fewer than 100 participants, and one was a 
mathematical model based on simulations rather than real data. Despite this, there were some 
interesting findings. Three studies found evidence that the detection of individual mutations 
were associated with CD4 count levels. De Mendoza et al performed a relatively large cross-
sectional analysis of 825 individuals living with HIV in Spain who had a GRT done at some point 
between 1999 and 2002 (602). In univariable analyses, the presence of any DRM, the K70R and 
M184V mutation were associated with higher CD4 counts, whereas presence of the L74V and 
the number of both primary and compensatory PR mutations were associated with lower CD4 
counts. After adjusting for viral load, only the number of compensatory PI resistance mutations 
and detection of K70R remained associated with CD4 counts. The detection of any drug 
resistance did not seem to correlate with CD4 counts.  
Although this study indicated that patients may gain some absolute CD4 count benefit from 
remaining on a regimen to which the virus has developed resistance, it suffered from a 
number of weaknesses. First of all, the study population consisted of both treatment 
experienced and treatment naive individuals (although the number of treatment naive 
individuals was relatively low). Secondly, results which were not significant in the multivariable 
results (i.e. those with an associated p>0.05) analysis are not presented, which makes it 
difficult to assess whether the odds ratios shifted towards one following adjustment, or 
whether the analysis simply did not have high enough power to detect a significant difference. 
And finally, as this was a cross-sectional analysis it is hard to draw any conclusions regarding 
the causal effect of DRM on CD4 counts, and the study provides no evidence to support that 
DRM may be associated with CD4 changes over time.  
Nicastri et al reported results from a cohort of 43 individuals who received care at two clinical 
sites in Italy (603). Despite the small sample size, the authors found that presence of M184V 
was associated with a viroimmunologically discordant response to HAART, defined as having a 
CD4 count increase of 100 cells/mm3 or more despite ongoing VF, after controlling for a 
number of potential confounding factors (OR=25.48, 95%CI=1.43-453.93). The final study, by 
Antinori et al, also took place in Italy and reported data from 354 patients who had a genotypic 
resistance test result available and were experienced VF at this time (604). In this cross-
sectional analysis, the odds of discordant virological responses, defined as above, were found 
to be higher among individuals with the RT M184V (OR=1.92, 95%CI=1.25-3.07) mutation or 
the L241 (OR=6.18, 95%CI=1.77-21.55) and V82A (OR=1.75, 95%CI=1.06-2.89) mutations. The 
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Y181C mutation was associated with lower odds of CD4 count recovery (OR=0.35, 95%CI=0.18-
0.65). After adjustment for a range of factors, including VL, the L24I and Y181C associations 
remained statistically significant. Similar to the analysis by De Mendoza et al, insignificant 
multivariable results were not present in the paper, which makes it hard to assess whether the 
attenuation of the association with the M184V and V82A mutations was an issue related to 
power, or whether the effect of these mutations on CD4 counts were at least in part mediated 
through viral load.  
In contrast, five studies found no association between resistance measured in a number of 
different ways and CD4 counts, including a large and relatively recently published study 
longitudinal study of 826 patients from the Italian ARCA cohort by Gianotti et al from 2011. 
However, as the hypothesis behind this analysis was that DRM would interfere with 
immunological recovery, its design allowed individuals to switch regimens. Given that 
mutations can disappear from the majority circulating virus relatively quickly following the 
cessation of selective drug pressure (326), it is possible that this design feature masked any 
potential associations. The odds ratios for M184V in the multivariable model also indicated 
that the detection of M184V was possibly associated with discordant immune-virological 
responses, but that the study may not have had sufficient power to detect this (OR=1.31, 
95%CI=0.97–1.77,p=0.076). The mathematical modelling study by Vaidya et al suggested that 
the presence of Enfuvirtide resistance could result in beneficial CD4 counts despite ongoing 
viral replication among individuals who are re-administered this specific drug following VF on 
it, but as this analysis was not based on clinical data the results are somewhat speculative. As 
the EuroSIDA resistance database does not contain genotypic data of HIV regions outside RT 
and PR this hypothesis could not be directly tested in this chapter. 
5.2.1.What this analysis adds 
Previous studies have been relatively small and have found conflicting results regarding the 
impact of DRM on CD4 count changes. Many have only presented partial results, meaning that 
adjusted estimates of the effect key mutations such as M184V on CD4 count changes have not 
been published. The studies have also used a range of inclusion criteria, many have been cross-
sectional and most assessed CD4 response using a binary immunological discordance 
categorisation. Using the EuroSIDA cohort and UK CHIC/UK HIV RDB presents an opportunity to 
evaluate the association between detection of DRM and CD4 count changes as these large 
cohorts hold historical data on a population which may have been exposed to failing regimens 
for relatively long periods of time. In addition, the large size of both contributing studies 
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allowed me to derive more accurate estimates of the effect of DRM on CD4 counts over time 
among patients who remain on failing regimens compared to currently available estimates. 
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Table 5.1. Papers reporting on the effect of drug resistance on CD4 counts following VF, by year of publication  
Author Year Design and Setting Study Size Main Results REF 
Gianotti et al 2011 Longitudinal analysis of individuals who 
had a GRT at VF (VL>50 while on ART) 
between 2000-2004 in the Italian ARCA 
cohort 
826 No individual mutations in the pol gene were associated with an increase or decrease in the odds 
of immune recovery, defined as an estimated CD4 slope greater than zero, after adjustment for 
potentially confounding factors including VL (defined as the viraemia detectability ratio). However, 
a number of mutations were associated with the odds of immune recovery in univariable analysis. 
These included 154V (OR=1.60,95%CI=1.12–2.29,p=0.009) and V82A (1.63, 95%CI=1.14–2.33, 
p=0.007). M184V was only borderline associated with the odds of immune recovery in both 
univariable (OR=1.26, 95%CI=0.96–1.66),p=0.097) and multivariable analyses (OR=1.31, 
95%CI=0.97-1.77, p=0.08).  
(605) 
Vaidya et al 2010 Mathematical model of the effect of 
Enfuvirtide (ENF) use despite VF and 
extensive drug resistance 
N/A Results from the modelling suggests that re-administration of ENF following VF and resistance 
development to the drug had no impact on VL levels, but still allowed for CD4 count increases due 
to the lower fitness of the ENF resistant virus.  
(606) 
Solomon et al 2003 Laboratory study of CD4 cell activation, 
CD4/VL responses and viral genotype in HIV 
outpatient clinics in Melbourne 
81 The authors found no association between any specific or the total number of mutations and 
discordant immunological/virological response, defined as confirmed VL>400 and a CD4 slope 
above 0, although presence of the Y181C mutation was associated with non-response to therapy, 
defined as a CD4 slope below 0 and a confirmed VL >400. Specific effect sizes were not reported in 
the analysis.  
(607) 
De Mendoza et 
al 
2005 Cross-sectional analysis of patient data 
(both treatment naïve and those 
undergoing VF, as defined by treating 
physicians) submitted to a Spanish 
reference laboratory between 1999 and 
2002  
825 (762 
treatment 
experienced 
patients). 
Patients with DRM had higher median CD4 counts in univariable analyses, but not after adjusting 
for VL. After VL adjustment, the number of compensatory PI resistance mutations were associated 
with lower CD4 counts (-15.39 cells/mm3, 95%CI=23.32-7.47, p <0.001). K70R and M184V were 
associated with higher and L74V with lower CD4 counts, but only K70R remained significant after 
VL adjustment (+48.78 cells/mm3, 95%CI=3.72-93.82, p=0.034).  
(602) 
Nicastri et al
 
 
  
2003 Analysis of the genotypic and virological 
profiles among patients with 
immunologically discordant responses, 
defined as a confirmed VL>3000 but 
increasing CD4 counts (>100 cells/ml more 
compared to pre-HAART values) 
43 Only the M184V mutation was significantly related to experiencing discordant immunological 
virological responses (OR= 25.48, 95%C=1.43 -453.93) 
(603) 
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Dionisio et al 2003 Analysis of patients experiencing VF 
(defined as a rebound after initial 
suppression to undetectable levels, or a 
decline in HIV RNA of <0.5 or 1.0 log by 4 
and 8 weeks of treatment) at two 
outpatients clinic in Italy during a 3 year 
period.  
16 The total number of resistance mutations was correlated with the RNA slope (r=0.554, 
P=0.026) but not the CD4 slope (r=–0.251, p=0.348). 
 
(608) 
Barbour et al  2002 Longitudinal study of adults on a stable PI 
based regimen despite ongoing and 
persistent viral replication (HIV RNA>500 
copies/mL) 
20 No difference in the resistance phenotype was found between patients who experienced CD4 
count declines during prolonged failure and those who did not. Effect estimates were not 
provided.  
(609) 
Antinori et al 2001 Longitudinal study of individuals 
experiencing VF (defined as a reduction of 
the HIV RNA of less than 1 log after 8 
weeks or persistent HV RNA >80 copies/mL 
after 6 months of treatment or any 
rebound, confirmed with at least two 
consecutive tests after reaching 
undetectable viraemia) with a GRT from 
two outpatient centres in Rome 
354 The presence of M184V, L24I and V82A was associated with higher odds immunological recovery 
(defined as an increase in the CD4 cell count of greater than 100 cells/mL from starting HAART 
until the GRT), whereas Y181C was associated with lower odds of immunological recovery in 
univariable analyses. After adjustment, only the L24I (OR=6.93, 95%CI=1.80-26.57,p<0.01) and 
Y181C (OR=0.40, 95%CI=0.20=0.80, p<0.01) associations persisted.  
(604) 
Belec et al  2000 Cohort of individuals on PI-based cART 
comparing discordant immunologic and 
virologic responders (failure to achieve an 
undetectable HIV RNA but nonetheless 
experiencing an increase in the CD4 count 
of greater than 50 cells/L as compared to 
baseline at months 3,6,9 and 12) to both 
complete responders (suppressed VL and 
increased CD4 count) and non-responders 
(not suppressed and decreasing CD4 
count).  
59 The number of primary and secondary PI mutations was higher among individuals with discordant 
responses (primary mutations: 0.92 ± 0.14; secondary mutations: 1.85 ± 0.22) compared to 
complete responders primary mutations: 0.12 ± 12; secondary mutations: 1.62 ± 0.32, but was 
only slightly lower than among complete non-responders (primary mutations: 1.25 ± 0.16, 
secondary mutations: 2.88 ± 0.29). The pattern of mutations did not differ between discordant and 
non-responders.  
 
(610) 
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5.3.Methods  
5.3.1. Inclusion criteria 
For this chapter, I used the D40 update of the EuroSIDA database and the 2014 version of the 
UK CHIC cohort/HIVDRD. The datasets held data on 18,914 and 47,201 individuals respectively. 
For this analysis, I defined an episode of virological failure (VF) as 2 or more consecutive 
measures of VL >500 copies/mL over any time frame while the individual was kept on exactly 
the same ART regimen. Duplicate VL measures were cleaned out before the start of the 
analysis using a standard algorithm developed by the EuroSIDA cohort. This involved removing 
any duplicate VL dates with discordant VL values were from the dataset. I only considered 
periods of time when individuals were kept on a failing regimen, as mutations may disappear 
relatively quickly once drug pressure is removed. 
The start date of an episode was defined as the first viral load (VL) measurement >500 
copies/mL, and the end date the first VL measurement below 500 or at the point where the 
ART regimen was changed (defined as either stopping or adding one or more drugs to the 
regimen). I required two consecutive high viral loads to ensure that we did not include 
individuals who were experiencing viral blips. The threshold of 500 copies/ml was chosen for 
two reasons: i) the episodes covered calendar times during which, because of the availability 
of the assays, viral load could not be detected below 500 copies/mL and ii) historically, it has 
been challenging to genotype at lower viral loads. During each failure episode, I further 
required individuals to have at least one resistance test and at least one CD4 count (611). An 
individual contributed all CD4 count measurements taken after the start and before the end of 
each failure episode to the analysis, and the baseline date for the estimation of the CD4 count 
slope was defined as the date of the first available CD4 measurement after the start date of 
the episode. Participants could contribute one or more failure episodes. A graphical illustration 
of how failure episodes were defined can be seen below in Figure 5.2. A list of patients in UK 
CHIC who are also in EuroSIDA was available from the UK CHIC statistician (S. Jose, UCL), which 
allowed me to ensure that duplicate patients were not included.  
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Figure 5.2. Hypothetical data illustrating the inclusion of failure episodes  
Hypothetical Data. The start of a VF episode was defined as the first of a of >=2 consecutive VL 
measurement >500 copies/ml after at least 6 months of ART exposure. The end of a VF episode was 
defined as the date a change in the drug regimen occurred or when VL<500 copies/ml, whichever 
occurred first. An individual contributed all CD4 counts occurring at or after the start of failure until 
the end of the failure episode. Baseline was defined as the first CD4 count taken at or after the start 
of failure. Detected resistance was presumed to be present throughout the duration of the VF, 
irrespective of when it was detected.  
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Figure 5.3. Selection of individuals for inclusion in the study 
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5.3.2. Resistance data  
In order to define antiretroviral drug associated resistance, I used all of the 4 major genotypic 
interpretation systems (IAS, Stanford, ANRS and Rega). These systems are based on slightly 
different mutation lists, and as I wanted to be able to study a large number of potentially 
important mutations I decided that it was too restrictive to use just one classification list. 
Although the Stanford, ANRS and Rega systems commonly attach scores to mutations, I only 
considered the presence or absence of each mutation for the construction of any and class-
wide resistance categories. I used the IAS list to classify minor PI mutations, as this is the only 
drug resistance mutations algorithm that clearly distinguishes between minor and major 
mutations. Any resistance was defined as the detection of at least one mutation mentioned in 
either of the 4 classification systems. Individuals with only minor PI mutations were considered 
as having no detected resistance. The class-wide resistance categories studied were: NRTI 
resistance, NNRTI resistance, any PI resistance excluding minor PI mutations and any PI 
resistance including minor PI mutations. I evaluated the effect of all individual mutations that 
were detected in >1% of episodes, as mutations below this threshold were deemed too rare to 
be of potential clinical relevance. Resistance was presumed to be present from the start of the 
failure episode until the end, irrespective of at which point during the episode it was detected 
by the genotypic test. If there was more than one resistance test done during the same VF 
episode, all resistance tests contributed to the construction of the resistance exposures.  
5.3.2.1. Principal Component Analysis  
As mutations often co-occur in patterns that are particularly favourable for viral survival, we 
conducted a principal component analysis (PCA) to identify clusters of mutations. As explained 
in more detail in Chapter 2, PCA is a variable reduction technique that transforms a number of 
correlated variables into a smaller number of linearly uncorrelated variables, principal 
components (PC), that explain as much of the variance in the original dataset as possible (612). 
The contribution of each original variable to a given PC is given by a weight (loading), and 
these can be used to infer clusters of mutations that all load onto the same PC. Once PCs have 
been extracted, individuals in the dataset can be assigned a score on each PC which represents 
how closely their mutation pattern aligns with that captured by the PC. These scores can be 
used as exposures in consequent models (612). For this analysis I converted each PC from a 
continuous score into a binary exposure variable, using the 3rd quartile as a cut-off point. 
I identified how many components to retain through graphical inspection of a scree plot, and 
retained components subjected to a varimax (orthogonal) rotation (451). Factor loadings 
below 30 were considered negligible, between 30-40 weak, above 40 strong and above 70 very 
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strong. Mutations with loadings above 40 were interpreted as forming part of a cluster 
captured by that PC; those with loadings between 30 and 40 were considered weakly 
associated with the cluster.  
 To simplify the interpretation of our results and because I expected that most clusters would 
be gene specific, I ran separate PCA’s for RT and PI mutations. For simplicity and to aid the 
interpretability of my results, I did not differentiate between different amino-acid substitutions 
in the same position. The PCA was conducted using only the first VF episode for each 
individual, meaning that each individual contributed only one line of data.  
5.3.3. Statistical methods 
Characteristics of participants in the two cohorts and of individuals with and without 
resistance across the whole study population were compared using the basic statistical 
methods described in Chapter 2. I compared CD4 slopes using linear mixed models according 
to the presence or absence of (1) any resistance, (2) class of resistance and individual DRM and 
(3) according to the PCA derived scores. I did so using the PROC MIXED procedure in SAS (613). 
The study population varied according to the objectives of the analysis:  
1) Among all individuals I compared the CD4 decline according to presence and absence 
of any resistance as defined in section 6.3.2.  
2) Among those individuals with any resistance I compared the CD4 decline according to 
presence and absence of class-wide resistance and all individual DRM that reached the 
prevalence threshold. Individuals with no resistance were excluded from this analysis.  
3)  Among those individuals with any resistance I compared the CD4 decline according to 
those with “high” (>Q3) and “low” (<Q3) scores. Individuals with no resistance were 
also excluded from this analysis.  
 
I restricted the study population for objective (2) and (3) as a raised VL levels without detected 
resistance may be indicative of ART non-adherence. Throughout the chapter I used a 2-level 
random effects model with a random intercept and a random slope for time. The two levels 
represented each episode and the individual CD4 count measurements. This allowed CD4 
slopes slope (i.e. the change over time in the CD4 count value) and intercepts (i.e. the CD4 
count value at the start of the viral failure episode) to vary between episodes, although the 
episodes themselves were presumed to be independent. I evaluated the use of a 3-level 
random effects model with an added level for individual, but this was found to explain a very 
small additional proportion of the variance and led to convergence problems when studying 
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the effect of individual DRM. In addition, the estimable results differed very little according to 
the inclusion further random effects. It was therefore decided to use a 2-level model. I used an 
unstructured covariance matrix for all models.  
As I chose to test specific DRM on the basis of a prevalence threshold and not an a-priori 
hypothesis, I adjusted these p-values using the Benjamini-Hochberg procedure for correcting 
the false discovery rate (FDR) (614). As described in Chapter 2, this produces a q-value, which 
converts the p-value into a corrected value that represents the probability of a significant 
finding being a false positive. I used a q-value threshold of 0.05 to indicate significant results.  
5.3.3.1. Model building strategy  
Potential confounders were identified using guidance from clinical experts and visualised in a 
directed acyclic graph (DAG) as described in Chapter 2. The DAG showing the causal 
assumptions of this analysis can be seen in  Figure 5.4. Assuming that this DAG completely 
describes the clinical situation, it implied that adjustment for age, hepatitis C status, risk group, 
subtype and viral load would allow me to estimate an unconfounded effect of DRM on CD4 
counts. Although it was considered as a potential confounder in my DAG, VL can also be 
considered as a causal pathway variable, as the effect of any mutation on replicative capacity 
may at least in part be mediated through changes in the VL. For this reason, I conducted step-
wise adjustments as follows:  
1) Exposure alone, as defined in 5.3.3. 
2) Model 1 + age, hepatitis C status, risk group and subtype 
3) Model 2 + time-updated VL 
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 Figure 5.4. DAG for the effect of DRM on CD4 decline 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.3.2. Variable categorisation  
Individual mutations were entered in the models as binary variables, and separate models 
were constructed for each exposure variable. I modelled CD4 counts linearly on a raw 
(cells/mm3) scale to ease the interpretation of the results. Viral load (log10 scale) was included 
on a continuous scale and age categorised into 4 roughly equal sized categories after checking 
linearity assumptions. The remaining covariates were categorised according to the principles 
laid out in Chapter 2 (Table 4.5).  
 Table 5.2 Covariates included in the model 
Variable Categories Time-updated 
Hepatitis C co-infection1 Yes, No, Missing No 
Mode of transmission MSM, IDU, Heterosexual, Other No 
Subtype B, Non-B No 
Age(years) 35, 35-40, 40-45, >45 No 
Viral Load (log copies/mL) Linear, per log10 scale Yes 
1. Defined as having a HCV antibody positive test at some point before baseline 
2. Due to model convergence problems (infinite likelihood) experienced when including VL as linear on the log10 scale for 
three specific mutations, VL was included as a categorical covariate in the multivariable models (<1000, 1000-5000, 
5000-10000, 10000-20000, 20000-100000, >100000). This is highlighted through footnotes in the results.  
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I also estimated the level of viral suppression by comparing current VL levels with an 
individual’s viral set point, which was defined as the mean of all pre-ART VL measures. Current 
VL measures equal to or above the viral set point were said to be ‘Not supressed’, measures 
less than 1.5 log10 copies/ml below the set point were said to be “somewhat supressed” and VL 
measures more than 1.5 log10 copies/ml below the set point were said to be “supressed”. 
Unfortunately, the viral set point could only be calculated for a subset (N=2196) of people who 
had pre-ART VL data available. For this reason, it was not adjusted for in multivariable models.  
5.3.3.3. Sensitivity analyses 
I conducted sensitivity analyses in order to evaluate the reliability of some of our assumptions 
and analytical strategy. These were:  
  
1) Excluding virological failure episodes during which the VL fluctuated greatly, defined as 
at least a doubling of the VL as measured on a log10 scale between any two VL measures 
taken during an episode (364), in order to exclude treatment of recent infections and 
large VL fluctuations potentially caused by poor adherence.  
2) Requiring individuals to have at least 3 CD4 counts during the VF episode compared to 
at least one in the main analysis  
3) Additionally, adjusting for the class of drug used (NNRTI, PI (single), PI (boosted) and 
Other)
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5.4.Results  
5.4.1. Characteristics of the study population 
5,357 individuals contributing 7,661 failure episodes were included in the analyses; 2,757 
(36%) from EuroSIDA and 4,904 (64%) from UK CHIC/HDRB. Individuals contributed a median 
of 3 (IQR=2-5) CD4 measurements during a median of 1 (Range=1-9) failure episodes that 
lasted for a median of 5 (IQR=2-13) months. Baseline characteristics of the participants can be 
seen in Table 5.4 and Table 5.3. Overall, the study population consisted primarily of white 
(68%) males (76%) who had acquired their HIV infection through sex with another man (55%). 
The median VL at the start of episodes was high (8,200, IQR=1,829-52,672 copies/ml] and the 
CD4 count relatively low (257, IQR=145-393, cells/mm3). The majority of episodes also started 
with VL values that were lower than their estimated viral set point values (73.6% of those that 
had an estimated set point). The median GSS at the start of each episode was 1, meaning that 
on average participants were using only one drug which was predicted to be active against 
their virus at the beginning of the episode, and 25% of the study population was receiving a 
regimen that was estimated to have no activity (IQR=0-3). 
There were some differences between individuals included from UK CHIC and from EuroSIDA 
(Table 5.3), most probably reflecting known differences between HIV positive people in the UK 
as opposed to mainland Europe. Individuals in EuroSIDA were more likely to report injecting 
drug use (p<0.001) and more likely to be infected with a subtype B virus (p<0.001). They also 
had lower RNA values at baseline (median: 7,200 vs 8,928 copies/ml, p<0.001). Individuals 
from EuroSIDA contributed double the FU time per episode than individuals from UK CHIC 
(median: 8 vs 4 months, p<0.001) and had a lower average GSS at the start of their episodes 
(median: 1 vs 2 active drugs, p<0.001), likely reflecting the fact that in EuroSIDA there is a 
higher proportion of patients entering the cohort with extensive previous use of antiretrovirals 
as compared to UK CHIC.  
There were also some differences between those individuals who had resistance detected at 
baseline and those who did not (Table 5.4). The viral load was considerably higher during VF 
episodes where no resistance was detected (p<0.001), and, intriguingly, there was some 
suggestion that CD4 counts were also higher during episodes with no resistance, although this 
finding was only marginally significant (p=0.05). Episodes where no resistance was detected 
also tended to be shorter (p<0.001) and to have shorter gaps between CD4 measurements 
(p<0.001). 
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Table 5.3. Characteristics of the study population according to source cohort, per episode 
   
 
Total Episodes EuroSIDA CHIC P-value  
   N (%)  N (%)  N (%)   
At baseline, per individual  5357 1914 3443  
Gender Male 4088 (76.3) 1501 (78.4) 2587 (75.1) 0.007 
  Female 1269 (23.7) 413 (21.6) 856 (24.9)   
Ethnicity White 3592 (68.2) 1590 (83.9) 2002 (59.4) <.001 
  Non-white 1673 (31.8) 306 (16.1) 1367 (40.6)   
Risk Group MSM 2862 (55.0) 940 (51.8) 1922 (56.7) <.001 
  PWID 485 (9.3) 330 (18.2) 155 (4.6)   
  Heterosexual 1726 (33.1) 494 (27.2) 1232 (36.3)   
  Other 134 (2.6) 51 (2.8) 83 (2.4)   
Subtype B 3659 (72.2) 1430 (87.9) 2229 (64.8) <.001 
 Non-B 1409 (27.8) 197 (12.1) 1212 (35.2)   
Hepatitis C Yes 698 (9.1) 83 (9.7) 3891 (57.2) <.001 
 No 4461 (58.2) 569 (66.4) 615 (9.0)   
Unknown 2502 (32.7) 205 (23.9) 2297 (33.8)  
Age (Median, IQR)  Years 38.5 (34.6, 42.9) 39.5 (34.8, 46.2) 38.2 (34.6, 41.8) 0.092 
Baseline date (Median, IQR) Year 12/00 (06/98-11/04) 11/98 (106/97-11/01) 07/02(05/99-03/06) <.001 
During FU, per episode  7661 2757 4904  
Viral suppression2 VL above set point 745 (26.4) 86 (21.2) 659 (27.3) 0.017 
 VL <1.5 log10 copies/ml below set point  1195 (42.4) 194 (47.8) 1001 (41.5)  
 VL >1.5 log10 copies/ml below set point 880 (31.2) 126 (31.0) 754 (31.2)  
CD4 at the start of VF   Median( IQR), cells/mm3 257 (145, 393) 260 (149, 407) 254 (142, 387) 0.092 
RNA at the start of VF   Median( IQR), copies/mL 8200 (1829, 52672) 7200 (1801, 39000) 8928 (1841, 60205) <.001 
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FU time contributed   Median( IQR), months 5 (2, 13) 8 (3, 17) 4 (1, 10) <.001 
Number of CD4 
measurements  
 Median( IQR), months 3 (2, 5) 4 (2, 6) 3 (2, 5) <.001 
Time betw en CD4 
measurements (Median, IQR) 
 Median( IQR), months 3 (1, 5) 4 (2, 5) 3 (1, 4) <.001 
Genotypic Sensitivity Score (GSS) during each episode1 (Median, IQR) 1 (0, 3) 1 (0, 2) 2 (1, 3) <.001 
1. Calculated using the ANRS (v 23) interpretation system. 
2. The set point could be estimated for 2820 episodes 
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Table 5.4. Characteristics of the study population according to the detection of resistance, per episode 
    Total Episodes No Resistance Any resistance P-value 
    N (%)  N (%)  N (%)   
At baseline, per individual  5357 625 4732  
Gender Male 4088 (76.3) 482 (77.1) 3606 (76.2) 0.613 
  Female 1269 (23.7) 143 (22.9) 1126 (23.8)   
Ethnicity White 3592 (68.2) 443 (72.3) 3149 (67.7) 0.022 
  Non-white 1673 (31.8) 170 (27.7) 1503 (32.3)   
Risk Group MSM 2862 (55.0) 382 (62.1) 2480 (54.0) 0.002 
  PWID 485 (9.3) 50 (8.1) 435 (9.5)   
  Heterosexual 1726 (33.1) 167 (27.2) 1559 (34.0)   
  Other 134 (2.6) 16 (2.6) 118 (2.6)   
Subtype B 3659 (72.2) 450 (75.8) 3209 (71.7) 0.039 
 Non-B 1409 (27.8) 144 (24.2) 1265 (28.3)   
Hepatitis C Yes 698 (9.1) 83 (9.7) 3891 (57.2) <.001 
 No 4461 (58.2) 569 (66.4) 615 (9.0)  
 Unknown 2502 (32.7) 205 (23.9) 2297 (33.8)  
Age (Median, IQR)  Years 38.5 (34.6, 42.9) 40.3 (35.9, 43.8) 38.3 (34.5, 42.8) 0.046 
Baseline date (Median, IQR) Year 12/00 (06/98-11/04) 12/03 (11/99-08/07) 09/00(05/98-06/04) <.001 
During FU, per episode  7661 857 6804  
Viral suppression2 VL above set point 745 (26.4) 160 (35.2) 585 (24.7) <.001 
 VL <1.5 log10 copies/ml below set point  1195 (42.3) 183 (40.3) 1012 (42.8)  
 VL >1.5 log10 copies/ml below set point 880 (31.2) 111 (24.5) 769 (32.5)  
CD4 at the start of VF Median (IQR), cells/mm3 257 (145, 393) 273 (158, 406) 255 (143, 392) 0.046 
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RNA at the start of VF  Median (IQR), copies/mL 8200 (1829, 52672) 22600 (3155, 102265) 7400 (1755, 45266) <.001 
FU time contributed  Median (IQR), months 5 (2, 13) 3 (1, 8) 6 (2, 13) <.001 
Number of CD4 measurements   Median (IQR), months 3 (2, 5) 2 (2, 4) 3 (2, 5) <.001 
Time between CD4 measurements  Median (IQR), months 3 (1, 5) 2 (1, 4) 3 (2, 5) <.001 
Genotypic Sensitivity Score (GSS) during each episode1 (Median, IQR) 1 (0, 3) 3 (3, 4) 1 (0, 3) <.001 
1. Calculated using the ANRS (v 23) interpretation system. 
2. The set point could be estimated for 2820 episodes 
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A large number of different combinations of antiretroviral drugs were used for the duration of 
the VF episodes (Table 5.5). The vast majority of the episodes (84.5%) were taking place when 
individuals were receiving more than 3 drugs, although 15.6% of episodes occurred while 
individuals were receiving mono or dual therapy. Of those receiving exactly 3 drugs, the most 
common combination was one NNRTI and 2 NRTI. The most common combination was 
Zidovudine, Lamivudine and Nevirapine, used in 3% of the episodes. This was followed by dual 
therapy consisting of Lamivudine and Stavudine or Zidovudine and Lamivudine. The regimens 
used likely reflect the early calendar years included in the analysis.  
Table 5.5. Most commonly used regimens1, per episode 
 N % 
Zidovudine+Lamivudine+Nevirapine 232 3.03 
Lamivudine + Stavudine 228 2.98 
Zidovudine + Lamivudine 211 2.75 
Lamivudine + Stavudine + Nelfinavir 192 2.51 
Tenofovir + Efavirenz + Emtricitabine 183 2.39 
Tenofovir + Indinavir/r + Atazanavir + Emtricitabine  147 1.92 
Zidovudine + Lamivudine + Efavirenz 141 1.84 
Zidovudine + Lamivudine + Abacavir 140 1.83 
Lamivudine + Stavudine + Nevirapine  129 1.68 
Lamivudine + Stavudine + Indinavir 128 1.67 
Zidovudine + Lamivudine + Nelfinavir 125 1.63 
Tenofovir + Indinavir/r + Emtricitabine 115 1.5 
Didanosine + Stavudine + Nevirapine 111 1.45 
Zidovudine + Lamivudine + Indinavir 111 1.45 
Zidovudine + Lamivudine + Indinavir/r 98 1.28 
Didanosine + Stavudine + Efavirenz 87 1.14 
Lamivudine + Abacavir +Nevirapine 87 1.14 
Zidovudine + Didanosine 86 1.12 
Didanosine + Stavudine 85 1.11 
Tenofovir + Indinavir/r + Darunavir/r + Emtricitabine 80 1.04 
Lamivudine + Abacavir + Efavirenz 78 1.02 
1. Only regimens used during more than 1% of episodes are reported 
 
The prevalence of individual drugs used can be seen in Figure 5.5. Lamivudine (3TC) was used 
most commonly, in just over 55% of the episodes. This was followed by Indinavir, Stavudine 
and Atazanavir.  
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Figure 5.5. Individual drugs used during each episode1 
1. 3TC=Lamivudine, FTC=Emtricitabine, AZT=Zidovudine, DDI=Didanosine, D4T=Stavudine, ABA=Abacavir, TDF=Tenofovir, NEV=Nevarapine, EFA=Efavirenz, SAQ=Saquinavir, IND=Indinavir, 
NEL=Nelfinavir, LOP=Lopinavir, ATA=Atazanavir, TIP=Tipranavir, AMP=Fos-amprenavir, FUS=T-20 (Fuseon), DAR=Darunavir, ETR=Etravirine, MVC=Maraviroc, RPV=Rilpivirine, 
RAL=Raltegravir 
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5.4.2. Resistance prevalence  
At least one resistance mutation was detected in 6,804/7,661 episodes (88.8%). Of those 
episodes during which no resistance was detected, 9.8% had only minor PI mutations and 1.3% 
had no mutations detected whatsoever. The prevalence of any NRTI resistance was 68.0%, any 
NNRTI resistance 58.2% and any PI resistance (excluding minor PI mutations) 51.0%. Estimates 
of class-specific resistance prevalence according to the different interpretation systems are 
also provided in Figure 5.6. The prevalence appeared reasonably similar across the different 
identification systems, although the Rega system appeared to provide a lower estimate of the 
prevalence of PI mutations as compared to the other systems.  
Four mutations in the RT (G190T, T69S, T66i, W71i) and four in the PI (V32i, I47I, G48Q, G73F) 
were not detected in the dataset, and 82 RT mutations and 62 PI mutations were detected at a 
frequency of less than 1%. These were not evaluated as individual mutations in this analysis. 
The prevalence of the remaining 55 RT mutations and 64 PI mutations can be seen in Figure 
5.7 and Figure 5.8. In the RT gene, the M184V substitution that confers resistance to NRTIs, 
typically 3TC and/or FTC, was most commonly detected, followed by the K103N mutation that 
confers resistance to most NNRTIs. In the PR gene, minor PR mutations were the most 
common, with the L63P substitution detected in just over 55% of episodes. The most common 
major PI mutation was L90M (10%).  
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 Figure 5.6. Prevalence of any and class-specific resistance according to the IAS (2015), Stanford (2015), Rega (2013) and ANRS (2015) interpretation systems, in 
7661 viral failure episodes 
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Figure 5.7. Prevalence of mutations in the RT gene detected in >1% of episodes, in 7661 VF episodes 
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Figure 5.8. Prevalence of mutations in the PI gene detected in >1% of episodes, in 7661 VF episodes 
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5.4.3. Clusters of mutations  
The scree plots I used to decide how many principal components (PC’s) to retain for the RT and 
PI PCA can be seen in Figure 5.9. These plots showed approximate breakpoints after five (RT) 
and two (PI) principal components (PC’s) (Figure 5.9), and therefore I decided to retain five RT 
components and two PI components. In total, these factors explained a low proportion of the 
total variance: 27.7% and 17.3% respectively.  
 
Figure 5.9. Scree plot for RT (a) and PI (b) mutations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)  
(b)  
Assumed breakpoint 
Assumed breakpoint 
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The extracted factors were subjected to a varimax rotation (Chapter 2, page 100) to aid the 
interpretability of the results, and the rotated factor patterns are shown in Table 5.6-Table 5.7 
(PI mutations). Briefly, these tables show how strongly each mutation correlates with the 
extracted PC. The strength of the correlation, the loadings, have been rounded and multiplied 
by 100 in order to ease the interpretation of the tables. Loadings with values between 30 and 
40 are highlighted in light gray, between 40 and 70 in medium gray and above 70 in dark gray. 
For simplicity, extracted components are referred to as clusters from now on. The loadings are 
used to describe the clusters characteristics. However, for the extraction of individual scores 
all mutations contribute as described in Chapter 2, page 100.  
The 1st RT cluster primarily consisted of substitutions in positon 215, 67, 41, 210, 219, 44, 118 
and 70. These substitutions correspond roughly to the TAM mutations, a well-characterised 
cluster of mutations. The strongest contributions came from TAM-1 mutations (210, 215 and 
41) as well as from substitutions in position 67. The 2nd RT cluster corresponded to the 151M 
cluster, with substitutions in position 151, 116, 77, 75. There were also some weak 
contributions from substitutions in position 62 and 65. The 3rd RT cluster corresponded weakly 
to the TAM2 cluster (substitutions in positon 70, 219 and, weakly, 67). The mutations that 
formed part of the 4th and 5th RT clusters did not represent any already known mutation 
patterns. Substitutions in positions 74, 221 and 181 contributed to the 4th RT cluster, with 
weak contributions from substitutions in position 103, 108 and 100. Substitutions in position 
101, 103 and 225 contributed to the 5th. The 4th RT cluster therefore represents broad NNRTI 
resistance (221 and 181), but also resistance to abacavir and didanosine. The 5th cluster 
represents general resistance to NNRTI drugs.  
Major PI mutations in positions 46, 48 53, 54, 58, 82, 84 and 90 all contributed to the 1st PI 
cluster, as did minor mutations in position 10, 24, 33, 53, 64, 71 and 73. Together, these 
substitutions confer broad PI resistance. The 2nd PI cluster consisted of 4 minor PI mutations 
in position 20, 36, 69 and 89, with some weak contributions from substitutions in position 16 
and 15. 
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Table 5.6. Rotated Factor Pattern for RT mutations 
 
Component 1 
TAM  
Component 2  
151 Complex 
Component 3 
TAM2 
Component 4 
Cross NNRTI + ABC/DDI 
Component 5 
Cross NNRTI  
r40F 17 -4 -8 -1 0 
r41L 72 -22 -35 1 2 
r44AD 54 -14 -39 5 -9 
r62V 11 37 -14 5 -1 
r65ENR -3 37 4 23 -17 
r67EGHNS 72 -11 31 -31 2 
r68ins 4 3 -3 -1 -1 
r69ADGNS 35 -3 25 -18 -6 
r69ins 4 2 2 1 -3 
r70EGNQRST 42 2 65 -39 8 
r74IV 31 6 7 48 26 
r75AILMST 31 40 -13 -2 3 
r77I 12 66 -22 -22 10 
r90I 2 8 11 6 2 
r98GS 12 -1 2 6 -9 
r100IV 12 1 6 31 51 
r101EHINPQRT 24 17 18 25 -38 
r103HNRST 17 10 17 39 48 
r106AIM 6 9 7 8 -22 
r108I 22 15 7 32 8 
r115F 5 43 1 13 -8 
r116Y 9 76 -17 -30 11 
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r118I 56 -12 -33 -4 -7 
r138AGKQRS -2 6 7 7 -10 
r151LM 10 77 -14 -28 10 
r179DEFILMT 9 5 18 9 -16 
r181CFGISV 27 23 19 42 -31 
r184IV 37 2 3 7 17 
r188CFHL 8 -2 -2 6 -3 
r189I 6 3 -5 14 2 
r190ACEQSTV 30 21 20 25 -40 
r191I 3 -3 -5 -1 -8 
r210W 67 -20 -48 6 -5 
r215ACDEFGHILNSVY 77 -21 -12 -8 4 
r219EHNQRW 59 0 54 -28 7 
r221Y 16 15 14 42 -15 
r225H -3 5 8 21 43 
r227CL 1 -1 5 -4 -4 
r230ILV 2 2 8 7 10 
r234I 0 -1 -2 -1 0 
r238NT 12 0 8 8 13 
r318F 3 -1 8 2 10 
r348I 1 -1 -3 1 2 
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 Table 5.7. Rotated Factor Pattern for PI mutations 
 
Component 1 
Cross PI 
Component 2 
Accessory/Non-B 
p10CFIMRV 63 3 
p11IL 14 7 
p15AV -9 37 
p16E -4 32 
p20IMRTV 28 53 
p23I 10 0 
p24FIM 35 2 
p30N -1 -13 
p32IL 25 -1 
p33FIMV 31 1 
p34QV 22 -2 
p35GN 7 15 
p36ILV 9 75 
p38W 7 0 
p41IT 2 6 
p43TR 13 -3 
p45I 2 -2 
p46ILV 65 -6 
p47AIV 24 1 
p48ALMQSTV 36 0 
p50LV 14 5 
p53LWY 41 1 
p54ALMSTV 78 9 
p58E 30 5 
p60E 6 7 
p62V 27 -16 
p63IP 26 -44 
p64LMV 63 12 
p66F 13 3 
p69IKNQRY -11 76 
p70E 3 1 
p71ILTV 57 -27 
p73ACFSTV 40 -16 
p74AEPS 17 23 
p76V 20 4 
p77I 6 -47 
p82ACFGLMST 71 3 
p83D 9 10 
p84ACV 51 -4 
p85V 20 -3 
p88DGST 5 -10 
p89IMRTV -9 83 
p90M 60 -14 
p93LM 10 -8 
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5.4.4. CD4 count changes over time  
In univariable analysis, the estimated average CD4 decline was 20 cells/mm3/year (95%CI=-22; -17) 
in the entire population. The overall CD4 decline according to absolute levels of current VL as well as 
levels of viral suppression can be seen in Table 5.8. CD4 declines were somewhat steeper at very 
high viral loads (>100,000 copies/mL; p=0.01), but at lower viral loads no large differences according 
to strata of current VL were evident. CD4 declines were less steep (although still not negligible at 23 
cells/mm3 loss per year) when current VL levels were below pre-ART set-point values (p=0.008, Table 
5.8). These results are in slight contrast with some previous findings (364,615), and possible reasons 
for these discrepancies are outlined in the discussion .  
 Table 5.8. CD4 count (cells/mm3) decline per year in overall study population and according to 
time-updated VL levels and time-updated VL levels compared to viral set point 
 Unadjusted  Adjusted1  
  Slope (95% CI) P interaction2 Slope (95% CI) P interaction2 
Absolute VL   0.010   0.012 
<1000 -11.25 (-16.33; -6.16)   -11.47 (-16.83; -6.11)   
1000-5000 -10.95 (-14.13; -7.77)   -11.22 (-14.61; -7.82)   
5000-10000 -9.80 (-13.25; -6.35)   -10.48 (-14.13; -6.83)   
10000-20000 -9.86 (-13.38; -6.34)   -10.82 (-14.55; -7.09)   
20000-100000 -12.64 (-15.83; -9.44)   -13.31 (-16.70; -9.92)   
>100000 -17.21 (-21.07; -13.35)   -18.00 (-22.03; -13.98)   
VL in relation to set-point (N=2820) 
   0.066   0.008 
Not supressed -29.69 (-36.57; -22.81)   -33.67 (-40.92; -26.42)   
Somewhat supressed -22.75 (-28.66; -16.84)   -23.78 (-30.00; -17.56)   
Supressed -25.14 (-32.67; -17.61)   -26.07 (-33.91; -18.24)   
1. Adjusted for drug type, age, hepatitis C, risk-group, subtype and GSS. 439 individuals were excluded due to missing values 
for subtype and risk group.  
2. Testing the null hypothesis that the slope is the same in each RNA strata.  
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5.4.5. Influence of any and class-wide resistance on CD4 slopes  
Figure 5.10 shows the estimated difference in annual CD4 decline according to the detection of 
any resistance of resistance associated with specific drug classes. CD4 counts declined less 
rapidly during episodes where drug resistance was detected compared to episodes where 
resistance was not detected, with an estimated difference of 28 (18-39) cells/mm3/year after 
comparing decline in people with resistance (-17, 95%CI=-20; -15 cells/mm3/year) to that 
among those with no resistance (-46, 95%CI=-56; -36) cells/mm3/year, interaction p<0.001). 
These findings persisted after adjustment for the pre-specified confounders (difference=28 
[17-39] cells/mm3/year, p<0.001) and after further adjustments for VL (difference=32 [21-42] 
cells/mm3/year, p<0.001, Figure 5.10).  
Figure 5.10. Difference in annual CD4 count changes (cells/mm3) according to the detection 
of any and class of drug resistance present1,2,3,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. The first category, “Any (no minor PI) compares those without resistance to those with at least 1 DRM from any 
classification system, excluding IAS minor PI mutations 
2. The consequent four categories compare those with at least 1 DRM from the specified drug class to those with any 
other DRM. Individuals without resistance were excluded from these comparisons 
3. Model 1 adjusted for age, hepatitis C, risk group and subtype. Model 2 additionally adjusted for viral load (log-
scale, continuous).  
4. Separate models were constructed for each exposure 
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Among individuals with detected drug resistance, CD4 counts declined less rapidly during 
episodes where NRTI resistance was detected compared to episodes where NRTI resistance 
was not detected (-15 (-18; -12) v -40 (-48; -33) cells/mm3/year, interaction p<0.001). 
Adjustment for pre-specified confounders and VL did not change these estimates markedly 
(Figure 5.10). There was also evidence that CD4 counts declined faster during episodes where 
NNRTI resistance was detected in both univariable (-22 (-26; -19) v -10 (-15; -5) 
cells/mm3/year, interaction p<0.001) analyses and after adjustment (Figure 5.10). 
There was no evidence to suggest that CD4 decline differed according to the detection of PI 
resistance including minor PI mutations (Figure 5.10). However, there was some weak 
evidence suggesting that CD4 decline was less steep during episodes where major PI mutations 
were detected, both in univariable (difference=6 (-1-12) cells/mm3/year, p=0.07) and 
multivariable models (difference=8 (1-14) cells/mm3/year, p=0.02 in model 1, difference= 6 (-0; 
12) cells/mm3/year, p=0.05 in model 2).  
5.4.6. Influence of individual mutations on CD4 slopes 
The difference in CD4 decline between episodes with and without a given mutation after 
adjustment for pre-specified confounders is shown in Figure 5.11. Mutations are ranked with 
increasing q-values from top (most significant associations after controlling for multiple 
testing) to the bottom (least significant associations after controlling for multiple testing). 
After correcting for multiple testing, the strongest association was found for M184V, with 
episodes where M184V was detected experiencing somewhat less steep CD4 declines 
(difference= 17 (11-23) cells/mm3/year, q<0.001). These findings did not change markedly 
after additional adjustment for VL (difference=16 (10-21) cells/mm3/year, q<0.001, Figure 
5.12). There was also reasonable evidence that the T215Y and D67N mutations were 
associated with less steep CD4 declines both before (difference=11 (5-17) and 11 (5-17) 
respectively, both q=0.012) and after (difference=10 (4-16) and 12 (6-17), q=0.019 and 0.003 
respectively) adjustment for VL. One NNRTI mutation, V179D, was associated with steeper CD4 
declines, although there was uncertainty around the exact magnitude of the effect 
(difference=-44 (-69; -19) cells/mm3/year, q=0.012, Figure 5.12). There was also some weak 
evidence (q=0.05) suggesting that those with the L74V mutation experienced somewhat 
steeper CD4 declines, but the association was no longer significant after controlling for VL 
(Figure 5.12).  
Of the PI mutations studied, two remained associated with a less steep CD4 decline after 
correction for multiple testing: V82A and I54V ( Figure 5.13). The strongest association was 
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found for the V82A mutation, where CD4 decline was estimated to be 18 (10-25) 
cells/mm3/year less steep during episodes where the mutation was detected compared to 
episodes without the mutation (q<0.001). CD4 decline was also 13 (5-20) cells/mm3/year less 
steep during episodes where I54V was detected (q=0.015). Again, results were similar after 
further adjusting for VL in the model (Figure 5.14). 
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Figure 5.11. Difference in annual CD4 count changes according to the detection of RT 
mutations1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Adjusted for age, hepatitis C, risk-group and subtype. 439 individuals were excluded due to missing values 
for subtype and risk group. 
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Figure 5.12. Difference in annual CD4 count changes according to the detection of RT 
mutations (Model 2, adjusted for VL)1,2 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Adjusted for age, hepatitis C, risk-group, subtype and VL . 439 individuals were excluded due to missing 
values for subtype and risk group. 
2. For M184V, it was necessary to adjust for VL as a categorical variable due to convergence issues.  
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 Figure 5.13. Difference in annual CD4 count changes according to the detection of PI 
mutations1 
 
 
 
1. Adjusted for age, hepatitis C, risk-group and subtype . 439 individuals were excluded due to missing values 
for subtype and risk group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  
1. Adjusted for age, hepatitis C, risk-group and subtype . 439 individuals were excluded due to missing 
values for subtype and risk group. 
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Figure 5.14. Difference in annual CD4 count changes according to the detection of PR 
mutations (Model 2, adjusted for VL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Adjusted for age, hepatitis C, risk-group, subtype and VL . 439 individuals were excluded due to missing 
values for subtype and risk group. 
2. For K20T and I93L, it was necessary to adjust for VL as a categorical variable due to convergence issues.  
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5.4.7. The effect of mutation clusters on CD4 count change 
The effect of the mutation clusters on CD4 count changes are shown in Figure 5.15. Individuals 
with scores in the highest quartile of the 3rd RT cluster (weakly corresponding to TAM-2 
mutations) experienced reduced CD4 declines (difference=9 (2-16) cells/mm3/year, p=0.007), 
as did individuals with scores in the highest quartile of the 1st PI cluster, which represented 
broad PI resistance (difference=14 (7-20) cells/mm3/year, p<0.001). Individuals with scores in 
the highest quartile of the 5th RT cluster, which included K103N, experienced steeper CD4 
declines (difference=-9 (-16; -3) cells/mm3/year, p=0.007) compared to individuals with lower 
scores on this component. There was also some very weak evidence that scores in the highest 
quartile of the 1st RT cluster, corresponding roughly to TAM-1 mutations, were associated with 
somewhat reduced CD4 declines (p=0.03) 
Figure 5.15. CD4 decline according to RT1 and PC2 clusters identified by the PCA3 
 
 
 
 
 
 
 
 
 
 
 
 
1. RT1= TAM1, RT2=151M, RT3=TAM2, RT4=NNRTI/NRT, RT5=NNRTI 
2. PR1=Cross PI, PR2=Minor PI 
3.  Model 1 adjusted for age, hepatitis C, risk group and subtype. Model 2 additionally adjusted for viral load 
(log-scale, continuous). 439 individuals were excluded due to missing values for subtype and risk group. 
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5.4.8. Sensitivity analyses 
The results from the sensitivity analyses are shown in Table 5.9-Table 5.12 for any resistance, 
class-wide resistance, the significant DRM identified above and the PC components 
respectively. When restricting to episodes without very large VL variations (N=7,575 episodes, 
98.8% of the original dataset) the point estimates and confidence intervals of main findings 
only shifted by a few cells/mm3/year, and the conclusions remained unchanged. When 
excluding episodes with fewer than 3 CD4 counts (N=4613 episodes, 60.2% of the original 
dataset), the statistical significance of some of the findings was reduced. Specifically, the q-
values associated with all individual mutations apart from M184V and V82A no longer met the 
0.05 threshold. No other findings were materially different (Table 5.11). Adjusting for the class 
of drug (NNRTI, PI, NNRTI+PI, Other) received during the regimen did not affect any of the 
findings (Table 5.12). 
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Table 5.9. Summary of the main results in the original analysis1 
 Unadjusted   Adjusted (1)  Adjusted (2)  
 Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
N=7,661 
Any 26.39 (13.65 - 39.13) <.001 28.11 (17.11 - 39.12) <.001 31.07 (20.63 - 41.51) <.001 
Class-wide Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
NRTI 25.45 (17.19 - 33.71) <.001 26.66 (18.12 - 35.20) <.001 28.40 (20.28 - 36.52) <.001 
NNRTI -12.47 (-18.35 - -6.60) <.001 -11.99 (-18.23 - -5.75) <.001 -9.59 (-15.50 - -3.67) 0.001 
PI (no minor) 5.51 (-0.52 - 11.53) 0.073 7.40 (1.03 - 13.78) 0.023 6.09 (0.05 - 12.12) 0.048 
PI (minor) 12.27 (-7.92 - 32.47) 0.234 12.71 (-10.69 - 36.11) 0.287 11.51 (-10.68 - 33.70) 0.309 
Individual DRM Difference (95%CI) Q Difference (95%CI) Q Difference (95%CI) Q 
M184V 14.46 (8.82 - 20.11) <.001 17.61 (11.65 - 23.58) <.001 16.03 (10.40 - 21.66) <.001 
T215Y 9.39 (3.74 - 15.04) 0.022 10.67 (4.67 - 16.66) 0.012 9.88 (4.20 - 15.56) 0.019 
D67N 10.53 (4.80 - 16.27) 0.013 11.15 (5.03 - 17.27) 0.012 11.65 (5.86 - 17.45) 0.003 
L179D -41.04 (-64.31 - -17.77) 0.016 -44.23 (-69.06 - -19.41) 0.012 -38.15 (-61.69 - -14.60) 0.033 
L74V -15.85 (-25.19 - -6.50) 0.021 -15.00 (-24.88 - -5.12) 0.049 -12.62 (-21.98 - -3.26) 0.104 
V82A 14.51 (7.45 - 21.58) 0.003 17.64 (10.13 - 25.14) <.001 15.83 (8.72 - 22.94) <.001 
I54V 11.00 (4.06 - 17.94) 0.032 12.69 (5.29 - 20.09) 0.015 11.26 (4.24 - 18.28) 0.033 
Clusters Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
RT 1  5.90 (-0.29 - 12.09) 0.062 7.17 (0.57 - 13.78) 0.033 6.90 (0.65 - 13.15) 0.03 
RT 2  3.42 (-2.84 - 9.69) 0.284 5.43 (-1.27 - 12.14) 0.112 5.71 (-0.63 - 12.05) 0.078 
RT 3  9.28 (3.11 - 15.45) 0.003 9.14 (2.53 - 15.75) 0.007 9.41 (3.16 - 15.67) 0.003 
RT 4  -3.32 (-9.70 - 3.07) 0.308 -2.33 (-9.10 - 4.43) 0.499 0.51 (-5.90 - 6.92) 0.876 
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RT 5 -10.45 (-16.87 - -4.03) 0.001 -9.41 (-16.25 - -2.56) 0.007 -7.87 (-14.36 - -1.38) 0.017 
PI 1  10.67 (4.47 - 16.87) <.001 13.69 (7.06 - 20.31) <.001 11.67 (5.39 - 17.95) <.001 
PI 2  0.13 (-6.40 - 6.66) 0.969 -0.13 (-7.02 - 6.77) 0.972 -0.18 (-6.73 - 6.36) 0.956 
1. Adjusted for age, hepatitis C, risk-group, subtype (1) and VL (2). 439 individuals were excluded due to missing values for subtype and risk group.  
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Table 5.10. Sensitivity 1: Excluding large VL variation1 
 Unadjusted   Adjusted (1)  Adjusted (2)  
 Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
N=7,575 
Any 29.94 (19.15 - 40.74) <.001 29.85 (18.62 - 41.07) <.001 32.13 (21.45 - 42.82) <.001 
Class-wide Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
NRTI 25.26 (16.91 - 33.61) <.001 -14.61 (-17.86 - -11.36) <.001 -5.35 (-8.47 - -2.24) <.001 
NNRTI -12.00 (-17.91 - -6.08) <.001 -21.95 (-25.70 - -18.19) <.001 -12.24 (-15.83 - -8.65) 0.002 
PI (no minor) 5.37 (-0.70 - 11.44) 0.083 -15.71 (-19.40 - -12.03) 0.026 -7.12 (-10.64 - -3.60) 0.057 
PI (minor) 13.30 (-7.14 - 33.73) 0.202 -17.78 (-20.87 - -14.70) 0.241 -8.80 (-11.76 - -5.85) 0.296 
Individual DRM Difference (95%CI) Q Difference (95%CI) Q Difference (95%CI) Q 
M184V 14.17 (8.50 - 19.84) <.001 17.27 (11.26 - 23.28) <.001 15.54 (9.85 - 21.23) <.001 
T215Y 9.53 (3.86 - 15.21) 0.024 10.73 (4.70 - 16.76) 0.011 9.89 (4.16 - 15.62) 0.021 
D67N 10.61 (4.86 - 16.37) 0.012 11.13 (4.98 - 17.27) 0.011 11.59 (5.75 - 17.43) 0.004 
L179D -40.95 (-64.16 - -17.75) 0.016 -44.22 (-68.98 - -19.46) 0.011 -38.06 (-61.62 - -14.50) 0.036 
L74V -15.42 (-24.79 - -6.05) 0.025 -14.59 (-24.50 - -4.68) 0.064 -12.90 (-22.32 - -3.48) 0.096 
V82A 14.77 (7.70 - 21.84) 0.003 17.92 (10.41 - 25.43) <.001 16.08 (8.94 - 23.22) <.001 
I54V 10.78 (3.82 - 17.73) 0.04 12.43 (5.01 - 19.85) 0.02 10.90 (3.84 - 17.96) 0.045 
Clusters Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
RT 1  5.56 (-0.65 - 11.77) 0.079 6.73 (0.10 - 13.36) 0.047 6.38 (0.08 - 12.67) 0.047 
RT 2  3.21 (-3.10 - 9.52) 0.319 5.20 (-1.55 - 11.96) 0.131 5.16 (-1.26 - 11.58) 0.115 
RT 3  9.73 (3.54 - 15.92) 0.002 9.52 (2.89 - 16.15) 0.005 9.80 (3.51 - 16.10) 0.002 
RT 4  -3.47 (-9.88 - 2.93) 0.288 -2.59 (-9.38 - 4.21) 0.456 0.04 (-6.41 - 6.50) 0.989 
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RT 5 -9.90 (-16.33 - -3.46) 0.003 -8.86 (-15.73 - -1.99) 0.011 -7.44 (-13.97 - -0.90) 0.026 
PI 1  10.25 (4.04 - 16.47) 0.001 13.21 (6.56 - 19.85) <.001 11.23 (4.90 - 17.55) <.001 
PI 2  0.11 (-6.45 - 6.67) 0.973 -0.09 (-7.03 - 6.84) 0.979 -0.02 (-6.62 - 6.58) 0.996 
1. Adjusted for age, hepatitis C, risk-group, subtype (1) and VL (2). 439 individuals were excluded due to missing values for subtype and risk group.  
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Table 5.11. Sensitivity 1: Only including viral failure episodes in which 3 or more CD4 counts measurements were available11 
 Unadjusted   Adjusted (1)  Adjusted (2)  
 Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
N=4,613 
Any 26.64 (15.47 - 37.81) <.001 25.71 (14.11 - 37.30) <.001 28.07 (17.02 - 39.12) <.001 
Class-wide Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
NRTI 23.44 (14.67 - 32.20) <.001 24.09 (15.02 - 33.16) <.001 25.27 (16.62 - 33.93) <.001 
NNRTI -12.00 (-18.03 - -5.96) <.001 -11.35 (-17.77 - -4.93) <.001 -9.63 (-15.73 - -3.52) 0.002 
PI (no minor) 6.05 (-0.15 - 12.26) 0.056 7.78 (1.22 - 14.34) 0.02 6.68 (0.44 - 12.91) 0.036 
PI (minor) 14.89 (-5.96 - 35.75) 0.162 12.88 (-11.25 - 37.01) 0.295 13.75 (-9.21 - 36.72) 0.24 
Individual DRM Difference (95%CI) Q Difference (95%CI) Q Difference (95%CI) Q 
M184V 14.16 (8.34 - 19.98) <.001 17.20 (11.05 - 23.36) <.001 15.38 (9.55 - 21.21) <.001 
T215Y 7.61 (1.82 - 13.39) 0.131 8.64 (2.50 - 14.78) 0.099 7.85 (2.01 - 13.69) 0.124 
D67N 8.96 (3.08 - 14.83) 0.059 9.05 (2.79 - 15.31) 0.091 9.56 (3.61 - 15.51) 0.065 
L179D -37.70 (-61.87 - -13.52) 0.059 -41.28 (-67.12 - -15.45) 0.051 -37.10 (-61.67 - -12.54) 0.073 
L74V -16.28 (-25.80 - -6.76) 0.032 -15.41 (-25.47 - -5.35) 0.064 -13.39 (-22.95 - -3.82) 0.103 
V82A 13.81 (6.63 - 20.99) 0.01 16.81 (9.19 - 24.43) <.001 14.96 (7.72 - 22.21) 0.003 
I54V 10.69 (3.63 - 17.74) 0.059 12.35 (4.84 - 19.87) 0.05 10.97 (3.82 - 18.12) 0.073 
Clusters Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
RT 1  4.86 (-1.45 - 11.17) 0.131 6.08 (-0.65 - 12.81) 0.076 5.77 (-0.62 - 12.16) 0.077 
RT 2  3.01 (-3.40 - 9.42) 0.357 4.85 (-2.01 - 11.70) 0.166 4.93 (-1.58 - 11.44) 0.138 
RT 3  9.14 (2.84 - 15.44) 0.004 8.09 (1.34 - 14.84) 0.019 8.27 (1.87 - 14.68) 0.011 
RT 4  -2.41 (-8.96 - 4.13) 0.47 -1.46 (-8.40 - 5.47) 0.679 0.83 (-5.77 - 7.43) 0.806 
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RT 5 -10.16 (-16.76 - -3.57) 0.003 -8.81 (-15.84 - -1.77) 0.014 -7.64 (-14.34 - -0.95) 0.025 
PI 1  10.19 (3.87 - 16.50) 0.002 12.96 (6.21 - 19.70) <.001 11.04 (4.62 - 17.45) <.001 
PI 2  -0.22 (-6.99 - 6.54) 0.948 -0.38 (-7.53 - 6.77) 0.916 0.19 (-6.62 - 7.00) 0.956 
1. Adjusted for age, hepatitis C, risk-group, subtype (1) and VL (2). 439 individuals were excluded due to missing values for subtype and risk group.  
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Table 5.12. Sensitivity 1: Additionally adjusting for type of drug received during the VF episode1 
 Unadjusted   Adjusted (1)  Adjusted (2)  
 Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
N=7,661 
Any 26.39 (13.65 - 39.13) <.001 27.82 (16.82 - 38.81) <.001 29.12 (18.75 - 39.49) <.001 
Class-wide Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
NRTI 25.45 (17.19 - 33.71) <.001 26.17 (17.65 - 34.69) <.001 26.45 (18.37 - 34.52) <.001 
NNRTI -12.47 (-18.35 - -6.60) <.001 -11.72 (-17.96 - -5.48) <.001 -9.62 (-15.50 - -3.74) 0.001 
PI (no minor) 5.51 (-0.52 - 11.53) 0.073 7.74 (1.38 - 14.11) 0.017 6.60 (0.60 - 12.59) 0.031 
PI (minor) 12.27 (-7.92 - 32.47) 0.234 13.22 (-10.16 - 36.60) 0.268 13.63 (-8.42 - 35.68) 0.226 
Individual DRM Difference (95%CI) Q Difference (95%CI) Q Difference (95%CI) Q 
M184V 14.46 (8.82 - 20.11) <.001 17.45 (11.49 - 23.41) <.001 17.45 (11.49 - 23.41) <.001 
T215Y 9.39 (3.74 - 15.04) 0.022 10.63 (4.65 - 16.62) 0.012 9.57 (3.93 - 15.20) 0.023 
D67N 10.53 (4.80 - 16.27) 0.013 11.22 (5.11 - 17.33) 0.012 11.57 (5.82 - 17.32) 0.003 
L179D -41.04 (-64.31 - -17.77) 0.016 -43.88 (-68.68 - -19.07) 0.012 -38.59 (-61.98 - -15.19) 0.024 
L74V -15.85 (-25.19 - -6.50) 0.021 -14.79 (-24.66 - -4.92) 0.056 -14.79 (-24.66 - -4.92) 0.052 
V82A 14.51 (7.45 - 21.58) 0.003 17.79 (10.30 - 25.28) <.001 16.37 (9.32 - 23.43) <.001 
I54V 11.00 (4.06 - 17.94) 0.032 12.90 (5.51 - 20.29) 0.012 11.70 (4.73 - 18.67) 0.023 
Clusters Difference (95%CI) P Difference (95%CI) P Difference (95%CI) P 
RT 1  5.90 (-0.29 - 12.09) 0.062 7.25 (0.65 - 13.84) 0.031 6.62 (0.42 - 12.82) 0.037 
RT 2  3.42 (-2.84 - 9.69) 0.284 5.54 (-1.15 - 12.24) 0.105 5.34 (-0.96 - 11.64) 0.097 
RT 3  9.28 (3.11 - 15.45) 0.003 8.97 (2.37 - 15.56) 0.008 9.04 (2.83 - 15.24) 0.004 
RT 4  -3.32 (-9.70 - 3.07) 0.308 -2.25 (-9.00 - 4.51) 0.515 -0.39 (-6.75 - 5.98) 0.906 
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RT 5 -10.45 (-16.87 - -4.03) 0.001 -9.24 (-16.08 - -2.40) 0.008 -7.76 (-14.21 - -1.32) 0.018 
PI 1  10.67 (4.47 - 16.87) <.001 13.85 (7.24 - 20.46) <.001 12.27 (6.04 - 18.51) <.001 
PI 2  0.13 (-6.40 - 6.66) 0.969 0.10 (-6.79 - 6.99) 0.977 -0.09 (-6.59 - 6.41) 0.979 
1. Adjusted for drug type, hepatitis C, risk-group, subtype (1) and VL (2). 439 individuals were excluded due to missing values for subtype and risk group.  
2. Due to convergence issues, it was not possible to adjust for age, and VL had to be included as a categorical variable. 
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5.5. Discussion 
5.5.1. Detection of any resistance and CD4 declines 
This chapter described the effect of drug resistance on CD4 decline among patients maintained 
on a failing treatment regimen. The first main finding is that CD4 counts declined less markedly 
during episodes where resistance any was detected compared to episodes with no resistance. 
The most likely explanation for this finding is that the comparator group (i.e. people in which 
no drug resistance was detected despite a situation of uncontrolled viremia during 
antiretroviral treatment) are individuals who are not adherent to therapy. As described in 
Chapter 1, drug resistance requires selective drug pressure in order to emerge. However, if 
patients are not taking any drugs the lack of drug pressure will mean that resistance is unable 
to emerge despite on-going viral replication. This is consistent with what has been found in 
other studies, where individuals who are not taking their ART were shown to experience both 
higher levels of VL replication and a more rapid CD4 decline (332). In addition to a more rapid 
CD4 decline, I also found that episodes without any detected resistance had higher starting 
viral load values, which provides further support for this hypothesis. Although the difference in 
CD4 decline according to the detection of drug resistance persisted in sensitivity analyses 
where I attempted to remove the effect of poor adherence, it is possible that the design of this 
sensitivity analysis only allowed me to exclude individuals who took intermittent treatment, 
but retained those patients who were taking no drugs at all. A validated measure of adherence 
or another more objective assessment of adherence, such as drug levels in plasma, would be 
required in order to confirm or refute the theory that a lack of detected resistance reflects 
poor adherence. Unfortunately, these are both currently missing in the EuroSIDA data.  
Most previous studies have assessed the relationship between any drug resistance and a single 
CD4 measurement. For example, De Mendoza et al found an association between the 
detection of any resistance and higher CD4 counts in a cross-sectional analysis (602). In 
contrast, I did not find any evidence that CD4 counts at the start of failure episodes differed 
according to the detection of drug resistance. However, cross-sectional analyses assessing this 
question are hard to interpret due to the potential for reverse causality. Previous studies 
looking at the effect of any resistance on longitudinal CD4 count changes are not common, and 
in the literature review I could only identify one study that described the effect of any 
resistance on longitudinal CD4 trends specifically. This study, a longitudinal analysis by Dionisio 
et al of 16 patients from Italy, failed to show an association between the detection of any 
resistance and CD4 slopes (608), although the analysis is likely to be underpowered because of 
the small sample size.  
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5.5.2. The relationship between class-wide resistance, individual DRM and CD4 
decline  
In order to compare the relative effect of different types of resistance on CD4 decline, I 
separately evaluated resistance mutations associated with specific drug classes (NRTI, NNRTI 
and PI) as well as individual DRM after restricting to episodes for which at least one DRM was 
detected. This was done to potentially remove the allegedly poor adherent group in which no 
resistance was detected despite virological failure on treatment. The results from this analysis 
showed that CD4 counts appeared to decrease less steeply during episodes where NRTI 
resistance was detected. This is an interesting observation, and it is possible that these findings 
reflect differences in replication capacity associated with certain mutations that confer NRTI 
resistance (507). In addition, I found weak evidence indicating that CD4 counts declined less 
rapidly also during episodes where major PI mutations were detected, although the magnitude 
of this effect was not as large as for NRTI resistance. CD4 counts also declined less rapidly 
during episodes where major and minor PI resistance were detected, although these 
differences were not significant. In contrast, CD4 counts declined more steeply during episodes 
where NNRTI resistance was detected, consistent with reports that many NNRTI mutations 
have relatively high fitness.  
Manual step-wise adjustment showed that adjustment for VL had very little effect on the 
effect estimates. The lack of impact of the VL adjustments on the estimates appear to indicate 
that the findings are not mediated through viral load. This is an interesting result and 
somewhat counterintuitive from a virological stand point. However, the presence of drug 
resistance has been associated with reduced rates of CD8+ T cell activation independent of the 
level of viral replication, which in turn is associated with a slower rate of CD4 decline (616). 
This indicates that it is possible that the presence of resistance could affect CD4 cell kinetics in 
beneficial ways that are not mediated through viral load (617). However, it is also possible that 
the adjustment for VL does not completely remove the effect mediated through VL. It has 
been shown that in many situations a model adjusting for a mediating variable does not 
accurately estimate the total direct effect of the exposure on the outcome, and in some cases 
spurious associations between the exposure and outcome can be introduced as a result of 
such adjustments (618–620). This should be born in mind when interpreting the results from 
the step-wise adjustments.  
Regarding specific individual mutations, I found evidence to suggest that CD4 counts declined 
less markedly during episodes where the mutations M184V, T215Y, D67N in the reverse 
transcriptase and V82A and I54V in the protease were detected. The M184V mutation in the 
reverse transcriptase has been frequently shown to adversely impact replicative capacity 
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(595,621–623), and it has been suggested that preserving this mutation could result in a 
clinical benefit for patients (599,600). The size of the reduction in CD4 decline associated with 
the M184V mutation (17 cells/mm3/year) was smaller than that associated with NRTI 
resistance overall (27 cells/mm3/year). When restricting the analysis to episodes where the 
M184V mutation was not detected, the size of the NRTI effect reduced only marginally (24 
cells/mm3/year). This indicates that other NRTI mutations could also be influencing the speed 
of the CD4 decline. In my analysis, D67N and T215Y were both associated with moderately 
reduced CD4 declines of around 10 cells/mm3/year. D67N has been shown to have relatively 
high RC (507,624), whereas the T215Y mutation has been associated by some researchers with 
an impaired RC when this mutation is present in a WT sequence background (623,624). 
However, these results are not consistent. Devereux et al found that the D67N mutation was 
associated with in vitro reduced fitness, ranging between a 10.5-24.7% reduction (623), 
whereas an analysis by Eastman et al from 1998 estimated that the relative fitness of the 
T215Y/F mutation following drug withdrawal could be as high as 98% compared to WT (625). 
Comparisons are further complicated by different laboratory methodologies as well as 
differences in the formulas used to calculate relative fitness estimates (626).  
The V82A mutation has been reported to negatively impact the processing capacity of the PR 
which has been hypothesised to cause a lower replication capacity (627). This is in agreement 
with a small study determining the effect of PR mutations after interruption of therapy, which 
showed a 21-49.3% loss of fitness associated with the presence of the V82A mutation 
(326,626). However, other in vivo experiments have estimated that the fitness of V82A in the 
presence of Ritonaivr was as high as 96-98% compared to a WT virus (625). I54V, a 
nonpolymorphic mutation which is selected primarily by indinavir and lopinavir and reduces PI 
susceptibility when present in combination with V82A (394), has also been previously found to 
moderately reduce fitness (623), in support of my findings.  
One NNRTI and one NRTIassociated mutations were weakly associated with steeper CD4 
declines: V179D and L74V, although the evidence supporting an association with L74V 
disappeared upon adjustment for VL. V179D is a polymorphic NNRTI mutation, which can act 
in synergy with K103N to reduce Nevirapine and Efavirenz susceptibility (394). There is 
substantial evidence that viral variants with the K103N mutation have high fitness (507), and it 
is possible that the presence of V179D could act as a marker for the presence of K103N. In my 
analysis episodes in which K103N also showed steeper CD4 declines, although not significantly 
so after adjusting for multiple testing. However, the V179D mutation has been found to 
outgrow strains carrying the Y181C or V106A mutation and to only have a slight reduction in 
replication capacity compared to wild-type in an analyses by Archer et al., although the 
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researchers were unable to definitively establish the relative replication capacity of V179D due 
to insensitivity in the direct sequencing assay for that mutation (628).  
The finding that CD4 declines are less steep during episodes where the M184V mutation was 
detected is in agreement with a very recent analysis by Hoffman et al. who analysed a large 
cohort of patients from South Africa and found that CD4 counts declined 11 cells/mm3/year 
less rapidly during episodes of persistent viraemia during which M184V was detected 
compared to episodes during which it was not, although chance could not be ruled out as an 
explanation of this finding (p=0.1) (629). Other studies of resistance and CD4 decline have, as 
previously mentioned when describing the results from my literature review, been relatively 
small and found conflicting results. Antinori et al also found evidence that both M184V and 
V82A were associated with immunological recovery despite on-going viral replication in 
univariable analyses, although not in multivariable analyses adjusting for viral load (604). 
Nicastri et al found that the M184V mutation was more commonly detected among patients 
who experienced discordant virological-immunological responses than among patients who 
did not (603), which supports a potential immunological benefit of the presence of this 
mutation. These two papers did not present any insignificant multivariable results, and it is 
therefore difficult to assess whether adjustment for VL simply affected statistical significance 
or whether the magnitude of the effect was largely attenuated and close to a difference of 
zero, as the authors interpretation of the data would imply. The only trial investigating the 
effect of an M184V preserving strategy in the context of cART, COLATE, did not find any 
virological benefit or 3TC continuation (599). However, the patients in the trial are not 
representative of those of the population studied here as not many were people kept on 
failing regimens. Indeed, the vast majority of these patients received 3 or more active drugs in 
addition to 3TC, and by 48 weeks from the date of enrolment into the trial, around half of 
these patients had achieved a VL<50 on their new regimen. In contrast, the median GSS of the 
baseline regimens in my analysis was relatively low, at 1, and patients follow-up was censored 
if viral suppression was achieved. The conclusions reported by the COLATE investigators was 
that any benefit of a M184V preservation strategy may only be apparent among patients for 
whom a fully suppressive regimen cannot be constructed (599).  
5.5.3. Clusters of mutations  
I identified a total of seven clusters of mutations in this analysis, five in the RT and two in the 
PR region. Three of the RT clusters were relatively well-known, and closely resembled the well-
described TAM mutations and the Q151M complex. I also identified two previously 
undescribed RT clusters. These broadly represented cross-NNRTI and ABC/DDI resistance and 
cross-NNRTI resistance respectively. The first PR cluster I identified represented broad PI 
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resistance, and contained a large number of both major and minor PI mutations. The second 
PR cluster was smaller, consisting of four minor PI mutations.  
Other analyses have used a range of analytical techniques to study clustering of mutations. 
Wittkop et al also applied PCA to data from the ANRS cohort in order to derive scores 
summarising the correlation of mutations in the PR gene (630). Their analysis extracted two 
principal components. The first of these had heavy loadings from substitutions in position 10, 
90, 46, 54, 82, 33, 70 and 71. The second PC did not have as many significant loadings, 
although substitutions in 20, 36, 35 and 69 contributed to the component. Interestingly, these 
corresponds reasonably well with the clusters I identified. All of the mutations found to 
contribute to the first PC in the ANRS analysis also contributed to the first PC extracted in this 
chapter, although my analysis captured contributions from a slightly larger number of 
mutations. The 2nd PC in the ANRS analysis captured the correlation of some minor PI 
mutations, 3 of which (20, 36 and 69) also contributed to the 2nd PR PC that I identified. Similar 
clusters in the protease gene have been described by other researchers as well (631,632). Wu 
et al calculated the binomial correlation coefficient for a number of PI mutations and used this 
to construct unrooted neighbour joining trees describing clusters in the PR gene (631). They 
found evidence of a cluster involving positions 35, 36, 20 and 62; as well as 54, 82, 24 and 46. 
Similarly, Kagan et al studied correlations between pairs of mutations, and found strong 
correlations between substitutions in position 54 and 82 (632). In their analysis, the positions 
which had the highest number of correlations were 10, 46, 71, 90, 20, 73, 82, 63, 84, and 54.  
Mutations tend to cluster for a variety of reasons. Kagan et al conducted a structural analysis 
of the protease and found that most mutations with strong binary correlations were located 
within a relatively short physical distance from each other (632). This indicates that mutations 
which correlate strongly may have a degree of functional dependency, that is, interact directly 
with each other. However, their analysis also described correlations between some mutations 
located further away from each other, most notably for substitutions in position 46 relative to 
positon 90. This correlation is harder to explain, and the authors suggest that substitutions in 
position 46 may increase the catalytic activity of the protease, and therefore have a strong 
selective advantage irrespective of the location of other mutations (632). Further biochemical 
and structural analyses of the protease gene are needed in order to explain why and how 
these patterns of PI resistance emerge.  
In terms of RT mutation clusters, Rhee et al studied correlations between mutations in both 
the RT and PR gene (633). Similar to the findings described here, the main clusters identified 
were TAM-1, TAM-2 and Q151M. These clusters have been relatively well described as they 
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confer complete cross-NRTI resistance (TAM-1 and TAM-2) or resistance to all NRTI’s apart 
from TDF (151 complex) (335). The strongest correlation between an NRTI and NNRTI 
resistance mutation pair identified by Rhee et al was for substitutions in 74 and 181. This is in 
agreement with my analyses, where these two mutations contributed to the same component.  
Despite the PCA analysis seeming to relatively accurately capture known clusters of mutations 
relatively accurately, the extracted components explained a low proportion of the overall 
variance in the dataset. This indicates that the variables included in the PCA may only be 
weakly correlated. However, other researchers who have applied PCA to HIV resistance genes 
in order to study clusters of mutations have found similarly low proportions of total variance 
explained (630,632,633).  
5.5.4. The TAM-2 cluster and a cluster of broad PI resistance may be associated with 
reduced CD4 decline  
Individuals with scores in the highest quartile of the 3rd RT cluster (TAM-2) experienced 
somewhat reduced CD4 declines, as did individuals with scores in the highest quartile of the 1st 
PI cluster, which represented broad PI resistance. Individuals with scores in the highest 
quartile of the 5th RT cluster, which included K103N, experienced steeper CD4 declines 
compared to individuals with lower scores on this component.  
Although the TAM-2 mutations D67N, K70R and K219Q have relatively low fitness costs when 
present alone (507), the presence of 70R has been shown to result in a 6-fold reduction in 
fitness when it emerges in viruses already carrying D67N mutation , and a 9.4-fold reduction in 
fitness when present in viruses carrying both D67N and K219Q (634). My results are in 
agreement with this, and indicate that the presence of these mutations in combination may 
have an effect on CD4 decline. Such a combined effect may also explain why the detection of 
each of these 3 mutations individually resulted in less steep CD4 declines, although only 
significantly so for the D67N mutation after correcting for multiple testing. The impact of 
major PI resistance mutations on replication capacity is complex to predict as these mutations 
often appear in combination with several minor PI mutation that can restore viral fitness (507). 
However, it is possible that the 1st PI cluster could capture the effect of a number of major PI 
mutations which, when present in combination, could be associated with favourable CD4 
changes. I also found weak evidence that the 5th RT cluster was associated with steeper CD4 
declines. The mutations that formed part of this cluster include K103N and L100I, both of 
which are known to have a very small fitness cost or, in the case of L100I, has been shown 
have higher fitness than WT viruses (507). The lack of an association between the cluster 
representing the 151M resistance pattern agrees with previous research finding that this 
cluster does not seem to affect fitness (507).  
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5.5.5. CD4 decline and viral load thresholds 
Although there was a general tendency for a better CD4 count recovery in people showing viral 
load suppression comparing to each individual estimate of maximum level of viral replication, 
it is worth noting that I couldn’t find any clear VL threshold below which CD4 counts did not 
decline. This is in slight contrast with previous studies which have found that CD4 slopes tend 
to be less steep for lower viral loads (362,364,635), including a EuroSIDA analysis that studied 
CD4 counts trends among patients receiving cART (615). This analysis found that overall, CD4 
counts remained stable at VL values between 500-10,000 copies/mL in the population. 
However, there was a significant interaction with type of cART regimen, with individuals on an 
NNRTI based regimen still experiencing significant CD4 count decreases in the 500-10,000 
copies/mL strata , and the increase in CD4 counts at VLs below 10,000 copies/mL appeared to 
be restricted to individuals receiving a ritonavir-boosted PI (615). The use of PI’s in my analysis 
was relatively high (60%), but only 76 individuals received a ritonavir-boosted PI (1%), and this 
difference in treatment regimens used, mostly as a consequence of the early calendar years 
included in my analysis, might explain the discrepancies. The PLATO cohort, which has 
previously reported increasing CD4 counts for individuals with a VL<10,000 copies/mL, was 
designed to only include individuals with triple-class resistance (364). The PLATO study 
population is therefore relatively different compared to the one described here, as I did not 
require individuals to have detected resistance in order for them to be included. A recent 
analysis of patients failing first line ART in low income settings, which had a similar design and 
analytical approach to my analysis, was also unable to identify a clear VL threshold above 500 
copies/ml below which CD4 counts remained stable (636). Nonetheless, it is worth noting that 
CD4 decline in this analysis was less marked among individuals who had a viral load supressed 
below the mean of their pre-ART VL levels, and higher among those individuals who had a 
VL>100,000 copies/mL.  
5.5.6. Limitations and strengths  
There are several important limitations to this analysis. Firstly, as different mutations can 
modulate the fitness effects of other mutations (634), the pattern of resistance is likely to 
reflect the fitness of a given strain more accurately than the presence of absence of individual 
mutations. I attempted to study the combined effect of mutations on CD4 decline through 
PCA, but other techniques, such as fitness landscapes (637), may capture such interactions 
more accurately. Secondly, I did not have a validated measure of adherence available in either 
UK CHIC or EuroSIDA. Adherence could influence the results as it is likely to influence both the 
presence of resistance and CD4 decline (638). A validated measure of adherence would also 
have been required  in order to verify the hypothesis that people with no detected resistance 
are those with the poorest adherence. Power and limited data may also have been an issue. 
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Despite using combined data from two large cohorts, the relatively low prevalence of 
individual mutations means that some of the estimates, particularly for rare mutations, suffer 
from low precision. If appropriate data sources are identified, it would be of value to repeat 
these analyses in larger cohorts in order to derive more precise effect estimates. I was also 
unable to assess the impact of mutations or mutational patterns in gene regions apart from 
the RT and PR. It would have been of interest to study the effect of mutations in the envelope 
or integrase genes (507). This would be of particular interest as it has been reported that 
mutations in gag can modulate the fitness of PR resistant viruses (639,640). A further 
limitation is the lack of resistance testing for some patients leading to the potential for 
selection bias. As shown in Chapter 3, not all individuals who experience VF are tested for 
resistance, and these individuals differ in important ways from those that are tested for 
resistance. This could limit the generalisability of my findings.  
As previously stated, the median follow-up contributed by patients in this study was relatively 
low. It is possible that a virus which initially harbours fitness-compromising mutations develop 
compensatory mutations that restore fitness over time. A 2006 study by Machouf et al found 
that as mutations accumulated the presence of resistance stopped having a beneficial effect 
on VL levels, and instead seemed to cause steeper VL declines as compared to WT strains 
(641). This conclusion is echoed by Barbour et al in a 2002 analyses of CD4 count trends among 
patients maintained on a failing PI regimen (609). Although the authors found relatively 
durable benefits from therapy maintenance, there were a number of patients who 
nonetheless experienced decreasing CD4 trends. This indicates that any benefit derived from 
being maintained on a failing regimen is likely to reduce over time as the viruses accumulate 
compensatory mutations (609,641). Although it was not possible to restrict this analysis to 
individuals contributing longer FU due to small numbers, it is important to take this likely 
limitation into account when interpreting the results.  
In terms of strengths, the main strength of this analysis is the large sample size. Using data 
from both EuroSIDA and UK CHIC allowed me to include over 5,000 individuals, making this the 
largest analysis investigating this question to date. This allowed me to assess the effect of a 
range of individual DRM on CD4 trends in addition to describing the effect of any and class-
wide resistance. In contrast to the majority of previously published studies I was also able to 
describe CD4 count changes over time rather than at a single time-point. The analytical 
approach, including correcting for repeated measures and multiple testing, also represents a 
strength in comparison to previous research.  
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5.5.7. Conclusions  
Bearing these limitations in mind, our findings provide some support for the hypothesis that 
CD4 decline may be less marked when individuals experiencing VF are maintained on regimens 
that preserve specific mutations associated with reduced viral fitness. This could have 
implications for individuals in low income settings who have failed all existing available lines of 
ART, and suggests that in these instances the inclusion of lamivudine/emtricitabine and a 
boosted PI may be the best option in terms of composing a salvage regimen. However, the 
likely effect of the presence of a particular mutation on annual CD4 decline is likely to be 
complex to predict due to the presence of epistatic interactions and potentially confounding 
effects which are hard to measure, such as residual drug action and adherence. Further 
research is needed to evaluate the clinical benefits of specific treatment strategies that aim to 
preserve particular resistance patterns among individuals for whom a fully suppressive ART 
regimen cannot be prescribed, as well as to elucidate the mechanisms through which any 
beneficial effect is mediated. Until then, efforts should focus on ensuring that those who 
experience VF have access to individualised care and a broad range of antiretroviral drugs, and, 
where possible, novel ART drugs through compassionate early access programs. The clinical 
implications of the findings and suggestions for further studies are discussed in more detail in 
Chapter 8.  
5.5.8. Dissemination of results 
These findings were presented at the Glasgow HIV Therapy conference in 2014 (Appendix VIII). 
A paper based on the analyses is under review with Antiviral Therapy.  
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Chapter 6 . Rate of accumulation of drug resistance 
mutations during virological failure according to 
the level of viral replication  
 
6.1. Introduction and Objectives  
In the previous chapter I showed that the detection of certain resistance mutations among 
individuals kept on a failing treatment regimen may have a small but significant positive effect 
on CD4 cell count trends. Although it is always preferable to switch to a fully suppressive 
regimen if such a regimen is available (642), there are nonetheless some situations which 
result in individuals being maintained on failing treatment regimens. Firstly, among patients 
who have extensive and complex resistance patterns, there may be no option to switch to a 
fully suppressive regimen even in high income settings. Secondly, in low income settings, it is 
recommended that individuals have adherence interventions and a confirmatory viral load (VL) 
measurement taken before a switch in therapy occurs. Due to programmatic delays this means 
that individuals may be maintained on a regimen to which they have developed resistance for 
long periods of time (72,643). The WHO also recommends routine viral load monitoring, but as 
this is not available in all settings clinical and immunological criteria are still used to determine 
when a person should switch treatment (72,629). This can further delay treatment switches as 
CD4 counts can remain high despite ongoing viral replication and the presence of resistance 
(629). There may also be a reluctance among clinicians to switch patients until symptoms 
appear, in order to preserve further treatment lines for as long as possible. Finally, clinicians in 
low income settings may not be able to switch patients failing second line therapy in a timely 
manner as access to third or higher line regimens is generally limited (586). This could affect a 
potentially large number of people. In a 2010 multi-cohort analysis, Pujades-Rodriguez and 
colleagues estimated that 18.8% of individuals receiving second line therapy in a variety of low 
income settings met WHO failure criteria after a median of 11.9 months following the start of 
second line therapy, meaning they would need access to third line regimens (587). Taken 
together this means that despite the large availability of different drugs in high income 
settings, globally, there is still a proportion of people living with HIV who are maintained on 
failing treatment regimens. 
One of the primary concerns when maintaining individuals on failing treatment regimens is the 
accumulation of resistance mutations which may compromise subsequent lines of treatment 
once they become available and contribute to the spread of transmitted resistance (422,644). 
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Estimates of resistance accumulation are relatively rare, as it requires repeated resistance 
testing (356,645–647). The rate of resistance accumulation is also influenced by a number of 
different factors, including adherence, the type of treatment used, the fitness impact of 
specific mutations and the level of viral replication (417,648). However, despite its importance, 
the relationship between viral replication and resistance accumulation in routine clinical care 
has been poorly defined. Higher levels of viral replication should, in theory, lead to a higher 
number of replication errors and consequently an increased number of resistance-conferring 
mutations occurring. However, while some authors have found this to be the case (336,355), 
others describe an inverse U-shaped relationship between viral load levels and resistance 
detection, where the probability of detecting resistance is the highest at intermediate levels 
and lowest at the extremes (565,567,649). Others have found no relationship between VL 
levels and the development of resistance (500,650,651).  
Differences in study design and in the timing and categorisation of the VL exposure variable is 
likely to at least partly explain these differences. Several different study designs can be, and 
have been, used to study the relationship between viral replication and drug resistance using 
observational data. First of all, the prevalence of resistance can be described according to the 
viral load at the time the resistance test was done (336,486,565). This simple, cross-sectional 
approach can generate useful information for clinicians looking to determine the chance of 
detecting resistance when doing a test, but interpretation of the association between the viral 
load and resistance detection is difficult due to the potential of reverse causality as only a 
single time-point is studied. This means that it is not clear whether a particular mutation 
appeared and consequently affected the VL, or whether the VL levels affected the appearance 
of mutations. As tests done at high VLs are more likely to amplify and consequently have 
results recorded, it is also possible that any observed relationship simply reflects limitations in 
the genotyping technology. Alternatively, the prevalence of resistance can also be described 
according to a viral load measure taken before the test was done: for example, at the first 
raised VL following suppression or at the start of a certain treatment regimen (652). Again, this 
generates useful information for clinicians looking to determine the consequent risk of 
resistance development given the viral load observed at a key previous point of the person’s 
care. However, resistance testing is typically infrequent and it is possible that any detected 
resistance was already present at the time the viral load measurement of interest was done. 
The final option involves using repeated resistance tests, and calculating the rate of 
accumulation of new resistance mutations (356). This is a better approach as it allows knowing 
which new mutations have been acquired, although the timing of the appearance of resistance 
mutations is still interval censored.  
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In this chapter, I used the latter approach and aim to describe how the rate of resistance 
accumulation is affected by well characterised a priori definitions of viral exposure when 
individuals are maintained on a failing treatment regimen. The specific objectives were to:  
1) Estimate the rate of accumulation of any and specific resistance mutations while 
individuals are maintained on a failing treatment regimen 
 
2) Investigate how the rate of accumulation of any resistance varies according to a 
number of exposure variables designed to capture different aspects of patients’ 
history of viral replication:  
 
a. Viral load levels at the start of an episode of virological failure (VF) (defined 
below) 
b. Average VL during a VF episode 
c. Peak VL during a VF episode  
d. Estimated VL slope during a VF episode  
e. Copy-years viraeamia, a measure of cumulative VL exposure over the total 
duration of the failure episode 
 
6.2. Literature Review  
I expanded the literature review done in Chapter 3 to include papers from non-European 
settings, added the search terms “accumulation” and “rate” and selected any papers that 
reported on the relationship between drug resistance and viral load levels. To narrow the 
search, I excluded studies which reported only on a specific mutation or resistance to a specific 
drug, but included those studying a class of resistance. I further excluded those studies which 
only focused on restricted populations (eg, prisoners) as they are likely to not be comparable 
with the population in the EuroSIDA cohort, which was used for this analysis. The search 
results are shown in Figure 6.1 below, and the data extracted from the studies summarised in 
Table 6.1.  
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Figure 6.1. Identification of articles for inclusion in the literature review 
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Table 6.1. Results from the literature review 
Author Year Data Source N Study Design  VF definition and timing of VL 
measurement 
Relationship between VL and resistance  Ref 
Pinoges et al 2015 Electronic health data 
from MSF clinics in 
Malawi, Kenya, Uganda 
and Cambodia 
2,257 Cross-sectional 
 
 
 
VF was defined as a VL> 400 (limit of detection). 
VL was measured at the time of the genotypic 
test. VL was not categorised.  
Not assessed in multivariable models. The median 
VL was higher among individuals who had resistance 
to TAM’s compared those with no TAM’s (73,785 vs. 
13,806 copies/mL; P = 0.001) 
(653) 
Santoro et al  2014 Retrospectively 
analysed plasma 
samples from patients 
in central Italy 
2,200 Cross-sectional VF was defined as a VL>50. VL was measured at 
the time of the genotypic test. The VL strata 
considered were 50-200, 201-500, 501-1000, 
1001-10000, 10001-100000 and >100000.  
The prevalence of resistance varied significantly by 
viremia strata (p<0.001), and was characterized be a 
bell-shaped curve. The prevalence according to 
increasing VL categories were: 53, 70, 74, 86, 77 and 
63 % respectively. The highest prevalence was found 
at the 1001-100000 category (86%). Multivariable 
analyses were not performed.  
(567) 
Franzetti et al 2014 Cohort study in Italy 
(ARCA cohort), 2003-
2012 
5,246 Cross-sectional  VF was defined as a VL > 200 copies/mL after at 
least 6 months of ongoing treatment. VL was 
measured at the time of the genotypic test. The 
categories considered were <4 log10 copies/mL, 
4-5 log10 copies/mL and >5 copies/mL.  
The odds of detecting resistance to either PI, NRTI or 
NNRTI was higher in lower VL categories. Although a 
linear trend was not evaluated, the odds ratios 
appeared to indicate that the odds of detecting 
resistance was consistently the highest in the lowest 
VL category (<4 log 10 copies/mL; aOR=3.06 [2.59-
3.61]; 2.61 [1.89-3.60] and 1.70 [1.40-2.07 for NRTI, 
NNRTI and PI resistance respectively) as compared 
to the highest.  
(486) 
Assoumou et al 2013 The ANRS laboratory 
network in France 
506 Repeated cross-
sectional 
VF was defined as a VL>50 after at least 6 
months of cART. VL was measured at the time of 
genotyping. The VL strata considered were 50-
500, 501-1000 and > 1000.  
The frequency of resistance increased with plasma 
viral load: 49% 51-500, 65% 501-1,000 and 67% in 
>1000. Multivariable analyses were not conducted.  
(488) 
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De Luca et al  2013 The SEHERE 
collaboration in CHAIN  
20323 Repeated cross-
sectional  
VF was not defined; patients included had at 
least 90 days of treatment and a genotype 
available. VL was measured at the time of 
genotyping. VL was modelled linearly.  
VL was not linearly associated with the detection of 
any resistance (aOR=1.0, 95%CI=1.0-1.1), although a 
higher VL was associated with decreased odds of 
detecting NRTI resistance (aOR=0.95, 95%CI=0.9-1.0) 
and increased odds of detecting NNRTI (aOR=1.1, 
95%CI=1.1-1.1) and PI (aOR=1.1, 95%CI=1.1-1.2) 
resistance.  
(336) 
Liégeois et al  2012 WHO survey of clinics 
in Gabon 
375 Cross-sectional VF was defined as a VL>300 while on ART. VL 
was measured at the time of genotyping among 
those with a VL>1,000. VL was modelled linearly.  
VL at the time of genotyping was not linearly 
associated with the detection of drug resistance 
mutations (DRM) (p=0.75) in univariable analyses. 
Multivariable analyses with VL were not conducted, 
effect sizes were not presented.  
(650) 
Li et al  2012 University of California, 
San Francisco, SCOPE 
cohort 
47 Cross-sectional VF was defined as a detectable VL above the 
detection limit of the assay but below 1,000 
copies/mL. VL was measured at the time of 
genotyping. Details of how VL was modelled not 
published.  
No association between VL and the detection of 
DRM was reported.  
(651) 
Praparattanapan et al 2011 Retrospective analysis 
from a clinic in Chiang 
Mai, Thailand 
59 Cross-sectional VF was defined as receiving NNRTI-based ART for 
at least 6 months, having achieved an 
undetectable VL and consequently having 
another VL>1000. The evaluated VL was 
measured at the same time as the GRT.  
Compared the probability of detecting a range of 
individual mutations: The only difference found was 
that the detection of 3-5 NRTI mutations was more 
likely to be detected at VL>4 log (p=0.001). Effect 
sizes were not published.  
(654) 
Cozzi-Lepri et al 2011 Analysis from the 
EuroSIDA cohort 
227 Longitudinal, 
repeated resistance 
tests 
VF was defined as having one VL>500 after at 
least 6 months of receiving an NNRTI regimen 
while still receiving an NNRTI regimen. The VL 
evaluated was measured at the start of the VF 
episode, with GRT’s occurring at a later time-
point. VL  
A 1 log increase in the VL at start of the VF episode 
was associated with a lower risk of consequently 
detecting NNRTI resistance (adjusted RR=0.8, 
95%CI=0.64-1.01, p=0.06).  
(647) 
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Sigaloff et al 2011 Analysis from the 
PASER-M network at 13 
sites in 6 African 
countries 
250 Cross-sectional VF was evaluated retrospectively after a switch 
to second line therapy had occurred. VL was 
measured at the same time as the genotyping. 
VL was modelled linearly.  
VL was borderline linearly associated with the 
detection of NRTI cross-resistance (aOR= 1.57, 
95%CI=1.00 to 2.47), but not with the detection of 
TAM’s (uOR=1.09, 95%CI=0.73 to 1.60).  
(655) 
Prosperi et al  2011 Analysis of the SEHERE 
database 
11492 Cross-sectional VF was not considered an inclusion criteria. 
Patients with resistance tests taken after at least 
6 months of uninterrupted ART were included. 
VL was measured at the time of the genotypic 
test. The categories considered were <50; 51-
200; 201-500; 501-1000; 1001-10000; 10001-
100,000 and <100,000.  
VL strata was associated with the detection 
resistance (all p<0.0001) . Resistance increased at 
higher VL levels, peaking in the 1001-10000 copies 
stratum (reference). Higher stratum than this was 
followed by a decrease (OR=0.4, 95%CI=0.34–0.46 
amongst those with VL>100,000 copies/mL). It was 
lowest at VL<50 copies/mL (OR=0.14, 95%CI=0.11–
0.17).  
(649) 
Bannister et al 2011 Analysis of the 
EuroSIDA database 
using multiple 
imputation 
6498 Cross-sectional VF was not considered an inclusion criteria. 
individuals were required to have started ART 
and have a VL measured within 3 months before 
the GRT.  
Estimated resistance prevalence was lowest when 
the current VL was <50 copies/mL, although this was 
not formally evaluated; effect estimates were not 
published.  
(473) 
Lima et al 2010 The HAART 
observational medical 
evaluation and 
research cohort in 
British Colombia, 
Canada 
1820 Longitudinal, no 
repeated resistance 
tests 
VF was not considered an inclusion criteria. 
Individuals were required to start HAART 
between 2000 and 2007. VL was measured 
throughout the FU period, and categorised as 
“change in VL” from the start of treatment until 
the emergence of resistance or censoring, 
whichever came first.  
Change in VL was significantly associated with the 
emergence of resistance (p<0.001). The lowest odds 
or resistance development was found among 
individuals with a VL change of <-2 log10 copies/mL 
over the total FU (reference), ie, a VL decrease. The 
odds of detecting resistance was higher at VL 
decreases that were not that marked, but not higher 
at VL increases (aOR=1.23, 95%CI=0.50-3.03) 
(656) 
Mackie et al 2010 The UK HIV Drug 
Resistance Database 
3791 Cross-sectional VF was not considered an inclusion criteria. 
Individuals were required to have started ART 
and have a VL within -4 to +2 weeks of the 
resistance test. VL was categorised into strata: 
<300, 300-999, 1000-2999, 3000-9999, 10,000-
29,999, 30,000-99,999 and >100,000.  
Detection of resistance was most frequent among 
tests performed at VL of 300-10,000 copies/mL 
(reference) and decreased above and below these 
levels. It was highest at VL>100,000 (RR=0.69, 
95%CI=0.65–0.74) Trend the same irrespective of 
the type of resistance.  
(565) 
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Hanson et al  2009 Cote d’Ivore national 
drug access program  
 645 Longitudinal, no 
repeated resistance 
tests 
VF was not considered an inclusion criteria. All 
individuals with >300 days of FU after ART 
initiation and at least 2 clinic visits were 
included. Each patient had VL measured on 3-
monthly visits after the start of ART. If VL was 
above 1000 copies/mL, a resistance test was 
done. VL was modelled at baseline (start of ART) 
and as change in VL from the start of ART: 
baseline VL in categories of <10,000; 10,000-
100,000; >100,000 and missing and VL change as 
<0.5; 0.5-2, 2-4 and >4 log10 copies/mL.  
Both baseline VL and change in VL was associated 
with the development of resistance in multivariable 
models. In terms of baseline resistance, the risk of 
detecting resistance decreased with increasing VL 
values, and was the lowest when baseline VL was 
>100,000 (aHR=0.30, 95%CI=0.16, 0.57). Considering 
change in VL, the risk of detecting resistance was the 
lowest when the change in VL was the smallest: with 
the lowest risk of detecting resistance found among 
those with a <0.5 log/10 copies/mL change in VL 
over the study period (aHR=0.12, 95%CI=0.05, 0.27) 
(652) 
Cozzi-Lepri et al 2007 Analysis of EuroSIDA 
data 
110 Longitudinal, 
repeated resistance 
tests 
VF was defined as a VL>400 copies/mL. 
Repeated resistance tests were required, and VL 
had to be raised from the first until the 2nd test. 
VL was measured throughout FU, and the 
difference in VL between the two tests was 
evaluated linearly for association with resistance 
accumulation.  
A suggestion of an association change in viral load 
between t0 and t1 and the rate of accumulation of 
IASDRM [+0.35 (95% CI, –0.12 to 0.83) mutations per 
log10 larger increase in viral load; p=0.14.  
(356) 
Tozzi et al  2006 Analysis of data from a 
clinic in Rome, Italy 
602 Cross-sectional VF was defined as a failure to achieve virological 
suppression, or of at least two VL >1,000. VL was 
measured at the GRT. VL was modelled linearly.  
There was no linear relationship between VL and the 
probability of developing NRTI (p=0.25), NNRTI 
(p=0.90) or triple class resistance (TCR; p=0.67). 
There was a borderline (p=0.048) association 
between pVL and the odds of developing PI 
resistance (aOR=0.68, 95%CI-0.61=1.00) for each log 
increase in the VL.  
(500) 
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Napravnik et al 2005 Analysis of data from a 
clinic at the university 
of North Carolina 
98 Longitudinal, 
repeated resistance 
tests  
VF was not considered as an inclusion criteria. 
Individuals were required to have two resistance 
tests taken more than 30 days apart. VL was 
measured during the FU period (1st to 2nd 
resistance test). Several measures of VL was 
used: peak, baseline, average and change in VL. 
All VL measures were evaluated in several ways: 
categorical, linear and using quadratic splines.  
The average VL level between the two tests was 
associated with the development of resistance, with 
the highest risk of resistance development having 
been found among those with 3-4 log VL (aRR=2.11, 
95%CI=1.43–3.09), and lower risk of resistance 
development among those with a VL below 3 or 
above 4. The change in VL between the two tests 
was also associated with resistance development. 
Those who experienced an increase in the VL > 0.2 
cp/ml were at a greater risk of developing resistance 
(aRR=1.93, 95%CI=1.23–3.01). The other measures 
of VL were associated with the risk of developing 
resistance in univariable analysis but not after 
adjustment: No effect sizes or formal comparisons 
were presented.  
(646) 
Harrigan et al  2005 Analysis of the HOMER 
cohort in Canada 
1191 Longitudinal, did not 
consider repeated 
resistance test 
VF was not considered as an inclusion criteria. 
Individuals were required to start ART between 
1996-1999. VF was measured throughout FU; 
resistance tests were ordered for VL measures 
with a VL >1000 copies/mL.VL at the start of ART 
was modelled linearly.  
VL at the start of the VF epsiode was linearly 
associated with the detection of DRM both in 
univariable and in multivariable analyses, with 
higher VL associated with a higher risk of detecting 
resistance (aHR=1.59, 95%CI=1.29–1.96; p<.001) 
(355) 
Phillips et al 2005 Cohort study in the UK 
(UK CHIC and UK 
HIVDRB), 1998-2005 
7891 Longitudinal, did not 
consider repeated 
resistance tests 
VF was not considered an inclusion criteria. 
Individuals were required to start ART for the 
first time after 1996. VL at the start of ART was 
categorised into <100,000, >100,000 and 
missing.  
A VL of >100,000 copies/mL at the start of ART led to 
an increased risk of resistance detection (aHR=1.36, 
95%CI1.12–1.65)  
(501) 
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Bangsberg et al  2003 The REACH cohort in 
San Fransisco  
148 Longitudinal, 
repeated resistance 
tests 
VF was defined as a VL>50 copies/mL. Individuals 
were genotyped twice during a period of VF 
while on stable ART to estimate the rate of 
resistance development. VL at the start of ART 
was evaluated linearly on the log scale.  
VL at the start of the episode was not associated 
with the development of DRM (aRR=0.0846, p=0.61) 
(657) 
Kantor et al 2004 Stanford University 
Hospital 
106 Longitudinal, 
repeated resistance 
tests 
VF was not considered an inclusion criteria, 
although individuals were required to have two 
resistance tests while maintained on the same 
treatment regimen. Changes in the VL between 
the two tests was evaluated.  
No difference in the development of new mutations 
among patients with rising or declining VL levels, 
effect sizes or p-values were not reported.  
(357) 
Richman et al 2004 Cross-sectional analysis 
of cohort study in the 
US (HCSUS study), 1998 
101100 Cross-sectional VF was defined >500 copies/mL. VL was 
measured at the time of the GRT, and 
categorised into two categories: 500-30,000 and 
>300,000.  
Individuals with VL in the lower category had higher 
categories of resistance (OR, 2.91; 95% CI, 1.93–
4.39)  
(476) 
Adjé-Touré 2003 Analysis of data from 
the UNAIDS drug 
access initiative in 
Abidjan, Cote d’Ivore 
86 Longitudinal, did not 
consider repeated 
resistance tests 
VF was not considered an inclusion criteria. 
Individuals were required to have been on ART 
for at least 6 months. VL was measured 
throughout FU, and VL at the start of a VF 
episode and change in VL from the start of ART 
was evaluated for its association with DRM 
linearly.  
VL at the start of ART was not linearly associated 
with the detection of resistance (aOR=0.6, 
95%CI=0.2–2.0), although virological response was 
strongly associated with the detection of resistance 
(aOR= 2.8, 95%CI=1.3–5.9) The lower the maximal 
virological response, the higher the odds of 
detecting resistance 
(658) 
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In total, 25 articles that described the relationship between VL and drug resistance were 
included. The majority of these used a cross-sectional approach to study risk factors for 
detecting drug resistance, although a reasonable number (N=8) were longitudinal. A variety of 
viral load measures were used, the most common approach was to evaluate the relationship 
between resistance and VL at the time of the genotypic resistance test (GRT) (13/25 studies). 
Overall, the results were conflicting, and appeared to vary according to the classification of the 
VL measurement, the type of resistance present as well as the comparator arm used.  
A number of authors that studied the relationship between the VL and the detection of 
resistance in a cross-sectional manner reported on an inverse U-shaped relationship, whereby 
the risk of detecting resistance was highest at intermediate VL levels and decreased both at 
low and high VL levels (565,567,649). Santoro et al, who conducted a large retrospective 
analysis of a clinical database in Italy, found a higher prevalence of resistance at VL levels 
between 1,000-10,000 copies/mL and lower prevalence of resistance at lower and higher viral 
loads (567). Mackie et al, described a similar trend using data from the UK HIV drug resistance 
database (565), where the highest prevalence of resistance was found among VL levels 
between 3000-10,000 copies/mL. An analysis of the SEHERE database in chain also confirmed a 
U-shaped relationship between resistance and VL, with resistance prevalence peaking at VL 
levels between 1,000 and 10,000 copies/mL (649). There are some suggestions that at VL levels 
below 1,000 the prevalence of resistance may increase in a more linear fashion (488), although 
most analyses have included too few resistance tests conducted at low viral loads to 
comprehensively confirm this (565). The authors of these studies suggest that the bell-shaped 
relationship between resistance and VL at the time of genotyping is likely to at least in part 
reflect adherence, with very high VL levels potentially being indicative of poor adherence 
(565,649). Poor adherence would allow both high viral replication and remove any selective 
pressure from the virus, thus resulting in a lack of resistance.  
Among those modelling VL as a continuous variable, the majority of studies failed to find a 
linear association between VL at the time of genotyping and the detection of any resistance 
(336,500,650,651). However, Richman et al, analysing the large HCSUS cohort from the US, 
found some evidence that the lower the current VL the higher the odds of detecting resistance 
(476). This is in contrast with an analysis by Sigaloff et al of the PASER-M data from several 
countries in Africa, which found a linear association between VL levels and detection of cross-
NNRTI resistance: the higher the VL the greater the odds of detecting cross-NRTI resistance 
(655). If the true relationship between resistance and current VL follows an inverse U-shape, it 
is possible that including VL simply as a linear covariate may have led to a misspecification of 
the model which could explain these seemingly contradictory findings. However, it is also 
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possible that the relationship between VL and resistance could vary according to the class of 
resistance detected, as the findings by De Luca et al suggests (336). In an analysis of the 
SEHERE collaboration in the CHAIN study primarily focused on time-trends in resistance, De 
Luca and colleagues find that VL at the time of genotyping is associated with decreased odds of 
detecting NRTI resistance and increased odds of detecting NNRTI and PI resistance (336). 
However, they found no evidence for a linear association between VL and the detection of any 
resistance. This suggests that both the class of drug the virus is resistant to and the statistical 
categorisation of the VL variable could influence the results found.  
Out of the studies using a longitudinal design, the most detailed investigation into the 
relationship between viral load and resistance development was conducted by Napravnik et al 
in 2005 (646). They used data from 98 patients from a clinic in North Carolina, USA, and 
studied the rate of resistance accumulation among patients with at least two GRT’s taken 
more than 30 days apart. They considered how several different measures of the VL affected 
the risk of accumulation of new resistant mutations detectable in majority virus. After 
adjustment for pre-specified confounders (final model specifications were not included in the 
paper), VL at the start of the VF episode and peak VL was found to not be associated with 
resistance despite considering these variables both as categorical, linear and using more 
sophisticated modelling using splines. However, the average VL level between the two tests 
was associated with the development of resistance. The highest risk of resistance development 
was found among those with intermediate (3-4 log10 copies/ml) average VLs. The change in VL 
between the two tests was also associated with resistance development, and individuals who 
experienced a greater increase in the VL were found to be at a greater risk for developing 
resistance (646). These results are in slight contrast to a similar study by Kantor et al, who also 
characterised the rate of resistance development among patients with repeated GRT’s 
accessing care at Stanford University Hospital. With a sample size of 106 patients, they could 
not identify any difference in the rate of accumulation of new resistance mutations according 
to the VL trend between the two tests (357). However, two other studies employing a similar 
study design have found that the level of change in the VL between two resistance tests 
influenced the rate of development of resistance (356,656). Only one studied assessed a 
combined measure of VL levels and the duration of exposure to a certain VL level (658). 
Specifically, in an analysis of patients from Abidjan, Cote d’Ivore, Adje-Toure et al found that 
maximum virological response, which they defined as the difference between two VL 
measurements divided by the time between them, was as strong predictor of resistance 
development. The authors also found that VL at the start of therapy was not a predictor of 
resistance development after adjustment for maximum virological response (658).  
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6.2.1.What this analysis adds 
A relatively large number of studies have reported on the relationship between VL levels and 
drug resistance, although most have done this as a secondary aim and did not consider 
different ways of modelling the VL. Relatively few studies reported on the rate of accumulation 
of drug resistance taking resistance patterns at the start of the VF episode into account, and 
only two small studies reported on the accumulation rate in relation to measures of viral 
exposure. A description of how new resistance accumulates given different levels of viral 
replication can provide important information for clinicians evaluating the implications of 
maintaining a patient on a failing treatment regimen, particularly in contexts where resistance 
testing is not available. Given the paucity of published studies assessing this comprehensively 
there is a gap in the literature on the relationship between the VL and the risk of resistance 
development. EuroSIDA is an ideal cohort to analyse this question due to the relatively large 
availability of repeat resistance tests, arising primarily from retrospective genotyping done on 
prospectively stored plasma samples. 
278 
 
6.3. Methods  
6.3.1. Inclusion Criteria 
Persons from the EuroSIDA cohort, database version D42, who experienced VF to a cART 
regimen during prospective FU with at least one resistance test available during this VF 
episode were included. VF was defined in using a similar approach to that used in Chapter 5, 
but a lower VL cut-off was used as I was interested in also characterising resistance 
development also at lower viral loads. VF was therefore defined as two or more consecutive 
measures of VL >50 copies/ml while the individual was kept on the same ART regimen, in 
individuals who had been on ART for at least 6 months at the start of the VF episode. This was 
defined as the first VL measurement >50 copies/mL of two consecutive > 50 copies/mL, and 
the end date as the first VL measurement below 50 copies/mL or at the point where the ART 
regimen was changed (defined as either stopping or adding one or more drugs to the 
regimen). Individuals were also required to either be experiencing their first VF from naive or 
have a resistance test available no more than 3 months before the start date of their VF 
episode. This allowed us to estimate the level of resistance at the start of episodes.  
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Figure 6.2. Hypothetical data illustrating the inclusion process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
This individual started treatment at 1 month since inclusion in the study, but did not fully suppress. A resistance 
test was ordered after 4.5 months, and the individual swapped to 3TC+FTC+LOP. This was classed as the start of VF 
as it was the first of two consecutive VL measures above 50 copies/mL on this regimen and it was more than six 
months since initiation of a new regimen. Another resistance test was done after 10.5 months and the regimen 
swapped after 11.5 months. The FU time contributed ranged from the start of the VF episode until the second 
resistance test.  
This individual started ART from naïve, and experienced VF after 6 months of not suppressing, when he had a VL 
measurement above 50 copies/mL. A Resistance test was done at 8 months since ART initiation. As this was the first 
regimen given from naïve, no resistance test was required before the start of the FU time and the individuals was 
assumed to start the VF episode at the time of the first eligible VL measurement. The person contributed FU time 
until their resistance test.  
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Individuals could contribute more than one failure episode, and more than one resistance test 
during a single failure episode. A flowchart of the selection process is shown below in Figure 
6.3.  
Figure 6.3. Selection flowchart 
 
 
 
 
 
 
 
 
 
 
 
6.3.2. Viral load replication exposures 
Based on the results from the literature review, it was decided to evaluate five different 
exposure measures for the VL: 
 
1. VL at the start of the VF episode  
2. Peak VL, defined as the highest VL measurement taken between start of the VF 
episode and the last resistance test during a VF episode 
3. Average VL, calculated as the mean of the VL measurements taken between the start 
of the episode and the last resistance test during a VF episode 
4. VL trajectory, the estimated VL slope between the start of the episode and the last 
resistance test during a VF episode 
5. Copy Years Viraemia (VCY), calculated using the trapezoidal approximation described 
in detail below 
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The exposures were proposed by me and consequently refined and finalised following 
discussion with a EuroSIDA working group of clinicians (J. Lundgren, O. Kirk), virologists (R. 
Paredes) and statisticians (A. Phillips and A. Cozzi-Lepri). It was decided to not study the 
influence of current VL in a time-updated manner, due to the difficulties in interpreting the 
results from such an analysis. This is because tests at higher VLs are more likely to amplify and, 
any routinely conducted tests which fail to amplify are not reported to the EuroSIDA resistance 
database. Therefore, resistance is by definition more likely to be detected at higher current 
VLs.  
VL trajectories were estimated using univariable linear mixed models with a random intercept 
and slope for time, using all VL measurements that occurred between start of the VF episode 
and the last resistance test during a VF episode for each individual. VCY is a measure of 
cumulative VL exposure over time. Briefly, VCY is defined as the number of copies of VL 
circulating in plasma per year, integrated over time. Typically this is calculated using 
seroconversion as the origin time-point, when this is known (659). However, the same formula 
has been adapted to be used from other fixed timepoints (660). In this chapter, I calculated 
VCY from the start of the VF episode, which means that VCY represents the cumulative 
exposure to viral replication experienced from the start of VF up to the last documented 
resistance test during the VF. Using routinely collected data with VL levels only measured at 
specific time points, the integral is approximated using a time-weighted sum calculated using 
the trapezoidal rule (Equation 6.1).  
Equation 6.1. Formula for the estimation of copy-years viraemia 
 
 
 
(659) 
Where Ki(Ji) represents copy years viremia in individual i, Vi(j) and Vi(j-1) are the viral load at 
respectively assessment j and assessment j-1 for participant i, ti(j) and ti(j-1) are respectively 
the date of assessment j and j-1 for individual i. If copy years viremia is calculated from 
infection, ti(0) is the date of HIV seroconversion and Vi(0) is assumed 0. In practice, this is the 
equivalent of summing up for each individual the product of the mean of two consecutive VL 
measurements (Vi(j) and Vi(j-1)). VCY for the first VL date and measurement in a series of 
measures is calculated by setting t(j-1) and v(j-1) to 0. The first VCY measure during each VF 
episode was therefore by definition zero.  
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There has been some discussion as to whether the VL measurements should be added 
together on a logarithmic or on a linear scale (660). Sempa et al conducted a literature review 
to study how the VCY has been estimated in different studies. Although a majority of studies 
using VCY add together measurements on a linear scale and consequently calculate the 
logarithm the sum, there are examples where this has not been done (660,661). Different 
approaches may lead to different estimates. Summing the measures on a linear scale gives 
greater weight to higher VL measurements, whereas summing under the log VL curve gives 
greater weight to repeated measures of intermediate values (660). Sempa et al compared the 
effect of VCY calculated both ways on mortality, and found that only VCY calculated by 
summing under the log VL curve was predictive of mortality. In the light of this, they 
recommend taking the 10th logarithm of the VL measurements before applying the trapezoidal 
rule and that is the approach I chose to follow. I calculated the VCY for the entire follow-up 
time and used this as a constant, rather than time-updated, predictor in all models. Due to the 
nature of my study design, all individuals by definition reached the pre-specified study end-
point (receiving a resistance test), and therefore, using the sum of the VCY per episode rather 
than a time-updated measure should not produce invalid results due to conditioning on future 
events.  
The first three VL exposures were classified according to pre-specified VL thresholds broadly 
following prior WHO thresholds for defining VF: 51-500; 501-1,000; 1,001-5,000; 5,001-10,000; 
10,001-100,000 and >100,000 copies/mL (72). It was decided a-priori to model these as 
categorical variables and to use the “5,001-10,000” category as the start of the VF episode 
category on the basis of the results from the literature review. VL trajectories and VCY were 
instead grouped using the quartiles of the distribution (Table 6.2). For the VL slope and VCY 
exposures, the lowest category (eg slopes less steep than +0.12 log10 copies/mL/year and VCY 
lower than 0.94 log10 copy × year/mL) was used as the baseline category. Quartiles and 
medians were determined per episode rather than per individual.  
Table 6.2 VL exposure categories  
Exposure (unit) Categories 
Start of the VF episode VL (copies /mL) 51-500; 501-1,000; 1,001-5,000; 
5,001-10,000; 10,001-100,000 and 
>100,000 
Average VL (copies /mL) 51-500; 501-1,000; 1,001-5,000; 
5,001-10,000; 10,001-100,000 and 
>100,000 
Peak VL (copies /mL) 51-500; 501-1,000; 1,001-5,000; 
5,001-10,000; 10,001-100,000 and 
>100,000 
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6.3.3. Resistance data  
Resistance was defined using the IAS (2015) list (662). I did not consider as broad a definition 
of resistance as in Chapter 5, as the focus of this chapter lay on the risk of detection of any 
resistance rather than on individual mutations. Any resistance was defined as the detection of 
one or more IAS mutations, excluding minor PI mutations. A genotypic sensitivity score (GSS) 
was used as a secondary end-point, and the GSS was calculated using the ANRS (2015) 
interpretation rules (663). The level of resistance at the start of the VF episode was estimated 
in a cumulative manner using all resistance tests available before the start of the VF episode. 
For those experiencing the first VF from ART-naïve where no previous resistance tests were 
available, individuals were presumed to have no resistance mutations. If more than one 
resistance test was done after the start and during the same failure episode, both were used 
to determine the number of new mutations and the FU time censored at the date of the latest 
resistance test.  
6.3.4. Covariate selection and categorisation  
Besides viral load exposure, other factors were been considered as covariate as they were 
considered to be potential confounders of the association between viral load and the risk of 
accumulation of resistance. The final set of covariates has been selected on the basis of the 
results from the literature review and data availability in EuroSIDA. As the main interest was 
trying to assess causality, the selection of the final model was based on a directed acyclic graph 
(DAG) or causal diagram, shown below in Figure 6.4.  
 
 
 
VL slope (log10 copy /mL/year) <Q1 (<0.12), Q1-M (0. 12-0.17) 
M-Q3 (0. 17-0.21), >Q3 (>0.21) 
VCY (log10 copy × year/mL) <Q1 (<0.94), Q1-M (0.94 -2.35) 
M-Q3 (2.35 -4.63), >Q3 (>4.63) 
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Figure 6.4. DAG for the effect of VL on resistance development 
 
This DAG implies that the CD4 at the start of the VF episode CD4 (indicated as 
“Baseline_CD4”), line of therapy at the start of the episode, HIV subtype, mode of HIV 
transmission (indicated as “Risk_group”), calendar year of the episode start date, GSS of the 
failing regimen (indicated as “Baseline_GSS) and the duration of the episode (indicated as 
“Time_since_baseline”) are independent predictors of VL and resistance development 
Consequently, these variables should be included in the multivariable model in order to 
estimate the total direct effect of VL on resistance development. The selected variables, 
together with their a priori categorisation, can be seen in Table 4.5.  
Table 6.3 Categorisation of potential confounders included in the multivariable model 
Variable Categories Time-updated 
Mode of HIV transmission MSM, PWID, Heterosexual, Other N/A 
HIV Subtype  B, Non-B N/A 
cART type NNRTI-based, Unboosted PI-based, 
Boosted PI-based, Other three drug 
regimen, Mono/Dual 
N/A 
Calendar Year 96-97,98-99, 00-01, 02-03, 04-05, 06-
07, 08-09, >10 
No 
CD4 count at the start of the failure 
episode 
<200, 200-350, 350-500, >500 No 
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Duration of the episode  <4 months, 4-8 months, 8-16 months, 
>16 months 
Yes 
Line of therapy at the start of the 
episode1 
1,2-3, 4-5, >5 N/A 
GSS at the start of the episode 2 or lower, 3 or higher No 
1. Any change or gap in a regimen was counted as a new line of a regimen 
 
The first three cART categories (NNRTI, unboosted PI and ritonavir boosted PI) were defined as 
those receiving exactly 3 drugs, of which 2 were NRTI and the remaining drug was either an 
NRTI, boosted PI or a ritonavir boosted PI. Ritonavir was not counted as a separate drug. 
Although CD4 is likely to affect both VL and possible resistance development in a time-updated 
manner, adjustment for this type of time-dependent confounding requires the use of more 
advanced statistical techniques, such as marginal structural models. This is because CD4 count 
is a time-dependent confounder affected by prior treatment as well as prior viral load values. 
As this lay outside the scope of this thesis it was decided to proceed with adjustments using 
start of the VF episode CD4 values only.  
6.3.5. Statistical methods 
Characteristics of the included participants at the start of the failure episode and during 
follow-up was summarised descriptively. The rate of resistance development was calculated as 
the number of new mutations to the failing regimen detected during consequent resistance 
tests divided by the time between start of the VF episode and the final resistance test (Person 
Years of Follow-Up, PYFU). Multivariable Poisson models with generalised estimating 
equations (GEE) were used to model the rate of resistance development. GEE were used to 
correct for the fact that episodes coming from the same participants cannot be assumed to be 
independent. Separate models were constructed for each VL exposure variable of interest.  
6.3.6. Sensitivity analyses 
The analysis was repeated with the following variations:  
1. Counting only the mutations that were classed as conferring resistance to the 
specific regimen an individual was maintained when constructing the 
outcome.  
2. Using mutations from each main class of drug resistance (NRTI, NNRTI and PI) 
as the outcome.  
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6.4. Results  
6.4.1. Characteristics of the study population  
Overall, 464 individuals contributing a total of 549 episodes were included. 159 (34%) 
individuals experienced VF while receiving their first ART regimen started from ART-naive. 40 
(25%) of these nonetheless had a previous resistance test which allowed for an estimation of 
their start of the VF episode resistance patterns, for the others I assumed that no transmitted 
resistance was present. The median duration of the episodes was 8 (Inter Quartile Range 
[QR]=4-16) months, with a median of 1 (IQR=1-1) resistance tests and 3 (IQR=2-6) VL 
measurements taken during the episode. The characteristics of individuals at start date of the 
failure episode can be seen in Table 6.4.  
 
Table 6.4. Characteristics of the study population at the start of VF  
Per individual (N=464)   Total N (%) 
Gender Male 374 (80.6) 
  Female 90 (19.4) 
Age, years Years, Median(IQR) 40 (34, 47) 
Mode of HIV transmission  
  
  
MSM 228 (52.1) 
PWID 76 (17.4) 
Heterosexual 122 (27.9) 
Other 12 (2.7) 
Ethnicity White 387 (84.3) 
  Other 72 (15.7) 
Subtype B B 354 (84.7) 
  Non-B 64 (15.3) 
VL cp/ml, Median(IQR) 4150 (717, 32450) 
CD4 cells/mm3, Median(IQR) 259 (158, 407) 
Line of regimen Number, Median (IQR) 5 (1, 9) 
Type of cART regimen NNRTI-based 52 (11.2) 
  Unboosted PI-based 93 (20.0) 
  Boosted PI-based 82 (17.7) 
  Other 126 (27.2) 
  Mono/Dual 111 (23.9) 
Number of drugs in the cart regimen Number, Median (IQR)  3 (3, 3) 
Calendar year Month/Year, Median (IQR)  02/00 (10/97-10/02) 
Per episode (N=549)     
Duration of episodes Months, Median (IQR) 8 (4, 16) 
Resistance tests  Number, Median (IQR) 1 (1, 1) 
VL measurements  Number, Median (IQR) 3 (2, 6) 
 
The majority (80.6%) of individuals were male, and the median age of the study population 
was 40 (IQR-34-47) years. The majority acquired HIV through sex with another man (52.1%), 
and the vast majority were of white ethnicity (84.3%) and were infected with a subtype B virus 
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(84.7%). Most individuals experienced VF episodes in early calendar years, with the median 
date of the start of the VF episode date February 2000 (IQR=October 1997-October 2002). The 
median CD4 count at start of the VF episode was 259 (IQR=158-407) cells/mm3, and this did 
not differ markedly compared to the median CD4 count at the end of episodes (257, IQR=140-
407 cells/mm3).  
The most common type of cART received at start of the VF episode was “Other” regimens 
(27.2%), which included all regimens composed of more than 3 drugs. However, receiving 
mono/dual therapy was also relatively common (23.9%), as was receiving cART with an 
unboosted PI (20.0%). The median number of drugs received was 3 (IQR=3-3). 14 episodes 
(2.6%) occurred while the individual was receiving monotherapy. Regimens taken by 1% (N=5) 
or more of the study population can be seen in Table 6.5 below.  
Table 6.5. Most common regimens used at start of the VF episode 
Regimen N % 
Zidovudine /Lamivudine 27 5.82 
Zidovudine/ Lamivudine /Indinavir 26 5.6 
Lamivudine /Stavudine/ Indinavir 18 3.88 
Zidovudine /Didanosine 17 3.66 
Lamivudine / Stavudine / Saquinavir /Ritonavir 14 3.02 
Zidovudine / Lamivudine /Nevirapine 12 2.59 
Lamivudine / Stavudine /Nelfinavir 11 2.37 
Zidovudine /Zalcitabine 11 2.37 
Lamivudine / Stavudine 9 1.94 
Zidovudine / Lamivudine / Nelfinavir 9 1.94 
Zidovudine / Lamivudine /Efavirenz 7 1.51 
Didanosine / Stavudine 6 1.29 
Didanosine / Stavudine / Nevirapine 6 1.29 
Lamivudine / Stavudine / Nevirapine 6 1.29 
Lamivudine / Stavudine / Nevirapine / Nelfinavir 6 1.29 
Zidovudine / Lamivudine /Abacavir 6 1.29 
Zidovudine / Lamivudine / Saquinavir 6 1.29 
Lamivudine / Stavudine / Ritonavir 5 1.08 
Tenofovir/ Ritonavir /Atazanvir/Emtricitabine 5 1.08 
Zidovudine 5 1.08 
Zidovudine / Zalcitabine /Saquinavir 5 1.08 
 
The most common regimen was dual therapy with Zidovudine and Lamivudine, followed by 
triple therapy of Zidovudine, Lamivudine and Indinavir. Stavudine (D4T) featured relatively 
frequently in the regimens, and only 2 individuals were on current WHO recommended first 
line therapy (TDF+FTC+EFV), which prevented me from investigating resistance accumulation 
among these individuals alone. The treatment patterns are likely to reflect the fact that most 
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of the start dates of the episodes occurred relatively soon after or before cART was made 
widely available.  
A breakdown of the frequency distribution of the episodes according to values of the VL 
exposures considered can be seen in Table 6.6. Most individuals had both start of the VF 
episode VL (29.7%), average VL (39.7%) and peak VL (36.0%) values of between 10,001 and 
100,000 copies/mL. Very few individuals had peak VL values below 1,001 copies/ml (N=30). 
The vast majority of individuals had positive values of the VL slope (indicating that the VL was 
increasing during the episode), with only seven individuals (1.5%) estimated to have 
decreasing VL values between the start and end of their VF episode. Because so few individuals 
had a decreasing slope, it was not possible to model these in a separate category. 
Table 6.6. Values of the VL exposure variables at start of the VF episode 
Exposure Variable Category  N  % 
Start of the VF episode VL (copies /mL) 51-500 86 18.5 
501-1,000 45 9.7 
 1,001-5,000 116 25.0 
 5,001-10,000 30 6.5 
 10,001-100,000  138 29.7 
 >100,000 49 10.6 
Average VL (copies /mL) 51-500 29 6.3 
 501-1,000 34 7.3 
 1,001-5,000 118 25.4 
 5,001-10,000 55 11.9 
 10,001-100,000  167 36.0 
 >100,000 61 13.2 
Peak VL (copies /mL) 51-500 12 2.6 
 501-1,000 18 3.8 
 1,001-5,000 87 18.8 
 5,001-10,000 48 10.3 
 10,001-100,000  184 39.7 
 >100,000 115 24.8 
VL slope (log10 cp/mL/year) <Q1 (<0.12) 111 23.9 
 Q1-M (0. 12-<0.17) 110 23.7 
 M-Q3 (0. 17-<0.21) 121 26.1 
 >Q3 (>0.21) 122 26.3 
VCY (log10 cp * year/mL) <Q1 (<0.94) 118 25.4 
 Q1-M (0.94 -<2.35) 109 23.5 
 M-Q3 (2.35 -<4.63) 113 24.4 
 >Q3 (>4.63) 124 26.7 
 
6.4.2. Prevalence of resistance 
The prevalence of resistance to any drug at the start of episodes was 71%, and this had 
increased to 92% by the end of episodes (Figure 6.5). At least one new resistance mutation 
accumulated in 57% of all included episodes. On average, NRTI resistance was most commonly 
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detected both at the start (67%) and at the end of episodes (88%). The prevalence of NNRTI 
and PI resistance was nearly equal at the start of episodes (46% respectively), but NNRTI 
resistance was slightly more common than PI resistance at the end of episodes (60% v 58%). 
The prevalence of individual NRTI, NNRTI and PI mutations can be seen in Figure 6.6-Figure 6.8. 
The most common NRTI resistance mutation was M184V, K103N the most common NNRTI 
mutation and L90M the most common PI mutation.  
 
Figure 6.5. Prevalence of any resistance and resistance respectively to NRTI, NNRTI and PI at 
the beginning and end of a VF episode 
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Figure 6.6. Prevalence of NRTI resistance mutations at the beginning and end of a VF episode 
 
 
 
291 
 
Figure 6.7. Prevalence of NNRTI resistance mutations at the beginning and end of a VF episode 
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Figure 6.8. Prevalence of PI resistance mutations at the beginning and end of a VF episode 
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6.4.3. Crude rates of resistance accumulation  
Overall, 932 new IAS mutations accumulated during 615 person years of follow-up, leading to 
an overall crude rate of resistance development of 1.51 (95%CI=1.37-1.68) new mutations per 
year. This is the equivalent to one new mutation accumulating per every 6.7 months of an 
individual being kept on a failing regimen. The equivalent rate of GSS reduction was 0.49 
(95%CI=0.43-0.56), or the equivalent of one virologically active drug (which formed part of the 
failing regimen) lost as a result of every two years of someone being maintained on the same 
failing treatment regimen.  
The rate of accumulation of any, class, and individual mutations where at least one mutation 
accumulated can be seen in Table 6.7 below.  
Table 6.7. Rates of accumulation of any, class and individual mutations over the 
614.5 included person-years of follow-up (PYFU)  N  Rate/year (95%CI) 
 932  1.52 (1.37 - 1.68) 
NRTI 462  0.75 (0.67-0.85) 
NNRTI 223  0.36 (0.30-0.44) 
PI 247  0.40 (0.34-0.48) 
 N  Rate/10 years (95%CI) 
RT mutations    
M41L 37  0.6 (0.45-0.81) 
A62V 11  0.18 (0.1-0.32) 
K65R 5  0.08 (0.03-0.2) 
K65E 2  0.03 (0.01-0.13) 
D67N 51  0.83 (0.64-1.07) 
H69D 8  0.13 (0.07-0.26) 
H69N 9  0.15 (0.08-0.28) 
K70E 1  0.02 (0-0.12) 
K70R 45  0.73 (0.56-0.96) 
I74V 21  0.34 (0.23-0.52) 
V75I 7  0.11 (0.05-0.24) 
F77L 1  0.02 (0-0.12) 
Y115F 5  0.08 (0.03-0.19) 
F116Y 1  0.02 (0-0.11) 
Q151M 2  0.03 (0.01-0.13) 
M184I 22  0.36 (0.24-0.54) 
M184V 102  1.66 (1.38-2) 
L210W 30  0.49 (0.35-0.68) 
T215F 19  0.31 (0.2-0.48) 
T215Y 38  0.62 (0.46-0.83) 
K219Q 24  0.39 (0.27-0.57) 
K219E 21  0.34 (0.23-0.52) 
V90I 8  0.13 (0.06-0.26) 
A98G 9  0.15 (0.08-0.28) 
L100I 5  0.08 (0.03-0.19) 
K101E 5  0.08 (0.03-0.19) 
K101H 1  0.02 (0-0.12) 
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K101P 3  0.05 (0.02-0.15) 
K103N 41  0.67 (0.49-0.9) 
K103S 4  0.07 (0.02-0.17) 
V106A 8  0.13 (0.07-0.26) 
V106M 3  0.05 (0.02-0.15) 
V106I 7  0.11 (0.05-0.24) 
V108I 14  0.23 (0.14-0.38) 
E138A 7  0.11 (0.05-0.24) 
E138K 2  0.03 (0.01-0.13) 
E138Q 1  0.02 (0-0.12) 
E138G 1  0.02 (0-0.11) 
V179D 3  0.05 (0.02-0.15) 
V179F 1  0.02 (0-0.12) 
V179L 1  0.02 (0-0.12) 
Y181I 7  0.11 (0.06-0.24) 
Y181C 31  0.5 (0.36-0.71) 
Y188L 5  0.08 (0.03-0.2) 
Y188H 2  0.03 (0.01-0.13) 
G190A 24  0.39 (0.26-0.58) 
G190S 8  0.13 (0.07-0.26) 
H221Y 16  0.26 (0.16-0.42) 
P225H 4  0.07 (0.02-0.17) 
F227C 1  0.02 (0-0.12) 
M230L 1  0.02 (0-0.12) 
PI mutations    
D30N 11  0.18 (0.1-0.32) 
V32I 11  0.18 (0.1-0.32) 
M46I 31  0.5 (0.36-0.71) 
M46L 13  0.21 (0.12-0.36) 
I47V 11  0.18 (0.1-0.32) 
G48V 12  0.2 (0.11-0.34) 
I50V 1  0.02 (0-0.12) 
I50L 1  0.02 (0-0.12) 
I54L 9  0.15 (0.08-0.28) 
I54M 8  0.13 (0.07-0.26) 
Q58E 8  0.13 (0.07-0.26) 
T74P 7  0.11 (0.05-0.24) 
L76V 7  0.11 (0.05-0.24) 
V82A 28  0.46 (0.32-0.66) 
V82F 8  0.13 (0.07-0.25) 
V82T 11  0.18 (0.1-0.32) 
V82S 6  0.1 (0.05-0.21) 
N83D 2  0.03 (0.01-0.13) 
I84V 21  0.34 (0.22-0.52) 
N88S 4  0.07 (0.02-0.17) 
L90M 37  0.6 (0.44-0.82) 
 
 
295 
 
NRTI mutations accumulated at a rate of 0.75 (95%CI=0.67-0.85) new mutations/year, NNRTI 
mutations at 0.36 (95%CI=0.30-0.44) new mutations/year and major PI mutations at a rate of 
0.40 (95%CI=0.34=0.48) new mutations/year. The individual mutation that accumulated the 
fastest was M184V at 0.17 (95%CI-0.14-0.20)/year.  
The rate of resistance accumulation according to the various measures VL exposure can be 
seen in Figure 6.9.  
Figure 6.9. Crude rates (95% CI)/year of resistance development according to VL exposure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The VL level at the start of a VF episode was borderline associated with resistance 
development (p=0.07). The rates were higher with higher levels of VL up until VL values 
between 5,001-10,000 copies/mL. In categories above this the rate of resistance development 
was relatively stable. There was also an association between average VL levels and resistance 
accumulation (p=0.005), with resistance accumulation being considerably higher at VLs in the 
10,001-100,0000 category and at VLs above 100,000. In contrast to the association with start 
of the VF episode VL, the 5,001-10,000 category had the lowest rates of resistance 
development.  
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However, the rate of accumulation was not associated with the level of peak VL (p=0.87). The 
rate of resistance accumulation also varied according to both the slope of VL change between 
the start and the end of episodes (p=0.009) and according to VCY (p<0.001). Accumulation was 
highest at low to intermediate VL slope values (Q1-Median), and was considerably lower in the 
lowest (Min-Q1) and highest (Q3-Max) categories. In contrast, accumulation of resistance 
appeared to decrease in a linear fashion according to increasing VCY.  
Rates of resistance accumulation also varied according to a number of the selected covariates 
(Table 6.8). Specifically, there was evidence that the rate of accumulation was lower among 
individuals receiving boosted PI therapy compared to other drug classes (p=0.003), individuals 
with CD4 counts >500 cells/mm3 compared to those with lower CD4 counts (p=0.006) and 
those infected with a subtype non-B virus compared to a B virus (p=0.009). Resistance 
accumulation was higher during episodes of long duration (p<0.001) and among individuals 
with lower GSS at the start of the VF episode (p<0.001).  
 
Table 6.8. Rates (95%CI) according to values of the selected covariates 
 
  
  N  PYFU Crude Rate (95%CI)/year P 
Mode of HIV 
transmission 
  
  
MSM 523 330 1.58 (1.37 - 1.84) 0.54 
PWID 130 86 1.51 (1.18 - 1.92)  
Heterosexual 203 155 1.31 (1.07 - 1.61)  
  Other 22 15 1.46 (0.81 - 2.63)  
cART Type NNRTI 151 75 2.03 (1.60 - 2.57) 0.003 
  Unboosted 
PI 
170 91 1.88 (1.55 - 2.28)  
  Boosted PI 120 111 1.08 (0.80 - 1.45)  
  Mono/Dual 246 160 1.54 (1.30 - 1.83)  
  Other 245 179 1.37 (1.09 - 1.72)  
ART-Naive Yes 581 382 1.52 (1.35 - 1.72) 0.96 
  No 351 232 1.51 (1.25 - 1.82)  
Calendar Year of 
VF 
  
96-97 85 71 1.19 (0.83 - 1.72) 0.18 
98-99 250 142 1.76 (1.40 - 2.21)  
  00-01 177 145 1.22 (0.93 - 1.60)  
  02-03 167 115 1.45 (1.07 - 1.96)  
  04-05 162 87 1.85 (1.38 - 2.49)  
  06-07 69 34 2.00 (1.24 - 3.23)  
  08-09 9 11 0.84 (0.31 - 2.28)  
  >10 13 8 1.59 (0.60 - 4.24)  
CD4 count at start 
of the VF episode  
  
  
<200 318 157 2.03 (1.71 - 2.40) 0.006 
200-350 257 188 1.37 (1.09 - 1.71)  
350-500 196 134 1.46 (1.10 - 1.94)  
  >500 161 135 1.19 (0.96 - 1.48)  
Line of Therapy 1 313 217 1.44 (1.17 - 1.77) 0.55 
  2-3 106 55 1.91 (1.39 - 2.64)  
  4-5 118 78 1.44 (1.17 - 1.77)  
  >5 395 264 1.91 (1.39 - 2.64)  
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Time since start 
of the VF episode 
  
 < 4 months 124 167 0.74 (0.52 - 1.05) <0.00111 
4-8 months 162 120 1.35 (1.02 - 1.77)  
  8-16 months 237 143 1.66 (1.31 - 2.10)  
  >16 months 409 184 2.23 (1.83 - 2.71)  
Subtype B 90 82 1.70 (1.52 - 1.90) 0.009 
  Not-B 763 449 1.10 (0.81 - 1.49)  
GSS at start of the 
VF episode 
  
2 or lower 911 497 1.83 (1.62 - 2.07) <.0001 
3 or higher 21 117  0.18 (0.08 - 0.38)  
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6.4.4. Univariable and multivariable models of resistance accumulation  
After adjustment for DAG-identified potential confounders, average VL (p=0.009), VL slope 
(p<0.001) and VCY (p<0.001) remained associated with the risk of resistance development in a 
multivariable Poisson regression model (Figure 6.10). For the VL at the start of VF episode, 
although adjustments did not shift its pattern of association with resistance development 
markedly, the p-value grew considerably larger (p=0.58). For average VL, there was a more 
marked modification of the relationship with the risk of resistance accumulation from that 
observed in univariable analyses, although the lowest rate of resistance accumulation 
nonetheless occurred at intermediate values of average VL (5,001-10,000; reference category, 
Figure 6.10). In contrast, the multivariable models indicated that resistance accumulation was 
still higher at low-intermediate values of VL slope (0.12-<0.17 log10 copies/mL/year, 2.84, 
95%CI=1.90-4.24), and lower at both the highest (0.17-12 log10 copies/mL/year, 1.37, 
95%CI=0.98-1.90) and the lowest (<12 log10 copies/mL/year, reference) quartiles of estimated 
VL slopes. The sharp decline of resistance accumulation with increasing VCY was confirmed by 
multivariable modelling, with a rate ratio of only 0.02 (95%CI=0.01-0.04) in the highest quartile 
of VCY compared to the lowest. 
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Figure 6.10. Unadjusted and adjusted rate ratios for the development of resistance according to VL exposure 
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6.4.5. Sensitivity Analyses 
I re-ran the analyses counting only mutations associated with reduced susceptibility to the 
exact drugs included in the regimen an individual was maintained on during the VF episode for 
the construction of the outcome variable. The results can be seen in Table 6.9-Table 6.10 
below. Briefly, the overall rate of mutation accumulation was considerably lower when only 
taking mutations specific to the failing regimen into account, at 0.63 new mutations 
(95%CI=0.55-0.72) per year. However, the shape of the relationship between VL exposures and 
resistance accumulation remained the same, with an inversely U-shaped relationship between 
the VL slope and resistance development and a linearly decreasing relationship between 
increasing VCY and resistance development after adjustment. Although average VL was also 
associated with resistance accumulation, this relationship did not follow a clear shape.  
Table 6.9. Rates of development of mutations specific to a given regimen according to VL 
exposures  
  
  N  FU 
(years) 
Crude Rate 
(95%CI) 
P-value 
  
 
387 615 0.63 (0.55 - 0.72)  
Start of the 
VF episode 
VL (copies 
/mL) 
  
  
51-500 57 138 0.41 (0.31 - 0.56) 0.003 
501-1,000 29 68 0.42 (0.28 - 0.65)  
1,000-5,000 98 150 0.65 (0.51 - 0.85)  
  5,001-10,000 40 46 0.86 (0.56 - 1.32)  
  10,001-100,000 111 163 0.68 (0.53 - 0.88)  
  >100,000 52 49 1.06 (0.76 - 1.48)  
Average VL 
(copies /mL) 
  
51-500 11 28 0.39 (0.20 - 0.77) 0.002 
501-1,000 24 47 0.52 (0.37 - 0.72)  
  1,000-5,000 91 161 0.57 (0.45 - 0.72)  
5,001-10,000 38 100 0.38 (0.25 - 0.57)  
  10,001-100,000 159 227 0.70 (0.56 - 0.88)  
  >100,000 64 52 1.24 (0.92 - 1.67)  
Peak VL 
(copies /mL) 
  
51-500 6 9 0.67 (0.25 - 1.80) 0.90 
501-1,000 12 18 0.66 (0.40 - 1.11)  
  1,000-5,000 61 99 0.62 (0.48 - 0.79)  
  5,001-10,000 38 66 0.58 (0.41 - 0.83)  
  10,001-100,000 158 267 0.59 (0.47 - 0.75)  
  >100,000 112 156 0.72 (0.56 - 0.92)  
VL slope 
(log10 cp 
/mL/year) 
  
  
<Q1 (<0.12) 103 191 0.54 (0.42 - 0.69) 0.071 
Q1-M (0. 12-<0.17) 93 111 0.84 (0.61 - 1.16)  
M-Q3 (0. 17-<0.21) 90 122 0.74 (0.56 - 0.97)  
  >Q3 (>0.21) 101 191 0.53 (0.42 - 0.67)  
VCY (log10 cp 
* year/mL) 
  
  
<Q1 (<0.94) 59 37 1.58 (1.13 - 2.22) <0.0001 
Q1-M (0.94 -<2.35) 83 76 1.09 (0.86 - 1.40)  
M-Q3 (2.35 -<4.63) 106 141 0.75 (0.60 - 0.94)  
  >Q3 (>4.63) 139 360 0.39 (0.31 - 0.48)  
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Table 6.10. Unadjusted and Adjusted Rate Ratios of the development of specific resistance mutations according to VL exposures 
 
  
  Unadjusted RR P GP Adjusted RR P GP1 
Start of the VF 
episode VL (copies 
/mL) 
  
  
51-500 0.48 (0.28 - 0.81) 0.006 0.003 0.72 (0.38 - 1.38) 0.327 0.316 
501-1,000 0.49 (0.27 - 0.90) 0.022   0.58 (0.26 - 1.28) 0.174   
1,000-5,000 0.76 (0.46 - 1.25) 0.282   0.90 (0.49 - 1.66) 0.742   
  5,001-10,000   1.00       1.00     
  10,001-100,000 0.79 (0.48 - 1.29) 0.349   0.72 (0.39 - 1.33) 0.293   
  >100,000 1.23 (0.71 - 2.14) 0.464   1.25 (0.64 - 2.44) 0.506   
Average VL (copies 
/mL) 
  
  
51-500 1.04 (0.47 - 2.28) 0.928 0.002 3.98 (1.14 - 13.87) 0.030  0.027 
501-1,000 1.36 (0.80 - 2.32) 0.256   2.49 (1.09 - 5.71) 0.031   
1,000-5,000 1.49 (0.93 - 2.39) 0.094   1.79 (1.01 - 3.18) 0.047   
  5,001-10,000   1.00       1.00     
  10,001-100,000 1.85 (1.15 - 2.97) 0.011   1.47 (0.88 - 2.45) 0.140 
 
>100,000 3.27 (1.96 - 5.47) <.001   1.19 (0.68 - 2.10) 0.542   
Peak VL (copies /mL) 
  
  
51-500 1.16 (0.41 - 3.31) 0.779 0.899 2.42 (1.10 - 5.29) 0.028 0.144 
501-1,000 1.15 (0.61 - 2.15) 0.672   1.54 (0.71 - 3.35) 0.275   
1,000-5,000 1.06 (0.69 - 1.64) 0.787   1.44 (0.85 - 2.42) 0.173   
  5,001-10,000   1.00       1.00     
  10,001-100,000 1.02 (0.67 - 1.57) 0.921   1.72 (0.98 - 3.02) 0.061   
  >100,000 1.24 (0.81 - 1.91) 0.327   3.24 (1.71 - 6.13) <.001   
VL slope (log10 
cp/mL/year) 
  
  
<Q1   1.00       1.00     
Q1-M 1.56 (1.04 - 2.34) 0.032 0.071 2.34 (1.50 - 3.65) <.001 0.005 
M-Q3 1.36 (0.94 - 1.98) 0.102   1.48 (0.88 - 2.50) 0.141   
  >Q3 0.98 (0.70 - 1.37) 0.911   1.25 (0.82 - 1.90) 0.299   
<Q1   1.00       1.00     
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VCY (log10 cp * 
year/mL) 
  
  
Q1-M 0.69 (0.45 - 1.06) 0.092 <.001 0.57 (0.30 - 1.08) 0.085 <.001 
M-Q3 0.47 (0.32 - 0.71) <.001   0.14 (0.08 - 0.25) <.001   
  >Q3 0.24 (0.16 - 0.36) <.001   0.02 (0.01 - 0.04) <.001   
1. GP=Global P 
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I also evaluated the using class-specific resistance accumulation as the outcome (Table 6.11-
Table 6.12). There were some differences compared to the primary analysis: notably, average 
VL was not associated with the accumulation of NRTI or NNRTI resistance, and only weakly 
associated with the accumulation of PI resistance. However, the absolute values of the rate 
ratios were reasonably similar across both the main and sensitivity analysis. The associations 
between the VL slope and VCY and accumulation of resistance also remained similar when 
considering NRTI, NNRTI and PI resistance separately.
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Table 6.11. Rates of resistance accumulation of class-specific mutations according to VL 
  NRTI  NNRTI  PI  
 
  
  Crude Rate (95%CI) P-value Crude Rate (95%CI) P-value Crude Rate (95%CI) P-value 
Start of the VF episode 
VL (copies /mL) 
  
  
  
51-500 0.65 (0.50 - 0.83) 0.69 0.17 (0.11 - 0.29) 0.02 0.33 (0.22 - 0.49) 0.06 
501-1,000 0.73 (0.51 - 1.05)  0.37 (0.22 - 0.61)  0.18 (0.09 - 0.36)  
1,000-5,000 0.82 (0.66 - 1.02)  0.39 (0.28 - 0.56)  0.37 (0.25 - 0.54)  
5,001-10,000 0.75 (0.50 - 1.13)  0.54 (0.30 - 0.96)  0.56 (0.31 - 1.00)  
  10,001-100,000 0.82 (0.63 - 1.07)  0.39 (0.27 - 0.55)  0.49 (0.37 - 0.65)  
>100,000 0.63 (0.39 - 1.03)  0.55 (0.33 - 0.93)  0.59 (0.34 - 1.02)  
Average VL (copies /mL) 
  
51-500 0.79 (0.44 - 1.40) 0.61 0.11 (0.02 - 0.49) 0.01 0.32 (0.16 - 0.64) 0.035 
501-1,000 0.84 (0.54 - 1.30)  0.26 (0.14 - 0.47)  0.15 (0.06 - 0.37)  
1,000-5,000 0.76 (0.63 - 0.92)  0.36 (0.26 - 0.49)  0.37 (0.26 - 0.53)  
  5,001-10,000 0.59 (0.44 - 0.78)  0.21 (0.11 - 0.39)  0.20 (0.11 - 0.35)  
  10,001-100,000 0.81 (0.65 - 1.00)  0.40 (0.30 - 0.54)  0.49 (0.37 - 0.65)  
  >100,000 0.72 (0.45 - 1.13)  0.74 (0.51 - 1.07)  0.75 (0.51 - 1.11)  
Peak VL (copies /mL) 
  
  
51-500 0.56 (0.20 - 1.54) 0.77 0.34 (0.07 - 1.55) 0.84 0.34 (0.12 - 0.98) 0.65 
501-1,000 1.05 (0.62 - 1.79)  0.28 (0.11 - 0.67)  0.55 (0.29 - 1.06)  
1,000-5,000 0.83 (0.63 - 1.09)  0.31 (0.20 - 0.49)  0.28 (0.17 - 0.47)  
  5,001-10,000 0.69 (0.49 - 0.97)  0.38 (0.24 - 0.60)  0.43 (0.25 - 0.72)  
  10,001-100,000 0.76 (0.63 - 0.92)  0.34 (0.25 - 0.46)  0.42 (0.32 - 0.56)  
  >100,000 0.69 (0.53 - 0.91)  0.44 (0.31 - 0.61)  0.42 (0.30 - 0.60)  
VL slope (log10 
cp/mL/year) 
  
<Q1 (<0.12) 0.56 (0.44 - 0.71) <0.001 0.29 (0.20 - 0.42) 0.11 0.36 (0.26 - 0.49) 0.63 
Q1-M (0. 12-<0.17) 1.04 (0.78 - 1.39)  0.48 (0.32 - 0.72)  0.51 (0.34 - 0.76)  
  M-Q3 (0. 17-<0.21) 1.05 (0.86 - 1.28)  0.47 (0.33 - 0.69)  0.38 (0.25 - 0.57)  
  >Q3 (>0.21) 0.59 (0.46 - 0.76)  0.30 (0.22 - 0.41)  0.40 (0.29 - 0.56)  
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VCY (log10 cp * 
year/mL) 
  
  
<Q1 (<0.94) 1.58 (1.09 - 2.30) 0.0017 0.97 (0.63 - 1.49) <0.001 0.62 (0.36 - 1.07) <0.001 
Q1-M (0.94 -<2.35) 1.04 (0.77 - 1.41)  0.66 (0.48 - 0.91)  0.54 (0.37 - 0.80)  
M-Q3 (2.35 -<4.63) 0.71 (0.54 - 0.92)  0.40 (0.28 - 0.55)  0.67 (0.51 - 0.88)  
  >Q3 (>4.63) 0.62 (0.53 - 0.73)  0.22 (0.17 - 0.30)  0.25 (0.18 - 0.33)  
 
 
306 
 
Table 6.12. Unadjusted and Adjusted Rate Ratios of the development of class of resistance according to VL exposures 
  NRTI  N
N
R
T
I 
 NNRTI   PI   
 
  
  Adjusted RR GP1  Adjusted RR GP1 Adjusted RR GP1  
Start of the VF 
episode VL (copies 
/mL) 
  
  
51-500 0.67 (0.30 - 1.51) 0.800  0.46 (0.16 - 1.31) 0.536 0.68 (0.32 - 1.47) 0.659 
501-1,000 0.89 (0.36 - 2.20)    0.78 (0.28 - 2.21)   0.50 (0.17 - 1.46)   
1,000-5,000 0.96 (0.44 - 2.10)    0.71 (0.29 - 1.72)   0.72 (0.35 - 1.48)   
  5,001-10,000              
  10,001-
100,000 
0.84 (0.39 - 1.79)    0.51 (0.20 - 1.33)   0.69 (0.35 - 1.35)   
  >1 ,000 0.91 (0.38 - 2.15)    0.76 (0.28 - 2.12)   1.17 (0.54 - 2.57)   
Average VL (copies 
/mL) 
  
51-500 1.99 (0.65 - 6.10) 0.438  2.41 (0.29 - 19.79) 0.513 3.53 (0.81 - 15.43) 0.017 
501-1,000 2.35 (0.78 - 7.10)    1.77 (0.32 - 9.70)   1.77 (0.65 - 4.86)   
  1,000-5,000 1.60 (0.86 - 2.98)    1.21 (0.61 - 2.40)   1.55 (0.69 - 3.47)   
  5,001-10,000              
  10,001-
100,000 
1.35 (0.77 - 2.38)    1.43 (0.77 - 2.64)   1.07 (0.53 - 2.16)   
  >1 ,000 1.05 (0.56 - 1.94)    0.80 (0.38 - 1.67)   1.27 (0.62 - 2.63)   
Peak VL (copies 
/mL) 
  
  
51-500 2.11 (0.87 - 5.15) 0.439  1.51 (0.27 - 8.43) 0.468 2.77 (1.05 - 7.35) 0.556 
501-1,000 1.54 (0.70 - 3.39)    1.69 (0.56 - 5.08)   2.04 (0.52 - 8.00)   
1,000-5,000 1.10 (0.67 - 1.83)    1.49 (0.73 - 3.05)   2.19 (1.03 - 4.66)   
  5,001-10,000              
  10,001-
100,000 
1.25 (0.71 - 2.22)    1.60 (0.81 - 3.13)   2.59 (1.22 - 5.49)   
>1 ,000 1.85 (0.88 - 3.89)    2.24 (1.04 - 4.82)   5.63 (2.51 - 12.59)   
VL slope (log10 
cp/mL/year) 
  
  
<Q1              
Q1-M 2.95 (1.87 - 4.65) <.001  2.70 (1.48 - 4.93) 0.033 2.65 (1.41 - 4.99) 0.018 
M-Q3 2.15 (1.39 - 3.32)    1.38 (0.65 - 2.92)   2.11 (1.14 - 3.93)   
  >Q3 1.17 (0.73 - 1.86)    1.24 (0.68 - 2.27)   1.75 (1.00 - 3.05)   
307 
 
VCY (log10 cp * 
year/mL) 
  
  
<Q1              
Q1-M 0.52 (0.26 - 1.08) <.001  0.54 (0.27 - 1.07) <.001 0.49 (0.19 - 1.23) <.001 
M-Q3 0.15 (0.08 - 0.29)    0.06 (0.03 - 0.12)   0.25 (0.10 - 0.61)   
  >Q3 0.03 (0.01 - 0.06)    0.01 (0.00 - 0.02)   0.02 (0.01 - 0.06)   
1. GP=Global P 
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6.5. Discussion  
In this analysis I found that resistance mutations accumulated at a rate of 1.51 (1.37-1.68) new 
mutations per year in individuals being kept on a failing regimen. This is equivalent to one new 
mutation accumulating every 7 months and 1 drug option being lost every 24 months of a 
patient being kept on a failing regimen. This rate was lower when only considering mutations 
associated with a reduction in susceptibility to the drugs included in the failing regimen. The 
overall rate of resistance accumulation was slightly lower than in prior EuroSIDA analyses 
(356), but in line with recent estimates from the PASER-M and MARCH cohorts (1.45 new 
mutations/year) and an analysis by Napravnik et al of patients in North Carolina (1.61 new 
mutations/year) (645,646). However, the rate of NNRTI resistance accumulation was low 
compared to the analysis of the PASER-M data by Boender et al (645). This could reflect the 
relatively low proportion of individuals receiving NNRTI-based cART in my analysis.  
Resistance accumulation was borderline associated with VL at the start of episodes in 
univariable analyses, but this association was attenuated and no longer significant after 
controlling for HIV subtype and CD4 counts and GSS at start of the VF episode. This is 
consistent with earlier findings by Napravnik et al, who also found a univariable association 
between start of the VF episode VL measures and resistance development which was no 
longer significant after adjusting for potential confounders (646). It is also in agreement with 
findings by Adjé-Touré et al from a cohort of people recruited in Cote D’Ivoire (658) and 
Bangsberg et al (657), who both found that VL at the start of the VF episode was not 
associated with the risk of detection of resistance, at least when modelled linearly. However, 
the results are conflicting with those from other cohorts which have found both higher (355) 
and lower (486) risks of resistance detection with increasing VLs when considering VL at the 
start of the VF episode as a predictor. As mentioned in the introduction results from different 
studies looking at this question are often difficult to compare, particularly if the authors have 
included baseline viral load as a continuous variable. I decided a priori to include VL at the start 
of a VF episode as a categorical exposure. Although, given the body of existent evidence, the 
categorical approach is more likely to approximate the true underlying shape of the 
relationship between VL at the start of VF and risk of resistance accumulation, the choice of 
the categories can impact the estimated relationship. I chose categories that related to 
thresholds that have been used be the WHO to define VF and therefore have some clinical 
meaning.  
Out of all the VL exposures considered, the rate of resistance accumulation was independently 
associated with average VL during an episode, change in VL during an episode and VCY after 
adjustment for potential confounders. Regarding the average VL during the episode, I found 
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that those individuals with low to intermediate (5,001-10,000) average VLs were the least 
likely to show an accumulation of resistance. My findings contrast with those of Napravnik et 
al, who instead found that the risk of accumulating new mutations was the greatest among 
patients with similar average VL intermediate levels (646). Possible explanations for this 
discrepancy include differences in the case mix of patients (such as different patients receiving 
different regimens at different stages of HIV disease. It is also possible that the frequency of VL 
measurements impacted on the construction of the exposure variable. Reassuringly however, 
low levels of resistance accumulation was found at the highest levels of average VL both in this 
analysis and in the analysis by Napravnik et al after adjustment (646). No other studies 
included in my literature review evaluated the association between a summary measure of the 
average VL levels over a period of virological failure and the risk of resistance development.  
The relationship between estimated change in VL values (VL slope) and resistance 
accumulation appeared to follow an inverse U-shape in my analysis. Individuals with 
intermediate VL slope values (0.12-<0.21 log10 cp/mL/year) had the highest rates of resistance 
accumulation, and accumulation appeared to be lower among those with VL trajectories that 
either changed very little (<0.12 log10 cp/mL/year) or those that changed quite markedly (>0.21 
log10 cp/mL/year). These results seem to fit with a priori speculative thinking regarding the 
association between level of viral replication, adherence to therapy and risk of accumulating 
resistance. First of all, individuals with low VL slope values may be at lower risk of 
accumulating resistance because they are those not experiencing high enough levels of viral 
replication for mutation selection to occur. On the other hand, as has been previously 
hypothesised, individuals with sharp increases in the VL may have adherence issues leading to 
an absence of selective pressure (646,664). Napravnik et al also studied how changes in the VL 
slope during VF relate to the risk of resistance accumulation. They found that accumulation 
was lower when the VL slope was low or stable (<0.2 log10 copies/ml/year) and higher when 
the VL slope was high (>0.2 log10 copies/ml/year) (646). Although this differs slightly from the 
findings of my analysis in which resistance accumulation was relatively low at VL slope values 
of 0.21 log10 copies/mL or higher, the categorisation of the VL slope variable and choice of 
comparator group are likely to influence this comparison. Other studies have also assessed 
whether VL changes during a period of VF affects the rate of resistance accumulation 
(356,357,652) . Kantor et al, when analysing 106 patients receiving care at Stanford University 
Hospital, did not find any evidence that changes in the VL affected the rate of resistance 
accumulation markedly (357). Cozzi-Lepri et al, analysing data from the EuroSIDA cohort, 
found that a greater change in VL during the FU time was marginally associated with a greater 
accumulation of drug resistance mutations (356), although the investigation of this 
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relationship was not the primary objective of the analysis and therefore details of the size of 
the effect or modelling approach were not published. Hanson et al, analysing data from a 
cohort of people from the Cote d’Ivoire national drug access programme found that the lower 
the size of the VL decline after the start of treatment (not necessarily during VF), the lower the 
probability of detecting resistance (652). However, this analysis included individuals who were 
not experiencing VF rather than people on a stable failing regimen so their findings are not 
directly comparable with mine. 
VCY also showed a strong association with the risk of accumulation of resistance, with the rate 
of resistance accumulation decreasing markedly with increasing levels of VCY, with a maximum 
rate of accumulation of 3.8 new mutations/year seen in those with the lowest VCY group 
(<0.94 log10 cp * year/mL). Using pre-specified cut-offs for the categorical variable, the rate 
appear to decrease in a linear fashion. One potential explanation of this finding is that VCY acts 
as a proxy for selective pressure, with increasing VCY being indicative of poor adherence when 
properly accounting for the length of the episode, the actual exposure to different levels of 
replication or both. 
In terms of clinical relevance, the finding with perhaps the strongest policy implications is the 
lack of an association between VL at the start of VF and the consequent accumulation of 
resistance. This might, at least indirectly, indicate that VL levels at the start of failure used in 
isolation may not be an appropriate measure to determine whom, amongst people 
experiencing VF, to switch to another treatment immediately without waiting for a 
confirmatory VL and whom to target for adherence interventions. In addition to the lack of a 
significant association, mutations were found to still accumulate among those individuals 
whose failure VL was in the lowest 51-500 copies/mL category, consistent with previous 
findings (565). This suggests that there is no VL failure threshold below which resistance 
accumulation is negligible, and supports recent WHO guidelines lowering the threshold for the 
definition of VF in low income settings from 5,000 to 1,000 copies/mL (72).  
My analysis did not consider predictors of resistance accumulation apart from VL in detail, as 
risk factors for resistance was investigated as a main aim of Chapter 3. Nonetheless, some 
findings from other studies were consistent with those shown by the univariable analysis. This 
included the findings of lower resistance accumulation rates among individuals with non-B 
viruses (336), among those receiving a boosted PI (356,565,656) and among those with lower 
CD4 counts (649,656,665). I also found a higher rate of resistance accumulation with longer 
duration of treatment failure. This is in broad agreement with previous findings 
(357,486,649,651), although, as extensively discussed for specific predictors above, risk factors 
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for resistance accumulation are likely to vary somewhat according to the populations studied. 
Perhaps surprisingly, mutations appeared to accumulate faster at lower values of GSS in this 
analysis. This is in contrast to reports from prior studies (356,357), but, again, this is likely to be 
explained by differences in the populations studied. In an ideal world of perfect adherence to 
treatment, people with high GSS are those with little resistance being present and great 
chance of suppressing viral load given the large number of active options available. However, 
in the context of people failing regimen and remaining on such a regimen for some time, a high 
GSS is more likely to be associated with people whose lack of resistance is explained by non-
adherence. People with low adherence on a failing regimen are also expected to accumulate 
more resistance. Indeed, I found low rates of resistance accumulation among individuals with 
no detected resistance at the start of an episode (0.16 new mutations/year), providing some 
support for this hypothesis. 
6.5.1. Strengths and limitations  
This study has a number of strengths and limitations. In terms of strengths, it is the largest 
study to date to describe the accumulation of resistance in relation to VL exposures using 
repeated resistance tests. The clearly defined VL exposures and transparent modelling also add 
to the strengths of the analysis. However, there are also a number of limitations. Firstly, the 
individuals included experienced VF in very early calendar years and received regimens that 
would no longer be considered as first line treatment, even in low-income settings. This could 
limit the generalizability of the findings. However, the rate of accumulation of resistance found 
here was remarkably similar to that found in a much more recent analysis of individuals failing 
first line contemporary treatment (645). It was not possible to conduct a sensitivity analysis 
restricting the analysis to more recent calendar years, as the number of individuals 
experiencing VF with repeated resistance tests in recent calendar years was too low in 
EuroSIDA. Although the relationship between VL and resistance accumulation can partly be 
explained through biology, it is clearly also affected by behavioural factors such as adherence 
to therapy. The lack of a validated measure of adherence in this dataset is a significant 
limitation, as any of the hypothesised explanations for the shape of the relationships found 
which are related to adherence to treatment cannot be directly be tested. In order to 
maximise the number of people that could be included in this analysis I assumed that those 
starting their first ART regimen from ART-naïve and for whom a resistance test before initiating 
ART was not available, did not have any transmitted drug resistance. It is therefore possible 
that some of the resistance detected during failure were already present at baseline and were 
not accounted for. Finally, the methodology applied here implicitly assumed that resistance 
mutations accumulated at a stable rate until a GRT was done or results of the test recorded, 
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allowing for an accurate estimation of FU time. This is unlikely to be the case, and the use of 
the date of the last GRT to determine the end of the failure episode could lead to an under-
estimate of the true rate of accumulation over the episode (e.g. if mutations have emerged but 
not yet taken over the majority circulating virus and therefore remain undetectable by Sanger 
sequencing at the time of the GRT) or an over-estimate of the true rate (if mutations emerged 
long before the GRT was done so that too many person years are included in the 
denominator). Additional limitations of EuroSIDA is the relatively low prevalence of people 
enrolled when ART-naïve and the low prevalence of people harbouring non-B strains of HIV, 
although the latter is a limitation shared by most of the European cohorts of HIV-infected 
individuals. It is reassuring that cohorts in other settings found similar rates of resistance 
accumulation to those I estimated (645). 
6.5.2. Conclusion  
In conclusion, I have estimated that individuals maintained on a failing treatment regimen 
accumulate approximately 1 new mutation per every 7 months and lose 1 drug option for 
every 24 months of being maintained on the failing regimens. The lowest level of resistance 
accumulation is likely to occur among individuals whose VL changes less than 0.12 log10 
copies/ml/year and those with average VL values between 5,001 and 10,000 copies/mL. This 
seems to be consistent with what is known about the viral biology, as it is expected that 
resistance accumulates less in people with impaired viruses replicating at low levels. However, 
individuals with steeper VL increases (more than 0.21 log10 copies/mL/year) or high VCY values 
are also likely to experience low resistance accumulation. Although it is a hypothesis that could 
not be tested, the most likely explanation for this is poor adherence in those with a history of 
high level of high replication. Another key result is the lack of an association between VL at the 
start of a failure episode and the risk of resistance accumulation, possibly suggesting that the 
choice of maintaining a patient on a failing treatment regimen should take into account factors 
besides the level of viral load observed at first detection of viral failure. 
Although the aim of current antiretroviral therapy should always be to construct a fully 
suppressive regimen, there is a small proportion of people currently receiving care in clinics 
across Europe for whom this is not achievable because they have developed resistance to all 
drug classes of antiretrovirals, including integrase inhibitors. These findings provide important 
data on the rate of resistance accumulation to three historical drug classes should 
maintenance therapy be necessary. In addition, it provides insights into the rate of resistance 
accumulation that could reasonably be expected according to a wide range of measures of VL 
exposures each focussing on different aspects of viral load replication history. Future studies 
investigating the relationship between viral replication and resistance accumulation should 
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ideally include validated measures of adherence. Specific questions for future research, as well 
as potential alternative study designs, are discussed in more detail in Chapter 8.  
6.6. Dissemination of results  
Some of these results were presented at the 2015 International HIV Drug Resistance Workshop 
in Boston, and was awarded with the Chairman’s Poster Prize (Appendix IX). A manuscript is in 
preparation.  
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Chapter 7 . The effect of primary drug resistance on 
CD4 cell decline and viral load set point in HIV 
positive individuals before the start of ART 
 
7.1. Introduction and Objectives  
Chapter 5 and 6 described the impact of maintaining individuals on a failing treatment regimen 
on CD4 counts and resistance development. However, these are not the only concerns 
associated with the use of maintenance antiretroviral therapy (ART). Individuals with high VLs 
are more likely to transmit the virus (62,666), and maintaining individuals on ART despite the 
presence of on-going viral replication could therefore contribute to the spread of drug 
resistant strains. Transmitted drug resistance (TDR) has been associated with an increased risk 
of first line ART failure following the start of ART unless genotypic resistance testing (GRT) is 
used to construct a regimen that is predicted to be fully suppressive (373). However, it is also 
possible that the presence of TDRM or other genetic changes in the viral genome influence 
disease progression before the start of ART. Differences in fitness between viruses carrying 
different types of drug resistance mutations (DRM) and wild-type strains could result in 
differences in pathogenicity, and thus influence both the natural history and potential spread 
of HIV (375). DRM that strongly affect fitness have been speculated to result in lower set point 
viral loads and higher CD4 cell counts, and consequently a slower disease progression 
(667). However, it is also possible that DRM associated with low fitness costs or fitness 
increases could lead to an increased CD4 decline followed by a more rapid disease progression 
(375,379) as well as greater viral transmission potential (668). Genetic changes affecting such 
parameters are unlikely to be restricted to mutations commonly classed as evidence of TDR, as 
treatment associated polymorphic or compensatory mutations have also been shown to have 
an effect on the fitness of viral strains (669). 
Although all individuals should start treatment as soon as possible after being diagnosed with 
HIV (601,670,671), any such differences could influence both clinical outcomes among 
undiagnosed HIV-infected patients and the transmission dynamics of the HIV epidemic on a 
population level (669,672).This has important implications for mathematical models of the 
disease and consequently the development of public health policies (672,673). Previous 
research has found that the detection of any TDRM can lead to a more rapid disease 
progression in the first year after infection (375), but the impact of specific mutations has 
rarely been comprehensively evaluated. The aim of this analysis was therefore to investigate 
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the effect of resistance mutations on the viral load set point and CD4 count decline before the 
start of ART. 
The specific objectives for this analysis were:  
1) Compare CD4 changes among individuals with either any resistance, class-wide 
resistance or any single mutation to that among individuals infected with a virus 
without resistance.  
 
2) Compare the VL set point among individuals with either any resistance, class-wide 
resistance or any single mutation to that among individuals infected with a virus 
without resistance.  
 
3) Conduct a principal component analysis (PCA) in order to identify clusters of 
mutations, and evaluate the effect of reverse transcriptase (RT) and protease (PR) 
clusters on the CD4 count decline and VL set point through the use of extracted 
component based scores.  
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7.2.Literature Review  
I conducted a literature review in order to identify papers which have previously evaluated the 
association between resistance and CD4 counts and/or the viral load before the start of ART. In 
total, I could identify 16 papers (Figure 7.1). These are described in detail in Table 7.1, and the 
findings are briefly summarised below.  
 
Figure 7.1. Identification of articles for inclusion in the literature review 
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7.2.1.The effect of TDRM on CD4 counts and VL 
The majority of the studies (N=12) investigated the effect of the presence of any TDRM on CD4 
counts or the VL set point at a single point in time. In terms of CD4 counts, a significant 
number of studies failed to find an association between CD4 counts and any detected 
resistance (669,674–678). However, there were also studies reporting both positive and 
negative associations. A study by Karlsson et al of 1,491 newly diagnosed individuals in Sweden 
found that individuals with higher CD4 counts were less likely to have TDRM (679). This is in 
broad agreement with the results from a study by Huang et al, who analysed the data from 
patients receiving care in the Free State, South Africa. However, while Karlsson et al found an 
association between CD4 counts and resistance classed as transmitted by the WHO 
surveillance list, Huang et al only found an association between CD4 counts and the detection 
of treatment-associated resistance as defined using the Stanford system. In the analysis by 
Huang et al, the association between the detection of resistance and CD4 counts grew weaker 
when using the IAS list, and was no longer significant when using the WHO TDRM surveillance 
list to classify resistance (680). This indicates that it is important to distinguish between TDRM 
and treatment-associated resistance, as the classification system used may influence the 
findings. While Karlsson et al and Huang et al found that TDRM and treatment associated 
resistance mutations respectively were less likely to be detected at high CD4 counts, 
reasonably large studies from the UK (375), France (681) and the US (682) have all found that 
individuals with higher CD4 counts are more likely to have detected resistance before the start 
of ART. Differences in the resistance lists, study designs and study populations could be 
responsible for these discrepancies, although it is also possible that the class and extent of 
resistance present affect the findings. This would be in agreement with findings by Poon et al. 
They studied associations between Stanford scores for different classes of mutations and CD4 
counts using data from the observational CFAR network in North America (683). While lower 
scores for NRTI and NNRTI mutations on the Stanford scale were both associated with higher 
CD4 counts, no association was found between PI scores and CD4 counts.  
Two studies from the UK register on seroconverters studied the effect of TDRM on CD4 count 
changes over time (375,684). Bhaksharan et al conducted a preliminary analysis of 1,533 
individuals in 2004 and found that CD4 decline in the first year following infection appeared to 
be faster among individuals infected with TDRM compared to those with no detected TDRM or 
no pre-ART resistance test (684). However, this difference was not statistically significant, and 
there was no evidence for a difference after the first year. The analysis was repeated in 2006, 
and restricted to those individuals with known resistance test results (N=300). This more 
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recent analysis confirmed a faster CD4 decline among individuals with TDRM in the first year of 
infection (375). An analysis of 424 individuals from the German HIV-1 seroconverter study also 
showed that individuals infected with TDRM experienced a more pronounced CD4 cell loss in 
the first year of infection. However, these individuals also had overall lower VL levels 
compared to individuals without TDRM, and neither of the differences were statistically 
significant (676). One analysis, by Bezemer et al, classified the HIV genomes of infected 
individuals as “evolving” if they showed genetic changes as detected by repeated genotyping. 
Although the sample size was small (N=20), they found that individuals infected with evolving 
HIV viruses experienced slower CD4 declines compared to those infected with strains that 
were not evolving. The authors suggest that an evolving or changing HIV genome may be a 
marker of low fitness, as more changes are expected in viruses with impaired replication 
capacity, which in turn could correlate with slower CD4 declines (685).  
 In terms of viral load, again, most studies report no association with drug resistance (669,674–
676,686). A small number of studies reported that individuals with higher viral loads were less 
likely to have detected resistance (681,682). Harrison et al, analysing data from the UK drug 
resistance database, found that although the detection of any resistance was not associated 
with VL in either univariable or multivariable analysis, individuals with multiclass resistance or 
the M184V mutation had lower VL levels (686). In agreement with these findings, Poon et al 
also found that any amino acid change at position 184 of RT region was associated with a 
lower VL at baseline. When studying classes of resistance, Poon et al also found that higher 
Stanford scores for NRTI resistance was associated with lower VL levels, but higher scores for 
NNRTI resistance was associated with higher VL levels (683).  
Only one study looked at the impact of patterns of mutations on CD4 counts/the viral load. 
Theys et al constructed fitness landscapes to derive fitness values representing the relative 
fitness of a given genotype compared to that of a HXB2 reference strain. Although no 
associations with any TDR or any individual treatment associated mutations and VL/CD4 
counts were found, higher estimated fitness resulting from genetic variability in the PR (but 
not RT) was significantly correlated with both higher VL and lower CD4 count, most likely due 
to the presence of polymorphic and compensatory mutations in the PR gene (669).  
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7.2.2. What this analysis adds 
The majority of the studies identified for this review focused on studying associations between 
TDRM and both CD4 counts and the VL set point at a single-point in time; with considerably 
fewer studies looking at repeat CD4 measurements and assessing CD4 changes over time 
before the start of therapy. Most of the identified studies were also relatively small, with 8/16 
including fewer than 500 participants and very few studying the effect of individual mutations 
or the combined effect of clusters of mutation. Because of the inconsistent results identified in 
this literature review, the true role of TDRM and treatment associated compensatory 
mutations in the natural history of HIV remains largely unclear. This dataset, which comprises 
repeated viral load, CD4 count and genotypic test results in absence of antiretroviral treatment 
from HIV-infected individuals seen for care in a large number of European clinical centres 
offers a good opportunity to re-evaluate these questions using a much larger sample size than 
those previously available.
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Table 7.1. Papers reporting on the effect of resistance on CD4 counts/the VL before the start of ART  
Author Year Design & Setting N  Main Results  REF1 
Theys et al  2012 
Cross-sectional analysis of data from 
SPREAD, a European surveillance 
programme 
1782 
No association between TDR and CD4 counts or VL at baseline (p=0.14 and p=0.52, 
respectively). Adjustment for duration of infection or demographic variables did 
not change this. However, higher estimated fitness from a fitness landscape for PR 
was correlated with higher VL and lower CD4 count. No individual TDRM were 
found to be associated with VL or CD4 counts. However, a higher number of 
polymorphic mutations in the PR were associated with a higher viral load, a lower 
CD4 count and higher estimated fitness. No trends for RT polymorphic mutations 
were observed.  
(669) 
Karlsson et al  2012 
Longitudinal analysis of trends in TDR 
prevalence in Sweden; also described 
factors associated with TDRM  
1491 
Patients with higher CD4 counts were less likely to have TDRM in multivariable 
logistic models adjusting for subtype and MSM. However, patients with and 
without TDR had similar median CD4 and RNA plasma levels at baseline.  
(679) 
Youmans et al 2011 
Cross-sectional analysis of TDR 
prevalence in a cohort of newly 
diagnosed individuals in South 
Carolina  
1277 
No association between CD4 counts, viral load and TDRM. There were also no 
associations between the median first CD4 count and TDRM, but some evidence 
that the median first viral load was lower among individuals with TDRM.  
(678) 
Poon et al 2011 
Cross-sectional analysis using data 
from the CFAR network, an 
observational cohort from North 
America 
14111 
Increasing Stanford scores for NRTI and NNRTI mutations were associated with 
decreasing CD4 counts. Increasing Stanford scores for NRTI were associated with 
decreasing VL as well, but increasing NNRTI scores were associated with increasing 
VL. Stanford PI scores were not associated with baseline CD4 or VL. A number of 
individual mutations, including D67X and K219X, were associated with lower 
baseline CD4 counts. M184X was associated with lower VL at baseline, as was 
M46X and L210X.  
(683) 
Huaman et al 2011 
Retrospective study of 501 individuals 
newly diagnosed with HIV at the 
Henry Ford Hospital in Detroit from 
2006-2008.  
501  
Resistance mutations were more likely to be detected at higher CD4 counts, and 
less likely to be detected at higher VL values.  
(682) 
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Harrison et al 2010 
Analysis of patients in UK CHIC and 
the UK HDRD.  
7994  
Presence of resistance to a single drug class was not associated with VL in either 
univariable or multivariable analysis. However, patients with multiclass resistance 
had lower mean VL. No other associations found for individual mutations, apart 
from M184V which was associated with lower baseline VL. It appeared that the 
effect of multiclass resistance on VL was mediated completely through M184V.  
(686) 
Huang et al 2009 
Cross-sectional analysis of patients 
receiving care in the Free state 
province of South Africa in 2006 
 884  
Drug associated polymorphisms were concentrated among patients with low CD4 
counts when considering Stanford mutations; however, this association was only 
borderline significant when considering IAS mutations only (p=0.055) and even less 
so when only considering the WHO TDRM list (p=0.086). Authors speculate that 
this is probably the result of prior, undocumented drug exposure.  
(680) 
Peuchant et al 2008 
Analysis of recently infected patients 
from the Aquitaine cohort in France, 
1996-2006.  
295 
Baseline CD4 counts (at the start of ART) were higher in the resistant compared to 
the susceptible group (560 v 438 cells/mm3, p=0.04). Baseline VL was significantly 
lower in the resistant group compared to susceptible (p=0.002).  
(681) 
Payne et al 2008 
Cross-sectional analysis of resistance 
profiles from an audit of clinics in 
Yorkshire and the north-east of 
England.  
392  No associations found between TDR and baseline CD4 or VL.  (677) 
Poggensee et al 2007 
Analysis from the German HIV-1 
Seroconverter Study  
424 
Baseline median VL and CD4 count at the time of seroconversion did not differ 
between the individuals with susceptible and resistant HIV infection, but there was 
some indication that VL was higher among those with no TDRM when time of 
infection was determined very accurately. People with resistant viruses appeared 
to have lower VL over the first year, but also more pronounced CD4 cell loss, 
although these findings were not statistically significant.  
(676) 
Pillay et al  2006 
Longitudinal analysis from the 
CASCADE collaboration  
300  
Patients with TDRM experienced faster CD4 declines compared to those without 
TDRM, but only in the first year after infection. After one year, no differences 
between the two groups could be identified. Baseline CD4 counts were higher 
among those with resistance.  
(375) 
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Bezemer et al  2006 
Longitudinal analysis from the 
CASCADE collaboration  
20  
Some evidence that CD4 counts declined slower among patients who had evolving 
HIV viruses compared to those who did not have evolving viruses (p=0.043). 
Infection with a low fitness TDRM virus may have some protective effect, despite 
consequent reversions to wild-type viruses.  
(685) 
Oette et al 2004 Cross-sectional analysis of individuals 
starting ART in Germany 
184  No difference in CD4 counts or VL between people with and without resistance.   (675) 
Bhaskaran et al 2004 
Exploratory longitudinal analysis of 
UK register of HIV seroconverters 
1533 
Suggestion of CD4 decline in the first year that was quicker among individuals with 
TDRM, but this finding was not significant. There was a suggestion of higher 
estimated CD4 counts at seroconversion, which again was not significant. There 
was no indication of any differences in terms of CD4 counts between individuals 
with and without TDRM in later year.  
(684) 
Grant et al 2002 
Cross-sectional analysis of patients 
admitted to a hospital in San 
Fransisco, California 
226 
Found no difference between the presence of TDRM and pre-ART VL measures, but 
TDRM were associated with higher CD4 counts.  
(667) 
Rubio et al 1998 Study of patients starting ART at a 
centre in Spain.  
38  No difference in terms of CD4 counts or viral load between individuals with and 
without TDRM at the time of starting therapy.  
(674) 
1. REF=Reference 
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7.3.Methods  
 
7.3.1. Inclusion criteria 
For this analysis, I used the D40 update of the EuroSIDA database and data from the EU-TDR 
collaboration. I included individuals over the age of 18 who had at least one resistance test and 
at least one CD4 count and VL measurement available before starting ART. In total, 6,180 
individuals were included, and the selection process can be seen in Figure 7.1. 
 
Figure 7.2. Selection of individuals for inclusion in the study 
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7.3.2. Resistance data  
The classification of resistance present before the start of ART is complex. Because the 
literature review indicated that resistance classified according to the transmitted resistance 
surveillance list (687) and lists used to identify treatment associated resistance 
(394,662,663,688) might have a different impact on CD4 count and viral load, it was decided to 
study both resistance classically defined as TDRM using the WHO 2009 list (687), as well as 
drug resistance mutations (DRM) categorised according to the broader principles laid out in 
Chapter 5. Briefly, this involved using all four major resistance classification systems: ANRS, 
IAS, Stanford HIV database (HIVdb) and Rega. However, compensatory mutations, particularly 
in the protease (PR) gene, are also likely to influence the fitness of a given strain despite the 
fact that they may not directly affect drug-sensitivity. Therefore, non-polymorphic PR 
mutations associated with PI exposure were manually selected from the Stanford HIVdb 
according to the following rules:  
 
(1)  Non-polymorphic PR mutations with a prevalence of <1% among treatment naïve 
patients in the publicly available Stanford/HIVdb sequence database 
(2) Non-polymorphic PR mutations with a prevalence of >1% among PI experienced 
patients in the Stanford/HIVdb sequences database 
(3) Non-polymorphic PR mutations with a prevalence among PI experienced patients at 
least twice that among treatment naïve patients.  
 
The aim of the first rule was to exclude polymorphic PR mutations. This is similar to the 
approach used to determine the WHO list of TDRM, but the 1% threshold makes it slightly 
broader than the TDRM list which uses a 0.5% threshold. This allowed the inclusion of a 
greater number of potentially compensatory PR mutations. The aim of the second and third 
rules was to identify mutations likely to appear under the pressure of PI-based treatment. 
Mutations meeting (1), (2) and (3) were considered potentially compensatory. Finally, I 
included a number of polymorphic substitutions in the PR gene that have previously been 
associated with fitness and disease progression (669). This selection process resulted in a list of 
129 reverse transcriptase (RT) and 147 PR substitutions. Of these, I consequently evaluated 41 
which met a pre-specified prevalence threshold in our dataset (1%) for their effect on CD4 
counts and the VL (LL10I, L10V, T12N, I13V, I15V, GG16E, K20I, K20R, L33V, M36I, M36L, K43R, 
D60E, I62V, L63P, H69Q, H69N, H69Y, AA71T, A71V, T74S, V77I, L90I, QQ92K and I93L in the PR 
and M41L, D67N, A98S, K101Q , K101R, K103N, V106, V118I, E138A, V179D, V179I M184V, 
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V189I, L210W,T215S and K219Q in the RT). This threshold was chosen for the same reason as 
in Chapter 5, as mutations that occurred at a lower frequency were considered unlikely to be 
of clinical significance.  
CD4 decline and VL levels among individuals with any TDRM or DRM, drug class-specific TDRM 
or DRM and individual mutations were compared to that among individuals with no resistance, 
defined as no NRTI, NNRTI or major PI mutations mentioned in the WHO surveillance list or in 
either of the four interpretation systems. Drug resistance was presumed to be present 
throughout the duration of the follow-up, irrespective of at which point it was detected. If an 
individual had more than one resistance test present during their follow-up, their resistance 
was considered cumulatively.  
I also studied the impact of mutation patterns by conducting a principal component analysis 
(PCA) to identify clusters of mutations following the strategies outlined both in Chapter 2 (100) 
and Chapter 6 (217). After identifying clusters and extracting related scores, these were 
dichotomized using the 3rd quartile (Q3) as a cut-off point. This allowed me to broadly 
categorise individuals into those whose mutation pattern was similar to that described by a 
given cluster (“Above Q3”) and those whose mutation pattern was not similar to that 
described by the cluster (“Below Q3”).  
7.3.3. Statistical methods 
Characteristics of the included individuals were compared according to the detection of TDRM 
and DRM using the chi-squared test and Kruskal Wallis test as appropriate. I used linear mixed 
models with a random intercept and slope to estimate the effect of resistance on CD4 counts 
and the VL set point. CD4 decline according to the detection of resistance was estimated by 
including an interaction between time and an indicator variable for the resistance exposure in 
a mixed model using CD4 counts as the outcome. The effect of resistance on VL was estimated 
by considering the effect of resistance on the intercept from a mixed model using VL as the 
outcome. This estimates a mean VL level, which can be interpreted as the VL set point. The 
rationale for using only the intercept for the viral load outcome is due to the relative stability 
of viral load over the course of the natural history of HIV (689). As in Chapter 5, I corrected the 
false discovery rate using the Benjamini-Hochberg procedure to calculate q-values for the 
analysis of individual mutations, as these were not selected on an a priori basis.  
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7.3.3.1. Model building strategy 
As for the previous chapters, I drew a DAG as a visual guide to the covariate adjustment (Figure 
7.3). Potential variables included in the DAG were selected based on clinical judgement and 
previous publications, but restricted given the data available in the EU-TDR collaboration.  
Figure 7.3. DAG for the effect of DRM on CD4 decline before the start of ART 
 
 
 
 
 
 
 
 
Given that the assumptions of the DAG (no measurement error and no unmeasured 
confounding) are correct, adjustment for risk group, subtype, cohort, calendar year and VL 
would be minimally sufficient to estimate a total direct effect of DRM on CD4 decline before 
the start of ART. As in Chapter 5, I conducted sequential adjustments for both outcomes as 
follows:  
• Model 1: Adjusting for HIV risk group, viral subtype, calendar year of genotyping and 
cohort;  
• Model 2: Model 1 + additional adjustment for the first recorded CD4 measurement (VL 
outcome model) and the first recorded VL measurement (CD4 slope outcome model).  
 
Cohort was included as a surrogate marker for expected demographic differences, such as 
ethnicity and hepatitis co-infections status, that was hypothesised to act as potential 
confounders but for which we did not have data.
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7.3.3.2. Variable categorisation  
The resistance related exposures were all entered in the models as binary variables, and separate models 
were constructed for each of them. The type and, where relevant, categorisation of covariates included in 
the models can be seen in Table 7.2.  
 Table 7.2 Covariates included in the model 
Variable Categories Time-updated 
Cohort EuroSIDA, Not EuroSIDA No 
Mode of transmission MSM, IDU, Heterosexual, Other No 
Subtype B, Non-B No 
Calendar year of the (first) 
resistance test 
<99, 00-01; 02-03, 04-05, 06-07; 06-
07, >08 
 
No 
First Viral Load Linear, per log10 No 
First CD4 count Linear, per 100 cells/mm3 No 
 
7.3.3.3. Exploratory and sensitivity analyses  
I conducted an exploratory analysis stratified according to subtype status (B v non-B), as it was considered 
possible that the effect of the selected resistance exposure variables on disease progression could differ 
across subtypes. I formally evaluated interactions for those resistance variables found to be significant in 
the main analysis by including a three-way interaction between subtype, time and the resistance 
exposure (CD4 analysis) and by including an interaction between subtype and the resistance exposure (VL 
analysis).  
I also conducted a sensitivity analysis to address the risk of duplicate individuals from different cohorts 
having been included. It is possible that some patients in the EU TDR collaboration were included in the 
EuroSIDA database, although most of the centres that contributed data to the EU-TDR collaboration did 
so before they started contributing data to EuroSIDA. Unfortunately, it was not possible to identify 
potential duplicates on the basis of local ID’s or date of birth, as these variables were not available in the 
EU-TDR dataset. Linkage on the basis of year of birth, first CD4 count and first VL value gave very low 
matching rates, and it was not considered feasible to accurately link the datasets on the basis of the 
available variables. Instead, I conducted a sensitivity analysis where all data from EuroSIDA was excluded.  
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7.4. Results  
7.4.1. Demographic and clinical characteristics of the study population 
6,180 individuals met the inclusion criteria and were included in the analysis. The 
characteristics of these individuals according to the source cohort are shown in Table 7.3. The 
majority of individuals were male (77%), most had acquired their HIV through sex with another 
man (46%) and were infected with a subtype B virus (64%). Individuals contributed a median of 
5 CD4 measurements (IQR=3-9) and 4 VL measurements (IQR=2-8) over a median of 1.4 
(IQR=0.1-3.8) years. Most individuals (90%) had just 1 pre-ART resistance test, but 623 (10%) 
individuals contributed 2 or more resistance tests. The baseline median CD4 count was 420 
(IQR=289-583) cells/mm3, and the baseline viral load was relatively high at 4.5 log10 copies/mL 
(IQR=3.9-5.0). The VL set point as estimated from univariable models was 4.4 log10 copies/mL 
(95%CI=4.4-4.4), and CD4 counts declined with an estimated 54 (95%CI=-56;-52) 
cells/mm3/year. There were some differences between individuals included from EU-TDR and 
EuroSIDA clinics. Individuals from EuroSIDA tended to be younger (p<0.001), contribute data 
from earlier calendar years (p<0.001), were more likely to be MSM and PWID (p<0.001) and 
were less likely to have available subtype data (p<0.001) compared to individuals from EU-TDR 
clinics. Individuals from EuroSIDA also tended to have more advanced HIV disease with higher 
first VL values (4.6 [3.9-5.1] v 4.5 [3.9-5.9], p=0.01) and lower first CD4 counts (372 [255-510] v 
433 [300-595], p<0.001).  
The characteristics also varied according to whether individuals were infected with a virus 
carrying at least one TDRM, at least one DRM or no resistance (Table 7.4). Individuals with 
TDRM were more likely to be male than individuals with other DRM or no resistance (p<0.001), 
and they were generally genotyped in an earlier calendar year period (p<0.001). Individuals 
with at least one TDRM were also more likely to be infected with a subtype B virus, whereas 
individuals with other DRM were most likely to be infected with a non-B virus (p<0.001). In this 
cross-sectional part of the analysis, there was no evidence to suggest that either the median 
first CD4 or VL measurement differed according to resistance status (p=0.12 and p=0.40 for 
CD4 and VL respectively).  
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Table 7.3. Characteristics of the study population, according to cohort 
    Total N(%) EU-TDR EuroSIDA P-value 
Gender1 Male 4560 (77.3) 3646 (76.8) 914 (79.4) 0.057 
  Female 1339 (22.7) 1102 (23.2) 237 (20.6)   
Age, years Median, IQR 36 (30, 42) 36 (30, 43) 34 (29, 41) <.001 
Baseline Date Median, IQR  08/05 (12/02-07/07)  10/05 (10/03—7/07)  12/02 (02/97-01/08)  <.001 
Risk Group2 MSM 2689 (45.9) 2084 (44.3) 605 (52.5) <.001 
  PWID 635 (10.8) 456 (9.7) 179 (15.5)   
  Heterosexual 1911 (32.6) 1617 (34.4) 294 (25.5)   
  Other 623 (10.6) 549 (11.7) 74 (6.4)   
HIV subgroup B 3976 (64.3) 3252 (64.7) 724 (62.8) <.001 
  Non-B 1471 (23.8) 1301 (25.9) 170 (14.8)   
  Unknown 733 (11.9) 475 (9.4) 258 (22.4)   
Laboratory First RNA, cp/ml (Median, Range) 3 4.5 (3.9, 5.0) 4.5 (3.9, 5.0) 4.6 (3.9, 5.1) 0.014 
  First CD4, cells/mm3 (Median, Range) 420 (289, 583) 433 (300, 595) 372 (255, 510) <.001 
1. 281 individuals had missing data on gender 
2. 322 individuals had missing data on risk group 
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1. 281 individuals had missing data on gender 
2. 322 individuals had missing data on risk group 
Table 7.4. Characteristics of the study population, according to resistance presence 
  Total N (%) At least one TDRM Other resistance No resistance P-value 
Gender1 Male 4560 (77.3) 491 (83.2) 1894 (73.7) 2175 (79.4) <.001 
 Female 1339 (22.7) 99 (16.8) 676 (26.3) 564 (20.6)  
Age, years Median, IQR 36 (30, 42) 37 (30, 43) 35 (30,42) 36 (30,43) 0.05 
Baseline Date Median, IQR 08/05 (12/02-07/07) 12/04 (10/01-04/07) 09/05 (02/03-08/07) 08/05 (01/03-07/07) <.001 
Risk Group2 MSM 2689 (45.9) 316 (53.5) 1035 (40.6) 1338 (49.2) <.001 
 PWID 635 (10.8) 63 (10.7) 245 (9.6) 327 (12.0)  
 Heterosexual 1911 (32.6) 141 (23.9) 987 (38.7) 783 (28.8)  
 Other 623 (10.6) 71 (12.0) 284 (11.1) 168 (9.9)  
HIV subgroup B 3976 (64.3) 474 (76.7) 1565 (58.1) 1937 (67.5) <.001 
 Non-B 1471 (23.8) 66 (10.7) 820 (30.5) 585 (20.4)  
 Unknown 733 (11.9) 78 (12.6) 307 (11.4) 348 (12.1)  
Laboratory 
First RNA, cp/ml 
(Median, Range) 3 
4.5 (3.9, 5.0) 4.4 (3.8, 5.1) 4.5 (3.9-5.0) 4.5 (3.9-5.0) 0.40 
 
First CD4, cells/mm3 
(Median, Range) 
420 (289, 583) 426 (280, 610) 420 (280-570) 422 (296-588) 0.12 
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7.4.2. Resistance prevalence  
The overall prevalence of TDRM and DRM was 10% and 54%, respectively. Transmitted NRTI 
resistance was the class of TDRM most commonly detected, at 7.1%. This was followed by 
NNRTI (3.2%) and PI (2.6%) resistance. Regarding DRM, PI resistance was most common 
(31.3%), followed by NNRTI resistance (25.3%) and NRTI resistance (11.1%). The combined 
prevalence of minor and major PR mutations was, as expected, very high at 95.2%. The 
prevalence of individual mutations can be seen in Figure 7.4. Overall, 41 mutations were 
present at a frequency higher than 1% and were evaluated in multivariable models (Figure 
7.4). The most common mutations were PR mutations, with L63P present in 40.8% of 
individuals. The most common RT mutation was V179I (6.5%).  
Figure 7.4. Prevalence of transmitted and treatment associated resistance  
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Figure 7.5. Prevalence of individual mutations at baseline present at a frequency of 1% or higher 
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7.4.3. Clusters of mutations  
Following the principles laid out in Chapter 2, I identified two RT and two PR clusters through 
the use of PCA. The scree plots used to determine the number of components to retain can be 
seen in Figure 7.6a-b. Both the RT and PR clusters explained a low proportion of the overall 
variance, 24.3% and 15.6% respectively. 
Figure 7.6. Scree plots for the RT (a) and PR (b) PCA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)  
(b)  
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The contribution of each mutation to the extracted components, or clusters, can be seen in 
Table 7.5 and Table 7.6. The contribution, or loadings, in the tables can be interpreted as the 
standardised correlations between the resistance mutations and the unit-scaled components. 
For example, 116Y and 115F in RT had the highest correlation to the first cluster (loadings=83). 
The first RT cluster contained a large number of RT mutations that conferred both NRTI and 
NNRTI resistance. This included the 151M complex (substitutions in position 151, 115, 116 75, 
77 and 62) together with substitutions in positon 74, 65, 100, 188, 179 and 230. The strongest 
contributions came from the mutations forming part of the 151M complex. The second RT 
cluster contained another previously well described RT cluster, the thymidine analogue 
mutations (TAM), and included substitutions in position 41, 67, 219, 215, 210 and 70 as well as 
a polymorphic substitution in position 44, the 184 substitution and a substitution in position 
181 (Table 7.5).  
The first PR cluster contained a number of major PI substitutions (position 46, 82, 47, 30, 32, 
84, 48, 90, 50, 54 and 88) as well as a few minor PI mutations in position 73, 53 and 24. The 
second PR cluster contained 5 minor/polymorphic PR substitutions in position 20, 13, 36, 69 
and 89 (Table 7.6).  
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Table 7.5. Loadings for the RT PCA1 
 
RT Factor 1 
Cross NNRTI/NRTI 
RT Factor 2 
Cross NNRTI/NRTI 
RT41L 8 61 
rt103NSHTR 23 28 
rt67NGESHT 14 67 
rt219WHQNER 14 56 
rt184VI 27 44 
rt215SDYCFVIACEGHLN 6 67 
RT210W 19 59 
rt70RGQNSTE 27 41 
rt190TASCEQV 32 32 
rt101EPHIRQNT 13 18 
RT225H 56 7 
rt74VI 47 36 
RT77L 80 -7 
rt151ML 81 -6 
rt65REN 58 7 
rt100IV 54 20 
rt75MTASIL 66 4 
rt188LHCF 46 10 
RT115F 83 3 
RT116Y 83 -7 
rt181CISFGV 32 40 
rt230IVL 66 12 
rt106AIM 18 16 
rt179DLTIMEF 8 3 
rt62V 45 -6 
rt90I 1 3 
rt98GS 12 7 
rt108I 45 6 
rt138AKQGRS -1 4 
rt221Y 0 15 
rt44DA 31 41 
rt40F -2 11 
rt118I 15 29 
rt348I 0 -1 
rt234I 0 0 
rt238TN -1 19 
rt318F 0 -1 
rt189I 0 -1 
rt318F 0 -1 
rt189I 0 -1 
1. Factor loadings below 30 were considered negligible, between 30-40 weak (light gray), above 40 strong (medium 
gray) and above 70 (dark gray) very strong. Mutations with loadings above 40 were interpreted as forming part 
of a cluster captured by that PC; those with loadings between 30 and 40 were considered weakly associated with 
the cluster 
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1. Factor loadings below 30 were considered negligible, between 30-40 weak (light gray), above 40 strong (medium 
gray) and above 70 (dark gray) very strong. 
Table 7.6. Loadings for the PR PCA1 
 Component 1 Cross PI Component 2 Accessory non-B 
E34DQKV 0 1 
K55NR 10 -6 
T91A 3 5 
K45QI 1 0 
I66LVF 6 0 
C67F 14 -1 
L10YVCFIMR 21 5 
K20LIMRTV 11 64 
I13V -1 57 
D60E -2 -14 
I62V 5 -30 
AA71TVI 26 -28 
V77I 5 -39 
I93ML 5 -26 
L23I 9 -2 
M46LIV 55 -4 
V82TFSMACLG 64 -4 
I47VA 72 3 
I85V 13 6 
D30N 46 0 
V32IL 68 5 
G73TCASVF 65 1 
I84ACV 67 1 
F53YWL 57 -1 
I48VASTQLM 62 1 
L90M 60 -3 
I50VL 64 4 
I54ATSMVL 67 1 
L76V 8 1 
N83D 8 4 
L24IFM 59 1 
N88DSTG 51 2 
V11IL 4 3 
GG16E -3 34 
L33FIVM 19 -9 
M36ILV 4 76 
K43TIR 7 -5 
I15AV 4 15 
L63PI 9 -40 
H69KNQYIR -1 75 
L89RTFIMV 1 84 
Q58E 3 0 
E35GN 3 15 
K70E -1 -2 
R41IT 0 1 
T74ESA 3 15 
QQ92KR 0 17 
T12NKE 0 -1 
Q61D 3 1 
G17D -1 0 
Q18H 10 1 
V75I -1 0 
N37Q -1 -5 
P79D 0 -2 
A22V 7 5 
C95F 15 -4 
L38W 0 -1 
I64MVL 0 -12 
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7.4.4. Effect of resistance on CD4 cell decline  
7.4.4.1. Associations between TDRM, DRM and CD4 decline 
The CD4 cell decline was estimated to be 53 cells/mm3/year (95%CI=-56; -49) among 
individuals infected with viruses without resistance and 55 cells/mm3/year (95%CI=-63; -48) 
among those infected with a virus carrying any TDRM (p-value for difference=0.47). These 
estimates did not change markedly upon covariate adjustments (Figure 7.7a). There was also 
no evidence that the detection of TDRM according to specific drug classes was associated with 
reduced or increased CD4 declines (Figure 7.7a). The findings were similar when considering 
DRM rather than TDRM (Figure 7.7b), although there was slightly stronger evidence suggesting 
that the detection of NNRTI DRM was associated with steeper CD4 decline still compared to 
people with no resistance (difference = -6 cells/mm3/year, 95% CI=-12;0, p=0.04 after 
adjustment, Figure 7.7b). 
7.4.4.2. Associations between individual mutations and CD4 decline 
No individual mutation was associated with the CD4 slope (Figure 7.8). The strongest signals 
were found for the A71T and L10V substitutions in PR gene and K101Q in the RT gene, which 
were associated with a steeper CD4 decline albeit not significantly after correcting for multiple 
testing. The largest difference was found for K101Q. Individuals with this mutation 
experienced a CD4 count decline of 26 cells/mm3/year (95%CI=-45; -6) greater than those with 
no resistance detected. Individuals with the A71T or L10V mutation had CD4 counts which 
declined with around 16 cells/mm3/year faster (-17 [-29; -4] and -16 [-27; -2] respectively) 
compared to individuals with no resistance detected. Adjustment for VL did not markedly 
affect the estimates (Figure 7.9).  
7.4.4.3. Associations between clusters of mutations and CD4 decline 
The first RT and PR clusters did not seem to have any marked effect on CD4 decline (p=0.37 
and 0.17 respectively, Figure 7.10). In contrast, the second PR cluster, which contained minor 
mutations, was strongly associated with a less steep CD4 decline (p<0.001). The magnitude of 
the effect was not negligible; CD4 counts declined with 9 cells/mm3 (95%CI=4-15) less per year 
among individuals whose mutation pattern was similar to that described by this cluster. The 
second RT cluster (including TAMs) was marginally associated with a slightly steeper CD4 
decline (p=0.05). 
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Figure 7.7. The effect of any and class of transmitted (a) and treatment associated (b) 
resistance on CD4 decline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for viral 
load (log-scale, continuous).  
2. 322 individuals were excluded for missing risk group values  
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Figure 7.8. Adjusted difference in CD4 decline according to the presence of specific 
mutations (Model 1) 
 
 
 
 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort.  
2. 322 individuals were excluded for missing risk group values  
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Figure 7.9. Adjusted difference in CD4 decline according to the presence of specific 
mutations (Model 2) 
 
 
 
 
 
 
 
 
 
 
 
 
1. Model 2 adjusted for risk group, subtype, calendar year and cohort and the first VL measurement 
2. 322 individuals were excluded for missing risk group values  
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Figure 7.10. The effect of clusters of mutations on CD4 decline 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for viral 
load (log-scale, continuous).  
2. 322 individuals were excluded for missing risk group values  
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7.4.5. Effect of resistance on VL set point 
7.4.5.1. Associations between TDRM, DRM and VL set point 
Associations between the detection of TDRM, DRM and the VL point can be seen in Figure 
7.11. The estimated VL set point did not seem to vary according to the detection of TDRM after 
adjustment for the pre-specified confounders, including CD4 counts (difference=-0.05 log10 
copies/ml, 95%CI=-0.12; -0.01, p=0.13). There was some weak evidence that the VL set point 
was slightly lower among individuals with NRTI and PI TDRM compared to those with no 
resistance (p=0.03 and p=0.04 respectively), but the magnitude of these differences was 
relatively small (difference=-0.08 log10 copies/mL, 95% CI=-0.16; -0.01 and -0.13 log10 
copies/mL, 95%CI=-0.25; -0.01 respectively). There was no evidence that the detection of 
NNRTI TDRM was associated with the estimated VL set point (p=0.29). No associations were 
identified between any or class of DRM and the VL set point (Figure 7.11).  
7.4.5.2. Associations between individual mutations and VL set point 
After adjustment for all pre-specified confounders, there was evidence that the VL set point 
was lower among individuals who had either the G16E or the Q92K mutation in the PR (both 
q<0.001, Figure 7.12). The size of these differences was relatively small for G16E (-0.09, 
95%CI=-0.13; -0.06 cells/mm3/year), but larger for Q92K: -0.25, 95%CI=-0.33; -0.17 log10 
copies/year. Adjustment for CD4 counts did not alter these estimates (Figure 7.13). 
7.4.5.3.Associations between clusters of mutations and VL set point 
In agreement with the analysis of the impact of mutation clusters on CD4 decline, there was 
reasonable evidence suggesting that individuals whose mutation pattern aligned closely with 
the second PR cluster had lower VL set points both in univariable and multivariable analyses 
(adjusted p=0.004; Figure 7.14). Among those whose mutation pattern closely aligned with this 
cluster, the VL set point was on average 0.10, 95%CI=-0.17; -0.01 log10 copies/year lower 
compared to that among individuals with no resistance. In contrast, the second RT cluster was 
only weakly associated with a higher VL set point in univariable analyses, but this association 
did not persist after adjustment for confounders. 
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Figure 7.11. The effect of any and class of TDRM on estimated VL set point 
 
 
 
 
 
 
 
 
a) 
b) 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for CD4 
counts.  
2. 322 individuals were excluded for missing risk group values  
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Figure 7.12. Adjusted difference the VL set point according to the presence of specific 
mutations (Model 1) 
 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort.  
2. 322 individuals were excluded for missing risk group values  
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Figure 7.13. Adjusted difference the VL set point according to the presence of specific 
mutations (Model 2) 
 
 
 
 
 
 
 
 
1. Model 1 adjusted for risk group, subtype, calendar year, cohort and CD4 counts.  
2. 322 individuals were excluded for missing risk group values  
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Figure 7.14. The effect of clusters of mutations on the estimated VL set point 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for CD4 
counts.  
2. 322 individuals were excluded for missing risk group values  
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7.4.6. Exploratory and sensitivity analyses  
It can be hypothesised that HIV subtype might also affect CD4 count slopes and VL set point in 
the absence of therapy. A formal test for interaction between CD4 decline and subtype was 
borderline significant in multivariable models (p=0.04, difference= +7 cells/mm3/year [2-13] 
comparing slopes among non-B to B subtypes), meaning that those infected with a non-B virus 
experienced slightly less steep CD4 declines. There was also strong evidence that subtype 
influenced the estimated VL set point (p<0.001), with those infected with a non-B virus having 
slightly lower VL set points (difference=-0.13 log10 copies/mL/year, 95%CI=-0.18; -0.08).  
There were some notable differences in the results of the analyses evaluating the association 
between resistance and the CD4 outcome after restricting to individuals with a subtype B virus 
(Table 7.7). First of all, the effect of NNRTI DRM was stronger (adjusted difference=-10 
cells/mm3/year, 95%CI—17; -3, p=0.005). This latter finding appeared to be driving a weakly 
negative effect of any DRM on CD4 decline (adjusted difference=-6 cells/mm3/year, 95%CI=-
12;0, p=0.02). Tests for interaction indicated that the effect of NNRTI DRM varied significantly 
according to subtype (p=0.02). The effect of both the second RT and PR cluster on CD4 decline 
grew more extreme with wider confidence intervals, but interaction tests indicated that only 
the effect of the second PR cluster was likely to vary significantly according to subtype 
(p=0.007). Of note, only 3.6% of individuals with a subtype B virus reached the threshold to be 
classified as having a similar mutation pattern to that described by the second PR cluster, 
compared to 91.4% of individuals with a non-B virus. The evidence supporting an effect of the 
A71T and K101Q mutations on CD4 decline grew slightly stronger when restricting the analyses 
to individuals infected with a subtype B virus (both adjusted p=0.056), although interaction 
tests were only marginally significant (p=0.07 and 0.08 respectively).  
There were also significant changes to the findings regarding the effect of individual DRM on 
the VL set point: no DRM were found to be associated with the VL set point when restricting 
the analysis to individuals with subtype B viruses. The point estimates for both the G16E and 
Q92K substitutions also moved towards zero when restricting to this patient group. Tests for 
interaction indicated that the effect of at least the G16E mutation differed significantly 
according to subtype (p=0.001 for G16E and p=0.11 for Q92K). There also appeared to be no 
effect of any or class of TDRM, DRM or clusters of mutations on the VL set point among 
individuals with subtype B viruses.  
I also repeated the analysis after restricting to non-B subtypes, although this analysis was 
limited in terms of power, as only 1,471 (23.8%) individuals were infected with a non-B virus. 
Interestingly, the finding that the Q92K and G16E mutations may have a negative effect on the 
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VL set point grew stronger when restricted to non-B subtypes, as expected given the significant 
interaction tests. Although the effect of the second PR cluster on CD4 count decline was no 
longer significant when restricting to non-B subtypes, the point estimates were relatively 
similar in the restricted and main analysis (difference= 12 [6-31] cells/mm3/year when 
restricted to non-B viruses, p=0.18) despite the evidence supporting an interaction. None of 
the other findings from the main analysis were significant in the non-B population (Table 7.8).  
Removing EuroSIDA clinics from the analysis did not change any of the main conclusions, 
although the evidence that NNRTI DRM were associated with an increased CD4 decline grew 
slightly stronger (Table 7.9).  
 
 
349 
 
Table 7.7. Findings that were significant in the main analysis: Restricted to subtype B1,2 
  Unadjusted  Adjusted (1)  Adjusted (2)  
     Difference (95% CI) P Difference (95% CI) P Difference (95% CI) P 
CD4 count slope        
DRM - NNRTI Any -10.97 (-17.81; -4.12) 0.002 -9.86 (-16.77; -2.95) 0.005 -9.84 (-16.68; -3.00) 0.005 
RT FACTOR 2 Above Q3 -5.96 (-12.18; 0.26) 0.060 -6.19 (-12.48; 0.10) 0.054 -6.23 (-12.46; -0.01) 0.050 
PR FACTOR 2 Above Q3 19.52 (4.92; 34.12) 0.009 19.78 (4.84; 34.72) 0.009 19.79 (5.01; 34.56) 0.009 
VL set point        
TDRM - NRTI Any -0.05 (-0.14; 0.04) 0.254 -0.08 (-0.17; 0.01) 0.082 -0.07 (-0.16; 0.01) 0.089 
TDRM - PI Any -0.09 (-0.23; 0.05) 0.211 -0.09 (-0.23; 0.06) 0.244 -0.12 (-0.26; 0.02) 0.083 
PR FACTOR 2 Above Q3 -0.09 (-0.22; 0.03) 0.148 -0.09 (-0.21; 0.04) 0.184 -0.09 (-0.22; 0.03) 0.130 
PR - Q92K Compared to no 
resistance 
0.11 (-0.02; 0.23) 0.548 0.11 (-0.02; 0.23) 0.524 0.11 (-0.02; 0.23) 0.504 
PR - G16E Compared to no 
resistance 
-0.04 (-0.10; 0.01) 0.551 -0.04 (-0.10; 0.01) 0.524 -0.04 (-0.10; 0.01) 0.504 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for 
VL/CD4 counts as relevant 
2. 322 individuals were excluded for missing risk group values  
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Table 7.8. Findings that were significant in the main analysis: Restricted to non-B subtypes1,2 
  Unadjusted  Adjusted (1)  Adjusted (2)  
     Difference (95% CI) P Difference (95% CI) P Difference (95% CI) P 
CD4 count slope        
DRM - NNRTI Any -2.30 (-15.65; 11.05) 0.736 -2.18 (-16.02; 11.67) 0.758 -2.17 (-15.94; 11.60) 0.757 
RT FACTOR 2 Above Q3 -2.78 (-17.48; 11.91) 0.710 -2.74 (-18.38; 12.90) 0.732 -2.72 (-18.28; 12.84) 0.732 
PR FACTOR 2 Above Q3 13.48 (-4.60; 31.56) 0.144 12.48 (-5.91; 30.87) 0.183 12.50 (-5.79; 30.79) 0.180 
VL set point        
TDRM - NRTI Any -0.29 (-0.59; 0.01) 0.058 -0.17 (-0.48; 0.15) 0.305 -0.15 (-0.46; 0.16) 0.347 
TDRM - PI Any -0.22 (-0.59; 0.14) 0.232 -0.16 (-0.54; 0.22) 0.412 -0.07 (-0.44; 0.30) 0.705 
PR FACTOR 2 Above Q3 -0.11 (-0.27; 0.04) 0.156 -0.08 (-0.24; 0.08) 0.325 -0.09 (-0.24; 0.07) 0.281 
PR - Q92K Compared to no 
resistance 
-0.46 (-0.57; -0.34) <.001 -0.47 (-0.58; -0.35) <.001 -0.47 (-0.59; -0.35) <.001 
PR - G16E Compared to no 
resistance 
-0.16 (-0.25; -0.08) 0.002 -0.17 (-0.26; -0.09) 0.002 -0.17 (-0.26; -0.09) 0.002 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for 
VL/CD4 counts as relevant 
2. 322 individuals were excluded for missing risk group values  
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Table 7.9. Findings that were significant in the main analysis: Removing EuroSIDA clinics 
  Unadjusted  Adjusted (1)  Adjusted (2)  
     Difference (95% CI) P Difference (95% CI) P Difference (95% CI) P 
CD4 count slope        
DRM - NNRTI Any -8.31 (-14.88 - -1.74) 0.013 -8.31 (-14.88 - -1.74) 0.013 -7.23 (-13.89 - -0.57) 0.033 
RT FACTOR 2 Above Q3 -5.64 (-11.92 - 0.64) 0.078 -5.49 (-11.95 - 0.97) 0.096 -5.53 (-11.93 - 0.88) 0.091 
PR FACTOR 2 Above Q3 13.63 (7.54 - 19.72) <.001 12.90 (6.58 - 19.21) <.001 12.91 (6.65 - 19.17) <.001 
VL set point        
TDRM - NRTI Any -0.05 (-0.14 - 0.04) 0.261 -0.09 (-0.18 - 0.00) 0.056 -0.08 (-0.17 - 0.01) 0.070 
TDRM - PI Any -0.15 (-0.29 - -0.01) 0.036 -0.16 (-0.31 - -0.02) 0.030 -0.16 (-0.30 - -0.02) 0.022 
PR FACTOR 2 Above Q3 -0.16 (-0.21 - -0.12) <.001 -0.08 (-0.16 - 0.01) 0.096 -0.09 (-0.18 - -0.01) 0.032 
PR - Q92K Compared to no 
resistance 
-0.27 (-0.35, -0.19) <.001 -0.27 (-0.35, -0.19) <.001 -0.27 (-0.35, -0.19) <.001 
PR - G16E Compared to no 
resistance 
-0.11 (-0.15, -0.07) <.001 -0.12 (-0.16, -0.08) <.001 -0.12 (-0.16, -0.07) <.001 
1. Model 1 adjusted for risk group, subtype, calendar year and cohort. Model 2 additionally adjusted for 
VL/CD4 counts as relevant 
2. 322 individuals were excluded for missing risk group values  
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7.5. Discussion  
 
7.5.1. Clusters of mutations 
This analysis described the influence of HIV drug resistance, categorised in a number of 
different ways, on CD4 cell decline and the VL set point before the start of ART. I also used a 
simple data reduction technique, PCA, to study clusters of mutations. As expected given the 
absence of drug pressure, most of the clusters of mutations identified in this analysis differed 
slightly from those identified in individuals kept on failing treatment regimens in chapter 5. 
However, the second PR cluster was nearly identical to one identified in my prior analysis. This 
collection of minor PR mutations (involving positions 13, 20, 36, 69 and 89) did not have any 
effect on CD4 decline in the presence of failing treatment (Chapter 5). However, as shown in 
this analysis, individuals whose mutation pattern was close to that described by the cluster had 
slightly decreased CD4 declines before the start of ART and a lower VL set point. There was 
strong evidence that this effect varied according to subtype, and it appeared to be stronger 
among individuals infected with a subtype B virus.  
Substitutions in position 36 are very common in non-B subtypes, and viruses carrying this 
substitution have a higher replication capacity than subtype B WT viruses (690,691). In other 
subtypes, such as G or CRF02-AG, substitutions in position 36 tend to appear with substitutions 
in position 20. It has been suggested that the combination of these mutations may present a 
selective advantage to the virus (692). With this respect, my findings are somewhat 
counterintuitive as mutations associated with a higher replicative capacity would be expected 
to cause a higher VL set point and faster CD4 count decline. However, the identified cluster 
also contained a number of other minor PR mutations. It is possible that the effect of the 20 
and 36 mutations differ depending on the detection of other substitutions that form part of 
this cluster. On the other hand, one small previous study has found substitution 20I to be 
significantly correlated with lower VL during primary HIV infection (693), which provides some 
support for this cluster being associated with a less virulent form of HIV disease. However, it is 
important to note that I cannot rule out that unmeasured confounding or misclassification of 
the data affected the result. Only very few individuals among those infected with a subtype B 
virus had mutation patterns that closely resembled that described by the second PR cluster, 
and individuals infected with a non-B virus also had less steep CD4 declines and lower VL set 
points compared to those infected with a subtype B virus. It is possible that there is some 
misclassification of subtype in the dataset, and that this cluster is a marker for subtype. I also 
hypothesised that the presence of major mutations, not necessarily reaching the threshold for 
classification in the the PCA, may still be influencing the results. When I included “presence of 
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a major PI mutation” in the multivariable models as an indicator variable, the effect of the PCA 
cluster remained significant but grew weaker, and the point estimate moved towards zero 
(data not shown). This indicates that some of the effect may at least in part be mediated by 
major PR mutations.  
7.5.2. Effect on CD4 count decline 
Despite the large sample size, I was not able to find any definitive evidence that the detection 
of primary resistance mutations influenced CD4 decline. There was some weak evidence that 
NNRTI DRM were associated with a steeper CD4 decline, although this was not the case for 
NNRTI TDRM. The effect also appeared to be largely restricted to individuals infected with a 
subtype B virus, although the small sample size for the analysis restricted to non-B viral strains 
makes it hard to draw accurate conclusions. The modest fitness cost of most NNRTI mutations 
is relatively well described (507), and an increase in the speed of disease progression among 
individuals carrying NNRTI mutations would be biologically plausible. However, adjustment for 
VL did not shift the estimates markedly. Although this seems to suggest that any effect of 
these changes on the CD4 count slope acts through a mechanism other than higher viral 
replication and fitness, it is also possible that adjustment for the VL did not accurately estimate 
the direct total effect of resistance on CD4 decline (618) . This should, as outlined in Chapter 5, 
be borne in mind when interpreting the findings. There are a number of differences between 
the NNRTI TDRM and DRM lists that could explain why an association was found for NNRTI 
DRM but not TDRM. Of note, relatively strong but non-significant effects were found for two 
NNRTI DRM not included on the TDRM list: V179D and K101Q. K101Q is weakly selected 
among patients receiving NVP and EFV, whereas V179D is a polymorphic mutation that 
contributes to a lower susceptibility for all NNRTI’s (394). Interestingly, individuals carrying the 
V179D mutation were found to have significantly steeper CD4 declines during failing treatment 
compared to those without the mutation in one of my previous analyses (Chapter 5). This 
mutation has previously been found to have high relative replicative fitness compared to other 
common NNRTI mutations when assessed in growth competition experiments (628). 
No individual mutations were found to be associated with CD4 slopes, although patients 
infected with viruses harbouring A71T and 10V substitutions in PR region had non-significantly 
steeper CD4 declines compared to those with no resistance. Previous in vitro studies have 
linked changes in positions 10 and 71 with fitness recovery during treatment with protease 
inhibitors (694,695), and evidence from an in vivo study has suggested that neither the L10I/V 
nor the 71V/T mutation reduce the relative fitness of the virus once treatment is stopped 
(623). It is possible that these and other compensatory mutations occurring outside of the 
active site of the protease act to stabilize the structure of the enzyme, thereby restoring 
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fitness during the presence of selective drug pressure. Unlike major resistance mutations, 
these changes do not seem to impair the replicative capacity of the virus in absence of drug 
pressure, and could even confer an increased fitness compared to WT viruses which could 
manifest as a steeper reduction in the CD4 count before the start of ART. Theys et al have 
previously found a number of polymorphic mutations in the PR gene to be associated with a 
higher VL, lower CD4 count and higher estimated fitness from a fitness landscape (669). These 
mutations included A71T and L10V. Although this is intriguing, neither A71T nor L10V were 
associated with a higher viral set point in my analysis, as would be expected if they were 
associated with a markedly higher replicative capacity. It is also important to note that after 
correction for multiple testing I could not rule out that the effects found were due to chance.  
Other authors investigating the relationship between resistance and CD4 counts before the 
start of ART have tended to study associations between any TDRM and CD4 counts at a single 
point in time. As shown in the literature review, the results have been conflicting 
(375,669,676–679,681,682). One of the largest studies describing longitudinal CD4 count 
changes was conducted by Pillay et al, using data from the CASCADE collaboration. They found 
evidence that CD4 counts declined faster among patients with TDRM, but only during the first 
year of infection (375). Unfortunately, the date of infection was not available in my dataset, 
and therefore the hypothesis that TDRM have a differential effect by varying time since the 
date of HIV seroconversion could not be directly evaluated.  
7.5.3. Effect on the VL set point 
I found weak evidence that the detection of transmitted NRTI and PI resistance was associated 
with lower VL set points, but the overall differences between individuals with and without 
resistance was small – around 0.1 log10 copies/mL – for both associations. It is unclear whether 
a difference of this size would have an impact on the transmission dynamics of HIV on a 
population level or on clinical progression as a result of a reduction in virulence. There were 
slightly larger differences between individuals who had the G16E and Q92K mutations and 
those who had no resistance, with both mutations being associated with lower VL set points. 
The finding appeared to be restricted to individuals infected with non-B viruses. G16E is a 
minor PR mutation included in the IAS list, whereas Q92K was selected for inclusion by the 
manual scanning of the Stanford HIVdb and is not included in any of the major resistance 
systems. I was not able to identify any studies which evaluated the potential impact of these 
mutations on the viral set point or the replicative capacity of viral strains more generally, and 
the mechanism by which they could affect virulence is not elucidated.  
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A number of authors have described the relationship between TDRM detection and VL values 
(669,678,681,682,686). Harrison et al analysed data from the UK CHIC cohort and the UK 
HDRD. Although they did not find any evidence that resistance to a single drug class was 
associated with VL in either univariable or multivariable analyses, they did find some evidence 
that the M184V mutation was associated with a lower baseline VL (686). In this analysis, I did 
not find any evidence that the M184V mutation had such an effect on either CD4 counts or the 
VL set point. It should be underlined, however, that resistance mutations that markedly impair 
HIV replicative capacity, such as M184V, are likely to wane over time in the absence of 
treatment due to overgrowth by more fit variants (380). The prevalence of M184V in this 
analysis was relatively low, and it is possible that I did not have sufficient power to detect any 
possible associations.  
7.5.4. Differences according to subtype  
The differences observed in CD4 count slope and set point according to subtype are 
interesting, and in agreement with findings from Keller et al (696), who found that individuals 
infected with a non-B virus experienced slower rates of disease progression. However, the 
“non-B” categorisation is relatively broad, and is likely to include subtypes that could both 
increase and decrease the speed of disease progression (697). Due to small numbers, it was 
not possible to conduct analyses stratified by specific non-B subtypes, such as D or A. A 
number of the main findings appeared to vary significantly according to the subtype of the 
virus, with the possible effect of NNRTI DRM being apparent largely among individuals infected 
with a subtype B virus, whereas the effect of individual PR mutations G16E and Q92K appeared 
to be primarily present among individuals infected with non-B viruses. It is not clear whether 
these variations in the effect estimates according to subtypes are due to biological differences 
or whether the primary explanation can be found in socio-demographic differences between 
groups infected with different subtypes. As data on ethnicity and socio-demographics was not 
collected in the EU-TDR collaboration, it was not possible to adjust for these factors.  
7.5.5. Strengths and limitations 
My analysis strengths include the large sample size, the transparent methods for mutation 
selection, the comprehensive evaluation of both types of resistance, individual mutations and 
clusters of mutations and finally and the longitudinal nature of the analysis. However, there 
are also a number of significant limitations. The primary weakness is the lack of an available 
date of infection. I attempted to estimate a date of infection using the shape of VL trajectories 
by trying to identify time periods in which a peak in VL resembling that observed around HIV 
seroconversion was experienced. However the number of individuals who experienced a 
significant VL increase of >2 log10 copies/mL followed by a decrease was too low (1.9% of the 
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total population) to allow for sensitivity analyses restricted to people in whom the date of 
seroconversion could be estimated. A second limitation is the lack of repeated resistance tests 
for the vast majority of individuals, which meant that I had to make assumptions regarding 
how long mutations persisted for. For simplicity, I assumed that resistance was present 
throughout FU. As the median FU in this study was just over 1 year and TDRM can persist for 
several years (698), this does not seem to be an unreasonable assumption. Nonetheless, 
repeated resistance tests would have allowed for more accurate modelling of resistance data 
in a time-updated manner. A third limitation is the number of statistical tests conducted. 
Although I corrected for multiple testing using recommend methods (445), I cannot rule out 
that some of these findings represent chance findings.  
The generalisability of the study could also be limited, as individuals who received a resistance 
test before the start of treatment are likely to differ in a number of ways from individuals with 
TDRM who were not tested. As data on the source populations for the EU-TDR dataset were 
not available, it was not possible to assess the frequency of pre-ART genotypic testing. 
Nonetheless, it seems reasonable to assume that not everyone who is infected with a TDRM 
strain is tested for pre-ART resistance. EuroSIDA includes a number of centres in eastern 
Europe, where pre-ART resistance testing has been reported to be relatively uncommon, 
occurring in only 17% of cases (577). If those tested differ from those who were not tested in 
significant ways, it could mean that my results are only applicable to a subset of TDRM-
infected individuals who receive tests in clinical care. The data quality of the EU-TDR 
collaboration reflects the quality of the data control and management procedures in each 
contributing centre, and no central data cleaning or quality controls were undertaken at the 
time of data submission. As in most observational studies, it is therefore possible that there 
are data entry errors or misclassification present in the data that could have influenced my 
results.  
As confirmed in my analysis, the natural history of HIV may vary according to the subtype of 
the virus (696,697). Although exploratory analyses were performed separately for B and non-B 
subtypes, I was not able to study specific non-B subtypes. It is not clear to what extent my 
results will be applicable to different settings where other subtypes predominate. I was also 
not able to investigate the effect of TDRM on treatment response in those who eventually 
started ART, as viral loads after treatment initiation were not available within the EU-TDR 
collaboration. However, this question has been previously investigated in large European 
collaborations (373) as well as in EuroSIDA (699). Finally, the prevalence of TDRM, and in 
particular the prevalence of individual mutations, was relatively low. Despite the large dataset, 
my analysis may have suffered from a lack of power.  
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7.5.6. Conclusions 
Bearing the limitations in mind, my results suggests that a number of genetic changes in the 
HIV genome may have a small but significant impact on the CD4 cell decline and VL set point 
before the start of ART. In particular, individuals infected with a subtype B virus may 
experience steeper CD4 declines if they have evidence of NNRTI-associated DRM’s, whereas 
individuals infected with non-B viruses may have lower VL set points if they carry some minor 
PR mutations: G16E or Q92K. A cluster of minor PR mutations in position 13, 20, 36, 89 and 69 
may influence both the speed of CD4 decline and the viral set point, particularly among 
individuals infected with a subtype B virus. However, the effect sizes were relatively small, and 
it is not known to what extent variation in the VL set point of this scale will influence the 
probability of transmission. It is also important to note that none of the resistance exposures 
investigated were associated with a higher VL set point, which could indicate an increased risk 
of transmission. My findings should therefore not affect the roll-out and expansion of ART 
coverage. The benefits of wide-spread ART usage are also likely to significantly outweigh any 
negative impacts it may have on epidemic virulence. Nonetheless, it may be of value to directly 
measure VL and CD4 values as part of TDRM prevalence surveys in order to monitor any 
potential changes in the virulence of HIV, irrespective of whether these are driven by 
expanding TDRM prevalence, ART coverage or different evolutionary pressures. To fully 
understand the impact of primary drug resistance on HIV virulence and disease progression, 
future studies should measure the date of seroconversion and, ideally, estimate the replicative 
capacity of strains directly in order to definitively assess the impact changes in the HIV genome 
has on virulence. More specific suggestions for further studies are discussed in Chapter 8.  
7.5.7. Dissemination of findings 
An early version of these findings was presented at the 2016 Conference of Opportunistic 
Infections and Retroviruses (abstract nr: 486, Poster No 16-966) and at the 2016 HIV Drug 
Resistance Workshop, both in Boston (Appendix X). A manuscript is in preparation. 
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Chapter 8 . Discussion and Conclusions 
 
8.1. Summary of Thesis Findings 
Since the development and widespread deployment of cART, HIV-related mortality and 
morbidity has declined markedly (173,700). The emergence of drug resistance, which 
hampered the use of early therapies (187,189,281), has become less of a clinical concern in 
high-income settings due to the wide variety of drugs available and the remarkable potency of 
modern combination treatments (515). However, resistance remains a threat to the success of 
HIV treatment due to its potential to jeopardise the use of standardised first line ART regimens 
in settings where genotypic resistance testing (GRT) is not widely available (422,584,701). As 
the number of people living with HIV who are on treatment in low income settings increases, 
the number of people requiring second and third line regimens is also expected to increase 
(701). Although this should not prevent the expansion of HIV treatment, it does have financial 
implications and warrants both extensive surveillance and continued research into 
epidemiological and biological aspects of HIV drug resistance. European HIV cohorts, many of 
which were established at the beginning of the HIV epidemic, represent valuable data 
resources due to the breadth of data collected and the length of follow-up time available. 
Although geographical representativeness is a limitation, data of HIV-infected individuals 
included in cohorts in Europe can nonetheless be used to answer questions relevant for policy 
in both high and low income settings. The research conducted as part of this PhD thesis aimed 
to address outstanding questions in the field of HIV drug resistance that the data sources 
available to me were particularly suited to answer. These included questions regarding the 
recent epidemiology of HIV drug resistance in Europe, as well as investigations into the 
consequences of maintenance therapy which is primarily used in low income settings today. 
This chapter summarises the main findings, discusses the overall implications and limitations of 
the research and presents suggestions for further research.  
8.1.1. Chapter 3: Patterns of Resistance Testing and Detected Drug Resistance in 
Europe 
Routinely collected data from observational cohorts are commonly used to estimate the 
prevalence of resistance in different settings, although many different methodologies are 
employed in order to construct an appropriate denominator (336,473,475,478,493). In Chapter 
3, I described the frequency of use of genotypic resistance testing (GRT) following virological 
failure (VF) over time in Europe, and describe the prevalence of resistance in people who were 
tested and had a genotypic result available within the cohort. My analysis indicated that only 
around 1/3 of individuals experiencing VF received a resistance test within 12 months of the 
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date of experiencing VF, and that this proportion decreased after 2004. In a sensitivity analysis 
using stricter definitions of VF, the proportion receiving a test was higher but still below 50%. 
This seems to indicate that the use of GRT following VF on average across Europe is well below 
that recommended by clinical guidelines (601). However, clinical decisions are complicated by 
a number of different factors, and there are several possible reasons that could explain why 
the observed frequency of testing was lower than what is recommended in treatment 
guidelines. For example, perceived poor adherence is likely to discourage clinicians from 
requesting a GRT. My results indicated that individuals of non-white ethnicity and people who 
had acquired their HIV through injecting drugs were less likely to receive a resistance test, and 
both of these groups tend to have suboptimal adherence and issues regarding access to 
treatment (511,512). I also found that compared to individuals in Southern Europe , those in 
Eastern Europe were less likely to receive a GRT, whereas those in Northern and Central 
Western Europe were more likely to receive a GRT. As these results were adjusted for a 
number of different demographic and clinical factors, this indicates that either differences in 
clinical practice or in access to different technologies could cause disparities in the standard of 
care that HIV positive people receive in different regions of Europe. However, it is also possible 
that there are differences in the case mix of patients studied that are driving the discrepancies 
that I could not fully adjust for.  
In contrast, the prevalence of resistance in people who were tested at failure was relatively 
high, at almost 80%. There was a suggestion from the analysis that this prevalence peaked in 
2003-2004, and that this was lower in both earlier and later calendar years. However, the 
decline in resistance detection observed after 2004 was less marked compared to what has 
been described in previous European studies (336,478), possibly as a result of the different 
European regions included. Indeed, geographical region also had an impact on the odds of 
detecting resistance, with individuals receiving care in Northern and Central Eastern Europe 
less likely to have detected resistance as compared to those in Southern Europe. Although 
resistance was detected in the majority of the tests, the proportion of individuals both 
experiencing VF and, of those, who had a GRT, declined drastically over time. This suggests 
that of all individuals on cART, it is a small and decreasing proportion who experience VF with 
drug resistance.  
Taken together, these findings suggest that clinicians in Europe may use GRT in a targeted way: 
whereby individuals more likely to have resistance are also those tested. The geographical 
differences identified have implications for public health policy, particularly for EU-countries 
where minimising inequalities in health care is a political priority (702). It also suggests that 
continued surveillance of acquired drug resistance prevalence is crucial, to ensure that gains 
360 
 
made in wealthier European countries (478,515) are replicated across the region. The fact that 
acquired resistance on ART is declining is re-assuring also in view of the fact that less 
circulating resistant strains at VF should lead to a decrease transmission of resistant HIV.  
8.1.2. Chapter 4: Long-term Virological Outcomes and Resistance Patterns among 
Treatment Experienced Patients Receiving Raltegravir  
Relatively recently, a new class of HIV drugs have been brought to the market. Integrase strand 
transfer inhibitors (INSTI) have been licensed for use in the EU since 2007, and their use has 
increased considerably since due to their high virological efficacy and favourable side-effect 
profile. Although the barrier of resistance to first generation INSTI is relatively low, the second 
generation INSTI dolutegravir is reported to have a high barrier to resistance (528). In 2015, 
15% of individuals in EuroSIDA on cART and under FU were receiving raltegravir, the first 
licensed INSTI. Although the virological efficacy of RAL has been shown in numerous clinical 
trials (519,521,524), there are not many reports on long-term outcomes of RAL in routine clinic 
settings. In addition, resistance patterns following VF to RAL have not been well described 
outside of a clinical trial setting. In Chapter 4, I characterised long term virological responses to 
RAL and described resistance patterns following VF to RAL by conducting an analysis which 
involved retrospective genotyping of stored plasma samples which were collected around the 
time of VF. I found that by 7 years from starting RAL for the first time, approximately 10% of 
individuals starting RAL with a suppressed VL had experienced VF. This was higher among 
those who started RAL with a detectable VL. Although risk factors varied according to whether 
individuals started RAL with a suppressed or raised VL, those with more advanced HIV disease, 
as indicated by low current CD4 counts and lower CD4 nadirs, were more likely to experience 
VF in both groups.  
Relatively few individuals experienced VF overall (n=262, 11%), and even fewer had an 
available stored plasma sample in the timeframe that I defined (from 3 months before to the 
end of the VF episode; n=33, 13%). The genotyping success was also relatively low (N=11, 
34%), primarily as a consequence of the low VL threshold (50 copies/mL) used as the inclusion 
threshold for selecting the plasma samples. This limited the resistance aspect of the analysis to 
a description of resistance patterns observed. Despite the small numbers, the number of 
individuals genotyped is similar to that included in previous similar analyses 
(534,545,551,553,556,566), possibly reflecting the relative rarity of VF on RAL in clinical care. 
Among those with integrase resistance, I found evidence of at least partial resistance to 
another drug in the INSTI class, Dolutegravir (DTG) among 2 out of 4 people with integrase 
resistance, due to the presence of the N155H + E92Q mutation in one sample and the 
Q148H+G140S mutations in the other.  
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My analysis included the longest amount of FU of any analysis of RAL efficacy in routine clinical 
care published to date, but the estimates of virological efficacy presented here are 
nonetheless in line with those of other observational studies (546,549). DTG can show efficacy 
following RAL failure, but this is limited by the presence of resistance. The detection of INSTI 
resistance mutations which can compromise the response to DTG or other drugs in the INSTI 
class supports the use of GRT following RAL failure to determine which individuals are 
potential candidates for use of INSTI as part of salvage regimens.  
8.1.3. Chapter 5: The Effect of Drug Resistance Mutations on CD4 Count Decline in 
HIV Positive Individuals Maintained on a Failing Treatment Regimen 
Both Chapter 3 and Chapter 4 confirmed that experiencing VF with drug resistance is becoming 
increasingly rare, but constructing suppressive regimens can still be a challenge for individuals 
with very complex resistance patterns, or in low income settings, due to a combination of 
acquired resistance over sustained periods of virological failure and limited drug availability. 
When a fully suppressive regimen cannot be constructed, it may be necessary to keep 
individuals on suboptimal treatment for extended periods of time. It has been hypothesised 
that the use of drugs that preserve resistance patterns associated with a less fit virus in such a 
maintenance regimen may result in a clinical benefit for these patients, but the evidence 
supporting this assertion is weak and conflicting (598,599). Therefore, the aim of Chapter 5 
was to describe the effect of acquired drug resistance mutations on CD4 decline among HIV 
infected individuals maintained on a virologically failing regimen. This analysis found that 
overall, individuals with resistance experienced significantly less steep CD4 declines compared 
to those without any detected resistance. This is in line with previous research finding that the 
absence of resistance despite ongoing viral replication may indicate issues with adherence to 
ART (417,664). Viral rebound without resistance can occur when there is an absence of drug 
pressure, as the wild type strain tends to outcompete resistant strains due to its fitness 
advantage. Among people in whom resistance was detected, my findings indicated that those 
with any NRTI mutation, or a number of individual mutations in the RT (e.g. M184V, D67N, 
T215Y) and PR region (e.g., V82A or I54V) also experienced less steep CD4 declines compared 
to those with other mutations. In contrast, those with any NNRTI resistance,the NNRTI 
mutation V179D or NRTI mutation L74V mutation experienced steeper CD4 declines. I also 
identified clusters of resistance using a fairly novel statistical approach in clinical HIV resistance 
research (a principal components analysis - PCA), and found that a cluster of resistance 
mutations conferring NNRTI resistance, including the K103N mutation, was associated with 
steeper CD4 declines. Conversely, a cluster of mutations conferring broad PI resistance was 
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associated with less steep CD4 declines. I also partially explored the hypothesis that the effect 
could be entirely mediated by viral load. Although results are not conclusive, it could not be 
ruled out that that there is a direct effect of the mutations on CD4 count decline, or that this 
effect is mediated through alternative pathways. 
The mutations I found to be associated with less steep CD4 declines have been reported to 
confer reduced viral fitness, so my findings support the hypothesis that lower viral fitness 
could be clinically beneficial (507,703). If my findings are confirmed, it would suggest that the 
inclusion of LAM/3TC and a boosted PI is a good option for maintenance therapy, whereas 
maintaining an individual on an NNRTI based regimen for extended periods of time should be 
avoided. The results also provide support for expanding access to VL monitoring in low income 
settings, which would allow rapid detection of VF to first line, NNRTI-containing, cART. The 
findings from the PCA further support the avoidance of NNRTI agents as part of any salvage 
regimen, but also highlights that the effect of a single mutation on clinical outcome is likely to 
be complex to predict as it, at least in part, depends on other mutations.  
8.1.4. Chapter 6: Rate of Accumulation of Drug Resistance Mutations During 
Virological Failure According to the Level of Viral Replication  
One of the primary concerns when individuals living with HIV are maintained on a failing 
treatment regimen is the risk of further accumulation of resistance. In chapter 6 I estimated 
the rate of accumulation of drug resistance among people maintained on the same failing 
treatment regimens, and focused on describing how the level of viral replication might affect 
the rate of resistance development as this is not well described in the literature. I found that 
resistance accumulated at a rate of 1.51 (95%CI=1.37-1.68) new mutations per year. This is the 
equivalent of individuals, on average, accumulating approximately 1 new mutation per every 7 
months and losing 1 drug option for every 24 months of being maintained on a failing regimen. 
Accumulation rates were highest for M184V (0.17, 95%CI=0.14-0.20 events/year), the K103N 
(0.07, 95%CI=0.05-0.09 events/year) and L90M (0.06, 95%CI=0.04-0.08 events/year) 
mutations. Although these estimates come from relatively early calendar years of HIV-infected 
patients seen for care in Europe , they are very similar to rates of resistance accumulation 
observed in other geographical settings (645,646).  
Of note, the rate of resistance accumulation did not appear to vary according to VL values at 
the start of a VF episode nor the VL peak reached during the episode. However, VL measures 
that took into account VL changes throughout the episode: the average VL level, estimated VL 
slope and copy years viraemia (VCY) were all associated with the risk of resistance 
development. The risk of developing resistance appeared to be lowest when the average VL 
level during the episode was between 5,000-10,000 copies/mL or when the VL during the 
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episode increased with less than 0.12 log10 copies/mL/year or when it actually decreased. 
These results are consistent with the notion that there is faster selection of resistance when 
there is some, although suboptimal, drug pressure. Indeed, individuals with steeper VL 
increases of more than 0.21 log10 copies/mL/year or high VCY values over the failing episode 
were found to experience relatively low levels of resistance accumulation  
One the aims of this analysis was to evaluate whether it was possible to identify a VL threshold 
close to the beginning of a VF episode below which resistance was unlikely to accumulate. As 
mentioned above, the risk of detection of resistance during the failure episode seemed not to 
correlate with the initial level of viral load and therefore my analysis failed to identify such a 
threshold. This suggests that clinically important resistance is still able to develop even at 
relatively low VL values, and supports the recommendation to use a relatively low threshold 
for defining VF (72). The lack of an association between peak VL, VL at the start of a VF episode 
and resistance development also suggests that VL measures taken at a single point in time are 
not strong predictors of the consequent risk of resistance development. Among patients who 
are maintained on a failing drug regimen, VL and CD4 should be frequently monitored so that 
issues with adherence can be identified as soon as possible and risk of development of 
resistance minimized. In low income settings, efforts should focus on expanding access to 
second and third line treatment regimens to allow for timely ART switches after first-line 
failure.  
8.1.5. Chapter 7: The Effect of Primary Drug Resistance on CD4 cell Decline and Viral 
Load Set Point in HIV Positive Individuals Before the Start of ART 
Maintaining individuals on a failing treatment regimen also has implications for the 
transmission of resistance. Transmitted drug resistance (TDR) has been associated with an 
increased risk of VF to first line regimens unless GRT is used before the start of ART to guide 
treatment (373), but it may also influence the speed of HIV disease progression in absence of 
ART (375,669). Any changes in pre-treatment CD4 counts/the viral load as a result of 
treatment associated or transmitted drug resistance mutations could indicate that the 
transmission dynamics of the HIV epidemic could change if the expansion in ART coverage is 
followed by an increase in the prevalence of transmitted drug resistance. To investigate part of 
this hypothesis I used data from the EU-TDR collaboration and EuroSIDA to quantify the impact 
of a number of different mutations on both the CD4 count decline in the absence of ART and 
the viral load set-point after infection.  
I found little evidence for an association between transmitted resistance mutations, resistance 
mutations commonly classed as treatment associated and the speed at which CD4 counts 
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declined in absence of ART. There were weak associations between some classes of 
transmitted resistance (PI, NRTI) and the VL set point, although the absolute size of these 
effects was relatively small (a difference of approximately 0.1 log10 copies/mL when comparing 
people with or without mutations to these drug classes). Two individual mutations were 
associated with lower VL set points: the G16E and Q92K mutations. These are typically 
classified as minor PR mutations, and I was not able to identify any basic science studies 
investigating their effect on viral fitness. Of interest, although no individual mutations were 
significantly associated with CD4 decline after adjustment for multiple testing, there was some 
indication that two other polymorphic PR mutations that have previously been associated with 
fitness restoration in viral isolates, A71T and L10V, were associated with steeper CD4 declines 
before the start of ART (669,694,695).  
As in Chapter 5, I studied the pattern of mutations using a PCA approach to identify clusters of 
mutations. A cluster of minor PR mutations involving substitutions at positions 20, 36, 69 and 
89 was identified in both the analyses shown in Chapter 5 and Chapter 7. Pairwise correlations 
between mutations in position 20 and 36 have been previously reported (631,632), as have a 
clustering of mutations in position 20, 36 and 69 (630). These mutations appear particularly 
often among non-B viruses. Although the analysis in chapter 5 showed no evidence that this 
cluster affected CD4 decline in people receiving a virologically failing treatment, individuals 
whose mutation pattern closely aligned with the cluster had less steep CD4 decline and lower 
VL set points in absence of ART. It is not clear whether this mutational pattern represents a 
survival advantage to the virus, or if the clustering appears as a consequence of structural 
necessity among certain viral strains or subtypes (330,696). Regardless of the possible 
explanation, these data further support previous findings that patterns of mutations, 
particularly minor or polymorphic changes in the PR gene, are likely to have an important 
impact on pre-ART CD4 counts and VL (669). However, the effect that this may have on the 
transmission dynamics of HIV is not known. Future studies investigating this question should 
ideally use methods that take the entire genomic variation into account as well as utilising 
direct estimates of replicative fitness from laboratory studies. Further biochemical and 
structural analyses of the protease gene are also needed in order to explain why and how 
specific patterns of PI resistance emerge. 
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8.2. Limitations  
Limitations specific to each of the five analyses were discussed in each chapter, but some 
limitations are of a more general nature and arose as a consequence of the observational 
nature of the data. These are discussed in more detail in the following paragraphs.  
8.2.1. Data representativeness and generalisability 
Most of the analyses in the thesis have been carried out using data from the EuroSIDA cohort. 
Although a strength of the EuroSIDA dataset is the representativeness achieved as a 
consequence of the pan-European data collection and minimal exclusion criteria applied as 
part of EuroSIDA recruitment, there are some limitations concerning generalizability. Firstly, 
patients attending EuroSIDA clinics may differ in important ways from those attending non-
EuroSIDA clinics. EuroSIDA participating clinics tend to be university affiliated, larger centres of 
excellence based in urban areas. It is likely that the care provided at these centres is not 
representative of the care provided in an entire country or region. This is particularly an issue 
for the analyses in which resistance outcomes have been compared across geographical 
regions. Although limited numbers necessitated the grouping of clinics into regions, there is 
likely to be significant intra-regional variability in the quality of care provided (704). My results 
identify potential shortcomings in the clinical care provided in Eastern Europe, but it is not 
possible to establish whether this is true for the whole region or only for specific countries or 
clinics within a region.  
Some of the questions addressed in this thesis might be of relevance to clinical care in low 
income settings. However, the composition of the HIV epidemic differs according to 
geographical regions, with different subtypes dominating in different regions (113). This is a 
clear limitation, and findings reported here should ideally be confirmed in cohorts conducted 
in the settings where any policies deriving from the findings are most likely to apply.  
8.2.2. Data availability and missing data 
Although using cohort data allowed me to access more detailed clinical information than those 
typically collected for in surveillance or registry databases, there was nonetheless limited 
information available on certain key variables. In particular, the lack of availability of a 
validated adherence measure in both the EuroSIDA and UK CHIC cohorts is a significant 
limitation for the majority of my analyses. For example, knowing a person’s adherence status 
would have been necessary in order to validate the assumption that on-going viral replication 
without detected resistance is a consequence of very low adherence and an absence of 
selective pressure. However, although I was not able to investigate this directly, it has been 
found to be an accurate assumption in other studies (417,664). In addition, the lack of routine 
and reliable data on adherence to ART is a limitation shared by most European HIV cohorts.  
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Measuring adherence is complex, and although several different methods for estimating 
adherence have been developed there is no gold-standard measure employed across HIV 
cohorts (705). In general, direct methods, which involve measuring the amount of drug or drug 
metabolite directly, are considered more accurate than reported adherence, whether this is 
self-reported or reported by the treating clinician. As HIV cohorts evolve with the changing HIV 
research agenda, a simple, validated measure of adherence would represent a valuable 
additional data item. Such data would not only help answer some of the questions raised by 
my research, but also open up a variety of other research questions. For example, variation in 
adherence levels over time, in different countries and in relation to different type of drug 
regimens could be examined.  
Missing data is also an issue particularly relevant to resistance data. As explained in Chapter 3, 
not every person who experience VF with resistance had a resistance test available in the 
database. This can be due to a number of reasons, some of which could be related to the 
outcomes of my analyses resulting in possible endogenous selection bias. However, although I 
took the approach of only describing resistance prevalence among those with an available test 
result, recognising the limitations of this approach, other strategies have been previously 
explored using EuroSIDA data (473).  
8.2.3. Data quality 
The data sources used here contain information from a large number of individuals followed 
for long periods of time. In EuroSIDA, quality control visits and accuracy checks are completed 
by the coordinating centre as outlined in Chapter 2, but it is likely that there are nonetheless 
errors present in the data used. Such errors can include data entry errors as well as issues that 
arise as a consequence of data management or processing. If these errors are systematic and 
differential, for example, more likely to occur among individuals from a particular geographical 
region, it can introduce bias in the analyses. The most effective way of ensuring high data 
quality is to prevent errors being introduced at the study design and data collection stage. 
Going forward, the EuroSIDA quality control procedures are being updated to reflect the 
challenges of a growing dataset. This has involved both streamlining data collection to focus 
only on key variables, but also introducing additional data control checks to be undertaken at 
the statistical centre.  
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8.2.4. Resource limitations  
As with most research, the analyses presented here were constrained by finite resources. 
Genotyping, particularly using modern technologies, is still relatively expensive. This meant 
that I consciously applied relatively restrictive time-windows for the analysis in Chapter 4 when 
I sent samples for genotyping. The relatively low genotyping success rate in that analysis 
indicates that a cost-effective approach to further genotyping would prioritise samples with a 
higher VL, as this was the primary factor associated with genotyping success. Collaboration 
with industry or other funding providers may allow for more genotypic data to be collected 
going forward, and it is likely that the EuroSIDA resistance database will be expanded with 
more sequencing results from the integrase region. Future EuroSIDA publications might 
therefore be able to provide further insights into the risk of developing resistance on 
raltegravir.  
8.2.5. Sample size and statistical power considerations  
As no additional data collection was undertaken for most of the analyses in this thesis, the 
statistical power was fixed and determined by the existing data. Power was a particular issue in 
Chapter 5 and 7, where I aimed to establish the effect of individual mutations on CD4 count 
changes and the viral load set point. As the prevalence of single mutations can be low, and the 
magnitude of the detected association small, some of these estimates were relatively 
imprecise despite the large datasets used. Although the analysis in Chapter 5 and 7 are among 
the largest to date investigating the respective questions, it would nonetheless be of interest 
to expand existing collaborations to allow for even more precise estimates of these effects.  
8.2.6. Unmeasured confounding  
A problem in all observational studies is that of unmeasured confounding. Although 
multivariable statistical methods can account for bias introduced through measured 
confounding, it is not possible to adjust for confounders that were not measured. It is also 
possible that errors and inaccuracies in the measurements of certain variables result in 
residual confounding being present in the effect estimates, even after multivariable 
adjustment. I cannot rule out that the estimates presented here are affected by bias as the 
result of unmeasured or residual confounding. The only way to ensure that effect estimates 
are not affected by confounding is by conducting a large randomized clinical trial without any 
differential loss-to-follow-up. A trial could potentially be done to address the question set out 
in Chapter 5, regarding which regimens and ART drugs are most effective for use in 
maintenance therapy to preserve the CD4 count response. However, in order to recruit 
sufficient numbers of individuals that have no other treatment options available, the trial 
would need to involve a large number of centres and to enrol from sites mostly located in low 
income settings. The complicated ethical issues involved in conducting such a trial, where 
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people are maintained on an ineffective treatment when effective treatment options are 
available in other settings, makes it less likely that one will be carried out. 
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8.3. Clinical Implications and Further Research 
Bearing these limitations in mind, my research nonetheless has a number of important 
implications. Firstly, the analyses in Chapter 3, and to a lesser extent Chapter 4, confirmed that 
aspects of clinical care for HIV vary significantly according to geographical region. Taken 
together with the findings from other analyses (575–577,579,706), this adds to a growing body 
of evidence showing that care for HIV in the Eastern European region lags behind that in other 
areas of Europe. Further research identifying the specific factors that explain these 
discrepancies, including on a health-systems level, would help design targeted interventions. 
Given that infectious diseases do not respect borders, a comprehensive and collaborative 
approach including a sharing of resources may be needed by countries in the WHO European 
region in order for the 90-90-90 target to be achieved.  
The results shown in Chapter 3 also confirmed that experiencing VF with resistance is 
becoming increasingly rare. This confirms the well-known success of the introduction of 
modern cART (515). However, the results presented here also indicate that the use of GRT to 
detect resistance following VF is lower than what might have been expected according to 
current guidelines. Although this discrepancy between guidelines and clinical practice can be 
explained by actions that are consistent with good clinical practice and may not necessarily 
jeopardise clinical outcomes, it is important to further understand what motivates clinicians in 
different countries to request GRT for some patients and not others. Mixed methods studies 
including interviews and qualitative analyses might be able to address this question. Although 
the use of GRT has been shown to be beneficial in clinical trials conducted in earlier calendar 
years, no trials evaluating the role of GRT have been done following the introduction of more 
modern ART classes, such as integrase inhibitors. The cost-effectiveness of resistance testing 
following the introduction of NGS has also been questioned; although recent evidence 
suggests that the use of NGS is cost-saving compared to Sanger sequencing (707). As many 
European health systems are attempting to identify areas for cost-saving, future research 
should include further evaluations of the cost-effectiveness of resistance testing, using both 
NGS and Sanger sequencing, in the context of modern cART.  
The research presented in Chapter 5 has some potentially important clinical implications. If the 
findings are replicated in other studies, including those in low income settings, it would 
suggest that current salvage regimens may benefit from the inclusion of particular drugs, such 
as Lamivudine and a boosted PI, whereas the use of NNRTI-containing regimens should be 
avoided. The findings also highlight the importance of expanding routine VL monitoring in low 
income settings so that those experiencing failure on first line treatment can be rapidly 
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switched from NNRTI-containing regimens. However, as mentioned previously, the ideal 
evidence to support the use of particular treatment and treatment switch strategies should 
come from randomized controlled trials. Although a trial evaluating different salvage regimens 
in low income settings would be complex to design, it could potentially provide very important 
information for clinicians faced with difficult treatment choices. In the absence of firm 
evidence from RCT’s, it is important to focus efforts and resources on expanding treatment 
options in low income settings. The analyses from Chapter 5 would benefit from being 
expanded to include an investigation of the impact of integrase resistance on CD4 decline. This 
is particularly important given the recent consideration given by the WHO to potentially swap 
current first line treatments to DTG based regimens.  
The potential benefit of maintaining a patient on a particular treatment regimen needs to be 
balanced with the risk of developing further resistance, which could contribute to the spread 
of transmitted resistance and jeopardise the use of newer ART drugs when these become 
available. The results shown in Chapter 6 indicates that new resistance is likely to develop at a 
rate of one new mutation for every 7 months of ongoing VF. Ideally, estimates of the rate of 
resistance accumulation would be calculated in studies where resistance testing is frequently 
repeated at set time-points for each individual. This would allow for a more accurate 
determination of the follow-up time contributed. An absence of sparse or missing genotypic 
testing results would also open up the possibility to perform extra analyses such as the use of 
marginal structural modelling to estimate the best time at which to switch ART to reduce the 
risk of resistance accumulation, or the use of standard regression models to accurately identify 
people who are most likely to develop further resistance so that they could be prioritised for 
treatment. Tools along these lines are already in development (643), and the research 
presented here supports the use of repeated VL measurements over the failure episode 
(rather than the level of copies/mL observed at the time of first failure for example) to identify 
those most likely to benefit from a treatment switch.  
The analyses presented in Chapter 7 indicates that the detection of viruses with genetic 
changes in absence of ART is unlikely to greatly affect the viral set point or speed of CD4 
decline among those who become infected with resistant HIV. However, the lack of a date of 
seroconversion complicates the interpretation of my findings, as it is impossible to establish 
exactly for how long the detected mutations have been circulating as dominant species. 
Further research investigating this question should ideally be carried out in cohorts where 
estimates of the date of seroconversion is available. A number of relevant analyses have been 
done in the CASCADE cohort, although these suffered from a relatively small sample size which 
limited their ability to investigate individual mutations (684). Alternatively, it could be valuable 
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to develop statistical methods that would allow for an estimation of the date of 
seroconversion on the basis of VL trajectories. The frequency of viral load measurements in 
the datasets used here was insufficient to fulfil this objective.  
In general, the lack of certain key data in this thesis, such as adherence measures, dates of 
seroconversion and irregular and missing genotypic testing data suggests that future studies 
should consider expanding data collection in order to capture a broader set of variables than 
that provided by routine health care data. EuroSIDA is currently undergoing a restructuring in 
order to better respond to future research priorities, and this represents an opportunity to 
expand or amend the data collection. In addition to HIV resistance data, there will likely be 
interest in resistance to the new direct acting antivirals (DAA) used to treat HCV, as it seems to 
be causing failure in a not negligible proportion of HCV-infected individuals. An expansive and 
comprehensive plasma sample repository, as that held by EuroSIDA, represents an ideal 
resource to investigate many of these questions as additional data, including both resistance 
genotyping and potentially drug concentration measurements as a marker of adherence, can 
be generated retrospectively when resources are identified.  
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8.4. Concluding Remarks  
HIV drug resistance has, fortunately, evolved from being a major barrier to successful 
treatment to, following the advent of modern cART, being of less clinical and of population 
level health importance. However, the theoretical potential for specific mutations to emerge 
and cause wide-spread impairment to the use of standard first line regimens highlights the 
importance of continued surveillance and research into this area. This thesis contributes both 
epidemiological data on HIV resistance testing, prevalence and incidence, as well as data that 
enhances our understanding of how drug resistance influences disease progression in the 
presence and absence of therapy. It is hoped that these findings can be used to both improve 
aspects of clinical care for people living with HIV, as well as to further the research agenda in 
the field of HIV drug resistance. Together with continued activism and advocacy for greater 
access to laboratory technologies and treatment, it is hoped that this can ensure greater 
health equity and a better quality of life for people living with HIV. 
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Appendix I: The EuroSIDA Study Group 
 
The multi-centre study group, EuroSIDA (national coordinators in parenthesis).Argentina: (M Losso), M 
Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (B Schmied), Pulmologisches Zentrum der 
Stadt Wien, Vienna; R Zangerle, Medical University Innsbruck, Innsbruck. Belarus: (I Karpov), A 
Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, Gomel State Medical University, 
Gomel; D Paduto, Regional AIDS Centre, Svetlogorsk. Belgium: (N Clumeck), S De Wit, M Delforge, Saint-
Pierre Hospital, Brussels; E Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, 
University Ziekenhuis Gent, Gent. Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta 
Sarajevo, Sarajevo. Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb. Czech 
Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, 
Plzen. Denmark: G Kronborg,T Benfield, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, 
Rigshospitalet, Copenhagen; NF Møller, C Pedersen, Odense University Hospital, Odense; L Ostergaard, 
Skejby Hospital, Aarhus, L Wiese, Roskilde Hospital, Roskilde; L N Nielsen, Hillerod Hospital, 
Hillerod. Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond 
Siseklinik, Kohtla-Järve. Finland: (M Ristola), I Aho, Helsinki University Central Hospital, 
Helsinki. France: (J-P Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; C Pradier, E 
Fontas, Hôpital de l'Archet, Nice; C Duvivier, Hôpital Necker-Enfants Malades, Paris.Germany: (J 
Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; O Degen, University 
Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, 
Hamburg; C Stefan, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; 
G. Fätkenheuer, Universität Köln, Cologne. Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical 
Immunology Research Center, TbilisiGreece: P Gargalianos, G Xylomenos, P Lourida, Athens General 
Hospital; H Sambatakou, Ippokration General Hospital, Athens. Hungary: (J Szlávik), Szent Lásló Hospital, 
Budapest. Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik. Ireland: (F Mulcahy), St. 
James's Hospital, Dublin.Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G 
Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University Hospital, Jerusalem; 
D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusalem. Italy: (A D’Arminio Monforte), Istituto Di Clinica 
Malattie Infettive e Tropicale, Milan; R Esposito, I Mazeu, C Mussini, Università Modena, Modena; F 
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Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la 
Sapienza, Rome; M Zaccarelli, A Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive 
Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A 
Ridolfo, Osp. L. Sacco, Milan.Latvia: (B Rozentale), Infectology Centre of Latvia, Riga. Lithuania: (V 
Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vilnius; R Matulionyte, Center of Infectious 
Diseases, Vilnius University Hospital Santariskiu Klinikos, Vilnius. Luxembourg: (T Staub), R Hemmer, 
Centre Hospitalier, Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit 
van Amsterdam, Amsterdam.Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, 
Oslo. Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A Horban, E Bakowska, 
Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A Grzeszczuk, Medical University, Bialystok; M 
Parczewski, M Pynka, K Maciejewska, Medical Univesity, Szczecin; M Beniowski, E Mularska, Osrodek 
Diagnostyki i Terapii AIDS, Chorzow; T Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, 
E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University 
of Medical Sciences, Poznan.Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital 
de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. Romania: (R Radoi), C Oprea, Spitalul de 
Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest. Russia: (A Panteleev), O Panteleev, St Petersburg 
AIDS Centre, St Peterburg; A Yakovlev, Medical Academy Botkin Hospital, St Petersburg; T Trofimora, 
Novgorod Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, 
Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research Institute of Epidemiology and 
Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E Borodulina, 
E Vdoushkina, Samara State Medical University, Samara.Serbia: (D Jevtovic), The Institute for Infectious 
and Tropical Diseases, Belgrade. Slovenia: (J Tomazic), University Clinical Centre Ljubljana, 
Ljubljana. Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S Moreno, J. 
M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I Bravo, 
Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant 
Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-Gasteiz. Sweden: (K Falconer), A 
Thalme, A Sonnerborg, Karolinska University Hospital, Stockholm; A Blaxhult, Venhälsan-Sodersjukhuset, 
Stockholm; L Flamholc, Malmö University Hospital, Malmö. Switzerland: (A Scherrer), R Weber, 
University Hospital Zurich; M Cavassini, University Hospital Lausanne; A Calmy, University Hospital 
Geneva; H Furrer, University Hospital Bern; M Battegay, University Hospital Basel; P Schmid, Cantonal 
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Hospital St. Gallen.Ukraine: A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, 
Crimean Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and 
Control CTR, Lviv.United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospital, 
London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, A 
Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); C Orkin, Royal 
London Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary's, 
London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, 
Edinburgh.The following centers have previously contributed data to EuroSIDA:Infectious Diseases 
Hospital, Sofia, Bulgaria Hôpital de la Croix Rousse, Lyon, France Hôpital de la Pitié-Salpétière, Paris, 
France Unité INSERM, Bordeaux, France Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany 
1st I.K.A Hospital of Athens, Athens, Greece Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy 
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy Ospedale Cotugno, III Divisione Malattie 
Infettive, Napoli, Italy Dérer Hospital, Bratislava, Slovakia Hospital Carlos III, Departamento de 
Enfermedades Infecciosas, Madrid, Spain Kiev Centre for AIDS, Kiev, Ukraine Luhansk State Medical 
University, Luhansk, Ukraine Odessa Region AIDS Center, Odessa, Ukraine 
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Appendix II: The UK CHIC study group 
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Appendix III: The UK HDRD Study Group 
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Appendix IV: The EU-TDR collaborating cohorts 
 
The European Transmitted Drug Resistance collaboration (EU-TDR) includes the following 
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Appendix V: Extra Mutations for Chapter 7 
 
Selected manually from the Stanford 
Drug Resistance Database 
Polymorphisms considered 
in Theys et al (2012) 
pr92K pr13V 
pr12N pr60E 
pr33I pr60E 
pr69R pr2V 
pr12K pr71T 
pr72L pr71V 
pr61D pr77I 
pr55R pr93L 
pr20M  
pr36V  
pr12E  
pr17D  
pr18H  
pr75I  
pr11I  
pr37Q  
pr92R  
pr93M  
pr72R  
pr79D  
pr35G  
pr66V  
pr20V  
pr43I  
pr72K  
pr10R  
pr71I  
pr89F  
pr11L  
pr22V  
pr34D  
pr55N  
pr91A  
pr34K  
pr45Q  
pr66L  
pr67F  
pr10Y  
pr20L  
pr34Q  
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Appendix VI: Publication arising from Chapter 3 
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Appendix VII: Conference Presentation arising from Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
391 
 
Appendix VIII: Conference Presentation arising from Chapter 5 
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Appendix IX: Conference Presentation arising from Chapter 6 
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